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Progression and regression of renal fibrosis is observed in patients with diabetic 
nephropathy (DN). The underlying pathways, especially those that promote 
regression of fibrosis, remain poorly understood in part due to the fact that most 
rodent DN models only mirror the early features of human DN. Another obstacle for 
optimizing treatment strategies is that albuminuria, the current gold standard 
biomarker of renal damage in DN, often lacks sensitivity and specificity for 
identification of those patients with diabetes who are at risk of a rapid decline in 
renal function. A novel DN model, in which diabetes was induced with 
streptozotocin in Cyp1a1mRen2 rats and hypertension was generated by inducing 
renin transgene expression with dietary indole-3-carbinol (I-3-C), mimicked many of 
the key biochemical, pathological and transcriptomic changes observed in the kidney 
of patients with DN. Recently, the model was extended to include a ‘reversal phase’ 
in which glycaemia was tightly controlled and blood pressure normalized for eight 
weeks after an ‘injury phase’ of 28 weeks. The present study aims to employ this 
novel rodent model to examine pathways activated in the kidney during and 
following reversal of hyperglycaemia and hypertension and to identify new 
biomarkers that might complement albuminuria in assessing risk of renal 
deterioration in patients with diabetes. 
Methods 
Tissue and urinary specimen from the Cyp1a1mRen 2 model of DN were analysed 
by realtime-PCR, Western-Blot, ELISA and staining techniques including 
immunohistochemistry, immunofluorescence and zymography. To establish in-situ 
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zymography a model of ureteric obstruction was used. Urinary peptidomic analysis 
as well as measurement of urinary exosomes and microparticles was performed in 
the model and in patients with DN utilizing liquid chromatography/tandem mass-
spectrometry, nanoparticle tracking analysis (NTA) or flow cytometry.  
Results 
Tight control of blood glucose and blood pressure during an 8 week ‘reversal phase’ 
did not significantly reverse the degree of renal fibrosis accrued during a 28wk 
‘injury phase’. However, it did result in a reduction in expression of genes encoding 
myofibroblast markers and extracellular matrix (ECM) proteins. Genes that were up-
regulated during both injury and reversal phases were implicated in adaptive 
immunity, phagocytosis, lysosomal processing and degradative metalloproteinases 
(MMPs). Paradoxically MMP activity was massively reduced during both injury and 
reversal phases. This may be due to an elevated level of tissue inhibitor of 
metalloproteinase-1 (TIMP-1) protein in both phases. After separating TIMP1 from 
MMP in renal tissue homogenates from animals of both the injury and reversal 
phases using gel electrophoresis, MMP activity was restored above that of controls. 
For biomarker discovery peptidomic analysis was performed on urine from rats at 
baseline and during the injury and reversal phases of the Cyp1a1mRen2 model of 
DN and from patients with moderately advanced DN and from normal controls. The 
use of two different search and analyse tools (Maxquant, Progenesis QI) resulted in 
the discovery of significantly altered peptides in the urine in rodent and human DN. 
Further studies focused on peptides derived from those proteins for which the 
corresponding gene was similarly regulated in the DN model and in human DN. 
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Urinary epidermal growth factor (uEGF) matched these criteria as the reduction of 
excretion during the injury phase in the DN model was paralleled by reduced EGF 
protein expression in renal tissue.  
Key biomarker candidates identified in the first two chapters were measured in 
urinary specimens of patients from the Edinburgh Type 2 Diabetes study (ET2DS) to 
test translational utility. MMP7 and other candidates, such as osteopontin or vascular 
endothelial growth factor (VEGF) were not of value in predicting renal outcomes. 
Reduced uEGF was significantly associated with increased mortality rate. In a 
subgroup of 642 study participants who were normoalbuminuric and had a preserved 
renal function at baseline, a lower uEGF to creatinine ratio was a risk factor for 
either developing an estimated glomerular filtration rate less than 60 ml/min per 
1.73m
2
, rapid (over 5% per annum) decline in renal function or the combination of 
both. The latter remained significant after correction for other covariates. Addition of 
uEGF resulted in a marginal improvement in a model derived from traditional risk 
factors for predicting rapid decline and the composite end-point.   
Urinary microparticle (20nm-1000nm) analysis was established in the rodent DN model 
and translated to patients with DN. Total urinary exosomes (20nm-100nm) or exosomes 
derived from specific renal cell types including podocytes and tubular cells, increased 
during the injury phase in the Cyp1a1mRen2 model followed by a decrease after reversal 
phase. In a pilot study comprising participants with advanced chronic kidney disease, the 
urinary exosome concentration correlated with renal function. In the ET2DS an 
increased exosome concentration at baseline indicated a higher risk for renal 
deterioration during four years follow-up even after correction for baseline eGFR. 
Urinary microvesicles (100nm-1000nm) concentration increased during the injury phase 
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in the DN model though correlation with renal function in humans was only significant if 
kidney-specific marker (podocalyxin) positive microvesicles were measured. 
Conclusion 
Normalisation of hyperglycaemia and hypertension in the DN model allows the study 
of genetic and protein regulation during the injury and reversal phases. ECM-
production but not ECM-degradation genes are down-regulated during the reversal 
phase. The lack of reduction in ECM during the reversal phase might be caused by 
persistently reduced MMP activity due to the presence of TIMP-1. Targeting TIMP 
might be a treatment strategy to promote reduction of renal fibrosis. 
For the first time, the analysis of urinary peptidomics was integrated with previous 
transcriptomic findings in the Cyp1a1mRen2 model and patients with DN for 
biomarker discovery. The approach was validated using different analysis tools and 
successfully identified candidate markers which were increased or reduced in DN. 
Candidates included uEGF, which identified patients with DN who were at risk of a 
rapid decline of renal function. Though the marker requires further confirmation in 
other cohorts, it might be especially useful for patients with type 2 diabetes, in whom 
renal decline is often uncoupled from the development of albuminuria.  
Finally, the DN model helped to develop the methodology of microparticle analysis. 
For the first time a potential prognostic value of urinary exosome analysis in patients 
with diabetes has been demonstrated. Future work will include further optimisation 
of the methodologies, including labelling of microparticles with multiple antibodies 
and increasing study participant numbers.  
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SUMMARY 
Diabetic Nephropathy (DN) increases the risk of cardiovascular death and end-stage 
renal failure, which necessitates dialysis or transplantation.  It represents a huge 
economic burden for health care systems. In order to develop new treatment 
strategies it is mandatory to gain deeper insight into the mechanisms that promote 
damage and repair in the kidney. Moreover, novel biomarkers are needed to identify 
patients at high risk of rapid decline in renal function as the established marker, 
urinary albumin, fails to identify all patients at risk. Improved risk biomarkers may 
enable therapies to be targeted towards those who would benefit most. 
This thesis examined a novel rat model of DN in which a combination of high blood 
pressure and high blood sugar reproduced the microscopic findings and gene 
expression patterns observed in the kidneys of patients with DN. To investigate 
repair mechanisms, blood pressure and blood sugar were tightly controlled for an 
additional 8 weeks (reversal phase) after a 28wk period of high blood pressure and 
high glucose levels (injury phase).  
Tight control of blood pressure and blood sugar levels halts the progress of renal 
scarring by switching off genes that promote scar production. Whilst degradation of 
scar is attempted through increased production of enzymes called matrix 
metalloproteinases (MMPs), these appear to be blocked by Tissue inhibitor of 
metalloproteinases (TIMPs). Strategies to neutralise the inhibitory effect of TIMPs 
might promote renal repair in patients with DN. 
To identify new biomarkers that predict renal prognosis, the identity and quantity of 
the peptides (small subunits of proteins) present in the urine of rats in the DN model 
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was analysed. A large number of peptides were excreted in higher or lower amounts 
in the urine of rats with high blood pressure and glucose compared with normal rats. 
One peptide originated from protein called epidermal growth factor (EGF), which 
was found to be decreased in the kidney and urine in rats with diabetes and 
hypertension  
A panel of promising biomarker candidates identified in the rodent model of DN 
were examined for their ability to predict renal outcomes in patients with type 2 
diabetes. Only one candidate, EGF, was able to predict renal outcomes even after the 
influence of other risk factors like baseline renal function, the amount of protein leak 
into the urine, sex, age or how tightly the patients’ diabetes was controlled was taken 
into account. 
Microparticles are small vesicles (<1 micrometre in diameter) released by cells either 
spontaneously or following induction by stimuli such as cellular damage. In the 
rodent DN model, increased urinary concentration of microparticles was associated 
with renal tissue damage. In patients with DN, the urinary concentration of very 
small (20-100 nanometres in diameter) microparticles, called exosomes, correlated 
not only with renal function but also seemed to be an indicator for future decline. 
Hence, microparticles might represent a new promising class of biomarkers. 
In conclusion, using the novel rat DN model helped to dissect damaging and repair 
mechanisms in the kidney and to identify new potential biomarkers that predict renal 
outcome. Future work is needed to further expand the knowledge of repair 
mechanisms and to confirm the validity of the biomarkers to enable earlier and more 
efficient treatment of patients with diabetic nephropathy.  
11 
ACKNOWLEDGEMENTS 
First of all, I would like to thank Dr. Bryan Conway for the opportunity to perform 
this work under his supervision. His exceptionally profound knowledge and 
constructive advice always helped me to make progress. The completion of this 
thesis would not have been possible without his guidance and feedback.  
He also kindly provided the samples from the rodent Cyp1a1mRen2 diabetic 
nephropathy model. 
Profound thanks to my second supervisor, Prof Jeremy Hughes, for his guidance, 
suggestions and active involvement during the whole project despite his professional 
commitments. 
I want to thank all the members of the Phagocytosis group within the Centre for 
Inflammation Research for their support and advice. I really enjoyed the productive 
atmosphere in the group. I am deeply indebted to Carolynn Cairns for teaching me 
new laboratory techniques with an invaluable experienced guidance. 
I am grateful to Spike Clay and Gary Borthwick for their help with the in vivo 
studies and to the team from the Histology Department for the processing of 
histological specimens.   
Dr. Andrew Cronshaw has to be thankfully credited for patiently introducing me into 
the field of peptidomic analysis and for his assistance with the measurement of 
samples. The data analysis was supported by Dr. Jonathan Manning, who 
programmed an R-implementation for MaxQuant data and Douglas Lamont who 
helped me using Progenesis QI in the Proteomics Facility, University of Dundee. 
12 
Profound thanks to Professor Jackie Price for allowing me to work with the urinary 
specimens from the Edinburgh Type 2 Diabetes study. I also benefited from 
Professor Price’s and Sara Jenks’ advice on epidemiological issues. 
I thank all participants of the RDS study for consenting to provide blood and urine 
samples. I am also thankful to all staff members from the Renal Diabetes and Renal 
Medicine Clinics of the Royal Infirmary of Edinburgh, who supported me during the 
recruitment and sample collection process. 
My sincere thanks go to Dr. Margaret Paterson, Dr. Wilna Oosthuyzen and Dr. John 
Pound for helping me using the NanoSight LM10 and the Attune Flow Cytometer. 
Without their profound explanations and patient advice my work on these 
instruments would not have been possible.  




ORAL PRESENTATIONS AND PUBLICATIONS 
Oral Presentations 
i. Boris Betz, Sara J. Jenks, Andrew D Cronshaw, Douglas J. Lamont, Carolynn 
Cairns, Jonathan R. Manning, John J. Mullins, Jeremy Hughes, Stella 
McLachlan, Mark W.J. Strachan, Jackie F. Price, Bryan R. Conway (2015) 
Urinary peptidomics in a rodent model of diabetic nephropathy 
highlightsepidermal growth factor as a biomarker for renal deterioration in 
patients with type 2 diabetes. Meeting 2015, The Scottish Renal Association, 
Dundee, UK 
ii. Boris Betz, Wilna Oosthuyzen, John Pound, James Dear, Jeremy Hughes, Bryan 
Conway. (2014) Profiling urinary exosomes in patients with Diabetes mellitus 
type 2 using the novel Nanosight Tracking Analysis (NTA) technique. 
Autumn meeting 2014, The Scottish Renal Association, Edinburgh, UK 
iii. Bryan R. Conway, Boris Betz, Tara A. Sheldrake, Jonathan R. Manning, Donald 
R. Dunbar, Jeremy Hughes, John J. Mullins (2013) Identifying mechanisms 
that promote injury and repair in diabetic kidney disease using a novel 
rodent model. Meeting 2013, European Diabetic Nephropathy Study Group, 
Barcelona, Spain 
Publications  
i. Conway B. R., Betz B., Sheldrake T. A., Manning J. R., Dunbar D. R., Dobyns 
A., Hughes J., Mullins J. J. (2014). Tight blood glycaemic and blood pressure 
control in experimental diabetic nephropathy reduces extracellular matrix 
production without regression of fibrosis. Nephrology (Carlton) 19 (12): 802-
813. 
ii. Betz B. B., Jenks, S. J., Cronshaw A. D., Lamont D. J., Cairns C., Manning J.R., 
Goddard J., Webb D. J., Mullins J. J., Hughes J., McLachlan, S., Strachan, M. 
W., Price, J. F., Conway, B. R. (2016) Urinary peptidomics in a rodent model 
of diabetic nephropathy highlights epidermal growth factor as a biomarker 
for renal deterioration in patients with type 2 diabetes. Kidney Int 89(5): 
1125-1135. 
iii. Betz, B. and B. R. Conway (2014).  Recent advances in animal models of 
diabetic nephropathy. Nephron Exp Nephrol 126(4): 191-195. 
iv. Betz, B. and B. R. Conway (2016). An Update on the Use of Animal Models in 




TABLE OF CONTENT 
1. Introduction ....................................................................................................... 29 
1.1 Diabetic nephropathy ................................................................................ 29 
1.1.1 Definition and Epidemiology ........................................................ 29 
1.1.2 Pathophysiology ............................................................................ 31 
1.1.3 Prognosis and treatment ................................................................. 39 
1.1.4 Biomarkers ..................................................................................... 41 
1.2 Rodent models of diabetic nephropathy .................................................... 45 
1.2.1 Overview ....................................................................................... 45 
1.2.2 The Cyp1a1mRen2 model ............................................................. 48 
1.2.3 Models of regression ..................................................................... 52 
1.3 Integrative Biology in Diabetic Nephropathy ........................................... 55 
1.3.1 Transcriptomic profiling ................................................................ 56 
1.3.2 Proteomics & Peptidomics ............................................................ 58 
1.4 Extracellular vesicles ................................................................................. 61 
1.4.1 Definition ....................................................................................... 61 
1.4.2 Measurement ................................................................................. 62 
1.4.3 Extracellular vesicles in Chronic Kidney Disease ......................... 64 
1.5 Objectives .................................................................................................. 66 
2. Materials and Methods ..................................................................................... 67 
2.1 Animal models .......................................................................................... 67 
2.2 Immunohistochemistry (IHC) and Immunofluorescence .......................... 68 
2.3 Homogenization of tissue samples ............................................................ 72 
2.4 rt-PCR ........................................................................................................ 73 
2.5 Western-Blot analysis ................................................................................ 75 
2.6 Gelatinase and Collagenase activity assay kits ......................................... 76 
2.7 Zymography .............................................................................................. 77 
2.8 Enzyme-linked immunosorbent assay (ELISA) ........................................ 79 
2.9 Measurement of urinary peptidomics ........................................................ 80 
2.10 Data analyses ............................................................................................. 84 
2.11 The RDS and the ET2D study ................................................................... 90 
16 
2.12 Nanopatricle Tracking Analysis (NTA) .................................................... 92 
2.13 Flow Cytometry (FCM) ............................................................................. 97 
3. Results .............................................................................................................. 101 
3.1 The Cyp1a1mRen2 Rat Model of Diabetic Nephropathy ....................... 101 
3.1.1 Introduction .................................................................................. 101 
3.1.2 Pathological parameters of the reversal model ............................ 101 
3.1.3 Genes upregulated specifically during injury phase .................... 105 
3.1.4 Genes upregulated during the injury and reversal phase ............. 110 
3.1.5 Regulation of factors for extracellular matrix degradation .......... 115 
3.1.6 In situ zymography in a reversed UUO model ............................ 120 
3.1.7 Discussion .................................................................................... 129 
3.1.8 Summary ...................................................................................... 141 
3.2 Urinary peptidomics ................................................................................ 145 
3.2.1 Introduction .................................................................................. 145 
3.2.2 Peptidomics in rat urine ............................................................... 145 
3.2.3 Characterisation of the urinary peptidome in the reversal DM+HTN 
model ............................................................................................ 148 
3.2.4 Urinary peptides in patients with diabetic nephropathy and healthy 
controls ......................................................................................... 160 
3.2.5 Urinary peptidomic analysis in the DN model with Progenesis QI
 ...................................................................................................... 164 
3.2.6 Validation of peptide regulation for the protein Epidermal Growth 
Factor ........................................................................................... 171 
3.2.7 Discussion .................................................................................... 175 
3.2.8 Summary ...................................................................................... 189 
3.3 Urinary Biomarkers ................................................................................. 191 
3.3.1 Introduction .................................................................................. 191 
3.3.2 Biomarker candidates for translational validation ....................... 191 
3.3.3 OPN and MMP7 in ET2D trial cohorts ....................................... 193 
3.3.4 uEGF in the ET2D study .............................................................. 197 
3.3.5 The ET2D subgroup of participants without “obvious renal 
damage” ....................................................................................... 203 
17 
3.3.6 Association of urinary EGF, KIM-1 and Gpnmb with renal 
endpoints ...................................................................................... 205 
3.3.7 uEGF and risk prediction models ................................................ 212 
3.3.8 Discussion .................................................................................... 217 
3.3.9 Summary ...................................................................................... 227 
3.4 Urinary Extracellular Vesicles ................................................................ 229 
3.4.1 Introduction ................................................................................. 229 
3.4.2 Assessing conditions for measurement of urinary exosomes 
concentration ............................................................................... 232 
3.4.3 Urinary exosome concentrations in the DM+HTN rat model ..... 236 
3.4.4 Urinary exosome concentrations in the RDS study ..................... 238 
3.4.5 Total urinary exosomes concentration in a subset of the ET2D 
study ............................................................................................. 244 
3.4.6 Protocol for the measurement of microvesicles .......................... 248 
3.4.7 BodipyMaleimide positive particles in the DM+HTN rat model 254 
3.4.8 BoM and podocalyxin positive particles in a subset of the RDS 
study ............................................................................................. 256 
3.4.9 Discussion .................................................................................... 258 
3.4.10 Summary ...................................................................................... 267 
4. General Summary and Future Work ............................................................ 269 
4.1 Summary ................................................................................................. 269 
4.2 Limitations and Future Work .................................................................. 273 
4.3 Concluding remark .................................................................................. 281 
5. References ........................................................................................................ 283 
6. Appendices ....................................................................................................... 301 






Abbreviation Full name 
ACE-I angiotensin converting enzyme inhibitors 
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ANG angiotensin 
ARB Angiotensin II receptor blockers 
BoM Bodipy-Maleimide 
BSA bovine serum albumin 
CE-MS capillary electrophoresis mass spectrometry 
CI confidence interval 
CKD chronic kidney disease 
CVD cardiovascular disease 
CysC Cystatin C 
DKD diabetic kidney disease 
DM Diabetes mellitus 
DN diabetic nephropathy 
ECM extracellular matrix 
eGFR estimated glomerular filtration rate 
ELISA Enzyme-linked immunosorbent assay 
ESRD end-stage renal disease 
ET2D study Edinburgh Type 2 Diabetes study 
EV extracellular vesicles 
FCM flow cytometer 
HTN hypertension 
IFN interferon 
IQR interquartil range 
LC-MS/MS liquid chromatography tandem mass spectrometry 
LDL low-density lipoprotein 
MALDI-TOF Matrix-assisted laser desorption/ionization time of flight 
mM Milli molar 




NF-κB Nuclear factor kappa-light-chain-enhancer of activated B cells 
20 
NO nitric oxide 
NO Nitric oxide 
NTA nanoparticle tracking analysis 
OPN osteopontin 
PAS periodic acid-Schiff 
PBS Phosphate-buffered saline 
QC quality control 
Qdot quantum dot 
RAGE receptors for glycolation end-products 
ROS reactive oxygen species 
ROS Reactive oxygen species 
RT room temperature 
rt reverse transcription 
SD standard deviation 
SEM standard deviation of the mean 
SOP standard operating procedure 
STZ streptozotocin 
T1D type 1 diabetes 
T2D type 2 diabetes 
TFA trifluoroacetic acid 
TIMP tissue inhibitor of metalloproteinases 
TNF-α Tumor necrosis factor- α 
uEGF:Cr urinary epidermal growth factor to creatinine ratio 
ZDF Zucker diabetic fatty 
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1.1 Diabetic nephropathy 
1.1.1 Definition and Epidemiology 
Epidemiology of Diabetes Mellitus and Diabetic Nephropathy 
According to the International Diabetes Federation (IDF) the worldwide prevalence 
of diabetes is 8.8% which will rise to 10.5% in 2040, meaning that by then 640 
million adult individuals will suffer from diabetes. In 2015, 14.5% of overall-
mortality was diabetes related and 700 billion dollars (approximately 12% of the 
health care budget) was spent on the treatment of diabetes and its complications 
(source: www.idf.org). These dramatic numbers are largely caused by diabetes 
related end-organ complications such as cardiovascular disease or diabetic 
nephropathy (DN). In fact, 50% of patients with type 2 diabetes (T2D) have evidence 
of diabetes-related renal impairment(Parving, Lewis et al. 2006). This is in line with 
the UK Prospective Diabetes Study (UKPDS) in which 50% of participants 
developed renal impairment over 15 years with 29% experiencing incident CKD III 
(eGFR <60ml/min/1.73m
2
)(Retnakaran, Cull et al. 2006). Regarding type 1 diabetes 
(T1D), the cumulative incidence over 30 years of developing renal impairment was 
up to 25%; of note, with intensified treatment (i.e. tight control of blood glucose and 
blood pressure levels) this rate declined markedly (Diabetes, Complications 
Trial/Epidemiology of Diabetes et al. 2009). 
Among patients with T2D the prevalence of DN is much higher for certain ethnicities 
e.g. African American(Thomas, Cooper et al. 2016). In addition, many single 
nucleotide polymorphisms (SNPs) and chromosomal rearrangements have been 
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associated with altered risk of DN (Review by Conserva et al.) (Conserva, Gesualdo 
et al. 2016). Other factors linked with a higher risk of DN are obesity, smoking, 
anaemia, duration of diabetes, poor glycaemic control, advanced age and systemic 
hypertension(Macisaac, Ekinci et al. 2014, Thomas, Cooper et al. 2016). 
Definition and Pathology 
Both type 1 and type 2 diabetes cause renal end-organ damage and DN is defined by 
both clinical and pathological features. There are no pathognomonic lesions for DN 
though a typical histological constellation of lesions exists: glomerular lesions 
include basement membrane thickening, different levels of mesangial expansion and 
nodular to advanced glomerulosclerosis. Additionally tubular atrophy and interstitial 
fibrosis and inflammation, arteriolar hyalinosis and large vessel arteriosclerosis can 
be observed (Figure 1). The presence of these criteria can be used to indicate 
different disease stages that have been defined recently in a consensus conference 
(Tervaert, Mooyaart et al. 2010). 
Clinically, albuminuria and a decline in renal function, as indicated by reduced 
glomerular filtration rate (GFR), are typical but not specific features of DN. While 
moderately increased albuminuria (2.5 mg/mmol [males], 3.5 mg/mmol [females] – 
30 mg/mmol creatinine) is an important risk factor for the development of DN, 
severely increased albuminuria (>30 mg/mmol creatinine) and/or GFR below 
60ml/min/1.73m
2 
are the defining thresholds for overt diabetic nephropathy(Tuttle, 
Bakris et al. 2014), though not all patients with DN develop albuminuria at an early 
stage of the disease.  
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Figure 1: Renal Pathology in Diabetic Kidney Disease 
 
Figure 1 demonstrates the histology of a normal kidney and the pathological changes in the 
glomerulus and tubules. Also shown are two photos of a glomerulus from renal biopsy tissue 
from a healthy control and a patient with DKD (PAS stain). Original magnification, ×400. 
DKD, Diabetic kidney disease. Figure taken from Reidy et al (Reidy, Kang et al. 2014). 
1.1.2 Pathophysiology  
There is not a single pathophysiological pathway in DN but multiple mechanisms 
that interact with each other in a complex way. Only some of the arguably most 
important disease mechanisms that are also relevant for this work will be mentioned. 
At an early stage high blood glucose causes glycosuria which together with 
glomerular hyperfiltration and hypertension result in renal enlargement characterized 
by tubular hypertrophy and hyperplasia. These factors also cause shear stress that 
activates intracellular pro-fibrotic pathways and contributes to glomerular basement 
membrane thickening and glomerulosclerosis.  
Hyperglycaemia stimulates cellular matrix (ECM) expansion through both increased 
production of ECM and by inhibiting ECM degradation. Glycosylation of circulating 
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free amino acids produces advanced glycosylation end products (AGE) that bind to 
the cellular receptors for AGE (RAGE) to activate intracellular pro-fibrotic 
pathways. Hyperglycaemia also directly increases the intracellular glucose level 
(Heilig, Concepcion et al. 1995) which activates the polyol and protein kinase C 
(PKC) pathways and leads to the formation of intracellular AGEs. Non-enzymatic 
glycosylation of matrix proteins results in the development of cross-links that inhibit 
matrix degradation.  
The endocrine vasoactive renin-angiotensin-aldosterone system plays an important 
role in the pathogenesis of intrarenal and systemic hypertension through the loss of 
autoregulation. Additionally, AT-II receptors might directly activate intracellular 
metabolic and pro-fibrotic pathways (Nagai, Yao et al. 2005).   
The innate immune system has recently been reported to be involved in the 
pathogenesis of DN. For example, the complement cascade has been demonstrated to 
contribute to renal damage in a rodent model and increased expression and 
deposition of complement was detected in biopsies from patients with DN (Wada 
and Makino 2013, Wada and Nangaku 2013). 
Endothelial deficiency of NO production is one of the key players in endothelial 
dysfunction. Effective endothelial NO synthase (eNOS) activity is diminished by 
reduced expression of the eNOS gene, post-translational modification of the protein 
or uncoupling leading to the production of superoxide anions and reactive oxygen 
species (ROS) instead of NO. Endothelial dysfunction might also cause dyslipidemia 
through impaired function of the enzyme lipoprotein lipase which in turn together 
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with increased ox-LDL levels is associated with local inflammation and macrophage 
infiltration.  
Inflammation 
As already indicated above, the metabolic, glycosylation and renin-angiotensin 
pathways are not separated from each other but might interact to promote 
progression of DN (Figure 2). For example, it is hypothesized that the cross-talking 
triangle between reactive oxygen species (ROS), protein kinase C and intracellular 
AGE can be maintained in an active state by any of the three aforementioned 
pathways (Kanwar, Sun et al. 2011). The activated triangle increases the expression 
of intracellular transcription factors such as nuclear factor kappa B (NF-B) that in 
turn promote the process of inflammation.  
Up-regulated transcription factors induce the production of cytokines. Cytokines 
contribute to inflammation via cell activation mediated by multiple pathways 
including the JAK/STAT pathway. The cytokines interleukin (IL)-1, -6, -10, -18 and 
TNF- are increased in animal models and in renal biopsies from patients with DN. 
Cytokines are released by renal cells (endothelial, tubular, mesangial cells, and 
podocytes) but also by macrophages and T-cells that migrate into the kidney. While 
TNF- is secreted by broadly pro-inflammatory Th1 cells, the increased expression 
of the modulatory IL-10 might point towards the presence of Th2 or regulatory T- 
cells (Treg), indicating an anti-inflammatory potential, but further studies are needed 
to investigate the role of T-cells in DN(Wada and Makino 2013). 
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Figure 2: Pathophysiological pathways in Diabetic Nephropathy 
 
Figure 2. One common downstream pathway for three main pathologic factors for diabetic 
nephropathy. The figure highlights the hypothetical crosstalk between advanced glycation 
end products, hyperglycemia/metabolic changes and the renin-angiotensin II (Ang-II) system 
via protein kinase C (PKC), ROS (reactive oxygen species) and AGE and oxidative stress. 
AT1, Ang II receptor; GLUT, glucose transporter; RNS, reactive nitrogen species. Figure is 
shortened and taken from Kanwar et al.(Kanwar, Sun et al. 2011) 
The presence of macrophages is a characteristic feature of DN in animal models and 
in human biopsies (Tesch 2010). After infiltration into renal tissue they may be 
polarised differently according to microenvironmental stimuli. Classically activated 
macrophages (M1) react to cellular injury and respond to cytokines such as IFN-
and damage-associated molecular pattern molecules. They promote the 
inflammatory reaction by secreting chemokines, cytokines such as tumour necrosis 
factor-α (TNF-α), and reactive oxygen species (ROS) and recruit pro-inflammatory 
Th1 cells. M1 macrophages express a characteristic subset of markers such as MHC 
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Class 2 and inducible nitric oxide synthase (iNOS). M2 macrophages are 
“alternatively” activated by interleukins such as IL-4 or IL-13. They are 
immunoregulatory, secreting IL-10 and recruiting Th2 and Treg cells. Specific M2 
markers are arginase-1 and mannose receptor(Braga, Agudelo et al. 2015) 
expression. M2 macrophages dampen the inflammatory process and are involved in 
the regulation of fibrosis process, what will be discussed below. 
The expression of chemokines and adhesion molecules is pivotal for the migration of 
immune cells into the kidney. Expression of CCL2 and CXCL12 is increased in 
murine DN models and the glomerular up-regulation of CXCR13 has been 
demonstrated in STZ-induced diabetic rat kidneys (Kikuchi, Ikee et al. 2004). 
Osteopontin  (OPN), another chemotactant molecule is overexpressed in renal tissue 
from rodent DN models and patients with DN (Kelly, Wilkinson-Berka et al. 2002, 
Li, Yang et al. 2003, Lorenzen, Shah et al. 2008, Nicholas, Liu et al. 2010, 
Woroniecka, Park et al. 2011). OPN seems to be a key player in macrophage and T-
cell recruitment (Kelly, Wilkinson-Berka et al. 2002) and activation but also directly 
activates ECM related pathways in renal cells(Nicholas, Liu et al. 2010) and 
influences podocyte signalling and motility(Lorenzen, Shah et al. 2008). OPN 
deficient mice were protected against renal damage in a DN model(Lorenzen, Shah 
et al. 2008, Nicholas, Liu et al. 2010).  
Fibrosis 
Glomerulosclerosis and tubulointerstitial fibrosis represent the common final 
pathway of inflammation as well as other injurious mechanisms in DN. Fibrosis 
causes the disruption of cellular architecture, cellular damage and loss. Clinically, 
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fibrosis is associated with renal functional impairment and albuminuria. In general, 
fibrosis is triggered by tissue damage, for example due to inflammation, and part of 
the subsequent healing response aimed at repairing wounds and replacing damaged 
cells. However, very severe and/or prolonged injurious stimuli are likely to cause an 
excessive response resulting in tissue scarring. Histologically, fibrosis is an 
intercellular accumulation of ECM proteins consisting of mainly collagens (I and IV 
in the glomerulus, I and III in the tubulointerstitium) and fibronectin but also elastin, 
laminin, proteoglycans and non-collagenous glycoproteins. All these ECM proteins 
are mainly produced by myofibroblasts that also generate contractility by expressing 
smooth muscle proteins, namely the characteristic -smooth muscle actin. In the 
glomerulus, myofibroblasts arise from in situ mesangial cells. In the 
tubulointerstitium several sources of myofibroblasts are discussed (Conway and 
Hughes 2012).  
The first potential source for myofibroblasts is the recruitment of circulating 
fibrocytes. However, the importance of that pathway has been questioned at least in 
models of fibrosis caused by ureteral obstruction (Lin, Kisseleva et al. 2008). The 
second source is the epithelium to mesenchymal transition (EMT) as tubular 
epithelial cells transform into myofibroblasts and migrate into the interstitium. 
Recent lineage tracking studies have cast doubt on this pathway as a major 
contributor to myofibroblast accumulation and stress the importance of pericytes. 
(Kriz, Kaissling et al. 2011) (Humphreys, Lin et al. 2010). Pericytes are perivascular 
cells that are in close association with endothelial cells but may detach from the 
microvasculature and infiltrate the tubulointerstitium where they adopt a fibroblastic 
phenotype. As a side effect of pericyte detachment the denuded capillary vessels are 
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deprived of pericyte support and may perish which may result in microvascular loss 
and the promotion of further tissue damage secondary to hypoxia and ischaemia. 





) and may also play a role in fibrosis. All these processes are induced by 
cytokines with transforming growth factor- (TGF- being involved in most of 
them.  TGF- is secreted by alternatively activated (M2) macrophages and 
accumulation of myofibroblasts is associated with the presence of macrophages 
(Brosius 2008, Tesch 2010). Studies in regression of liver fibrosis suggest that a 
subset of “reparative” M2 macrophages is also a key player for resolution of 
fibrosis(Duffield, Forbes et al. 2005). These macrophages have not yet been fully 
characterized, but they seem to have markers of phagocytosis and lysosomal 
processing like Glycoprotein (transmembrane) nmb (Gpnmb)(Li, Castano et al. 2010, 
Ramachandran, Pellicoro et al. 2012). They might mediate ECM degradation by 
secretion of the matrix-metalloproteinases (Fallowfield, Mizuno et al. 2007). 
Expansion of fibrosis is characterized by accumulation of ECM that results from an 
imbalance between ECM production by myofibroblasts and degradation of ECM by 
metalloproteinases (MMPs) and other proteases. The proteolytic activity of MMPs is 
zinc-dependent and a Zinc
++
-binding site is a structurally common feature of all 
MMPs. MMPs can be categorised by their substrate specificity: collagenases 
(MMP1,8,13 & 18), gelatinases (MMP2 & 9), stromelysins (MMP3,10 & 11), 
matrilysins (MMP7 & 26), membrane-type matrix metalloproteinases (MT-MMP14-
17, 24-25) and other MMPs (MMP12, 19-21, 23, 27 & 28) (Xu, Xiao et al. 2014). 
Except for MT-MMPs all MMPs are secreted into the extracellular space. While it is 
generally accepted that dysregulation of MMP expression and activity contributes to 
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progression of fibrosis in DN the exact mechanism and the role of individual MMPs 
remains unclear. The expression of MMPs is influenced by factors like NF-B, TGF-
ROS or the ERK1/2 MAPK pathway that are activated by hyperglycaemia and 
AGEs. The activity of MMPs is controlled by the blocking glycoproteins tissue-
inhibitors of MMPs (TIMPs). There are discrepant reports about MMP tissue 
expression in patients with DN (e.g. MMP2) (Xu, Xiao et al. 2014). Also, MMP 
expression and function in rodent DN models seems to be different from human 
DN(Xu, Xiao et al. 2014). Of note, many of the animal DN models in which the 
MMP/TIMP pathways have been studied are related to an early stage of human DN. 
The failure to recapitulate advanced human DN might be one reason that prevents 
animal models from accurately reflecting the mechanisms of MMP/TIMP regulation 
in human diabetic kidney. 
Systemic Hypertension and DN 
While the pivotal role of intraglomerular hypertension and the renin-angiotensin 
system has been described before, an astonishing “experiment of nature” has 
demonstrated that systemic hypertension is not simply a consequence of renal failure 
but a prerequisite for the development and progression of renal DN(Berkman and 
Rifkin 1973, Beroniade, Lefebvre et al. 1987): In two patients with type 1 diabetes 
and systemic hypertension due to unilateral renal artery stenosis, the typical 
pathologic lesions of DN only developed in the kidney contralateral to the artery 
stenosis. The suggestion is that the renal artery stenosis protected the kidney from 
hypertension and the subsequent development of typical DN lesions (Figure 3).  
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The important role of systemic hypertension is also supported by the fact that subtle 
disturbances of physiological blood pressure regulation such as nocturnal “non-
dipping” precedes the development of albuminuria and loss in eGFR in patients with 
diabetes(Lurbe, Redon et al. 2002, Agarwal and Andersen 2006). Furthermore only 
the combination of glycaemic and blood pressure control can effectively slow disease 
progression(Mogensen 1998) or even reverse albuminuria(Perkins, Ficociello et al. 
2003) as described in the next paragraph. 
Figure 3: An astonishing "experiment of nature" 
 
Figure 3. Schematic illustration of two exceptional case reports by Berkman et al. (Berkman 
and Rifkin 1973) and Beroniade et al. (Beroniade, Lefebvre et al. 1987). The unilateral renal 
artery stenosis protects the kidney from hypertension and preserves a normal glomerular 
architecture while diabetic glomerulosclerosis developed in the contralateral kidney (the 
arrowhead marks a nodular sclerotic [Kimmelstiel-Wilson] lesion). Two images of a 
glomerulus x400 PAS stain.  
1.1.3 Prognosis and treatment  
Treatment of DN 
The major therapeutic goal is the prevention of DN. Lifestyle changes and stringent 
glycaemic control can avoid the progression from impaired glucose tolerance to T2D 
or from T2D without related complications to end-organ damage such as 
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DN(Molitch, Adler et al. 2015).  Hallmarks in the therapy of DN include glycaemic, 
lipid and blood pressure control. For those with albuminuria, an ACE-I or an ARB is 
recommended, as the renin-angiotensin system also activates pathological pathways 
independent from hypertension (Molitch, Adler et al. 2015). There is some 
controversy about the target blood pressure. While the ADA (American Diabetes 
Association) has recently eased the target of systolic blood pressure to 
140mmHg(American Diabetes 2016), the  Kidney Disease Improving Global 
Outcomes guideline maintains the target systolic blood pressure of <130 mmHg for 
patients with moderate to severe albuminuria(KDIGO 2013). Though early results of 
the SPRINTtrial seemed to support the aim of strict blood pressure targets for the 
general population, the evidence level in DN is scarce and the aim is clinically hard 
to achieve(Tuttle, Bakris et al. 2014, Molitch, Adler et al. 2015).  Only limited 
information about this controversy can be gained from experimental medicine as 
most animal DN models are normotensive.  
Regression of DN 
It has been thought for a long time that once renal damage is established in patients 
with diabetes mellitus this inevitably progresses to ESRD(Mogensen, Osterby et al. 
1979). However this view has changed. With optimal control of blood glucose and 
blood pressure albuminuria can regress in almost half of patients with T2D(Perkins, 
Ficociello et al. 2003). Fioretto et al. demonstrated eventual regression of the typical 
histologic kidney lesions with restoration of almost normal glomerular structure and 
a marked reduction of collagen deposition in the tubulointerstitium in patients with 
T1D and moderate DN who underwent successful pancreas transplantation(Fioretto, 
Steffes et al. 1998, Fioretto, Sutherland et al. 2006). This regression however was 
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only visible 10 years after the transplant during which time period patients had been 
normoglycaemic and normotensive. The pathways underpinning such regression of 
DN remain poorly understood, at least in part for two reasons: first, there is no 
medical indication for serial biopsies in DN patients who respond to treatment; 
second, there are hardly any DN animal studies in which functional and histological 
regression upon intervention has been studied(Betz and Conway 2016).  
Progression of DN to ESRD 
A stringent therapeutic regime can delay the progression of DN and result in only a 
small percentage of patients developing ESRD. For example, less than 8% of patients 
developed ESRD over ten years in the STENO trial(Andresdottir, Jensen et al. 2014) 
and less than 1% in the intensive treatment group of the DCCT/EDIC trial(Diabetes, 
Complications Trial/Epidemiology of Diabetes et al. 2009). However, due to the high 
prevalence of diabetes mellitus, DN accounts for approximately 33% of all patients 
worldwide initiating RRT; in the USA, the rate exceeds 50%(Thomas, Cooper et al. 
2016). According to the US renal data system (www.usrds.org), $30.9 billion had 
been spent on dialysis treatment in 2015 and the 5-year survival for patients with 
diabetes and ESRD is 42%. These figures underline the urgency to identify diabetic 
patients at risk of renal deterioration in order to optimize their therapeutic regime and 
prevent or delay further progression.  
1.1.4 Biomarkers 
Endpoints 
End-stage renal disease (ESRD) as defined by an eGFR < 15ml/min/1.73m
2
, the 
initiation of chronic renal replacement therapy or kidney transplantation are the most 
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relevant clinical renal endpoints in studies(Nguyen, Tarnow et al. 2008, Niewczas, 
Gohda et al. 2012). However, given the long-time course for these endpoints to 
develop, interventional studies in DN patients would take many years in order to 
achieve sufficient outcome numbers. Surrogate endpoints are therefore needed that 
are robustly associated with an increased risk of developing ESRD. 
CKD III (eGFR < 60ml/min/1.73m
2
) is part of the clinical definition for DN and is 
associated with an increased risk of metabolic and endocrine complications, a higher 
rate of drug dosing errors and a higher rate of cardiovascular disease (CVD) or 
death(KDIGO 2013). Many studies use CKD III as a renal endpoint, often called 
incident CKD(Perkins, Ficociello et al. 2010, Kim, Song et al. 2013, Macisaac, 
Ekinci et al. 2014). However, the risk of developing this endpoint depends upon the 
baseline eGFR and therefore requires a relatively homogenous study population and 
appropriate statistical adjustment.  
The outcome “rapid progression of CKD” is characterized by a rapid and substantial 
loss of GFR. While the time for this loss in most studies is calculated/normalized per 
year of observation, there are discrepant definitions about the extent of GFR loss 
(Sheen and Sheu 2014). Some studies use an absolute number from 3 to 5 
ml/min/1.73m
2
/year(2013, Pena, Heinzel et al. 2015). Other studies calculate a 
relative loss of GFR per year ranging from 3.3% (Krolewski, Niewczas et al. 2014) 
to up to 20-30% (Ju, Nair et al. 2015, Looker, Colombo et al. 2015).  
Albuminuria 
Severe albuminuria (ACR>30mg/mmol) is an indicator for progression of CKD and 
increases the risk of ESRD, CVD, diabetes complications and death(Macisaac, 
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Ekinci et al. 2014, Molitch, Adler et al. 2015). However, not all diabetic patients 
with albuminuria develop DN and moderately increased albuminuria 
(“microalbuminuria”) can even be reversed(Perkins, Ficociello et al. 2003, Perkins, 
Ficociello et al. 2010). On the other hand, many patients with DN exhibit a rapid 
decline in eGFR without developing significant albuminuria. In large T2D cohorts  
(UKPDS, RIACE, NHANES) 30-60% of patients with an eGFR <60ml/min/1.73m
2
 
did not have more than mildly increased albuminuria(Thomas, Cooper et al. 2016). 
Therefore, novel biomarkers for loss of eGFR are needed, especially in patients in 
whom standard risk factors such as albuminuria or impaired renal function are 
absent. 
Alternative markers in diabetic nephropathy 
It would exceed the scope of this introduction section to discuss the complete myriad 
of markers that have been tested to predict the risk of developing DN or of 
progression of the disease. There are, however, two promising marker categories of 
special interest. 
As the inflammatory process is an early step in the development of DN these markers 
might precede albuminuria as an indicator of renal complications in diabetes. 
Transcription factors, cytokines and chemotactic factors are mediators of the 
inflammatory process. Indeed, serum concentrations of connective tissue growth 
factor (CTGF), soluble tumour-necrosis factor receptor (sTNFR) and osteopontin 
(OPN) are predictive for progressive renal function decline or ESRD in large cohorts 
of patients with T1D or T2D(Nguyen, Tarnow et al. 2008, Niewczas, Gohda et al. 
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2012, Gordin, Forsblom et al. 2014, Krolewski, Niewczas et al. 2014, Pena, Heinzel 
et al. 2015).  
Since albuminuria is rather a marker of glomerular dysfunction, tubular markers 
might be complementary as tubulointerstitial damage is the best pathological 
prognostic hallmark in human DN(Gilbert and Cooper 1999). Cystatin C (CysC) is a 
ubiquitously secreted cellular metabolic by-product and serum CysC is superior to 
creatinine for estimation of renal function(Macisaac, Ekinci et al. 2014, Molitch, 
Adler et al. 2015). CysC is freely filtrated in the glomerulus and completely 
reabsorbed in the tubules. Increased urinary CysC might indicate tubular damage and 
Kim et al. have demonstrated that urinary CysC levels predict progression of 
DN(Kim, Song et al. 2013). 
Renal expression and urinary secretion of kidney injury molecule 1 (KIM-1), 
neutrophil gelatinase-associated lipocalin (NGAL) and liver fatty acid binding 
protein (L-FABP) are increased in tubular damage. While two studies demonstrated a 
robust independent association between increased serum L-FABP and rapid renal 
deterioration and progression to ESRD in DKD(Kamijo-Ikemori, Sugaya et al. 2011, 
Araki, Haneda et al. 2013), another study examining L-FABP and studies assessing 
KIM-1 and NGAL had less convincing results(Conway, Manoharan et al. 2012, 
Nielsen, Reinhard et al. 2012, Chou, Lee et al. 2013, Mischak, Delles et al. 2015). 
The Edinburgh Type 2 Diabetes Cohort 
For clinical validation of biomarkers large cohorts of patients with diabetes are 
needed to achieve sufficient statistical power. These patients need to be followed for 
several years to assess long-term complications. Patients should be a homogenous 
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group regarding baseline clinical and epidemiological variables to reduce the 
influence of potential confounding factors. The Edinburgh Type 2 Diabetes Study 
comprises 1066 participants that have been demonstrated to be representative of 
elder men and women with type 2 diabetes in the Lothian area of Scotland, UK, and 
were followed for a period of four years. The study that will be further described in 
Materials and Methods section fulfils many of the mentioned requirements for 
biomarker validation studies. 
1.2 Rodent models of diabetic nephropathy 
1.2.1 Overview 
Although DN is a long-term complication of diabetes that progresses for several 
years, animal models that develop DN within weeks to months are necessary to 
effectively study pathological pathways and the consequences of interventions. Over 
several decades an abundant number of rodent DN models have been published. The 
Diabetes Complications Consortium (DiaComp) defined functional and histological 
criteria that characterize the ideal model which should have a high congruency with 
human disease (Table 1) (Brosius 2008).  
Remarkably, so far no rodent model meets all of the desired criteria. The inadequacy 
of current rodent DN models might be related inherently to the species employed or 
to the fact that pathophysiological pathways that are pivotal in human DN are not of 
importance in the models. 
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Table 1: Research criteria for validating progressive mice models of diabetic 
nephropathy according to the diabetes complications consortium 
(DiaComp).  
Function Greater than 50% decline in GFR over the lifetime of the animal 
Greater than 10-fold increase in albuminuria compared with controls for 
that strain at the same age and gender 
Histology advanced mesangial matrix expansion +/- nodular sclerosis and 
mesangiolysis 
any degree of arteriolar hyalinosis 
glomerular basement membrane thickening by 50% over baseline 
tubulointerstitial fibrosis 
Table 1. Table adapted from diacomp.org and Brosius et al.(Brosius, Alpers et al. 2009) 
Classical models and recent advances 
The mandatory pathological pathway in animal models is the presence of 
hyperglycemia. This can be achieved by administration of streptozotocin (STZ) that 
is cytotoxic to beta-cells of the pancreas. These models therefore reflect type 1 
diabetes characterized by the failure of insulin production. To imitate T2D, models 
such as the leptin deficient receptor db/db mice are utilized. These mice are 
hyperphagic and become obese, develop peripheral resistance to insulin, insufficient 
insulin production and consequently hyperglycemia(Qi, Fujita et al. 2005). However, 
as mentioned before, most of these models feature only the early histological and 
functional changes in DN (Figure 4). Of note the extent of histological and functional 
changes of DN depends on the mouse strain with DBA/2J mice and FVB mice much 
more prone to renal injury than C57BL/6J mice(Qi, Fujita et al. 2005, Betz and 
Conway 2016). These differences in strain susceptibility were capitalized on when 
the leptin deficient ob/ob mutation was crossed from C57BL/6J to the black and tan, 
brachyuric (BTBR) background(Hudkins, Pichaiwong et al. 2010). BTBR mice are 
naturally insulin resistant and in combination with the ob/ob mutation they develop 
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early hyperglycemia (six weeks of age) and their kidneys exhibit many histological 
and functional aspects of moderately advanced DN(Hudkins, Pichaiwong et al. 2010) 
in humans (Figure 4) and meet almost all criteria of the DiaComp (Table 1). 
However, these mice are difficult to breed and have a reduced life expectancy (high 
mortality after 24 weeks of age) which restricts the study of further progression in 
DN. 
Figure 4: Classical models of DN and recent advances 
 
Figure 4. Schematic illustration of differences between classical models of DN and recent 
advances. Increased histological damage and functional impairment is achieved by the 
change of background strain or addition of systemic hypertension. Figure slightly adapted 
from Betz et al.(Betz and Conway 2014) STZ=Streptozotocin; db/db  = leptin receptor 
mutation; ob/ob  = leptin deficiency; BTBR = black and tan, brachyuric, Cyp1a1mRen2  = 
transgenic rats with the murine renin cDNA inserted under an inducible promoter, eNOS = 
endothelial nitric oxide synthase. 
Another approach to increase the vulnerability of the kidney is to superimpose 
hypertension as hypertension seems to be a cornerstone in the development of human 
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DN(Berkman and Rifkin 1973, Beroniade, Lefebvre et al. 1987). Endothelial 
function is markedly compromised in db/db eNOS
-/- 
mice and beside hypertension 
these mice exhibit early onset albuminuria, decreased GFR, arteriolar hyalinosis, 
mesangial expansion, mesangiolysis, and nodular glomerulosclerosis(Zhao, Wang et 
al. 2006). However there is only minimal tubulointerstitial fibrosis which is of 
concern as it is a key prognostic hallmark in human DN(Gilbert and Cooper 1999).  
1.2.2 The Cyp1a1mRen2 model 
Hypertension can be induced in transgenic mRen2 rats by the constitutive expression 
of murine renin cDNA(Kelly, Wilkinson-Berka et al. 1998). The injection of STZ in 
these rats seems to initiate advanced DN however the utility of this model is limited 
by the malignant phase hypertension (Hartner, Cordasic et al. 2007). This difficulty 
is overcome in Cyp1a1mRen2 rats in which the renin expression is under control of 
an inducible promoter. Supplementation of the diet with indole-3-carbinol (I-3-C) 
activates a cytochrome P4501a1 promoter which induces expression of the murine 
Ren2 gene to produce renin-dependent hypertension(Kantachuvesiri, Fleming et al. 
2001). For the development of a DN model four experimental groups were (Conway, 
Rennie et al. 2012)studied: two groups (diabetes [DM] alone; diabetes and 
hypertension [DM+HTN]) were injected with a single dose of streptozotocin two 
weeks before the start of the experiment to induce diabetes mellitus. Two groups 
(HTN alone; DM+HTN) were fed with I-3-C to render them hypertensive. The 
control group remained untreated (Figure 5). 
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Figure 5: Experimental setting for the development of Cyp1a1mRen2 DN model 
 
Figure 5. Schematic illustration of the experimental setting for the development of the 
Cyp1a1mRen2 DN model(Conway, Rennie et al. 2012). The different experimental groups 
are colour coded with DM=diabetes, HTN=hypertension. 
During a period of 28 weeks animals developed severe hypertension, hyperglycaemia 
or both. Excretion of albumin in the urine (albuminuria) was slightly increased in the 
DM (14 -fold) or HTN (50-fold) groups. Interestingly, it was dramatically increased 
in the combinatorial DM+HTN group by more than 500 -fold in comparison to the 
control group. The increase was much higher than the albuminuria observed with 
DM and HTN alone supporting the hypothesis of the synergizing effects of diabetes 
and hypertension (Figure 6).  
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Figure 6. Serial blood glucose, systolic blood pressure and urinary albumin-to-creatinine 
(ACR) measurements during 28 weeks. The combination of hypertension and diabetes 
synergized to produce significantly more albuminuria than with DM or HTN alone.  Data 
given are means +/- SEM. *** p<0.001 vs control, ### p<0.001 vs diabetes alone, $ <p0.05 
vs hypertension alone. Figure adapted from Conway et al. (Conway, Rennie et al. 2012) 
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Figure 7. Representative images from periodic acid-Schiff staining (A) and picrosirius red 
staining (B) of the Cyp1a1mRen2 DN model. Glomeruli are highlighted in (A) with staining of 
the tubulointerstitium highlighted in (B). Only the combination of diabetes and hypertension 
promotes typical histological lesions. The arrowhead in (A) indicates a fibrin cap and the 
arrow in (B) highlights an area of tubulointerstitial fibrosis. Bars represent 25 M in (A) and 
50M in (B). Figure adapted from Conway et al. (Conway, Rennie et al. 2012) 
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Histologically, in the DM alone group there was very little fibrosis present in the 
glomerulus and tubulointerstitium, and a non-significant increase in the 
glomerulosclerosis index in the HTN alone group. Concurrent diabetes and 
hypertension significantly increased both glomerulosclerosis and tubulointerstitial 
fibrosis indices compared to all other groups (Figure 7). The latter is especially 
remarkable as most rodent models of DN lack this feature that is both typical of and 
important in human diabetic nephropathy (Betz and Conway 2014). 
 
1.2.3 Models of regression 
In patients with moderate DN as mentioned above, the state of normotension and 
normo-glycaemia achieved by pancreas transplantation can, albeit after ten years, 
result in the regression of renal functional and histological alterations caused by 
DN(Fioretto, Steffes et al. 1998). The underlying pathways are as yet poorly 
understood, and there are only a few models that have been employed to identify 
factors promoting regression.  
Pichaiwong et al. demonstrated that supplementation of leptin in a leptindeficient 
ob/ob BTBR mouse model induced normoglycaemia and regression of albuminuria 
and restoration of reduced GFR. Histologically, the extent of glomerulosclerosis and 
tubulointerstitial fibrosis decreased significantly (Pichaiwong, Hudkins et al. 2013). 
Reversibility of DN in the Cyp1a1mRen2 model 
In the Cyp1a1mRen2 DN model a reversal phase was created by normalizing blood 
pressure and controlling blood glucose levels for another 8 weeks (reversal phase) 
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after 28 weeks of hyperglycaemia and hypertension (injury phase) (Conway, Betz et 
al. 2014). This was achieved by increasing insulin therapy and stopping dietary 
supplementation with the Indole-3-Carbinol. Albuminuria decreased during reversal 
however it remained still significantly different from control (Figure 8).  







Figure 8. (A) Schematic illustration of the study design. (B) Blood glucose and (C) blood 
pressure are normalized during the eight week reversal phase while (C) albuminuria 
decreases but remains elevated compared to control. * p<0.05, ** p<0.01 vs peak injury. 
Data given are means +/- SEM. Figure adapted from Conway et al. (Conway, Betz et al. 
2014) 
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Figure 9. Representative images from (A) glomeruli and (B) tubulointerstitium of the 
Cyp1a1mRen2 DN model. The marked glomerulosclerosis (A, arrows) and tubulointerstitial 
fibrosis (B, arrows) remains unchanged after the reversal phase.  The arrow indicates (A) a 
fibrin cap and (B) tubulointerstitial fibrosis. Bars represent (A) 20 M and (B) 100M with (A) 
periodic acid-Schiff staining and (B) picrosirius red staining. Data for the (A) glomerular and 
(B) tubulointerstitial fibrosis index are given as +/- SEM, ** p<0.01 and *** p<0.001. Figure 
adapted from Conway et al. (Conway, Betz et al. 2014) 
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However, eight weeks of relative normoglycaemia and normotension did not have 
any effect on the glomerulosclerosis index nor on tubulointerstitial fibrosis (Figure 
9).  
To assess changes in the molecular profile of the kidney during the reversal phase, a 
microarray chip analysis was performed in the control group, in the “injury” group 
after 28 weeks of DM+HTN and in the reversal group. The interpretation and 
validation of the results will be part of this work. 
1.3  Integrative Biology in Diabetic Nephropathy 
In order to further advance an in-depth understanding of a complex disease like DN 
an integrative biology approach has been proposed (Harder, Hodgin et al. 2015) 
(Mischak, Delles et al. 2015). Integrative biology aims to characterize the interplay 
of the heterogeneous multitude of factors involved in pathophysiology and disease 
progression. This approach tries to integrate the field of clinical research comprising 
molecular, histological phenotyping as well as outcome studies, the field of disease 
modeling including animal models and the field of systems biology (Figure 10). The 
term “systems biology” can be defined as an unbiased hypothesis-free discovery-
based screening for disease related changes on different layers of the genome-
phenome continuum. These layers include genomics, epigenomics, transcriptomics, 
proteomics and metabolomics. Beside the deeper understanding of known disease 
pathways and the discovery of novel pathways, integrative biology might also help to 
identify characteristic biomarkers of the most relevant disease pathways that might 
indicate the risk of disease progression.  
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Figure 10: The concept of integrative biology of DKD 
 
Figure 10. The concept of integrative biology in DKD. The scheme illustrates the concept of 
integrative biology that combines systems biology tools (“-omics”) in model systems (animal, 
invitro studies) and in clinical research (outcomes, histology, molecular phenotyping) to 
analyze the complex pathophysiology of diabetic kidney disease (Harder, Hodgin et al. 
2015).  
1.3.1 Transcriptomic profiling 
Genetic profiling can be performed in whole kidney tissue homogenates or via laser-
capture technology of targeted areas (e.g. the glomeruli) in paraffin-fixed tissue 
sections (Lindenmeyer, Kretzler et al. 2007). Microarrays can analyse the expression 
of thousands of genes simultaneously, thereby drawing a very detailed molecular 
map of the kidney. There are now freely available online databases allowing 
researchers to compare their results with the molecular regulation from large disease 
cohorts. For diabetic nephropathy the database nephroseq (www.nephroseq.org) 
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comprises the transcriptomic results of several DN biopsy cohorts, such as 
Woroniecka et al. (Woroniecka, Park et al. 2011) and Ju et al. (Ju, Nair et al. 2015).  
Hodgin et al. compared the glomerular transcriptome of kidney biopsies from 
patients with early type 2 DN with three murine DN models: the DBA/2 mouse with 
STZ induced diabetes, the C57BLKS db/db and eNOS-deficient C57BLKS db/db 
mouse(Hodgin, Nair et al. 2013). The eNOS-knockout mouse model most closely 
resembled the gene expression changes observed in the kidneys of patients with DN. 
Interestingly, many novel potential pathophysiological pathways of DN identified in 
human disease were only detected in one of the animal models. This indicates that 
researchers must carefully choose their DN model according to their target pathway 
for investigation. 
The transcriptomic profiling in the Cyp1a1mRen2 DN model comprised the control, 
diabetes alone, HTN alone and the combination of diabetes and HTN groups (Figure 
5). Since the analysis was made from snap-frozen whole tissue kidney it mainly 
reflects molecular regulation of the tubulointerstitium as glomeruli only account for a 
small part of kidney mass(Conway, Rennie et al. 2012). The vast majority of genes 
significantly up-regulated or down-regulated compared to control were present 
exclusively in the combined diabetes+HTN group; indeed, there were only a few 
genes dysregulated in the diabetes alone group (Figure 11). Similar to functional and 
histological parameters, the molecular regulation confirms the synergistic effect of 
concurrent HTN and diabetes. Up-regulated genes were enriched in pathways of 
inflammation, the innate and adaptive immune system, complement cascade and the 
ECM network. From all dysregulated genes, about 40% were similarly altered in the 
tubulointerstitium of patients with DN according to the Nephroseq biopsy database 
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(www.nephroseq.org). The congruency between moderately advanced human DN 
and the Cyp1a1mRen2 DN model on a histological, functional and molecular level 
renders the model highly suitable to translationally investigate relevant pathways and 
their related markers. 
Figure 11: Patterns of renal gene expression changes in the Cyp1a1mRen2 DN model 
A B 
  
Figure 11. Venn diagrams demonstrate the number of genes (A) up-regulated or (B) 
downregulated more than 1.5-fold in the diabetes alone, HTN alone and combined diabetes 
& HTN groups in comparison with control animals at a corrected p<0.01. Figure adapted 
from Conway et al. (Conway, Rennie et al. 2012) 
1.3.2 Proteomics & Peptidomics 
Within the last decade there has been many reports published regarding the 
proteomics analysis of patients with diabetes mellitus for biomarker discovery 
(Mischak, Delles et al. 2015). In many of these studies urine was analyzed as it is 
easily accessible, relatively stable and pre-analytical preparation is less laborious 
than in blood. Finally, urine might be enriched with kidney specific components. In 
healthy persons almost 70% of urinary proteins originate from the kidney, therefore 
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some authors used the term “liquid kidney biopsy” (Klein, Bascands et al. 2016) 
(Pena, Mischak et al. 2016). 
Bhensdadia et al. identified several potential biomarkers by comparing the urinary 
proteomics of patients with T2D and rapidly declining renal function with patients 
with T2D and stable renal function(Bhensdadia, Hunt et al. 2013). They then confirm 
that haptoglobin indeed predicts rapid decline in renal function in a large cohort of 
patients with T2D. In a commentary on the study, Brosius highlights that haptoglobin 
gene expression is also increased in patients with T2D and nephropathy compared to 
controls (Brosius and Pennathur 2013). Schlatzer et al. performed urinary proteomic 
analysis in streptozotocin-induced diabetic rats with a very stringent data analysis 
approach. However, when the methodology was transferred to humans with T2D, 
none of the markers from the animal model was chosen for the creation of a 
biomarker panel that indicated decline in renal function in patients with 
T2D(Schlatzer, Maahs et al. 2012). 
Peptidomics focuses on the urinary peptide content, after removal of higher 
molecularweight proteins by filtration. Compared to proteomics, the analysis of 
peptidomics can be of pathophysiological advantage, for example, alterations in 
collagen fragments/peptides may indicate the (in)activity of metalloproteinases with 
specific cleavage sites(Maahs, Siwy et al. 2010) (Nkuipou-Kenfack, Bhat et al. 
2015). Due to their small size serum peptides might pass through a minimally 
damaged glomerular filtration barrier while intact serum protein do not and therefore 
they could represent the first marker of impaired glomerular function. Moreover, 
peptides are more resistant to cleavage in the bladder than proteins (Klein, Bascands 
et al. 2016). Finally, the complete removal of high-molecular weight proteins from 
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the sample reduces analysis time by MS compared to proteomics in large study 
cohorts.  
In 2009, Merchant et al. identified several peptide fragments that were altered in 
patients with T1D and early renal function decline compared to patients with stable 
renal function and they confirmed the increased expression of the parent proteins by 
immunohistochemistry on renal tissue sections from patients with T1D (Merchant, 
Perkins et al. 2009). Zurbig et al. demonstrate that a panel of 273 peptides (CKD273) 
can predict the development of DN in patients with T1 and T2D (Zurbig, Jerums et 
al. 2012). Recently, the CKD273 had been demonstrated to be independently 
associated with the risk for rapid decline in large cohort of CKD patients(Schanstra, 
Zurbig et al. 2015). The CKD273 panel comprises fragments from markers of renal 
pathophysiological processes such as clusterin, osteopontin and albumin; however 
the overwhelming majority (74%) of the peptides are collagen fragments. This 
underlines the importance of ECM expansion/turn-over in the development and 
progression of DN.  
An important issue to be addressed in the urinary peptidomic analysis is the daily 
fluctuation in urine volume that necessitates a normalization process. Furthermore, 
the approaches for sample preparation (e.g. use of trypsin), measurement (e.g. LC-
MS/MS vs CE-MS) and analysis (e.g. MaxQuant software vs MASCOTT) need to be 
standardised. The approach to these issues in the current work will be described in 
the Materials and Methods section and the comparison with different approaches 
from other studies will be mentioned in the discussion section. 
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1.4 Extracellular vesicles 
Although the involvement of extracellular vesicles (EV) in pathophysiological 
pathways and their potential role as biomarkers had been previously suggested 
(Pisitkun, Shen et al. 2004), the field has recently gained much interest in kidney 
research, not least due to advances in the technologies employed for EV detection.  
1.4.1 Definition 
Extracellular vesicles (EV) is a term used to summarize all forms of membrane-
bound vesicles. There is still no general consensus in the literature on 
nomenclature(Erdbrugger and Le 2016), however many authors categorize EVs into 
exosomes (20-100nm diameter), microvesicles (MV) (100-1000nm) and apoptotic 
bodies (>1000nm). Having been initially regarded to be “cell dust” it is now assumed 
that EVs play an important role in cell-to-cell communication (Burger, Schock et al. 
2013) and activation (Oosthuyzen, Scullion et al. 2016) or have antibacterial 
properties(Hiemstra, Charles et al. 2014).  Besides their size, EVs can be 
distinguished by their origin. The generation of exosomes starts with an invagination 
of the plasma membrane to form early endosomes, Intraluminal vesicles are formed 
within these endosomes by inward budding of the membrane. The resulting mature 
multivesicular bodies (MVB) are either degraded by merging with lysosomes or fuse 
with the plasma membrane thereby releasing exosomes into the extracellular space. 
Microvesicles, on the contrary, are formed by direct blebbing or outward budding 
from the plasma membrane (Figure 12). Both, exosomes and microvesicles carry 
surface markers of their parent cells with almost all microvesicles additionally 
expressing phosphatidylserine that is externalized during the generation 
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process(Thery, Ostrowski et al. 2009, Burger, Schock et al. 2013). Urinary exosomes 
contain proteins or mRNA species that are representative of all major segments of 
the nephron including: the glomerulus (eg. podocalyxin, nephrin), proximal (e.g. 
cubilin, aquaporin 1) and distal convoluted (e.g. sodium-chloride cotransporter) 
tubules, loop of Henle, and the collecting ducts (e.g. aquaporin 2) (Miranda, Bond et 
al. 2010, Salih, Zietse et al. 2014, Erdbrugger and Le 2016, Morrison, Bailey et al. 
2016). Additionally, it has been demonstrated that extracellular vesicles are released 
upon stimuli associated with inflammation, cell stress and injury such as 
lipopolysaccharide, reactive oxygen species, tumor necrosis factor-alpha but also by 
hyperglycaemia, and advanced glycosylation end-products (Burger, Schock et al. 
2013, Urbanelli, Magini et al. 2013, Salih, Zietse et al. 2014). As these factors are 
also involved in pathophysiological pathways of diabetic nephropathy (see above), 
the analysis of the urinary extracellular vesicle profile might present an attractive 
opportunity to detect and localize early cellular damage in DN. Alterations in the 
profile might even precede other markers like albuminuria. 
1.4.2 Measurement 
Standard methods for isolating exosomes from the urine require a large volume of 
urine (up to 200ml), are laborious (e.g. prolonged ultracentrifugation steps are 
required) and might affect sample quality as a loss of up to 40% of exosomes was 
suggested to occur during ultracentrifugation and purity was questioned for 
commercial EV precipitation approaches(Alvarez, Khosroheidari et al. 2012). 
Additional purification steps such as using a sucrose gradient result in a further 
reduction of the EV yield(Hogan, Johnson et al. 2014). 
63 







Figure 12. Transmission electron microscopy micrographs of cells A) releasing exosomes by 
the merging of a multivesicular body (MVB, arrow) that is packed with exosomes and the 
cellular membrane, B) releasing microvesicles by direct outward budding (arrows).  
Micrographs taken from Edgar(Edgar 2016) and Giusti et al. (Giusti, D'Ascenzo et al. 2013). 
C) Schematic illustration of nanoparticle tracking analysis (NTA). The light scattered from the 
particles is recorded by a digital camera and using the Stokes-Einstein equation particle size 
can be calculated. Picture taken from www.malvern.com 
Immunoaffinity precipitation methods utilizing magnetic beads are restricted to 
exosomes that express the chosen surface marker(Kowal, Tkach et al. 2014). 
Therefore analysis of exosomes by current methods is unlikely to be readily 
translated into the clinic (Miranda, Bond et al. 2010, Dear 2014, Erdbrugger and Le 
2016). A novel technology, nanoparticle tracking analysis (NTA) enables rapid and 
robust quantification of urinary exosomes(Dragovic, Gardiner et al. 2011, 
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Oosthuyzen, Sime et al. 2013). NTA is based on the principle that at a given 
temperature, the rate of Brownian motion of nanoparticles in solution is determined 
solely by their size as expressed in the Stokes-Einstein equation. In this method, laser 
light is directed at a fixed angle to particles in suspension, and the scattered light is 
captured using a microscope coupled with a high-sensitivity camera. By tracking the 
movement of individual particles over time, the software calculates their 
concentration and size (Figure 12). By incubating the sample with a fluorescently 
labelled antibody against an antigen expressed by a specific renal cell-type the 
number of exosomes released into the urine from the cell of interest may be 
determined. Major advantages of NTA are the small volume of urine (<1ml) required 
and the minimal processing of the urine sample prior to analysis.  
Whilst the size detection threshold of flow cytometry (FCM) instruments is too high 
(200nm-400nm) for exosome analysis, the instruments cover most of the size range 
of microvesicles. FCM is the most commonly used technique for MV analysis 
(Erdbrugger and Le 2016)  (van der Pol, Coumans et al. 2014). In FCM, the approach 
for gating of MVs differs between the studies, but many published protocols contain 
the use of a marker for externalized phosphatidylserine (Annexin V) and a restriction 
for particle size (<1µm and >100nm) (Burger, Thibodeau et al. 2014, Nielsen, Beck-
Nielsen et al. 2014). 
1.4.3 Extracellular vesicles in Chronic Kidney Disease 
Since the seminal study from Pisitkun et al. that characterized the content of urinary 
exosomes, many studies have identified promising urinary exosome biomarker 
candidates for detection and prognosis of CKD and DN(Pisitkun, Shen et al. 2004, 
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Erdbrugger and Le 2016, Morrison, Bailey et al. 2016). WT-1 positive exosomes 
correlate with renal function (Kalani, Mohan et al. 2013). Podocalyxin positive 
microvesicles precede albuminuria in DN rat models(Burger, Thibodeau et al. 2014). 
Dipeptidyl peptidase-IV positive particles correlate with ACR in patients with T2D 
(Sun, Deng et al. 2012). Urinary exosomal miRNA145 might represent a marker of 
incipient DN in humans and animal models (Barutta, Tricarico et al. 2013). 
Regucalcin seems to be downregulated in renal tissue and in urinary exosomes in 
rodents and patients with DN(Zubiri, Posada-Ayala et al. 2015). Proteomic analysis 
of isolated exosomes seems to be a promising approach for biomarker detection, 
though validation studies have yet to be performed (Raimondo, Corbetta et al. 2013, 
Zubiri, Posada-Ayala et al. 2014). Of note, regarding microvesicles and renal 
diseases, there are only a few studies measuring MVs in the urine with most studies 
using blood samples instead (Erdbrugger and Le 2016) potentially due to the higher 
concentration of MVs in serum/plasma. 
There are technical limitations for urinary EV analysis in large patient cohorts. Some 
studies apply a qualitative approach with the mere presence of the marker defining 
the diagnosis (Zubiri, Posada-Ayala et al. 2015). In other studies the large sample 
volume required (Barutta, Tricarico et al. 2013) or the time-consuming and 
technically difficult sample preparation or vesicle isolation procedure (Kalani, 
Mohan et al. 2013, Zubiri, Posada-Ayala et al. 2014) impedes their practical 
validation in large-scale study cohorts.  
This work will investigate whether the methodologies of nanoparticle tracking 
analysis and flow cytometry could possibly overcome some of these obstacles. 
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1.5 Objectives 
In this work the following questions are addressed. 
i. Can the analysis of the transcriptome and pathological phenotype in a novel 
Cyp1a1mRen2 reversal DN model facilitate the study mechanisms of injury 
and repair and identify markers of translational potential? 
ii. Can an integrative biology approach using urinary peptidomics confirm and 
complement the findings from (i)?  
iii. Can the biomarker candidates derived from (i) and (ii) be confirmed in a large 
human T2D cohort? 
iv. Can the measurement of urinary extracellular vesicles by NTA or FCM 
applied to human studies in a similar manner to conventional methodologies 
of biomarker measurement employed in (iii)?  
Figure 13: Integrated objectives of the work 
 
Figure 13. i. Transcriptomic analysis in the animal model and confirmation of the findings in 
renal tissue. ii. Peptidomics in urine from the animal model may identify non-invasive 
biomarkers of disease processes detected in the kidney in i. Similar studies in patients with 
DN generate novel biomarker candidates for further study in iii. large clinical cohorts. iv. 
analysis of extracellular vesicle profiles in the animal model may generate novel biomarkers 
which may then be tested in patients with DN (iii) i-iv refer to the objectives of this work (see 
above). 
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2. MATERIALS AND METHODS 
All materials if not indicated otherwise were bought from Sigma (SigmaAldrich, 
Dorset, UK). 
2.1 Animal models 
The Cyp1a1mRen2 DN model and reversal DN model 
It is important to point out that the studies on the Cyp1a1mRen2 model in the current 
thesis were performed on archived tissue from previous in vivo studies. These 
studies, including the initial description of the Cyp1a1mRen2 model of DN and the 
reversal model are described in detail in the introduction chapter and have been 
published (Conway, Rennie et al. 2012, Conway, Betz et al. 2014). 
Kidney tissue and urinary specimens from these studies were stored at -80°C degree. 
I was allowed to use them for further analysis in this work courtesy of my supervisor 
Dr. Bryan Conway.  
The reversible unilateral ureteric obstruction ([R-]UUO) model 
The methodology of the irreversible and reversible UUO model has been published 
before in detail (Hesketh, Vernon et al. 2014). In brief, following midline 
laparotomy, the left ureter was identified and ligated. A silastic tube placed around 
the ureter proximal to the ligature to prevent dilatation. Ten days after the initial 
surgical intervention the animals in the UUO-group and sham group were culled. In 
the animals of the RUUO-group a reversal of the ureteric obstruction was performed 
by anastomosing the ureter directly into the bladder. The animals were culled 29 
days after the reversal surgery. 
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The timeline of UUO and reversal phase are described in the result section. I together 
with my supervisor Dr. Bryan Conway planned and prepared the experiments. The 
surgery was performed by experimental animal surgeons, Gary Borthwick and Spike 
Clay, at the small animal facility, Queen’s Medical Research Institute (QMRI), 
University of Edinburgh. Procedures were performed under UK Home Office licence 
and approved by the Animal Ethics Committee of the University of Edinburgh. 
2.2 Immunohistochemistry (IHC) and Immunofluorescence 
After the harvest, kidneys were fixed overnight in 4% paraformaldehyde with 0.1M 
phosphate buffer or methyl-Carnoy (60% ethanol, 30% chloroform, 10% glacial 
acetic acid; for ED-1, transgelin, CD3, WT-1).  
They were embedded in paraffin wax and sectioned at 5m thickness and placed on 
slides in the Histology Department of the QMRI, University of Edinburgh. 
For most paraformaldehyde slides antigen retrieval was performed to break formalin 
induced protein cross-links that potentially mask antigenic sites. The slides boiled in 
TRIS-EDTA buffer (10mM Tris Base, 1mM EDTA, 0.05% Tween 20 at pH 9.0) for 
15min and cooled by rinsing in water for another 30min thereafter. After 
deparaffinization of the slides in xylenes for two times 5min, the slides were 
rehydrated in serial dilutions of 100%, 90%, 75% and 50% of alcohol and washed. 
The slides were exposed to 2% hydrogen superoxide Peroxidase-Blocking solution 
(Dako, Glostrup, Denmark) for 15min on a shaker to block the endogenous 
peroxidase activity of the tissue and washed again. Slides were placed in Sequenza 
racks (Ted Pella, Altadena, CA, USA) prior to blocking and staining. An 
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Avidin/Biotin Blocking Kit (Vector Laboratories, Burlingame, CA, USA) was used 
to block avidin and biotin binding sites in the tissue according to the manufacturer’s 
instructions. Then 3 drops of serum-free protein block (Dako) was put on the slides 
for 10min. They were incubated with 125l of the primary antibody in antibody-
diluent (Dako) at 4°C overnight. Next day, after washing with PBS, 125l of the 
species-appropriate biotinylated secondary antibody in diluent for 30min was added 
on the slide at room temperature (RT) (see Table 1 for antibody details and 
concentrations). Following further washing steps, 3 drops/ per slide of R.T.U. 
Vectastain Elite ABC (Vector Laboratories) was applied for 30 minutes. Subsequent 
to three washing steps with PBS, 125l of chromogen DAB solution (DAKO) was 
added to the slides for between 30 seconds to 3 minutes (depending on the antibodies 
applied) until brown staining was clearly visible. After another short wash, slides 
were counterstained for several seconds in haematoxylin and Scott’s tap water 
(SigmaAldrich, provided by Histology Core Facility, QMRI, University of 
Edinburgh). Slides were dehydrated in serial increasing strength alcohol dilutions 
and alcohol was cleared by placing slides in xylene for 10 minutes thereafter. Finally 
coverslips were mounted on the slides with DPX mounting medium (SigmaAldrich).  
Data collection and analysis 
For every tissue section 8 images were taken using a Zeiss Axioskop microscope 
(Zeiss) and QImaging Micropublisher 3.3 RTV camera and QCapture Pro imaging 
software (QImaging, BC, Canada).  
For collagen I&III positive staining was identified with ImageJ (NIH, Bethesda, MD, 
USA). The percentage positive staining was calculated as the number of positive 
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pixels (positive stained tissue area) divided by the total pixel number (total tissue 





) and M2 phenotype (mannose receptor, MR
+
) macrophages, the 
number of positive cells was counted in 20–30 ×400 tubulointerstitial fields/slide; for 
podocytes (WT-1
+
) the number of positive cells was counted in 20-30 hilar 
glomerular cross-sections/slide. The resulting numbers were averaged for each 
animal. On each slide all glomeruli were counted for total glomeruli number per 
section. For 20-30 hilar glomeruli per slide the surface was measured by manually 
marking the glomerular tuft area using Adobe Photoshop CS5 (Adobe).  
Table 2: List of antibodies for Western Blotting 
Primary antibody 
Specificity / Clonality / Isotype 
Manufacturer 




rabbit anti-collagen I 
mouse, rat / polyclonal / IgG 
Abcam / ab34710 
1:300 goat anti-rabbit IgG 
Vector BA-1000 
1:300 
goat anti-collagen III 
mouse, rat / polyclonal / IgG 
SouthernBiotech / #1330-01 




rat / polyclonal / IgG 
R&D Systems / AF3689 
1:50 horse anti-goat IgG 
Vector BA-9500 
1:300 
goat anti-EGF  
rat/ polyclonal / IgG 
Santa Cruz Biotechnology / sc-1343 




rat / monoclonal /IgG1 
AbD Serotec / MCA341R 
 
1:100 horse anti-mouse IgG 
Vector BA-2000 
1:300 
rabbit anti i-NOS 
rat / polyclonal / IgG 
Abcam / ab15323 
1:2500 goat anti-rabbit IgG 
Vector BA-1000 
1:300 
rabbit anti mannose-receptor 
rat / polyclonal / IgG 





Specificity / Clonality / Isotype 
Manufacturer 




Abcam / ab64693 
rabbit anti transgelin 
rat / polyclonal / IgG 
Abcam / ab14106 
1:8000 goat anti-rabbit IgG 
Vector BA-1000 
1:300 
rabbit anti WT-1 
human / polyclonal / IgG 
Santa Cruz / sc-192 
1:200 goat anti-rabbit IgG 
Vector BA-1000 
1:300 
mouse anti CD45RA 
rat / monoclonal / IgG1 
AbD Serotec / MCA340GA 
1:500 horse anti-mouse IgG 
Vector BA-2000 
1:300 
rabbit anti CD3 
human / polyclonal / IgG 
DAKO / A0452 
1:100 goat anti-rabbit IgG 
Vector BA-1000 
1:300 
Table 2. Details of the primary antibodies utilized for Western Blots including the respective 
secondary antibodies. 
Immunofluorescent double staining 
After dewaxing and rehydration (see above) the slide was exposed to 3 drops of 
serum-free protein block (Dako) for 10 minutes. Then it was incubated with rabbit 
anit-CD 3 (Dako) 1:200 in antibody diluent (Dako) at 4°C overnight. Next day, after 
washing with PBS, a secondary donkey anti-rabbit IgG Alexa Fluor 594 antibody 
(Life Technologies, ThermoFisher, Scientific, Paisley, UK) 1:300 in antibody-diluent 
was put on the slide for 50 minutes. After a subsequent washing and blocking step, 
the second primary antibody mouse anti CD45RA (Serotec) 1:200 in anti-body 
diluent (Dako) at 4°C with an overnight incubation was followed by the second 
secondary goat anti-mouse IgG Alexa Fluor 488 (Life Technologies) 1:300 in 
antibody-diluent with an incubation time of 50min. Finally, the slide was mounted 
with VectaShield mounting medium (Vector laboratories). Images were taken using a 
Zeiss Axioskop 2mot+ (Zeiss). 
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2.3 Homogenization of tissue samples 
For downstream analysis a piece (20-30mg) of cortex was cut off from snap frozen 
kidney and placed directly into 300-600l of the appropriate homogenate buffer for 
the downstream indication: Triton X 100/50mM Tris pH8/150mM NaCl for 
zymography and collagenase/gelatinase kit, RIPA buffer for Western-Blot (50mM 
Tris pH 7 – 8, 150 mM NaCl, 0.1% SDS [sodium dodecyl sulfate], 0.5% sodium 
deoxycholate, 1% Triton X 100 and a protease complete inhibitor mini cocktail 
[Roche, Basel, Switzerland]) or RA1 Lysis Buffer from Nucleospin RNA II kit 
(Macherey-Nagel, Duren, Germany) containing 1% beta-mercaptoethanol for PCR. 
Tissue was homogenized with metal beads in a mixer mill MM200 tissue 
homogeniser (Retsch, Haan, Germany) at 30 Hz for 120 seconds. 
For Western-Blot and the zymography/activity assays homogenate was then 
centrifuged at 10,000g for 10min at 4°C and the supernatant was further processed or 
stored at -20°C. 
Measurement of protein content 
Detergent compatible DC Protein Assay (Bio-Rad, Hercules, CA, USA) was used to 
determine the amount of protein/l in kidney homogenates for normalization of 
samples. The assay is based on the methodology of Lowry in which divalent copper 
becomes monovalent by forming complexes with free peptides bonds and reacts with 
radicals from aromatic amino acids reducing the Folin reagent that returns blue 
colour. After all kit reagents (25l alkaline copper tartrate and 500µl Folin reagent) 
and the sample (5l) had been mixed together in a 96-well flat bottom microplate 
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(Corning, New York, NY, USA) the reaction lasts 15min and the photometric density 
can be measured by a microplate reader at 750nm wavelength. By the simultaneous 
measurement of standards (0, 0.2-1.5 mg/ml of bovine albumin [SigmaAldrich]) a 




The extraction was performed using the Nucleospin RNA II kit (Macherey-Nagel).   
The homogenate in RAI buffer was transferred to a NucleoSpin Filter column with a 
syringe with a 0.9 mm needle (20 gauge) attached and spun at 11000g for 1min. 
After mixing with 350µl ethanol the filtrate was put on a NucleoSpin® RNA column 
with a silica membrane and processed in serial steps with membrane desalting buffer 
(MDB), DNase Reaction Buffer, RAW2 buffer and RA3 (2x times) buffer. The dried 
column was placed into a nuclease free collection tube and eluted with 60µl RNase-
free water by spinning at 11000g for 60s and placed on ice. 
cDNA synthesis by reverse transcription  
The mRNA in the samples was quantified using a NanoDrop ND-1000 
spectrophotometer (ThermoFisher Scientific, Cramlington, UK) at 340nm 
wavelength. 
For reverse transcription into cDNA the high capacity cDNA reverse transcription 
(RT) kit (Applied Biosystems, Warrington, UK) was used according to 
manufacturer’s instructions. In brief, 10µl mRNA in a concentration 0.1g/l were 
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mixed with 10l master mix (RT buffer [volume: 2l; final concentration: 1x], 
deoxyribonucleotide triphosphate [dNTP] mix (0.8l; 4mM), RT Random primers 
[2l; 1x], reverse transcriptase [1l; 50U], RNase inhibitor [1l], nuclease free 
water) [3.2l]) in a 96-well reaction plate. The transcription was performed in a 
PTC-100 Thermal controller (MJ Research, Reno, NV, USA) for two hours at 37°C 
followed by a termination at 85°C. 
Real-time polymerase chain reaction (RT PCR) 
TaqMan inventoried primers and TaqMan Universal PCR master mix (Applied 
Biosystems) was used: 5ng cDNA from the sample were mixed with 1l of 20x 
TaqMan inventoried primers and 10l of 2x PCR master mix and diluted with 
ddH2O to a total volume of 20l in a fast 96 well reaction plate (ThermoFisher 
Scientific). Altogether 40 cycles (10min at 95°C for DNA polymerase activation, 15s 
at 95°C for melting, 1min at 60°C for annealing and extension) were run on a 
Applied Biosystems Fast Real time 7500 PCR machine. The following primers were 
used (Applied Biosystems): tagln:Rn01642285_g1; col1a1:Rn01463848_m1; 
fn:Rn00569575_m1; foxp3:Rn01525092_m1; mmp2:Rn01538170_m1; 
mmp7:Rn00689241_m1; mmp12:Rn00588640_m1; mmp14:RN00579172_m1; 
timp1:Rn01430873_g1; timp2:Rn00573232_m1; timp3:Rn00441826_m1; 
egf:Rn00563336 and the housekeeping gene TATA-binding protein: 




The SDS Software 1.3.1. was used for analysis. The threshold in the Rn (normalized 
reporter with - without template) vs Cycle plot was set in the linear phase of the 
amplification curve excluding background noise at the first significant increase in 
Rn .  CT (threshold cycle) was determined for every sample by the software. The 
CT sample was calculated by subtracting the CT of the housekeeping gene from the 
CT of the gene of interest. Then the average CT of the reference group was 
subtracted from the CT of the other samples to determine the CT for each sample 
and the relative expression (RQ) is calculated as 2
-Ct
. 
2.5 Western-Blot analysis 
Gels are cast in an assembled Mini-PROTEAN Tetra system (Bio-Rad) with the 10% 
polyacrylamide gel mixed manually (For 2 gels: 29.2% Acrylamide, 6.67ml 0.8% 
Bisacrylamide (w/v), 5ml 0.4% SDS in 1.5M Tris-Cl pH 8.8, 8.33ml distilled water, 
100l 0.06% (w/v) APS, 10l TEMED (v/v)). Homogenates were normalized for 
individual protein concentration, mixed with 5x laemmli sample buffer (60mM Tris-
HCl pH 6.8, 2% SDS, 10% glycerol, 0.01% bromophenol blue) containing 5% (v/v) 
β-mercaptoethanol and boiled at 95°C for 10min. After the system had been filled 
inside with cathode buffer (50mM Tris, pH 8.6, 383.5mM glycine and 0.1% (w/v), 
SDS) and outside with anode buffer (50mM Tris, pH 8.6 containing 0.1% (w/v) 
SDS), samples (30g protein) were loaded on the gel. Samples were separated at 
constant voltage 80V for 70min and then transferred on a polyvinylidene fluoride 
(PVDF) membrane (Amersham Hybond P 0.2, GE Healthcare LifeSciences, Little 
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Chalfont, UK) for 60min at 90 volts in transfer buffer (50mM TRIS, 383.5mM 
glycine, 20% (v/v) methanol). Afterwards the membrane was washed twice for 5 
minutes in TBST (50mM TRIS pH 7.5, 150mM NaCl, 0.05% (v/v) Tween-20). Then 
it was blocked for one hour in 5% skim milk TBST followed by the incubation with 
the primary antibody (i.e. 1:000 rabbit anti-rat TIMP-1 [Biorbyt, Cambridge, UK] 
and 1:10000 rabbit anti-rat beta-actin [Abcam, Cambridge, UK] in 5% bovine serum 
albumin) at 4°C overnight. After two washing steps with TBST the secondary 
antibody horseradish peroxidase-conjugated anti-rabbit IgG (Dako) diluted in 5% 
skim milk TBS (at 1:2000 [TIMP-1] and 1:10000 [beta-actin]) was incubated for one 
hour at room temperature. After three wash steps with TBS, Pierce ECL Plus 2ml 
Substrate (ThermoFisher Scientific) was added on the drained membrane and 
incubated for 5min in the dark. ECL was carefully removed and the membrane was 
covered by a transparent foil and imaged on a Versadoc system (Bio-Rad). The 
densitometry was performed with Adobe Photoshop CS3 (Adobe, San Jose, CA, 
USA). 
2.6 Gelatinase and Collagenase activity assay kits  
Metalloproteinase activity was assessed using the EnzChek Gelatinase/Collagenase 
Assay Kit (Invitrogen, ThermoFisher Scientific, Paisley, UK). According to the 
manufacturer’s instructions 100 l of homogenates (at 1g/1l) were incubated with 
20l DQ gelatin or collagen (1mg/ml) respectively and 80l of reaction buffer in the 
dark for 24 hours. DQ gelatin/collagen is so heavily labelled with the conjugate 
fluorescein that the fluorescence is quenched. Cleavage by collagenase and 
gelatinase releases fluorescent peptides and the fluorescence can be quantified by a 
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plate reader at excitation/emission=380nm/500nm. Fluorescent intensity from the 
released peptides correlates with the collagenase/gelatinase activity. For QC, 
additional measurements were performed with some samples spiked with a general 
metalloproteinase inhibitor (1,10-phenanthroline, monohydrate, 0.5 mM) or samples 
were completely replaced by reaction buffer. 
2.7 Zymography 
Gel zymography  
For substrate zymography 10% polyacrylamide gels were manually cast like for 
Western-Blots, but in addition including either gelatin (1 mg/mL) or collagen (0.2 
mg/mL). Tissue homogenates were mixed 1:1 with zymogram sample buffer 
containing 62.5mM Tris pH 6.8, 25% glycerol, 4% SDS and 0.01% Bromophenol 
Blue (Bio-Rad), loaded on the gels (40l per lane at 2.5g/l) and separated by 
electrophoresis at a low constant voltage (40-60V) using PowerPac (Bio-Rad). The 
running buffer contained 25mM Tris, 192mM glycine, 0.1% SDS at a pH 8.3. After 
dismantling from the system, gels were washed twice with 2.5% Triton X-100 to 
remove SDS enabling protein renaturation followed by an incubation period for 48–
72 h at 37°C in incubation buffer (50 mM Tris HCl, 0.15 M NaCl, 10 mM CaCl, 
[Bio-Rad]). Gels were stained with 0.05% Coomassie Brilliant Blue (VWR, Radnor, 
PA, USA) in 25% methanol/ 10% acetic acid/water and de-stained in aqueous 4% 
methanol/8% acetic acid. The gels were scanned using Li-Cor Odyssey and the band 
intensities were quantified on Software Odyssey v.3.0 (Li-Cor, Lincoln, NE, USA). 
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In-situ zymography  
In-situ zymography was performed either on zinc-fixed paraffin-embedded or on 
frozen (-80°C) tissue sections generally based on the publications from Ahmed et 
al.(Ahmed, Haylor et al. 2007) and Hadler-Olsen et al.(Hadler-Olsen, 
Kanapathippillai et al. 2010) with modifications. Upon harvest, tissue was either 
snap frozen and mounted in Tissue Tek O.C.T (Sakura, VWR) or fixed in zinc-
buffered fixative (ZBF) (BD Biosciences, Oxford, UK), for 24 hours at room 
temperature, dehydrated and paraffin-embedded. 8m sections were cut in the 
Histology facility, QMRI, Univeristy of Edinburgh. For zymography cryo-sections 
were air dried for 10min at RT and washed for 10min in PBS to remove OCT. Zinc-
fixed tissues were kept at 59°C overnight and deparaffinised in xylene. Then they 
were rehydrated in graded alcohol baths. 150-200l of 2% DQ Gelatin (1mg/ml) 
substrate mixed in 50 mM Tris-HCl, 150 mM NaCl, 5 mM CaCl and 0.2 mM sodium 
azide (pH 7.6) was put on the sections. Subsequently, sections were incubated at 
37°C in the dark in a humidified chamber for two hours. Then gelatin was removed 
by gentle washing in dH2O followed by a fixation in 4% neutral-buffered formalin 
(40ml/L 37-40% Formaldehyde, Sodium phosphate, monobasic 4.0 g/L Sodium 
phosphate, dibasic (anhydrous) 6.5 g/L pH 7) for 10min in the dark. After another 
short wash sections were mounted with VectaShield mounting medium (Vector 
Laboratories), covered by a coverslip and kept in the dark. For analysis 5 images of 
the cortical area were taken per section using a Zeiss Axioskop 2mot+ (Zeiss, Jena, 
Germany) with an Hamamatsu Orca camera (Hamamatsu Photonics, Shizuoka, 
Japan). Whole image contrast/brightness was adjusted using Adobe Photoshop CS5 
(Adobe). Analysis was performed using ImageJ (NIH) with the number of positive 
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pixels expressed as a percentage of the total number of pixels(Hesketh, Kluth et al. 
2014).  
For double staining, instead of mounting the section was washed in PBS and exposed 
to 125l of serum-free protein block (Dako) for 10 minutes. Then it was incubated 
with rabbit anti-rat collagen I (Abcam) 1:300 in anti-body diluent (Dako) at 4°C 
overnight. Next day, after washing with PBS, a secondary donkey anti-rabbit IgG 
Alexa Fluor 586 (Life Technologies) 1:500 in antibody-diluent was put on the 
section for 50min. After a subsequent washing step, the section was mounted with 
VectaShield mounting medium. Images were taken using a Zeiss Axioskop 2mot+ 
(Zeiss). 
2.8 Enzyme-linked immunosorbent assay (ELISA) 
For ELISA in human studies the R&D Duoset Kits were used (detailed specification 
see Results) (R&D Systems, Abingdon, UK).  R&D Duoset was also used for 
measurement of urinary Epidermal Growth Factor (EGF) in the rat. The ELISAs 
were performed according to the manufacturers` instructions with the exception that 
for EGF, Osteopontin and MMP-7 volumes of samples, standards and of all 
chemicals were halved. In brief, Corning 96 Well EIA/RIA clear flat bottom plates 
(Corning) were coated with capture antibody (100l) overnight at RT. After three 
washes with PBS (Gibco, ThermoFisher Scientific) containing 0.05% Tween® 
(SigmaAldrich) plates were blocked with Reagent Diluent (1% BSA in PBS, R&D 
Systems) (400l) for 1-2 hours. After another 3x wash steps, 100l of samples or 
100l of standard concentrations that had been generated by serial dilution were 
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added to the plates for 2 hours. Following another three wash steps, plates were 
incubated with 100l of detection antibody, washed three times and incubated with 
100l Streptavidin-HRP for 20 minutes in the dark. After another 3x washes, 100l 
of 3,3’,5,5’-Tetramethylbenzidin (SureBlue TMB, KPL, Gaithersburg, Maryland, 
USA) was added and this converted into a blue soluble product over 20 minutes. The 
reaction was stopped by adding 50l 1N HCl which turned TMB into a yellow 
product. The optical density of each well was measured by a microplate reader at 
450nm wavelength with a correction set at 570nm. The standard curve was 
calculated and the concentrations of the samples interpolated from the curve.  The 
urinary TIMP1 (RayBiotech, Norcross, GA, USA) was performed according to the 
manufacturer’s instructions that were similar to the ones described above.  
2.9 Measurement of urinary peptidomics      
Sample selection for urinary peptidomic analysis 
All samples for the urinary peptidomic analysis had been stored at -80°C. These were 
urinary samples collected over 24 hours from the Cyp1a1mRen2 DN model(Conway, 
Rennie et al. 2012) including the control, diabetes mellitus (DM) alone, hypertension 
(HTN) alone and combined diabetes and hypertension (DM+HTN) groups. 
Additional samples were obtained from rats from the Cyp1a1mRen2 DN reversal 
model(Conway, Betz et al. 2014): these were serial samples from 24 hours urinary 
volume collections from the same animals at 3 time points: baseline, after 28 weeks 
injury phase (combined diabetes and hypertension) and after another 8 weeks 
reversal phase (reversal of hypertension and tight glycaemic control). All urinary 
samples were centrifuged at low speed (500g) for 5 mins to remove cellular debris. 
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Human samples were spot urine taken from RDS study participants that will be 
described in more detail below. Human “control” urine was taken with informed 
consent from healthy volunteers with no medical history of kidney related diseases. 
Urinary protein separation by electrophoresis 
After defrosting the samples (300l) were mixed with acetonitrile (SigmaAldrich) 
1:5 for precipitation and incubated overnight at 4°C. Then they were centrifuged for 
40min at 4000g at 4°C. The supernatant was removed and the pellet re-suspended in 
solution buffer containing 0.05M 1,4-dithiothreitol (DTT). Protein was measured 
with the RC DC Protein Assay (Bio-Rad) according to the manufacturer’s 
instructions. Select samples (300-500l) were dialyzed against >500x volume of 
dialysis solution following the manufacturer’s instructions using a Slide-A-Lyzer 
cassette with a 3.5-kDa molecular mass cutoff (ThermoFisher Scientific). Albumin 
was depleted from some samples using the Aurum Affi-Gel Blue Mini Column Kit 
(Bio-Rad) following the manufacturer’s instructions. Samples were mixed 4:1 with 
4xLDS buffer (Novex, ThermoFisher Scientific). 50l of the sample was loaded onto 
a precast gel (4–20% Mini-PROTEAN TG Precast Protein Gel, Biorad) and run for 
approximately 1 hour at 150V in MES-Buffer (Novex). Afterwards the gel was 
washed twice in dH2O for 15min. The gel was stained using GelCode Blue Stain 
Reagent (ThermoFisher Scientific) that is based on colloidal Coomassie dye G-250 
followed by a de-staining step with dH2O for two hours. The picture of the gel was 
taken by a smartphone camera (Samsung).  
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Sample preparation for urinary peptidome analysis 
The methodology was published recently(Betz, Jenks et al. 2016): After thawing, 5% 
of the total 24hr urinary sample volume was centrifuged in Millipore Amicon Ultra-4 
spin concentrators  (Merck Millipore, Bellerica, MA, USA) with a 10kDa cut-off 
cellulose membrane at 3220g for 15min at 4C. The resulting filtrate was acidified 
with 5% trifluoroacetic acid (TFA, SigmaAldrich) to pH4 and loaded onto a C8 
StageTip. The StageTips had been assembled manually by placing small C8 
membrane (C8 Empore Disks, 3M, Maplewood, MN, USA) into pipette 
tips(Rappsilber, Ishihama et al. 2003). The StageTip was wetted with 5l MeOH, 
washed by loading 10l 0.1% TFA and then the complete sample was subsequently 
loaded on the tip and centrifuged at low speed (500-2000g) for 1-5min. This was 
followed by two wash spins with 0.1% TFA. 40l 80% acetonitrile in 0.1%TFA 
(v/v) was used to elute the peptides applying low speed centrifugation. The 40l 
effluent was slightly warmed to evaporate acetonitrile. Then, the sample was re-
suspended in 50mM ammonium bicarbonate to a volume of 50l and reduced in 
5mM DTT at 60°C for 15 min. Afterwards, samples were slowly cooled to room 
temperature. Iodoacetamide was added to a final concentration of 15mM and the 
sample was kept in the dark for 15min for alkylisation. The samples were incubated 
with trypsin at 2.5ng/l overnight at 32°C to ensure the proteolytic digestion of high-
molecular weight (HMW) peptides and small proteins up to 10kDa. The concern was 
these HMW components might otherwise not fly and fragment in the instrument and 
be difficult to detect by LC-MS/MS(Fliser, Novak et al. 2007). After incubation the 
sample was re-acidified with 1% TFA and loaded on a C18 StageTip that had been 
assembled in the same way as described above. The C18 StageTip loaded with the 
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sample could be frozen and stored at -80°C for later analysis or the sample could be 
further processed by eluting the sample with acetonitrile that was subsequently 
removed by vacuum evaporation(Ohta, Bukowski-Wills et al. 2010). 
Matrix-assisted laser desorption/ionization – time of flight (MALDI-TOF) 
For analysis using DE-STR MALDI-TOF MS Voyager (Applied Biosystems) 0.5l 
of the sample was mixed with 0.5l CHCA (alphaCyano-4-hydroxycinnamic acid) 
and dried on a 100 well MALDI sample plate. The laser intensity was set at 
2200kW/cm
2
. Roughly 200-300 shots from different regions of the spot were 
averaged. The resulting spectra were further processed automatically by using the 
“advanced baseline correction” option (degree 0.1, flexibility 0.5, peak width 16), 
“noise filter smooth” (set 0.7) and “noise removal” (set 2). Then data was exported to 
Mascot search engine (Matrix Science) for protein identification.  
LC-MS/MS 
The measurement on LC-MS/MS was performed with the assistance of Dr. Andrew 
Cronshaw, Proteomics Facility, School of Biological Sciences, University of 
Edinburgh, according to the following published procedure (Betz, Jenks et al. 2016): 
“5l of the sample was loaded onto an Ultimate 3000 Series HPLC (Dionex) with a 
PicoTip Emitter (FS 360-100-8-N-20-C12, New Objective) in series with an 
LTQorbitrap mass spectrometer (ThermoFisher Scientific).  The PicoTip Emitter was 
packed with Reprosil-Pur C18-AQ 3m (Dr Maisch GmbH) to a length of 6.5-
7.5cm. The PicoTip column was equilibrated with solvent A (0.5% acetic acid in 5% 
acetonitrile) and eluted with a linear gradient, from 0%B for 9min; from 0 to 20%B 
over 9 to 40min; from 20 to 80%B over 40 to 48min; solvent B (0.5% acetic acid in 
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99.5% acetonitrile), over 65min at a flow rate of 0.7l/min for the first 9min and 
0.3l/min thereafter.  Data dependent acquisition was controlled by Xcalibur 
software (ThermoFisher Scientific).” 
2.10 Data analyses  
Data analysis of urinary peptidomics using MaxQuant, Perseus and an in-house 
algorithm 
For peak identification and label-free quantitation of raw data files from LC-MS/MS, 
the freely available software MaxQuant (version 1.4.1.2) was used 
(http://www.maxquant.org)(Cox and Mann 2008). MaxQuant automatically corrects 
for inaccuracies of retention times from peptides. Mass and intensity of the detected 
peaks were searched in in a species-specific way via Andromeda search engine that 
is downloaded at the same time. For the current study the FASTA file databases for 
“rattus norvegicus” (version 2013 containing 37202 sequences) and “homo sapiens” 
(version 2013 containing 154,578 sequences) were downloaded from UniProt 
Knowledgebase (www.uniprot.org). Each hit is scored by a peptide identification 
probability score. Programme settings in MaxQuant included: no enzyme specificity; 
mass accuracy window for precursor ion = 10 ppm (parts per million); mass accuracy 
window for fragment ions = 0.8Da; variable modification including only 
carbamidomethylation of cysteines and oxidation of methionine. The criteria for 
peptide identification were a mass accuracy of _10 ppm and a false detection rate 
(FDR) of p=0.05 to correct for multiple testing. From all peptides detected identical 
sequences with different charges were summarized. Peptides with a detection score 
below “50” had to be excluded to avoid false positive results. Obvious contaminants 
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like human keratin were removed. Finally, peptides were only further analysed when 
they were detected in a minimum of 3 samples from at least one group. Peptides 
were quantified by the individual peptide peak intensities expressed as relative 
abundance. 
For human samples data were further statistically analysed by the freely available 
software Perseus 1.4.0.17 (http://www.perseus-framework.org)(Tyanova, Temu et al. 
2016). A first quantitative correlation analysis in the Cyp1a1mRen2 reversal cohort 
was also done with Perseus. However, assessing differential representation of 
peptides quantitatively between sample groups was challenging due to a large 
number of missing values of individual peptide sequences. This made standard 
analysis by Perseus impossible. Therefore a non-parametric approach was chosen 
using a custom implementation of Rank Products in R-software. This implementation 
as an in-house algorithm was developed by Dr. John Manning, BHF CoRE 
Bioinformatics, University of Edinburgh. In brief, this programme generated lists of 
peptides that were significantly and consistently ranked highly in fold change 
between paired samples, irrespective of absolute values. This made a comparison 
between the relative abundance of peptides at baseline, injury and reversal possible. 
Data analysis of urinary peptidomics using Progenesis QI 
Progenesis QI software (version 4.0, Nonlinear Dynamics Limited, Newcastle upon 
Tyne, UK) was used to analyse the urinary peptidome of all groups from the 
Cyp1a1mRen2 DN model as published previously (Betz, Jenks et al. 2016) and 
based on the methodology by Atrih et al. (Atrih, Mudaliar et al. 2014): After import 
of the raw LC-MS/MS data and a visual check of the chromatograms for defects, the 
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alignment process was started with Progenesis QI automatically selecting a sample 
from the DM+HTN group as the most appropriate reference and aligning all other 
ion intensity maps to it with minimal manual corrections. The feature ions with 
charge states below 2+ or above 5+ were removed and the top five “ranks” for each 
feature were exported to MASCOT.  The settings for the MASCOT search were “no 
enzyme” to avoid loss of natural peptides, a peptide tolerance of 6ppm and allowed 
modifications Carbamidomethyl, Dioxidation, Gln>pyro-Glu and Oxidation within 
the Uniprot “Rattus norvegicus” database as used above. Data were searched against 
a decoy database with the homology and an identity threshold FDR of <5%. Peptides 
above an ion score threshold of 50 (corresponding to p-value 0.05) were re-imported 
into the Progenesis QI software. For peptides with at least three hits per group the 
differences in peptide intensities between sample groups were calculated by the 
ANOVA test with a significance threshold of p <0.01. The q-value threshold as a 
control for false positive p-values was set at 0.05. A q=0.05 for a peptide implies that 
5% is the minimal FDR threshold at which the respective peptide will be significant, 
i.e. 5% of all significant tests will be false positive.  
Estimations about the power in transcriptome and peptidome 
The power to detect a difference of 50% in genetic up- or downregulation 
respectively between control vs injury or injury vs reversal group with an estimated 
SD between 0.25 to 0.3 after normalization is 0.81 (calculated by the freely available 
program G*Power, Version 3.1.9.2, University of Kiel, Germany). 
The program MSstats (Version 2.4.0, Timothy Clough, Safia Thaminy, Susanne 
Ragg, Ruedi Aebersold, Olga Vitek. "Statistical protein quantification and 
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significance analysis in label-free LC-M experiments with complex designs" BMC 
Bioinformatics, 13:S16, 2012.) was used to estimate the necessary average fold 
change of difference in peptide abundance between the three groups in order to 
obtain a certain threshold of power. For this, several peptides that had been analyzed 
by Maxquant were uploaded into the R-based program and power-calculation was 
performed. On average, the difference in abundance has to be roughly 9.5fold in 
order to achieve 80% power.  
Figure 13a: calculation of power in peptidomics 
 
Figure 13a. Illustration of the correlation between increasing power and average fold 
changes in peptide abundances between groups with three groups, ten biological replicates 
per group and a False-Discovery-Rate=0.5 the power of 0.8 is achieved roughly at 9.5 times 
change in average. 
When the program Progenesis QI was used instead of Maxquant, the power was 
calculated for each compound individually based on the abundance variance, the 
sample size and the difference between the group means. By reducing the threshold 
for p-value from 0.05 to 0.01 and thereby dismissing compounds with smaller 
differences between the groups and by defining a q-value of 0.05 almost all of the 
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peptides retained and especially those mentioned in the current work (like the peptide 
for the protein EGF and Osteopontin) had a power value above 0.8 (e.g. 96.5% in 
EGF for the comparison between the control and injury group). However, in future 
work new peptide candidates should be ensured to be above a defined power 
threshold like 0.8. 
Data interpretation using freely available online databases 
The parent proteins of identified peptides were entered into the STRING database 
v10.0 (Szklarczyk, Franceschini et al. 2015) (www.string-db.org) to assess 
interactions. Also STRING provided for the respective genes the most enriched 
biological processes based on Gene Ontology (GO) project data. In addition the 
expression of the respective genes in the kidney in the Cyp1a1mRen2 (Conway, 
Rennie et al. 2012, Conway, Betz et al. 2014) model and in biopsies from patients 
with diabetic nephropathy via the renal biopsy database nephroseq.org was compared 
with the relative urinary peptide abundance (Woroniecka, Park et al. 2011, Ju, Nair et 
al. 2015). 
The genes that were exclusively up-regulated during injury phase and those that were 
up-regulated during injury and reversal phase were entered into the freely available 
database DAVID (Database for Annotation, Visualization and Integrated Discovery, 
National Institute of Allergy and Infectious Diseases, National Institutes of Health, 
Bethesda, MD, USA) (Huang da, Sherman et al. 2009) and the results from the 
analysis for KEGG (Kyoto Encyclopedia of Genes and Genomes) (Kanehisa, Sato et 
al. 2016) pathway and GO (Gene Ontology Consortium) (Gene Ontology 2015) 
databases are presented. 
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Statistical analysis in study cohorts 
Means +/- standard deviation (SD) and medians with interquartile ranges (IR) were 
provided for parametric and non-parametric data respectively. The statistical tests 
used to compare each dataset are given in the results. In general, parametric tests t-
test and ANOVA or non-parametric tests Mann-Whitney and Kruskal-Wallis were 
applied for comparison between two or several groups respectively. For correlations 
Spearman’s rho (non-parametric) or Pearson’s r (parametric) were calculated. 
Almost three quarters of ACR measurements (73%) in the ET2D study were below 
0.5mg/mmol therefore the following 3 categories were used: <0.5mg/mmol; 0.5-
1mg/mmol; 1-2.5mg/mmol (males) or 1-3.5mg/mmol (females). 
For logistic regression analysis ACR was log transformed into log(ACR)+1 and 
similarly uEGF:creatinine, OPN:creatinine and MMP7:creatinine and the 
concentration of exosomes were log transformed. Linear regression analysis as well 
as Cox regression was calculated for the respective outcomes. The variables for 
which the regression analyses were adjusted are listed in the respective tables. A 
two-sided P-value < 0.05 was considered statistically significant unless explicitly 
stated otherwise in the text. 
Most of the statistics and visualizations were performed on the SPSS package 
version 21 (SPSS Inc., Chicago, IL, USA) or on GraphPad Prism software version 6 
(GraphPad Prism Software Inc., San Diego, CA, USA). AUC-ROC curves were 
calculated using Medcalc version 15.8 (MedCalc Software, Mariakerke, Belgium). 
For calculation of the Hosmer-Lemeshow test with visualization and the calculation 
of integrated discrimination improvement (IDI) the R-software (version 3.1.3., 2015, 
The R Foundation for Statistical Computing, Vienna, Austria) with the package 
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“PredictABEL” from Kundu at al. (Kundu, Aulchenko et al. 2011) was used. The 
functions that are based on the publication by Pickering et al. (Pickering and Endre 
2012) were integrated into R-software to calculate IDIevent/non-event including the 
graphical visualization. 
2.11 The RDS and the ET2D study 
The RDS study 
To translate the findings from animal studies to the clinic, urinary samples from 
patients with (diabetic) chronic kidney diseases were required, ideally at different 
stages of the disease. A study with the title “Identification of biomarkers for 
pRogression and Regression in diabetic kidney DiseaSe” (RDS) was permitted to be 
performed as a clinical research project under the ethical approval of the “South East 
Scotland SAHSC BioResource” (REC reference 10/S1402/33). The study, which is 
still recruiting, includes the collection of outpatient samples from participating 
Diabetes/Renal clinics at the Royal Infirmary of Edinburgh and from healthy 
volunteers. Clinical data including renal parameters (e.g. creatinine and albumin in 
serum and urine) are recorded. As controls the following groups are additionally 
asked for participation: 1. patients with diabetes but without evidence of diabetic 
nephropathy (ACR<2.5mg/ml (males or <3.5mg/ml (females) and 
eGFR>60ml/min/1.73m
2
) 2. patients with chronic kidney disease (CKD) of an 
aetiology other than DN and 3. healthy controls. It is planned over a period of 2-4 
years to acquire serial samples and to monitor changes in renal function. These latter 
aspects are not part of this work. 
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The participants provided informed written consent and every patient was assigned 
an individual study number. The study information form and the consent form are 
attached in in the appendix. 
Sample collection and storage for the RDS study 
Samples were usually collected between 8-12am from non-fasting patients providing 
a “non-first-morning” urinary sample. The sample was immediately put on ice and 
within two hours centrifuged for 10min at 500g at 4°C. The resulting supernatant 
was aliquoted.  To the aliquots for exosome measurement a proteinase inhibitor mix 
including PMSF [phenylmethylsulfonyl fluoride] (SigmaAldrich) at a final 
concentration 0.5mM and Leupeptin (SigmaAldrich) at 20M was added. The 
samples were frozen down at -80°C. 
The ET2D study 
Urinary samples from the Edinburgh Type 2 Diabetes (ET2D) study were measured 
in this work. The samples were provided courtesy of Professor Jackie Price, Centre 
for Population Health Sciences, University of Edinburgh, and were defrosted on ice 
before measurement. The study protocol has been published in detail before(Price, 
Reynolds et al. 2008, Marioni, Strachan et al. 2010, Conway, Manoharan et al. 2012, 
Betz, Jenks et al. 2016). In short, in 2006, 1066 patients with T2D aged between 60 
and 74 living in the Lothian, Scotland, UK area attended the research clinic to 
participate in the Edinburgh Type 2 Diabetes study. At baseline epidemiological data 
was collected and a blood sample was obtained for measurement of different clinical 
parameters including HbA1c and serum creatinine for calculation of the estimated 
GFR (eGFR) by the CKD-EPI formula (Levey, Stevens et al. 2009). Patients 
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provided also a urine sample (978 samples [92%]) that was after measurement of 
albumin and creatinine stored at -20°C. After four years participants were invited for 
the follow-up visit that included similar procedures as described before. 75 (8%) 
participants (8%) had died before this invitation and another 137 participants (14%) 
did not attend. For these 212 patients eGFR was calculated based on the serum 
creatinine that was obtained from health records of their last outpatient clinic visit. 
Microalbuminuria was defined as an ACR>2.5 (male) mg /mmol or >3.5 (female) 
mg/mmol in two out of three consecutive measurements (Conway, Manoharan et al. 
2012). Incident CKD III is defined as two measurements of eGFR 
<60ml/min/1.73m
2
 with more than three months between the measurements (Betz, 
Jenks et al. 2016). 
2.12 Nanopatricle Tracking Analysis (NTA) 
The measurements were performed on a Nanosight LM10 machine (Malvern 
Instruments, Malvern, UK) with a sCMOS Camera, a 532 nm (green) laser and 
analysed by Nanosight software v2.3.017. In principle, a laser is directed at particles 
in solution and the scattered light from the particles is captured by a microscope with 
a digital camera. According to the Stokes-Einstein equation, the movement 
(Brownian motion) of free particles in liquid solely depends on their size if the 
temperature and viscosity are constant. Therefore, by calculating the velocity of 
tracked particles Nanosight Software can calculate the particle size. 
93 
Sample preparation 
Human urinary samples from the RDS and the ET2D studies that had been stored at  
-80°C were slowly defrosted on ice. Samples were vortexed thoroughly to optimize 
the exosome recovery(Zhou, Yuen et al. 2006). Samples and standards were diluted 
1:25 (ET2D) or 1:50 (RDS) with pre-filtered (syringe filters with 0.1um pore size, 
Millipore) PBS (GIBCO) or distilled water.  
Urinary samples from rats were taken from aliquots of the 24hours collection of the 
Cyp1a1mRen2 reversal study(Conway, Betz et al. 2014). Since urine had been 
collected by keeping the rats in metabolic cages, some urine samples contained 
debris that was easily pelleted by a centrifugation step at 500g for 5min before 
further processing. 
The best method to adequately normalize for differences in urinary concentration is a 
debated issue(Salih, Zietse et al. 2014).  For most urinary biomarkers, normalization 
to urinary creatinine is calculated to compensate for variations caused by diurnal 
variations in urinary output. This approach has been applied in humans for the 
measurement of urinary exosomes (Oosthuyzen, Scullion et al. 2016). In general, 
human urinary output does normally not vary more than 100% or 150%. However, 
the urinary 24 hours output in the Cyp1amRen2 reversal model increases up to 
1000% from baseline to injury. Normalization calculated after measurement could 
artificially create differences between the groups. Therefore urinary samples from the 
Cyp1a1mRen2 reversal DN model were beforehand normalized to the 24 hours 
volume, i.e. samples were diluted with filtered PBS according to their ratio to the 
sample with the highest volume.  
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Alternative normalization factors instead of urinary creatinine or 24 hours volume 
are the total exosome concentration or the use of “pan-exosome” markers. However, 
out of a number of the suggested housekeeping candidates (CD9, CD24, CD 81, 
TSG-101, ALIX) no consensus has been reached so far on the optimal choice(Salih, 
Zietse et al. 2014, Edgar 2016, Morrison, Bailey et al. 2016). Before measurement all 
samples were diluted 1:100.  All samples were kept on ice after thawing. In addition, 
for each measurement the sample temperature was measured by Nanosight LM10 
and integrated into the Brownian motion formula. 
For the fluorescent measurement of Qdot (605nm) (Life Technologies) conjugated 
antibodies, 1000l of sample volume was incubated with 1l of the respective 
antibody for 20-30 minutes. The following antibodies were used: rabbit anti-nephrin 
(ABT319, Milipore, polyclonal IgG), rabbit anti-cubilin (ab65773, Abcam, 
polyclonal IgG), rabbit anti-aquaporin 2 (ab3274, Millipore, polyclonal IgG) and as 
isotype control a mouse IgG (Invitrogen). 
Qdot conjugation with antibodies 
Qdot fluorophores are nanocrystals (5nm-20nm) that contain in their core aggregates 
of atoms of a semiconductor material (cadmium mixed with selenium or tellurium) 
surrounded by a zinc sulphide shell. Biomolecules are attached to the coating 
polymer layer. Upon excitation their fluorescent emission results from the formation 
of stable excitons. In comparison to traditional fluorophores Qdots have a more 
intense brightness and longer photostability. The emission wavelength depends on 
the size of the Qdot. 
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The conjugation of antibodies was performed with the Qdot Antibody conjugation kit 
605nm (Invitrogen) according to the manufacturer’s instructions. In short, 500l 
Qdots were activated by incubation with the amine-thiol crosslinker SMCC (N-
Succinimidyl 4-(N-maleimidomethyl)cyclohexane-1-carboxylate) for 60min and the 
antibody (1mg/ml) in 300l was reduced by incubation with DTT for 30min 
followed by binding to a dye labelled marker and by a desalting step using a 
desalting column. Thereafter Qdots and antibodies were incubated for 1 hour to 
conjugate. The process was quenched by addition of -mercaptoethanol for 30min. 
Subsequent to a concentration step by ultracentrifuging (7000rpm, 15min) the 
conjugate was purified by running through a separation media column. The resulting 
concentration of the conjugated Qdots is typically in the range of 1-2 M. 
Quality control 
Before every measurement run on the Nanosight LM10, silica beads (Kisker Biotech, 





respectively from a large stock of aliquots that had been prepared before 
were measured. 
Calculations for total, intra- and inter-assay variation were based on “User 
verification of performance for precision and trueness; approved guideline – second 
edition.” (Clinical and Laboratory Standards Institute.  CLSI document EP15-A2. 
Wayne, PA, USA: CLSI; 2005) as described by Chesher (Chesher 2008) with slight 
adaptions.  In brief, the within-laboratory precision expressed as standard deviation 
(SD) (St) by √ 
𝑛−1
𝑛
× 𝑠𝑟2 + 𝑠𝑏
2 with sr being the repeatability and sb the SD of means 
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with D = total number of days, n = total number of replicates per day, xdr=result for 
replicate r on day d, 
 
𝑥𝑑
 = average of all replicates on day d. In this work eight days 
were taken for observation period. The coefficient of variation is calculated as the 





For non-fluorescent light-scatter mode the standard camera level 16 was used. The 
gain was 512, the shutter 26 ms, threshold 10, minimal expected size and minimal 
track length were set as “auto”. For the fluorescent mode (532nm laser with long-
pass filter [430nm]) the detection threshold was set at 6. 
Measurement of exosomes by NTA Technology  
The optimal stage and focus for the camera was determined manually with the 
microscope (Gardiner, Ferreira et al. 2013). Before the measurements were recorded, 
1ml of filtered PBS was inserted into the measurement chamber to confirm that there 
were no particles. Then approximately 0.6 ml of the diluted samples or standards 
were sequentially inserted into the measurement chamber of the Nanosight LM10 
machine (Malvern Instruments, UK). For fluorescent measurement the level and 
position of the camera was checked in the light-scatter mode first before the long-
pass filter (430nm) was used. For each measurement altogether three video 
sequences for 30 seconds were recorded as replicates. Between each replicate 
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measurement an additional 0.1ml-0.2ml of the sample were inserted into the 
chamber. Between each sample the chamber was rinsed with filtered water and PBS 
until no particles were visible.  
For the analysis, the software tracks automatically the motion of particles in the 
recorded video sequences. From the velocity of particle movement the software 
calculates particle size based on the Stokes-Einstein equation and from the number of 
particles tracked the software calculates the concentration. The results are visualized 
in a size (x-axis) vs concentration (y-axis) plot. The total concentration for all 
particles between 20nm and 100nm was calculated as the area under curve (AUC20-
100nm) determined following the trapezoidal rule as published by Oosthuyzen et al. 
(Oosthuyzen, Sime et al. 2013, Oosthuyzen, Scullion et al. 2016).  
2.13 Flow Cytometry (FCM) 
For flow cytometry analysis the Attune (Life Technologies) Flow Cytometer that 
employs on acoustic focusing was used. This technique allows high flow rates and 
reduces background noise which is especially advantageous at low particle size 
range.  
Sample preparation 
For rat urine in the Cyp1a1mRen2 model, to compensate for the great variation in 24 
hours urinary excretion, as described above, urine was pre-diluted in filtered (0.1 
µm) PBS to an overall volume of 600µl with the samples diluted according to the 
ratio of their volume to the urine sample with highest 24 hours urinary volume.  
98 
For human urine 1 ml per sample was used and subsequently corrected for 
differences in urine concentration by reference to urinary creatinine. Microvesicles 
were isolated by differential centrifugation as described by Burger et al. (Burger, 
Thibodeau et al. 2014) with slight modifications: After a centrifugation at 2500g for 
20min to remove large debris the supernatant was transferred to a fresh 2ml 
Eppendorf tube and centrifuged at 20,000g for 20min to pellet the microvesicles. 
Afterwards the exosomes containing supernatant (approximately 550µl (rats) or 
950µl (humans) respectively) was removed and microvesicles remained in 
approximately 50 µl of residual diluted urine. 
Quality control 
Every sample run included an empty control (PBS without sample and dye) as well 
as Bodipy-Maleimide (BoM) without sample or sample without BoM. A 
performance test was run on a daily basis using Attune Performance Tracking Beads 
(Life Technologies) that contain a distinct mixture of beads of different sizes and 




For defining the size gate 200nm and 1000nm silica beads (Kisker) were used(van 
der Pol, Coumans et al. 2014). Serial dilutions were performed to exclude swarm 
detection. After preliminary optimizing experiments the following setting was used: 
For Side Scatter (SSC) the applied voltage was 3900mV, the threshold was 5. For 
Forward Scatter (FSC) the applied voltage was 3250mV and the threshold was 5. For 
the Blue laser (488nm) (530/30nm Filter) the voltage was set 1350mV. 
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Measurement of microvesicles by Attune FCM 
Eppendorf tubes containing approximately 50µl of suspended microvesicles were 
mixed with 3µl (rats) or 5µl (humans) of freshly thawed and diluted aliquots of 
Bodipy-Maleimide (50µM) (BODIPY FL N-(2-Aminoethyl))Maleimide), Life 
Technologies) to a final concentration of 3-5µM BoM (Enjeti, Lincz et al. 2008). 
Some samples were incubated with 3µl Annexin V Pacific Blue (BioLegend, 
London, UK) and the calcium concentration was increased to about 2.5mmol/l to 
ensure binding of Annexin V. In the human study 1µl of mouse anit-podocalyxin IgG 
antibody (TRA-1-60R, monoclonal, PerCP-conjugate, 1mg/ml, Novus Biologicals, 
biotechne, Abingdon, UK, 1mg/ml) or 1µl of mouse IgG (monoclonal, PerCP-
conjugate, 1 mg/ml, Novus Biologicals) as an isotype control was added. The sample 
was vortexed after addition of the respective antibodies, and kept for 60min in the 
dark. Subsequently samples were diluted with 130µl filtered (0.1 µm) PBS and 






3.1 The Cyp1a1mRen2 Rat Model of Diabetic Nephropathy 
3.1.1 Introduction 
As mentioned before there are few models that mimic the pathological features of 
advanced human DN. One of them is the Cyp1a1mRen2 rat model that combines 
hyperglycaemia with hypertension resulting in marked albuminuria, renal fibrosis 
and transcriptomic changes that are similar to those observed in the kidney of 
patients with DN(Conway, Rennie et al. 2012). In order to study mechanisms that 
promote renal remodelling and markers that indicate regression of albuminuria and 
fibrosis the model was extended to include a ‘reversal group’ in which glycaemia 
was tightly controlled using insulin and blood pressure normalised after an injury 
period(Conway, Betz et al. 2014).  
The analysis of this Cyp1a1mRen2 reversal DN model in this chapter was performed 
on archive tissue that was available to me from a previous study.  
3.1.2 Pathological parameters of the reversal model 
The key biochemical and pathological features of the model have been published 
previously(Conway, Betz et al. 2014) and are summarised in Table 3. Albuminuria 
increased in the diabetic and hypertensive rats (injury cohort) and decreased by more 
than 50% after eight weeks of tight blood glucose and blood pressure control 
(reversal cohort), although it remained persistently greater than in controls. After 
28wks of diabetes and hypertension, the creatinine clearance was not significantly 
different when compared with controls and it remained unchanged following 8wks of 
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relative normalisation of glycaemia and blood pressure.  The mean kidney:body 
weight ratio increased in the injury cohort compared with controls and while this fell 
significantly in the reversal cohort it remained significantly greater than in controls. 
There was a marked increase in the glomerulosclerosis and tubulointerstitial fibrosis 
indices in the injury cohort compared with controls and this remained persistently 
increased despite 8 weeks of tight glycaemic and blood pressure control.  
As both increased glomerular volume and reduced numbers of glomeruli can be 
phenomena associated with advanced human DN (Review by Fioretto et al.(Fioretto 
and Mauer 2007)), these parameters were determined in the current model. There 
were no differences in the mean hilar glomerular cross-sectional area or the number 
of glomeruli per tissue section between the cohorts (Figure 14). A trend towards a 
reduction in the mean number of WT1 positive podocytes/hilar glomerular cross-
section in the injury and reversal cohorts compared with control animals did not 
reach statistical significance (p = 0.07) (Figure 15). 
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Table 3: Parameters of the control and experimental groups 
 








       












Albumin to creatinine 















2.37 (0.63) 2.34 (0.40) 2.59 (0.63) 
Kidney weight (g) 1.38 (0.1) 1.64
a
 (0.21) 1.53 (0.19) 



























Table 3. Parameters of the Cyp1a1mRen2 model in controls, after 28 weeks of induced 
diabetes and hypertension (injury phase) and following 8 weeks of tight blood pressure and 
glucose control (reversal phase). The index score represents an average of all glomeruli 
/tubulointerstitial fields graded with 0: normal; grade 1: <25%; grade 2: 25–50%; grade 3: 
50–75% and grade 4: >75% of area sclerosed/fibrosed. a p<0.05 and aa p<0.001 v control; 
b p<0.05 and bb p<0.001 v injury cohort.  
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Figure 14. (A) The mean (SEM) planar glomerular hilar areas and (B) the mean (SEM) 
number of glomeruli per section was not altered between the control (n=6) injury (n=9) and 
reversal (n=9) groups. In (A) the glomerular area is expressed as % of the mean area from 
all controls  









Figure 15. Tissue sections were immunostained for the well-established podocyte marker 
WT1. (A)-(C) Representative images of WT1 positive cells (arrows) in the glomeruli of control 
(n=6), injury (n=9) and reversal (n=9) groups. The scale bars represent 20 µM. (D) For each 
animal the mean number (+/-SEM) of WT1+ cells per glomerulus was calculated in the 
control, injury and reversal groups. There was a trend (p=0.07) towards a reduction in the 
injury group. 
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3.1.3 Genes upregulated specifically during injury phase 
Of the 677 genes that were significantly upregulated in renal tissue of the injury 
group, 85 of these fell >50% towards control levels following 8 weeks of tight 
control of glycaemia and blood pressure (Appendix). The list was entered into 
DAVID (Database for Annotation, Visualization and Integrated Discovery, v6.8 
Beta)(Huang da, Sherman et al. 2009) for functional annotations and the most 
significantly over-represented category (p-value) was cell signalling, followed by 
secreted and extracellular matrix (Table 4). This was also reflected by pathway 
analysis using DAVID and the KEGG (Kyoto Encyclopedia of Genes and Genomes) 
database(Kanehisa, Sato et al. 2016) with extracellular matrix-receptor interaction 
being the most over-represented pathway (Table 4) (Conway, Betz et al. 2014). 
Expression of the alpha-1 chain of collagen Type I (Col1a1) and transgelin (a marker 
of smooth muscle cells and myofibroblasts, similar to α-smooth muscle actin) genes 
were validated by realtime-PCR. Following 8 weeks of reversal of hyperglycaemia 
and hypertension there was a marked reduction in the mRNA levels of transgelin in 
the reversal group compared to the injury cohort (Figure 16). In control animals 
transgelin was restricted to arterial smooth muscle cells. The expression of transgelin 
increased significantly in the injury group in the glomerular compartment with a non-
significant reduction in the reversal group (Figure 17). In the tubulointerstitial 
compartment transgelin staining was increased in both the injury and reversal cohorts 
(Figure 18). Thus, in contrast to transgelin mRNA expression that falls during the 
reversal phase, the immunohistochemistry results indicated that the tissue expression 
of transgelin protein was sustained. 
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Table 4: Analysis of genes upregulated specifically in the injury cohort 
A 
     




Signalling 46 59.7 5.30E-18 6.40E-16 
Extracellular matrix 12 15.6 1.50E-12 8.90E-11 
Secreted 24 31.2 5.70E-12 2.30E-10 
Disulfide bond 31 40.3 7.50E-11 2.30E-09 
Glycoprotein 30 39 9.40E-10 2.30E-08 








ECM-receptor interaction 9 11.7 1.00E-08 7.70E-07 
Protein digestion and absorption 8 10.4 2.20E-07 8.30E-06 
PI3K-Akt signaling pathway 12 15.6 5.20E-07 1.30E-05 
 
 
Table 4. List of (A) functional annotation categories and (B) pathways which are most 
significantly overrepresented amongst genes that are upregulated specifically in the injury 
cohort compared to control and reversal cohorts using the DAVID and KEGG databases. In 
both lists extracellular matrix genes are prominently represented. In (B) only pathways with 
p<0.05 were retained and pathways that were related to infections (e.g. Amoebiasis) were 
removed since they were not of interest in the current study. 
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Figure 16: Collagen I and transgelin gene expression 
A B 
  
Figure 16. Relative gene expression of (A) alpha-1 chain of type I collagen that is a key 
component of the extracellular matrix and (B) transgelin that is an established marker for 
myofibroblasts Both genes validate the microarray results as they are significantly 
upregulated specifically in the injury cohort. Data is presented as meanSEM. n=6 for all 
groups. **P < 0.01 and ***P < 0.001 vs controls; # P < 0.05 and ## P < 0.01 vs injury cohort. 
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Figure 17. (A)-(C) Representative images of transgelin immunohistochemistry and (D) 
quantification of the area staining positive for transgelin in the glomerular compartment. 
Transgelin expression is increased in the injury cohort compared to controls while in the 
reversal (n=9) group transgelin expression is not significantly different from either the injury 
(n=10) or the control (n=6) groups. Data is presented as meanSEM. Scale bars represent 
50M. *p<0.05 vs control. 
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Figure 18. (A)-(C) Representative images of transgelin immunohistochemistry and (D) 
quantification of the area staining positive for transgelin in the tubulointerstitial compartment. 
There is significantly increased expression of transgelin in the injury (n=10) and reversal 
(n=9) cohorts compared to control (n=6). Data is presented as meanSEM. Scale bars 





3.1.4 Genes upregulated during the injury and reversal phase 
Amongst the 677 genes that were upregulated after 28 weeks of induced 
hypertension and hyperglycaemia, the expression of 314 genes either increased 
further or fell by <20% of peak values following 8 weeks of tight blood glucose and 
blood pressure control (Appendix). Analysis of the gene list by DAVID suggested 
that there was a significant over-representation of genes implicated in the annotation 
categories of innate and adaptive immunity as well as degradation of ECM. This was 
reflected by pathway analysis (Table 5). Consistent with the microarray data, real-
time PCR confirmed that there was increased expression of the Foxp3 gene, a marker 
of regulatory T-cells (Tregs) in both the injury and reversal groups compared with 
controls. Aggregates of B-cells were also present during both injury and reversal and 
were typically located adjacent to blood vessels and associated with T-cells (Figure 
19). An infiltration of ED1
+
 macrophages was observed in the tubulointerstitium in 
both the injury and reversal cohorts, however there was no significant change in 
glomerular macrophage count (Figure 20). Immunostaining for inducible nitric oxide 
synthase (iNOS) and mannose receptor (MR) provided evidence supporting a switch 
in macrophage phenotype in the model. iNOS
+
 cells that might represent classically 
activated macrophages were increased in the injury group (Figure 21), whereas MR
+
 
cells that might represent alternatively activated macrophages were identified in both 




Table 5: Functional annotation and pathway analysis of upregulated genes during 
injury and reversal phase 
A 
     




Immunity 14 5 1.40E-05 2.80E-03 
Signalling 69 24.5 4.60E-05 4.70E-03 
Disulfide bond 52 18.4 5.20E-05 3.50E-03 
Zymogen 10 3.5 1.60E-04 8.00E-03 
Adaptive immunity 6 2.1 5.40E-04 2.20E-02 
Phosphoprotein 78 27.7 5.70E-04 1.90E-02 
Glycoprotein 48 17 1.50E-03 4.20E-02 
Cytoplasm 50 17.7 5.10E-03 1.20E-01 
Metalloprotease 6 2.1 1.10E-02 2.20E-01 










Primary immunodeficiency 8 2.8 5.50E-07 1.00E-04 
Hematopoietic cell lineage 9 3.2 2.10E-05 1.90E-03 
T cell receptor signalling pathway 10 3.5 2.30E-05 1.40E-03 
Natural killer cell mediated cytotoxicity 9 3.2 7.70E-05 3.60E-03 
Fc gamma R-mediated phagocytosis 8 2.8 2.20E-04 8.20E-03 
Phagosome 9 3.2 7.60E-03 1.30E-01 
NF-kappa B signaling pathway 6 2.1 9.40E-03 1.40E-01 
Antigen processing and presentation 6 2.1 1.30E-02 1.70E-01 
Cytokine-cytokine receptor interaction 8 2.8 3.70E-02 3.40E-01 
Cell adhesion molecules (CAMs) 7 2.5 3.90E-02 3.20E-01 
 
Table 5. List of (A) functional annotation categories and (B) pathways which are most 
significantly over-represented amongst genes that are upregulated in both the injury and the 
reversal cohort compared to control using DAVID and KEGG databases. Immunity and ECM 
degradation are annotation categories of interest while immunity pathways especially the T-
cell signalling seems to be enriched with genes upregulated in injury and reversal groups. In 
(B) only pathways with p>0.05 were retained and for clarity pathways that were related to 
infections (e.g. Toxoplasmosis and Tuberculosis) were removed since they were not of 
interest in the current study.  
112 






Figure 19. (A) Relative expression of the Foxp3 gene as a marker of regulatory T-cells is 
markedly increased in injury and reversal cohorts compared to controls, n=6 for all groups. 
Data is presented as meanSEM, *p<0.05 and **p<0.01 vs controls. (B) and (C) 
Representative staining CD45R
+
 cells in a reversal group animal demonstrates the 
persistence of B-cell aggregates (arrowhead in [B], green cells in [C]) in the renal cortex in 
the reversal cohort. B-cell aggregates are typically adjacent to blood vessels (B - arrowed) 
and associated with T-cells (C - red). In (C) CD45R coupled with Alexa Fluor 488 was used 












Figure 20. Tissue sections were stained for the macrophage marker ED-1 and the mean 
numbers of ED-1 positive cells (A) per glomerulus and (B) per x400 tubulointerstitial field 
were calculated and averaged for the control (n=6), injury (n=10) and reversal (n=9) groups. 
Representative images are depicted for each group with arrows indicating ED-1 positive cells 
in the tubulointerstitium. The scale bars represent 100 M There was a significantly 
increased tubulointerstitial infiltration of ED-1 positive macrophages in the injury and reversal 
cohorts. Data is presented as meanSEM. *p<0.05 and **p<0.01 vs controls.  
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Figure 21. (A)-(C) Representative images of iNOS positive cells (arrows) for the control, 
injury and reversal groups. The scale bars represent 100 M. (D) For each animal the mean 
number of iNOS +ve cells per x400 tubulointerstitial field was calculated and the mean ( 
SEM) averaged for the control (n=6), injury (n=10) and reversal (n=9) cohorts is provided. 
There was an increased infiltration of iNOS
+
 cells in the injury group compared to control and 
reversal.  ** p<0.01 vs all other groups. 
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Figure 22. (A)-(C) Representative images of mannose receptor positive cells (arrows) for the 
control, injury and reversal groups. The scale bars represent 100 M. (D) For each animal 
the mean number of mannose receptor +ve cells per x400 tubulointerstitial field was 
calculated and averaged. The mean (SEM) for the control (n=6), injury (n=10) and reversal 
(n=9) cohorts is provided. There was an increased infiltration of mannose receptor +ve cells 
in the injury and reversal groups compared to controls.  ** p<0.01 *** p<0.001 vs all other 
groups. 
3.1.5 Regulation of factors for extracellular matrix degradation 
Real-time PCR confirmed that the expression of multiple matrix metalloproteinase 
(MMP) genes was elevated in the injury group, with MMP-7 and MMP-12 being 
persistently elevated or further increased during reversal, whilst MMP-2 and MMP-
14 levels returned towards control levels in the reversal group (Figure 23)   
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Despite the reduction in pro-fibrotic gene expression and persistent increase in the 
expression of some MMP genes in the reversal group, there was no reduction in 
glomerular or tubulointerstitial fibrosis evident (Table 3). It is recognised that MMP 
gene expression may not correlate with proteolytic activity due to the presence of 
endogenous inhibitors of enzyme activity. Hence, the biological activity of ECM 
degrading enzymes was assessed in each group. There was a paradoxical decrease in 
renal MMP activity in both injury and reversal groups as assessed by gelatinase and 
collagenase activity assays (Figure 24). Gene expression of tissue inhibitor of 
metalloproteinases (TIMP)-1 and to a lesser extent TIMP-2, were increased during 
injury, TIMP-3 expression was not significantly increased (Figure 25). TIMP-1 gene 
expression fell significantly in the reversal group but remained significantly higher 
than controls, whereas TIMP-2 expression in the reversal group was not different 
from either the control or injury groups. In contrast to the pattern of renal gene 
expression, urinary excretion of TIMP-1 protein increased significantly after 28 
weeks of hypertension and hyperglycaemia and remained significantly elevated 
compared with controls despite 8 weeks of reversal of diabetes and hypertension. 
Expression of TIMP-1 protein in the renal cortex was persistently upregulated at a 
similar level in the injury and reversal groups (Figure 25).When TIMPs were 
physically separated from the MMPs using gel zymography, the gelatinase activity in 
both the injury and reversal cohorts tended to be greater than in controls and 
collagenase activity was significantly greater during reversal than in controls (Figure 
26). This was in stark contrast to the reduced MMP activity in whole kidney lysates, 
when endogenous inhibitors may be complexed with the degradative enzymes.   
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Figure 23. (A)-(D) The mean (SEM) relative expression of the MMP-2, MMP-7, MMP-12 
and MMP-14 genes was significantly increased in the injury and reversal groups compared 
to controls. n=6, * p<0.05, ** p<0.01 and *** p<0.001 vs control. ## p<0.01 and ### p<0.001 
vs injury cohort. 
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Figure 24.  Mean (SEM) activity in renal cortical kidney homogenates from the injury and 
reversal groups was markedly decreased for (A) Gelatinase and (B) Collagenase activity 
compared to control. For validation in every assay an enzymatic inhibitor was added. * 
p<0.05, ** p<0.01 and *** p<0.001 vs control, n=6 for all groups. 
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Figure 25. (A)-(C) Relative mean (SEM) expression of (A) TIMP-1, (B) TIMP-2 but not (C) 
TIMP-3 genes was significantly increased in cortical tissue homogenates from the injury 
group but not the reversal group in comparison with controls (n=6 for all groups). (D) The 
mean (SEM) 24 hour urinary TIMP-1 excretion in 5 animals from the reversal cohort was 
measured at 3 time points during the experiment. After 28 weeks of induced hypertension 
and hyperglycemia TIMP-1 excretion significantly increased compared to baseline and 
remained increased after 8 weeks of tight blood pressure and glycemic control. (E) Relative 
quantification of TIMP-1 protein by Western blotting with densitometry demonstrates 
increased expression in the renal cortex from injury and reversal animals compared to the 
controls (n=6 for all) Data is presented as meanSEM. (F) Representative Western blot 
image with a positive control (rTIMP1, 60kDa. Beta-actin (45 kDa) was used for 
normalisation for protein loading. * p<0.05 vs control cohort.  
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Figure 26. Representative images of gel-zymography demonstrating activity of (A) gelatinase 
(72kDa band) and (B) collagenase (52 kDa band) respectively in the control, injury and 
reversal groups. Gelatinase activity was non-significantly and collagenase was significantly 
increased in the reversal group. Data given are meanSEM. n=6 for all groups. ** p<0.001  
3.1.6 In situ zymography in a reversed UUO model 
To assess the tissue localisation of MMP activity, a reversible unilateral ureteric 
obstruction (R-UUO) model(Hesketh, Vernon et al. 2014) was employed, as depicted 
schematically in Figure 27. Successful de-obstruction was confirmed visually by 
assessing the size and tension of the renal pelvis(Hesketh, Vernon et al. 2014).   
Expression of type I collagen in the renal cortex by immunohistochemistry was 
markedly increased in the UUO group and remained elevated in the reversed UUO 
group compared to sham (Figure 28). Type III collagen expression was augmented in 
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the UUO group, and after reversal of UUO the expression of type III collagen 
remained markedly elevated but was not significantly different to either sham or 
UUO (Figure 29).  
In situ zymography was performed on cryosections of kidneys from sham, UUO and 
reversed UUO groups. While there was homogenous tubulointerstitial enzymatic 
activity in sham animals, proteolytic activity for DQ-gelatine® in the UUO group 
and in the reversed UUO group fell dramatically resulting in focal islands of residual 
activity (Figure 30). When collagen I staining was performed alongside in situ 
zymography there was an inverse spatial correlation between collagen deposition and 
enzymatic activity as illustrated in Figure 31. When the expression of collagen I was 
compared with gelatinase activity from renal cortex lysates from each animal, an 
inverse correlation was apparent (Table 6). Similar results were observed with type 
III collagen and gelatinase activity, though this marginally failed to reach 
significance. Finally as some suggest that fibrosis develops more distinctly in polar 
renal regions than in the central region and resolves more easily in the 
latter(Cochrane, Kett et al. 2005), enzymatic activity analysis was divided into 
pictures taken from the polar and central region. Separate analysis confirmed a trend 
towards higher proteolytic activity in the central region of both UUO and R-UUO 
animals (Figure 32) compared to polar areas, however without reaching statistical 
significance mainly due to great variance of enzymatic activity in the central regions.  
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Figure 27. A) Illustration of experimental design for the reversal UUO study. Mice underwent 
unilateral ureteric obstruction (UUO) or sham surgery. After 10 days the UUO D10 and sham 
surgery groups were harvested whilst some mice underwent surgical reversal of UUO. The 
reversed UUO D10/39 group was harvested after 10 days of unilateral ureteric obstruction 
and another 29 days of de-obstruction. If not otherwise indicated numbers were n=6 for 
sham surgery controls and UUO D10 and n=3 for R-UUO D10/39. B) Representative 
pictures of collagen type III for control, UUO D10 and R-UUO 10/39 demonstrate many 










Figure 28. (A)-(C) Representative images of collagen type I immunohistochemistry and (D) 
quantification of mean (SEM) area staining positive for collagen I in the tubulointerstitial 
compartment of each group. Mean (SEM) collagen expression is increased in these two 
groups compared to control. Scale bars represent 100M. *p<0.05 vs sham. n=6 for sham 
and UUO D10 and n=3 for R-UUO D10/39.  
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Figure 29. (A)-(C) Representative images of collagen type III immunohistochemistry and (D) 
quantification of the area staining positive for collagen III in the tubulointerstitial compartment 
of each group. There are many dilated tubules evident in the UUO D10 group but only few in 
RUUO D10/39. Mean (SEM) collagen expression is increased in the UUO D10 group 
compared to control. Scale bars represent 100M. **p<0.01 vs sham. n=6 for sham and 
UUO D10 and n=3 for R-UUO D10/39. 
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Figure 30. In situ zymography in murine kidneys. Representative pictures of in situ activity 
(bright green) utilizing a DQ-gelatine® substrate in kidneys from (A) sham animals, (B) 
animals after 10 days of renal obstruction (UUO D10) and (C) animals after an additional 28 
days of following reversal of de-obstructed kidneysUUO (R-UUO D10/39). For comparison 
and validation one (D) sham animal section was treated without substrate whilst another 
tissue section from one (E) sham animal was incubated with a mixture comprising 20mM 
EDTA and 60mM 1,10 phenanthroline (inhibitors of MMP activity) added to the MMP 
substrate. (F) Quantification of proteolytic -activity by assessing the mean (SEM) 
fluorescent intensities per section demonstrated a marked reduction of activity in the UUO 
D10 and RUUO D10/39 groups in comparison with control animals. n=6 for sham and UUO 
D10 and n=3 for R-UUO D10/39. Scale bars represent 200M 
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Figure 31: In situ -zymography and collagen III immunostaining in the UUO model 
 
Figure 31. Representative photomicrograph of one section from a kidney obstructed for ten 
days that was first incubated with DQ-gelatine as substrate for zymography and then labelled 
for deposition of collagen type III (red) that was present in areas with little proteolytic activity 
(dim green). Scale bars represent 100M. 
Table 6: Correlation between collagen types I & III and proteolytic activity in the UUO 
reversal model 
Spearman’s rho r p 
collagen I vs collagen III 0.81 0.011 
collagen I vs proteolytic activity -0.75 0.025 
collagen III vs proteolytic activity -0.66 0.059 
Table 6. The extent of correlation between Collagen type I and III protein expression and 
proteolytic activity in animals from each group was compared using Spearman’s Rank 
correlation. n=6 for sham and UUO D10 and n=3 for R-UUO D10/39. 
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Figure 32: Iin -situe Zymography ofin renal the polar and middle central regions of the 








Figure 32. Representative images of in situ activity (bright green) utilizing a DQ-gelatine 
substrate in kidneys from UUO and reversed UUO animals in the (A,C) polar and (B,D) 
middle central region. (E) Quantification of proteolytic activity using fluorescent intensity from 
photomictographs from the respective region. There was a (non-significant) trend for more 
gelatinase activity in the central middle regions compared to the renal polar zones. (F) 
Schematic illustration of the localization of the “p” polar region and “m” middle central region. 
n=6 for UUOD10 and n=3 for R-UUO D10/39. Scale bars represent 100M. 
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3.1.7 Discussion 
Although regression of both albuminuria(Perkins, Ficociello et al. 2003) and renal 
fibrosis (Fioretto, Steffes et al. 1998, Fioretto, Sutherland et al. 2006) has been 
observed in patients with DN, the mechanisms that mediate repair in the diabetic 
kidney remain poorly understood. The current study represents an attempt to 
characterise the pathways that may promote regression of DN in a 
pathophysiologically relevant model.  
Histopathological parameters of the Cyp1a1mRen2 rat reversal model 
Previous studies in this model determined that tight control of the two major clinical 
risk factors for progression of DN, namely hyperglycaemia and hypertension, 
resulted in a marked reduction in albuminuria and renal hypertrophy. However, there 
was no evidence of resolution of established glomerulosclerosis or tubulointerstitial 
fibrosis, despite 8 weeks of relative normoglycaemia and normotension (Conway, 
Betz et al. 2014). There was an almost significant trend towards rarefaction of 
podocytes as an additional pathological marker of glomerular dysfunction that has 
been demonstrated in the Cyp1a1mRen2 model (Advani, Wiggins et al. 2011) and 
the leptin -deficient BTBR ob/ob mouse model (Pichaiwong, Hudkins et al. 2013). In 
the latter model of DN Pichaiwong et al. demonstrate not only functional (reduction 
of albuminuria) but also histopathological reversal of renal injury by 
supplementation of leptin. The difference in the degree of reversibility of histological 
features between these models might be related to differences in strain and species 
(BTBR mice vs Fischer rats) and to the pathophysiology of the model (leptin 
deficient type 2 diabetes vs streptozotocin-induced type 1 diabetes). The failure of 
130 
structural resolution in the current study might better reflect the time course of 
human disease, in that it takes ten years of normoglycaemia following pancreatic 
transplantation to achieve regression of glomerulosclerosis, with no improvement 
documented after five years (Fioretto, Steffes et al. 1998). Therefore one might 
speculate that a longer reversal period might not only have stopped progression of 
fibrosis but induced regression on a histological level. 
Upregulation of “pro-fibrotic” genes specifically in the injury group 
There were considerable alterations in genetic profile between the control, injury and 
reversal groups (Conway, Rennie et al. 2012, Conway, Betz et al. 2014).  Prior to the 
study, it was hypothesized that the removal of injurious stimuli (hypertension and 
hyperglycaemia) might result in downregulation of genes promoting renal fibrosis 
and glomerulosclerosis. In support of this hypothesis, pathway analysis of the 85 
genes that were specifically upregulated during injury, but which fell >50% towards 
control levels identified enrichment for functional categories and pathways 
implicated in fibrosis.  Collagen is a major contributor to ECM and transgelin is a 
marker for myofibroblasts that play a key role in the production of ECM (Meran and 
Steadman 2011). The results of the pathway analysis together with the reduction in 
expression of col1a1 and transgelin genes in the reversal group suggest that 
normotension and normoglycaemia might be sufficient to switch off excess ECM 
production and halt progression of renal fibrosis. This is supported by the fact that 
there was no increase in glomerulosclerosis or tubulointerstitial fibrosis indices in the 
reversal compared with the injury group. However, transgelin was not reduced on a 
protein level in the kidneys from reversal animals. This might indicate that 
myofibroblasts remain in the kidney during the reversal phase. Kisseleva et al. 
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demonstrate that myofibroblasts remain in a quiescent state in the liver after pro-
fibrotic stimuli had been removed (Kisseleva, Cong et al. 2012). However, this 
remains a highly speculative hypothesis in the current model, and it would 
necessitate future studies with a lineage tracing approach to be confident that this is 
indeed the case.  
Upregulation of “immunity” genes in the injury and reversal groups 
The majority of genes that were upregulated during injury remained upregulated in 
the reversal phase (Conway, Betz et al. 2014). It is possible that these were 
potentially reactive genes activated by the presence of renal structural damage rather 
than by external stimuli. Categorizing the genes using functional annotations and 
pathway analysis revealed that these genes were over-represented in pathways 
related to signalling, innate and adaptive immunity and phagocytosis, while pro-
fibrotic pathways were not well represented. This suggests that there has been a 
switch away from ECM production towards degradation and that immune responses 
may be implicated.   
Although the role of adaptive immunity in DN has not been fully understood yet, T- 
and B-cell infiltration has been documented in the kidneys of patients with DN as in 
the current experimental study (Cohen, Lindenmeyer et al. 2008). Regulatory T-cells 
have been attributed with anti-fibrotic effects (Gandolfo, Jang et al. 2009) and their 
marker foxp3 was upregulated in both injury and reversal groups. B-cells have been 
associated with a pro-fibrotic role e.g. via IL-6 or immunoglobulin production as the 
depletion of B-cells resulted in reduced fibrosis in liver fibrosis (Novobrantseva, 
Majeau et al. 2005) and renal allograft models (Tse, Johnston et al. 2015). Therefore 
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one might speculate that persistence of B-cells in the current model could be an 
explanation for the lack of reduction in fibrosis despite the removal of the damaging 
stimuli. Depleting B-cells during the injury and reversal phase might be a speculative 
but interesting treatment strategy in future studies. 
While macrophages have been implicated in the pathogenesis of progressive DN 
(Chow, Nikolic-Paterson et al. 2004), it is now appreciated that a subset of 
‘reparative’ macrophages exists, which are essential for resolution of fibrosis 
(Duffield, Forbes et al. 2005, Hadler-Olsen, Kanapathippillai et al. 2010). 
Specifically in the injury group the increase in iNOS
+
 cells might indicate an 
infiltration of classically activated macrophages  that might be involved in the pro-
inflammatory process (Anders and Ryu 2011). Mannose receptor positive cells are 
increased in both the injury and reversal groups compared to control. This provides 
evidence for the presence of macrophages with anti-inflammatory properties (Anders 
and Ryu 2011). This is consistent with the transcriptomic changes observed in whole 
kidney cortex. In both injury and reversal groups there  is upregulation of genes 
involved in matrix degradation (MMP12 see below), phagocytosis and lysosomal 
processing (Conway, Betz et al. 2014) and this may hint towards the presence of a 
reparative/fibrinolytic macrophage phenotype as has been observed in regression of 
liver fibrosis (Ramachandran, Pellicoro et al. 2012).  
Upregulation of “fibrosis-degrading” genes and increased MMP activity is 
counteracted by TIMPs in the injury and reversal group 
Matrix Metalloproteinases play an essential role in the breakdown of ECM though 
they have pleiotropic effects in DN (Xu, Xiao et al. 2014). In the current study, 
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microarray analysis identified that several MMP genes were upregulated during 
injury, and this was subsequently confirmed by real-time PCR for the gelatinase 
MMP2, the matrilysin MMP7, the macrophage specific MMP12 and the membrane 
specific MMP14. Review of other DN models shows conflicting reports about MMP 
expression (e.g. MMP2 (Xu, Xiao et al. 2014)) that could be caused by the use of 
different strains/species (e.g. MMP2 increased in Sprague-Dawley rat (McLennan, 
Kelly et al. 2002) but downregulated in Wistar rats (Sun, Wang et al. 2006) in STZ-
induced DM) and diverse degrees of severity of DN (e.g. MMP7 upregulated in the 
current model of advanced DN but downregulated in rats following induction of 
diabetes alone (McLennan, Kelly et al. 2007)). Similarly, there are conflicting reports 
in human DN e.g. for MMP7 (McLennan, Kelly et al. 2007, Cohen, Lindenmeyer et 
al. 2008, Woroniecka, Park et al. 2011). 
Though the expression of some upregulated MMPs reverted towards control levels in 
the reversal group, others stayed persistently elevated or increased even further. This 
prompted the hypothesis that in the reversal phase in which the progression of 
fibrosis was halted the scene was nevertheless set for degradation of ECM. However 
despite the increase in expression of multiple MMP genes there was failure of 
regression of ECM in the reversal group. This prompted further mechanistic 
investigations focusing on the biological activity of proteolytic enzymes.  
Despite the upregulated MMP genes gelatinase and collagenase activity was 
markedly reduced in both the injury and reversal cohorts. This is in line with the 
study by Ahmed et al. who reported reduced MMP gelatinase and collagenase 
activity in a fibrotic rat kidney after a 5/6 nephrectomy (Ahmed, Haylor et al. 2007). 
It is also in line with earlier reports regarding reduced MMP-2 activity and increased 
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TIMP-2 expression in STZ-induced diabetic rodents (McLennan, Kelly et al. 2002, 
Sun, Wang et al. 2006, Takamiya, Fukami et al. 2013). The reduction in activity had 
been less marked in the latter two cited studies compared to the current study as the 
models utilized were associated with only modest DN (McLennan, Kelly et al. 2002, 
Sun, Wang et al. 2006).  
In all of the aforementioned studies reduction in MMP activity was explained by 
increased expression of tissue-inhibitor-of-metalloproteinases (TIMP) 1 and/or 2. 
TIMPs are regarded to be the major inhibitors of MMPs and the TIMP/MMP balance 
regulates ECM degradation (Xu, Xiao et al. 2014). TIMP-1 and TIMP-2 have a 
similar mode of action by directly blocking MMPs and seem to compensate for each 
other (Kim, Oda et al. 2001). In the current study both TIMP-1 and -2 upregulation 
during injury was confirmed by rt-PCR with both declining in the reversal group but 
not to the level of controls. Unlike TIMP-1 and TIMP-2, TIMP-3 is associated with 
anti-fibrotic effects (Wang, Famulski et al. 2014) and remained unchanged 
throughout the experimental groups. In contrast to the gene expression pattern, there 
was no significant decline in urinary TIMP-1 excretion in the reversal phase 
compared to the injury phase. This was mirrored by similar TIMP-1 renal protein 
levels in the injury and reversal groups as assessed by western blotting. An increased 
level of TIMP-1/2 in DN rat kidney has been reported by others at both the gene 
expression and protein level (McLennan, Kelly et al. 2002, Sun, Wang et al. 2006, 
Thrailkill, Clay Bunn et al. 2009, Takamiya, Fukami et al. 2013), however this study 
for the first time demonstrates the gene-protein uncoupling after optimisation of 
blood pressure and glucose levels in DN. Gel zymography demonstrated that after 
physical separation from TIMP the activities of MMP-1 and MMP-2 were increased 
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in whole tissue homogenate in both the injury and reversal groups. The increased 
activity of MMP-2 in zymography is contradictory to the study by McLennan et al. 
who used a less severe rat DN model (induction of diabetes with STZ 
alone)(McLennan, Kelly et al. 2002), but in line with Takamiya et al. who used a 
mouse DN model(Takamiya, Fukami et al. 2013) and McKittrick et al. who 
demonstrate increased urinary MMP-2 and MMP-9 activity by using gel zymography 
in a rat DN model (McKittrick, Bogaert et al. 2011). In summary, these results 
demonstrate that it is necessary to assess renal expression of TIMP and MMP but 
also the degree of MMP activity to gain a fully functional picture of the dynamic 
degradation angle component in the ECM turn-over process. 
TIMP upregulation is induced by the inflammatory and pro-fibrotic cytokines TGF-
beta, IL-6, TNF-alpha and IL-4 (Khokha, Murthy et al. 2013). Moreover CTGF 
directly increases TIMP1 production in mesangial cells exposed to high glucose 
concentrations (McLennan, Wang et al. 2004). Intracellular regulation of TIMPs 
seems also to involve the pathways of protein kinase A, protein kinase C and MAPK 
(Li and Curry 2009). These factors could explain the upregulation of TIMP during 
the injury phase in the DM&HTN DN model. However, since inflammatory 
pathways are downregulated during reversal phase, alternative mechanisms may 
contribute to the persistent presence of TIMP.  
TIMPs are bound to surface lipoprotein-related protein-1 at the cellular membrane 
followed by internalization and degradation. Blockade of this process could prolong 
bioactive half-life of TIMPs and significantly shift the balance of TIMP turnover 
(Yamamoto, Murphy et al. 2015). Recently Scilabra et al. reported that TIMP3 is 
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bound to a soluble form of lipoprotein-related protein-1 (sLRP-1) that prevents 
TIMP3 from endocytosis (Scilabra, Troeberg et al. 2013). 
TIMP-1-v2 has been identified as an alternative splicing variant of TIMP-1 that 
might modify TIMP-1 expression in cancer cell lines (Obro, Lademann et al. 2008). 
A similar modification of TIMP1 might be present in renal cells. 
Using the reversed UUO model for in-situ zymography 
Having demonstrated that MMP activity is dependent on the amount of TIMP 
present, a logical next step would be to determine where in the kidney MMP activity 
and TIMP expression is observed. In situ zymography on kidney sections would be 
the method of choice to localise MMP activity in vivo and provide some additional 
mechanistic information. Firstly, it could confirm the ex vivo results from renal 
homogenates. Secondly, it would help to exactly locate focal areas of insufficient 
degradation (low MMP but high TIMP expression) enabling construction of an 
“activity map” in a renal tissue section. Thirdly, it can be utilized as a surrogate for 
TIMP expression since despite multiple attempts using several TIMP-1 antibodies, 
none worked in IHC. Similar problems have been reported by others (Ahmed, Haylor 
et al. 2007). 
Unfortunately no cryosections or zinc fixed paraffin blocks (Hadler-Olsen, 
Kanapathippillai et al. 2010) were available from the current reversal model in which 
to perform in situ zymography. Since repeating the 38-weeks Cyp1a1mRen2 diabetic 
and hypertensive rat model was beyond the scope of the current study an alternative 
way of inducing a reversible stimulus for renal fibrosis was sought. A well-
established (Hesketh, Vernon et al. 2014) model of reversible UUO was chosen. 
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Although the initiating stimulus for fibrosis is clearly different between the DN and 
UUO models, many of the downstream mechanisms converge to the final common 
pathways for renal fibrosis (Chevalier, Forbes et al. 2009) often accompanied by an 
inflammatory component. 
Initially the model was planned to be performed on Fischer rats as utilised in the DN 
model (Conway, Rennie et al. 2012, Conway, Betz et al. 2014). However, the 
surgery procedure was associated with a high mortality rate. So after consultation 
with our local veterinarian the strain was changed to Sprague-Dawley rats. However, 
still some animals unexpectedly died after surgery. Therefore, it was hypothesized 
that the susceptibility of death could be species related and future studies should be 
carried out in mice. 
The extension of the obstruction period to ten days was employed to ensure that a 
significant level of tubular fibrosis had developed before reversal was undertaken. 
Though de-obstruction surgery was successful as indicated by a decompressed renal 
pelvis and small slightly atrophic kidney, there was no measureable reduction of 
collagen expression by IHC. There are conflicting reports about the presence of 
resolution of fibrosis after a prolonged time of de-obstruction (Ito, Chen et al. 2004, 
Cochrane, Kett et al. 2005, Tapmeier, Brown et al. 2008). Differences in reversibility 
might be related to species or surgical technique (Hesketh, Vernon et al. 2014). The 
fact that the removal of the damaging stimulus did not result in reduction of fibrosis 
might increase comparability to the DN model. 
In accordance with other studies in normal kidneys from sham animals there was a 
constant homogenous gelatinase activity in the tubular epithelium contrasted by 
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lower focal activity in the glomeruli (Ahmed, Haylor et al. 2007, Hadler-Olsen, 
Kanapathippillai et al. 2010). During obstruction and after de-obstruction gelatinase 
activity was dramatically reduced consistent with a marked expression of collagen. 
These findings are in line with Ahmed et al. who studied MMP activity by in situ 
zymography in a fibrotic 5/6 nephrectomy model (Ahmed, Haylor et al. 2007). The 
positive correlation between collagen deposition and reduced gelatinase activity 
supports the hypothesis that reduced MMP activity is responsible for the persistence 
of excess ECM. Since other studies demonstrate elevated MMP and TIMP 
expression and increased MMP activity following separation of the MMP and TIMP 
by gel zymography in UUO models (Iimura, Takahashi et al. 2004, Wang, Famulski 
et al. 2014) one might hypothesize that in the reversal phases of both the DN and 
UUO models, the blockade of MMP bioactivity by TIMP might be a key common 
pathophysiological pathway of sustained renal fibrosis. 
We observed (unpublished) when performing the R-UUO model that some regions 
within the kidney progressed to fibrosis at different speed depending on the 
localization:  Polar “regions” of the kidney seemed to undergo accelerated fibrosis in 
contrast to the “middle” or central region of the kidney. We hypothesized that the 
reduced blood flow in polar regions might be one possible explanation. Interestingly, 
a similar effect was reported by Cochrane et al. in their R-UUO model with the polar 
regions exhibiting excess ECM deposition while the middle regions had only subtle 
signs of renal damage (Cochrane, Kett et al. 2005). In the present study there was a 
non-significant tendency for increased gelatinase activity in the middle region 
compared to the polar region in both the obstructed and the de-obstructed kidney. 
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While this interesting observation requires further pathophysiological investigations 
in future UUO studies, it underlines the tight association between reduced gelatinase 
activity and renal fibrosis/collagen deposition and helps to validate the methodology 
of in situ zymography in the UUO model. 
It remains 
Limitations 
The study has some limitations. Firstly, in the model both the hyperglycaemia and 
hypertension were reversed at the same time, so the individual extent to which each 
component contributed to the findings in the reversal group cannot be determined. 
While proteinuria was reduced during reversal, it did not return to baseline and the 
resultant low-grade tubular injury could have caused some of the gene/protein 
expression changes during the reversal phase. The UUO model typically does not 
cause sustained glomerular damage in contrast to the DN model (Conway, Rennie et 
al. 2012, Hesketh, Vernon et al. 2014). Therefore comparability of in situ 
zymography results between the two models is restricted to findings in the tubular 
compartment. Finally the description of regulation of MMPs and TIMPs and their 
associations allows only speculative hypotheses about pathological functions. 
However, the aim of the current study was to demonstrate that not only the induction 
of injurious stimuli but also their reversal might have an effect on TIMP/MMP 
regulation and ECM homeostasis. Since the model has broad congruency with 
human DN (Conway, Rennie et al. 2012) it may explain why the resolution of 
established human DN fibrosis takes so long even under strict normotension and 
normoglycemia (Fioretto, Steffes et al. 1998).  
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Finally, as indicated before, the technical microarray analysis is not part of this work. 
Nevertheless, since flaws in the technical performance can affect the results that were 
used in this work, some potential pitfalls will be mentioned briefly. 
It is important to assure the quality of the extracted RNA by using a bioanalyzer 
(Agilent). Problems during the steps cDNA synthesis, amplification, labelling and 
hybridization can be detected by spiking with control material at different steps. 
Imaging artefacts during the staining process by air bubbles or solution impurities in 
the microarray cartridge can be detected by visual heat map inspection. 
Another disadvantage that is hard to account for is that the thousands of individual 
genes were analysed under the same conditions though since molecular properties 
differ between RNA/DNA fragments and might require different conditions to 
achieve optimal results (Jaksik, Iwanaszko et al. 2015). 
For normalization of the data the assumption has to be made that in general the total 
level of mRNA does not vary significantly among samples independent from the 
experimental conditions.  
A specific threshold for fold change has to be chosen to separate pathophysiological 
potential relevant differences from biological and technical variation. The chosen 
threshold of 0.5 resulted in an acceptable power of 0.8 for detection as described in 
the “Materials and Methods” section. However relevant gene expression changes that 
fall beyond the chosen threshold are less likely to be detected. 
141 
3.1.8 Summary  
Although Fioretto et. al. demonstrated 20 years ago that histological DN lesions are 
reversible little is known so far about the mechanisms that induce repair (Mauer and 
Fioretto 2013). Conway et al. demonstrated in the novel Cyp1a1mRen2 DN model 
that genes upregulated in DN enriched pathways associated with injury as well as 
with healing/repair (Conway, Rennie et al. 2012). From this, one might conclude that 
in DN pathologic stimuli activate inflammatory/injurious pathways resulting in tissue 
damage that in turn activates repair mechanisms. The analysis of the data presented 
suggests that activated injurious and reparative pathways co-exist in the DN model 
(Figure 33). Of interest, similar genetic patterns have been observed in human DN 
(Woroniecka, Park et al. 2011) (Ju, Nair et al. 2015). However, there is a caveat. 
Whether a gene has an injurious or a repair/protective function can depend on the 
species and the model chosen. This is reflected by conflicting studies claiming 
injurious or protective characteristics of some MMPs (e.g. MMP2 and 7) (Xu, Xiao 
et al. 2014). Targeting genes e.g. by knock-out may provide an ultimate answer about 
gene function, though compensatory mechanisms (e.g. TIMP-1 for TIMP-2 and vice-
versa) can make interpretation difficult (Kim, Oda et al. 2001). Individual knock-out 
of the multitude of genes involved in DN might be a time-consuming task. The 
Cyp1a1mRen2 reversal DN model provides a general approach to dissect the 
involved genes and pathways. The removal of damaging stimuli might selectively 
silence injurious pathways whilst reparative pathways remain activated due to the 
persistent damaged tissue (Figure 33).  
In this work this concept is epitomized in two pathological pathways of DN. First, 
there is the role of immune cells: During the injury phase, both M1 and M2 
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macrophage numbers are increased in the kidney, but during reversal phase only M2 
macrophages remain increased. This underlines the assumed role of M2 macrophages 
in ECM regulation (Anders and Ryu 2011) (Duffield 2014). The persistent 
upregulation of T-reg cells during injury and reversal phase might indicate a 
reparative role for this lymphocyte subpopulation.  
The second exemplary pathway is ECM regulation. In this chapter it was 
demonstrated that in a reversal Cyp1a1mRen2 rat model of DN the normalization of 
hypertension and hyperglycaemia seems to halt ECM production, although 
fibroblasts might persist in a quiescent state. However, the reduction of ECM is 
hampered by reduced MMP activity in contrast to the elevated MMP gene 
expression. The presence of TIMP-1 in both the injury and reversal groups might 
effectively block MMP activity (Figure 33). In situ zymography supports the spatial 
association between increased collagen deposition and reduced MMP activity. The 
increase in MMP activity following separation of TIMP and MMPs via gel 
electrophoresis suggests that strategies to block TIMP-MMP interaction in the 
diabetic kidney may increase MMP activity, which may facilitate regression of 
fibrosis. This hypothesis merits further investigation in future studies. 
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Figure 33: Hypothesized genetic regulation in the Cyp1a1mRen2 rat DN reversal model 
 
Figure 33. Schematic hypothesiszed illustration of genetic regulation in the Cyp1a1mRen2 
rat DN reversal model and hypothesized pathological effects. During the injury phase 
characterized by hypertension and hyperglycaemia for 28 weeks the genes that are 
associated with both ECM production (red, e.g. collagens) and degradation (blue, e.g. 
MMPs) are up-regulated. Eight weeks of the reversal phase with normotension and 
normoglycaemia are sufficient to switch off the ECM production genes completely. ECM 
degradation genes remain up-regulated but MMP activity is effectively blocked by TIMP. 
In conclusion, the Cyp1a1mRen2 reversal DN model supports the concept of a co-
existence of injurious and reparative mechanisms in DN. The removal of injurious 
stimuli by inducing normotension and normoglycaemia (that is also the therapeutic 
target in human DN) silences injury pathways whilst the reparative ones persist - 
supposedly until a certain level of recovery is achieved what can last in humans more 




3.2 Urinary peptidomics 
3.2.1 Introduction 
Previous studies in the Cyp1a1mRen2 rat model of DN confirmed that the model 
exhibited biochemical, pathological and transcriptomic changes consistent with 
human DN (Conway, Rennie et al. 2012). In the last chapter functional and pathway 
analysis of differentially expressed genes provided a deeper insight into the 
molecular basis of renal injury and repair processes within the model. The protein 
products of genes that were significantly altered during the injury and reversal phase 
could, if excreted into urine, be a potential source for non-invasive biomarkers that 
are informative regarding pathological renal processes. Albuminuria, the hitherto 
established biomarker in DN, is serum derived and more an indicator of glomerular 
leakage as a consequence of renal injury than a genuine marker of renal damage. 
Urine specimens from the rodent model and from a small human cohort of patients 
with DN were analysed by a non-biased so-called “shotgun” peptidomic approach to 
identify urinary markers that reflected the characteristic transcriptomic signature in 
DN. 
3.2.2 Peptidomics in rat urine 
Electrophoresis of rat urine 
Preliminary experiments were performed to assess the quantity and nature of the 
proteins present in the urine of control rats and those with induced diabetes and 
hypertension (DM+HTN) for 28 weeks. Figure 1 demonstrates the pattern of proteins 
found in the urine from control rats and DM+HTN rats following separation by 
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electrophoresis with subsequent Coomassie Blue staining of the gel. While in control 
animals the dilution of the urine enabled clear protein separation, in DM+HTN 
rodents there was a broad band of approximately 66kDa, most likely albumin, which 
hampered further separation. This effect persisted even after serial dilutions. An 
overnight dialysis of the urine to remove the high salt content in urine only 
minimally improved separation of the proteins.  Passing the urine through an 
albumin-specific immunoabsorption column did deplete the albumin from the 
sample, but also resulted in significant reduction of all other proteins (Figure 34). 





Figure 34. Electrophoresis of rat urine from control and DM+HTN samples and staining with 
Coomassie blue. A) Dilution of control urine samples resulted in a clear separation of bands, 
whereas resolution of bands in the DM+HTN samples was hampered by a large band at 
approximately 66kD (most likely albumin). Control sample (1) undiluted, (2) diluted 1:1, (3) 
diluted 1:5, and DM+HTN sample (4) undiluted, (5) diluted 1:1 , (6) diluted 1:5 . B) After 
albumin immunoabsorption filtering there were no clear protein bands visible. Pre-dialysis 
treatment of samples resulted in sharper but not more separated bands.  
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Peptidomic analysis from filtered rat urine 
From the pilot studies described above, it became quickly apparent that the large 
amount of albumin specifically in the DM+HTN animals would swamp the signal 
from other proteins during mass spectrometry and hence another approach was 
necessary. The approach chosen was to focus on the peptidome and low molecular 
weight proteins after removing all high molecular weight proteins including albumin 
by passing the urine through a 10kD molecular weight filter.  
The sample preparation protocol was designed with help from Dr Andrew Cronshaw, 
Proteomics Facility, School of Biological Sciences, University of Edinburgh and 
included several concentration steps after removal of most high molecular weight 
proteins by passing the urine through a 10kD molecular weight filter (Figure 35). 
The prepared samples were analysed by using MALDI-TOF mass spectrometry, and 
many peaks could be attributed to peptides. Using LC-MS/MS resulted in the 
detection of 10 times more peptides and was considered the preferred methodology.  
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control 45 320 
injury 85 954 
 
 
Figure 35. A) Schematic experimental protocol for isolation of low molecular weight proteins 
and peptides from whole urine. Italics indicate the rationale behind each stage in the process 
B) In one control and one DM+HTN, rat urinary analysis by LC-MS/MS was compared with 
MALDI-TOF MS. LC-MS/MS technology detects about 10 times more peptides than MALDI-
TOF MS in both the control and the injury animal. C) Distribution of the probability scores for 
detected peptides in the urine from a DM+HTN rat using MALDI-TOF MS. 
3.2.3 Characterisation of the urinary peptidome in the reversal 
DM+HTN model 
Figure 36 displays the experimental design for urine collection in the reversal model. 
In 10 rats, urine was collected for 24 hours at the start of the experiment, after 28 
weeks of combined induction of hypertension and diabetes mellitus (referred to as 
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injury phase) and after additional 8 weeks when both the diabetes and hypertension 
were tightly controlled (referred to as reversal phase). During the injury phase 
albuminuria and urinary volume were markedly increased compared with baseline 
(Table 7). After 8 weeks of reversal, both the urinary volume and albuminuria 
decreased significantly, however they remained significantly elevated compared with 
baseline levels (Table 7). 
Typical base peak chromatograms demonstrate that the peptide profiles of animals 
within each treatment group appeared similar, while the profiles from animals from 
different groups were more divergent. This gave confidence in the analysis protocol. 
Raw data from LC-MS/MS were analysed using MaxQuant to identify the peptide 
sequences which best fitted the retention time and charge. Altogether more than 3200 
different sequences were identified. Filtering steps as described in Figure 37 were 
applied to refine the search. Finally 1635 peptide sequences were selected for further 
analysis. For those, the probability score for detection peaked around 150. Roughly a 
third of the sequences were detected at all three experimental time points. Almost 
60% of peptides were detected in the injury or reversal phases but not at baseline, 
with the majority of these being common to both the injury and reversal phases, 
underlining the similarity in the peptidome between these two phases. Conversely, 
only 2% (28) were unique to the baseline urine samples (Figure 37). 
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Figure 36: Time points of sample collection in the Cyp1a1mRen2 reversal DN model 
 
Figure 36. Schematic experimental design demonstrates the time points of urinary collection 
at week 0 (baseline), after 28 weeks of combined hypertension and diabetes mellitus (injury 
phase) and after an additional 8 weeks of tight glycaemic control and removal of dietary 1-3-
C to reverse hypertension (reversal phase).  
Table 7: Characteristics of the urine from the experimental phases 
 mean (SD) or median (IQR) 
  Baseline  
week 0 
injury phase  
week 28 
reversal phase  
week 36 















creatinine-clearance 2.51 (0.69) 2.45 (0.31) 2.59 (0.55) 
 
Table 7. Albuminuria and urinary volume are dramatically increased at week 28 (injury 
phase) compared to baseline and are decreased significantly at week 36 compared to injury 
phase. N=10. a p<0.05 and aa p<0.001 vs baseline; b p<0.05 and bb p<0.001 vs injury 
phase 
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Figure 37. The MaxQuant software identifies and quantifies peptide sequences from MS-
profiles. A) Typical MS profiles from urinary samples with base peaks and retention times. 
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There is a similar pattern profile between different animals from the same group, with the 
pattern from animals of different groups being more divergent. B) Flow-Chart of the 
processing steps to filter non-relevant peptides from the MaxQuant software output. From 
roughly 14000 initial hits about 12000 were retained after different charges of the same 
peptides were summarized. Removal of contaminants and a probability/detection score 
below 72 (with an false discovery rate of 0.05) resulted in approximately 4000 peptides. 1635 
Peptides were retained after processing. C) The probability score indicates the likelihood that 
a peptide has been correctly identified. The diagram describes the distribution of probability 
scores (starting from a score of 72 as defined by an FDR threshold of 0.05) for the identified 
peptides. D) The venn diagram illustrates that roughly a third of all peptides had been 
detected in at least one animal at all three time points and almost half of the peptides were 
present during the injury and reversal phase only.  
Correlation of urinary peptidomics in the experimental groups  
For quantitation of peptides a label-free approach was utilized in which the height of 
the chromatographic peak corresponding to an individual peptide is proportional to 
the amount of peptide present in the sample. The relative abundance of each peptide 
was calculated by MaxQuant Software (see Materials and Methods) and is expressed 
as peak intensities. The patterns of relative peptide abundances in intensities were 
compared between two individual experimental phases. The strongest correlation 
was found between relative abundances of peptides present during the injury and 
reversal phases. There was a weak correlation between peptide abundances at 
baseline and the injury phase but a stronger correlation between baseline and reversal 
phase (Figure 38).  
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                    Log [mean intensities] 
Figure 38. Scatter plots demonstrating the degree of correlation in mean peak intensities of 
the peptides between two different time points compared with the other time points. The 
strongest correlation was between the injury and reversal phases followed by the reversal 
and control phases, p-value for all coefficients <0.001.  
Regulation of urinary peptidomics between all the experimental groups 
To compare the signal from peptides across all three groups an in-house custom 
implementation of Rank Products in R-software was developed and applied as 
described in the Materials and Methods. Altogether 1290 peptides were detected at 
sufficient frequency among specimens in order to be included into analysis by the 
algorithm. 
While the mean signal from most peptides did not change significantly between 
phases, 58 peptides had significantly increased peak intensities during the injury 
phase, 136 peptides had a decreased intensities during the injury phase compared to 
baseline. During reversal phase 42 peptides had decreased and 60 peptides increased 
peak intensities compared to the injury phase (Table 8). 
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Table 8: Peptides significantly changed in peak intensities between baseline and 
injury phase and injury and reversal phase 
Direction: 
Baseline to injury 
Direction: 




of related proteins 
increased increased 3 2 
increased decreased 26 15 
increased unchanged 29 15 
decreased increased 13 11 
decreased decreased 3 1 
decreased unchanged 120 35 
unchanged increased 47 18 
unchanged decreased 13 7 
unchanged unchanged 1036 161 
Table 8. Relative abundances from detected peptides are compared between baseline vs 
injury phase at week 28 and injury phase and reversal phase at week 36 using an in-house 
log-rank algorithm. The threshold for significant difference was p<0.05. Listed are number of 
unique peptides and the number of parent proteins. Since several peptides refer to the same 
parent proteins those can be present several times in the table. For 1290 from 1635 peptides 
(79%) were detected in enough animals at each time point to calculate a comparison. The 
relative abundance of most peptides (1036 from 1290) did not change significantly between 
time points. Some individual peptides and parent proteins are presented in the text or Figure 
6 respectively. The complete list is added as an appendix. 
Peptides with increased intensities during the injury phase were predominantly from 
serum derived proteins and were functionally associated with each other, such as 
albumin and apolipoproteins. Many of these peptides had decreased peak intensities 
from injury to reversal phase. Peptides with reduced peak intensities during the 
injury phase were often structural tubular or glomerular proteins (e.g. Uromodulin, 
Meprin A, Epidermal Growth Factor, Ezrin). During the reversal phase peptides with 
decreased peak intensities compared to the injury phase were related to serum 
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proteins (e.g. Apolipoproteins, serpins). Peptides with increased peak intensities in 
the reversal phase compared to injury phase were related to structural proteins and 
serum proteins (see Discussion) (Figure 39).  
Analysis for biological processes enriched with parent proteins demonstrated that 
inflammatory/defence mechanisms were top ranked for peptides with increasing peak 
intensities from baseline to injury phase and with decreasing peak intensities from 
injury to reversal phase. Conversely, negative regulatory cell metabolism was top 
ranked among peptides with decreased peak intensities in injury phase compared to 
baseline but increased intensities in reversal phase compared to injury (Figure 39). 
There was a considerable overlap of parent proteins, genes and biological processes 
which is a caveat when interpreting the results. 
RNA microarray data was available from renal cortex tissue of rats that were culled 
as control animals without further intervention, from rats that had undergone 28 
weeks of hypertension and hyperglycaemia and from rats with an injury phase 
followed by a reversal phase (Conway, Betz et al. 2014). 9 out of the 74 parent 
proteins from urinary peptides which were significantly different between the phases 
were related to renal genes that had a similar regulation on a genetic level (Table 9).  
Those that were increased during the injury phase (7) at both gene and urinary 
peptide level comprised collagens, markers of renal damage (e.g. clusterin, 
osteopontin), complement cascade factors (c2, c3) and fibrinogen. The two 
peptides/genes reduced during injury were pro-epidermal growth factor and meprin 
A. 
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Figure 39: Parent proteins [gene symbols] from peptides significantly changed in peak 
intensities between baseline and injury phase and injury and reversal phase 
A) Increased from Baseline to Injury phase 
 





GO:0006952 defence response 10 1.19E-08 
GO:0051346 
negative regulation of hydrolase 
activity 
8 1.86E-08 
GO:0006954 inflammatory response 8 3.63E-08 
GO:0010951 







B) Decreased from Injury to Reversal phase 
 










negative regulation of 
endopeptidase activity 
5 8.75E-05 
GO:0030162 regulation of proteolysis 6 9.26E-05 





C) Decreased rom Baseline to Injury phase 
 


























D) Increased from Injury to Reversal phase 
 























Figure 6. Illustration of functional protein associations from most parent proteins related to 
peptides with increased or decreased abundance in injury or reversal phase compared 
baseline or injury phase respectively using the String database (www.string-db.org). Proteins 
are represented by the gene symbol. The complete list of all peptides and related proteins is 
provided in the appendix. There were many associations between proteins in the category 
that were increased from baseline to injury. Most of them are serum proteins. Some of them 
were also present in the category that was decreased from injury to reversal indicating 
reduced glomerular leakage. There were few links between proteins in the category that was 
decreased from baseline to injury. Some of the structural proteins were present in the 
category that was increased from injury to reversal. 
The top four biological processes (GO: Gene Ontology Consortium) are provided for each 
category according to false discovery rate (FDR) (www.string-db.org). Of note, similar to the 
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peptides there were some overlaps in the processes between the categories. Inflammatory 
mechanisms are ranked “top four” for being enriched with proteins from peptides increased 
during the injury phase compared to baseline phase. Conversely, these were among the “top 
four” to be decreased from injury to reversal phase. Negative regulatory processes of cell 
metabolism were enriched pathways from peptides with decreased peak intensities from 
baseline to injury and increased intensities from injury to reversal phase. 
Table 9: Urinary peptides with similar regulation of related renal genes 
Gene Name injury group vs 
control group 
reversal group vs 
injury group 
Clu Clusterin increased unchanged 
Col1a1 Collagen alpha-1(I) chain increased decreased 
Col1a2 Collagen alpha-2(I) chain increased decreased 
C3 Complement C3 increased unchanged 
C2 Complement C2 increased unchanged 
Fga Fibrinogen alpha chain increased unchanged 
Spp1 Osteopontin increased unchanged 
    
Mep1a Meprin A subunit alpha decreased increased 
Egf Pro-epidermal growth factor decreased unchanged 
Table 9. The 254 peptides with significantly altered peptide peak intensities between the 
baseline, injury and reversal phases related to 74 unique proteins. These were compared 
with the genetic regulation assessed from the renal cortex of animals that were culled as 
controls, injury group or reversal group. A similar tendency in regulation compared to urinary 
proteins during baseline, injury and reversal phase was found for nine genes (12%).  
3.2.4 Urinary peptides in patients with diabetic nephropathy and 
healthy controls 
The methodology of urinary peptidomic analysis was applied to patients with 
diabetic nephropathy. Six healthy volunteers without a history of renal damage and 
ten patients with advanced chronic kidney disease from the renal and diabetic 
outpatients clinics of the Royal Infirmary of Edinburgh were analysed (Table 10).  
After informed consent was received, a spot urine sample was collected and the 
proportion of the volume used for analysis was adjusted according to the urinary 
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creatinine to correct for differences in urinary concentration between the patients. 
Urine samples were processed as described in the previous paragraphs for the rodent 
studies. Altogether 1181 peptides were identified with almost 80% being detected 
exclusively in the DN group (Figure 40).  
However many of those were only identified in one or two patients making it 
impossible to calculate statistical significance for differences in peptide peak 
intensities between the groups. 7 peptides, derived from seven parent proteins, had 
significantly less peak intensities in DN patients compared to healthy volunteers: 
These were Matrix Gla protein (MGP), Membrane-associated progesterone receptor 
component 1 (PGRMC1), Vascular endothelial growth factor A (VEGFA), 
Sodium/potassium-transporting ATPase subunit gamma (FXYD2), Angiopoietin-
related protein 2 (ANGPTL2), CD59 glycoprotein (CD59) and Tetraspanin-9 
(TSPAN9) (Figure 41).  
Conversely, 120 peptides, derived from 47 unique parent proteins, were significantly 
more abundant in patients than in controls. These included many serum proteins 
(Apolipoprotein, Anti-thrombin) but also proteins associated with renal injury and 
fibrosis (Clusterin, Osteopontin) and collagens. In pathway analysis serum processes 
(e.g. platelet function) were the top ranked pathways. 
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Table 10: Characteristics of patients with DN and healthy controls 
A B 
 Age Gender Stage 
CKD 
eGFR 
P1 44 M IV 26.7 
P2 65 M IV 8.8 
P3 82 M V 37.8 
P4 65 M IV 6.3 
P5 76 F IV 19.1 
P6 77 M IIIb 27.0 
P7 37 F IV 17.8 
P8 65 M V 8.2 
P9 41 M IV 16.4 
P10 74 M IV 29.9 
 
 Age Gender Stage 
CKD 
C1 61 M none 
C2 71 M none 
C3 66 M none 
C4 38 F none 
C5 41 M none 
C6 34 M none 
 
Table 10. Urinary peptidomics were analysed in a discovery cohort comprising ten patients 
with diabetes and chronic kidney disease and six volunteers without medical history of renal 
disease.  





Figure 40. In the analysis of urinary specimens from patients with chronic kidney disease 
and from healthy controls A) most of the peptides detected were exclusively found in 
patients. B) The abundances from urinary peptides from DN patients were typically 
significantly increased compared to healthy volunteers.  
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Figure 41: Parent proteins [gene symbols] from peptides significantly changed in peak 










GO.0002576 platelet degranulation 10 9.38E-12 
GO.0030168 platelet activation 11 2.96E-09 
GO.0016192 vesicle-mediated transport 17 1.40E-08 
GO.0051346 






Figure 41. Parent proteins from peptides with (A) increased or (B) decreased peak intensities 
in patients with CKD compared to healthy volunteers were entered into the String database 
(www.string-db.org) for illustrating functional protein associations. Proteins are represented 
by the gene symbol. There are many associations between proteins with increased peptide 
intensities in CKD patients. Most of them are serum proteins indicating glomerular leakage. 
This is also underlined by the analysis of peptide/protein enriched biological processes. The 
top-ranked according to FDR (false discovery rate) biological processes all relate to serum 
related processes. The list of all peptides is provided in the Appendix. 
3.2.5 Urinary peptidomic analysis in the DN model with Progenesis QI 
In a previous study the effects of inducing diabetes (DM) or hypertension (HTN) 
alone versus the combination of induced diabetes and hypertension (DM+HTN) on 
the biochemical, pathological and transcriptomic features in the kidney had been 
compared and the experimental and clinical characteristics of the groups are 
published (Conway, Rennie et al. 2012). In order to extend these findings, 
peptidomic analysis of urine from each of the groups was performed. The data 
obtained from the LC-MS/MS was processed by Progenesis QI software from 
Nonlinear Dynamics (Figure 42). The software permits alignment of chromatograms 
from different sample runs to compensate for variation in the LC separation 
technique between runs (Figure 43).   
After further processing, including removal of highly charged features, the complete 
dataset was exported to the Mascott search database for peptide identification. 
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Peptides were re-imported to Progenesis QI and matched with the relative abundance 
calculated from the peak intensities of the chromatograms.  Subsequently data were 
analysed by principal component analysis (PCA) to visualise similarities and 
differences in the variation in the global urinary peptide profiles between animals. It 
is important to emphasize that bi-plot principal component analysis (PCA) was not 
calculated for identification of the components explaining the variation but rather as 
quality control to detect outliers as recommended by the developers of Progenesis QI 
(http://www.nonlinear.com/progenesis/qi/v2.0/faq/pca.aspx). In this process, all 
peptides contributed to the position of a sample within the matrix. In the PCA it was 
apparent that control and DM+HTN groups were well segregated from all the other 
groups implying that the combination of diabetes and hypertension was significantly 
different to induction of diabetes or hypertension alone (Figure 44).  
The relative abundance that was calculated from the individual peak intensities of a 
peptide was considered to be significantly different when the p-value was below 0.01 
and the q-value that corrects for multiple testing was below 0.05. Figure 42 
summarizes the data processing in Progenesis QI (Figure 42). 
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Figure 42: Data processing in Progenesis QI 
 
Figure 42. Schematic illustration of the most important steps using Progenesis QI for 
analysis of raw LC-MS/MS data. The right column lists the number of remaining peaks, 
features or peptides respectively after each step. 
Figure 43: Alignment in Progenesis QI 
 
Figure 43. Representative screen shot illustrates the alignment process with peptides 
separated by retention time (y-axis) and m/z (x-axis).  At the beginning a reference run to 
which all other runs were aligned was automatically chosen by Progenesis QI. Many 
peptides of the reference run (magenta) had been eluted earlier than the current run (green). 
Vectors (blue) can be set automatically and checked manually between individual peptides 
to align the entire peptidome.  
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Figure 44: Principal component analysis of the urinary peptidome from the 
Cyp1a1mRen2 DN model 
 
Figure 44. Principal component analysis of global urinary peptide profiles in the diabetic 
and/or hypertensive rat model. The plot shows principal component 1 (PC1) that is 
calculated from the combination of peptides explaining the most variation on X axis and 
principal component 2 (PC2) on Y axis for the combination of peptides explaining the second 
most variation. A blue dot summarizes all peptides from an urinary specimen from an animal 
of the control group (control), orange points denote specimens from the Hypertension alone 
group (HTN), violet data points denote specimens from the Diabetes mellitus alone group 
(DM) and green data points denote specimens from the combined (DM+HTN) injury model. 
There is an apparent clustering between the groups with the DM+HTN animals being 
separate from all other groups.  
Urinary peptide profiles in the Cyp1a1mRen2 DN model 
Altogether 269 peptides were identified to have significantly (p<0.01) increased peak 
intensities in at least one of the diabetes  hypertensive groups compared with the 
control group. The distribution of these differentially excreted peptides mirrored the 
distribution of genes significantly increased in the renal cortex of diabetic  
hypertensive animals compared to control (see Introduction) (Conway, Rennie et al. 
2012) (Figure 45). The complete list of peptides is given in the Appendix. The 
majority of peptides with increased peak intensities compared with controls were 
exclusively identified in the urine from the DM+HTN animals. A volcano plot 
illustrates the distribution of the peptides that were significantly different between 
the control and DM+HTN group (Figure 46).  
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Out of those peptides with increased peak intensities in the diabetes  hypertensive 
groups compared with the control group were some of special interest because the 
genes encoding their parent proteins had been confirmed to be up-regulated in the 
renal cortex of the DN model and in kidney biopsies from patients with DN (Table 
11). For comparison with molecular regulation in human DN the free online database 
nephroseq.org was used. Nephroseq.org contains the results of microarray analysis 
from many studies e.g. comparing gene regulation in DN biopsies with healthy 
controls (Woroniecka, Park et al. 2011). 
Only 16 peptides were significantly decreased following induction of diabetes  
hypertension compared to controls. One of these peptides, derived from epidermal 
growth factor, was the only one for which a parallel reduction in the corresponding 
gene expression was observed in the renal cortex in both the DM+HTN rat model 
and in patients with DN (Table 12). 
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Figure 45: Peptides with significantly altered peak intensities in the DN model 




Figure 45. (A) Peptides in the hypertension alone (HTN), diabetes alone (DM) and injury 
(HTN+DM) groups that are significantly increased compared to control group. Most of them 
are significantly increased exclusively in the injury group. (B) Only 16 urinary peptides were 
increased in control animals. N=6-10. 
Figure 46: Comparison of urinary peptidome between the control and the 
hypertension+ diabetes (HTN & DM) group of the Cyp1a1mRen2 DN model 
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Figure 46. Volcano plot demonstrates the fold change (log2) in relative abundance (x-axis) 
plotted against the P-value (–log100, y-axis) for urinary peptides from the injury (DM+HTN) 
animal group compared with control animals. The dotted line represents p=0.01. The red dot 
indicates the pro-epidermal growth factor. 
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Table 11: Selected peptides with significantly increased relative peptide abundance 
in the injury group compared to control 
Max fold 
change 
P-value Score Protein ID Sequence Description 
3.80E+03 5.20E-03 60.74 P04639 DNWDTLGSTV
GR 
Apolipoprotein A-I 



















4.95E+02 1.36E-03 59.38 Q01177 LGSDVQQIAVT
KL 
Plasminogen 
5.11E+01 3.43E-04 111.56 Q6P734 DSEVTSHSSQ
DPLVVQEGSR 










1.35E+02 2.77E-05 98.52 P02770 TVDETYVPKEF Serum albumin 






























Table 11. Peptides of interest that had significantly (p<0.01) increased relative abundance in 





genes had similar changes in expression in renal tissue from the DM+HTN model (
*
) or from 
human DN biopsies (
#
) compared with respective controls. 
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Table 12: Selected peptides with significantly relative peptide abundance in the injury 
group compared to control 
Max fold 
change 
P-value Score Protein ID Sequence Description 














6.59E+01 1.11E-04 61.37 Q63461 DQELTITSEAI
R 
Proline-rich protein 
1.29E+02 4.82E-04 52.65 P02783 GGSFGEEAS
EEISS 
Seminal vesicle 
secretory protein 4 
Table 12. Peptides of interest that had significantly (p<0.01) decreased relative abundance 
in the DM+HTN injury group in comparison with controls. Pro-epidermal growth factor was 
the only peptides for which the corresponding gene had similar change in expression in renal 
tissue from the DM+HTN model (*) or from human DN biopsies (#) compared with respective 
controls. 
3.2.6 Validation of peptide regulation for the protein Epidermal Growth 
Factor 
The regulation of the peptide representing Epidermal Growth Factor (EGF) was 
validated on a protein and gene level with material available from both the DN 
(Conway, Rennie et al. 2012) and the reversal (Conway, Betz et al. 2014) models. 
Excretion of urinary EGF (uEGF) declined early (8 weeks) after induction of 
hypertension and diabetes and remained at that level until week 28. After an 
additional eight weeks of reversal phase there was a slight increase with this time 
point being significantly different neither from baseline nor from 28 weeks. On a 
genetic level referring to the previously published microarray database (Conway, 
Betz et al. 2014) there was a significant decrease in EGF gene expression in the renal 
cortex during the injury phase compared with controls. There was a non-significant 
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trend for EGF gene expression to increase after the reversal phase. Polymerase chain 
reaction to confirm the results from microarray could only be performed in the 
control, DM alone, HTN alone and DM+HTN groups since tissue from the reversal 
group was not available. This demonstrated that expression of the EGF gene was 
reduced in the renal cortex of DM+HTN rats compared to controls (Figure 47). 
Immunohistochemistry in renal tissues of the control group demonstrated ubiquitous 
expression of EGF in tubular cells (Figure 48). After 28 weeks of injury phase there 
was a focal reduction of EGF staining in atrophic and damaged kidney injury 
molecule-1 positive tubules (Figure 49). 
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Figure 47: Renal and urinary expression of epidermal growth factor in the 






























































































Figure 47. (A) In the Cyp1a1mRen2 reversal cohort the level of urinary EGF decreased 
significantly during the injury phase (Hypertension and Diabetes) and during the first four 
weeks of the reversal phase compared to baseline. Urine had been collected for 24 hours 
and measured uEGF concentration multiplied by urinary volume. n=10, ** = p<0.01 vs 
baseline. (B)  Gene Microarray analysis in renal cortex from controls and animals at the end 
of the injury phase and after an additional reversal phase indicates significant down-
regulation of the EGF gene. n=6. * = p<0.05 vs all others. (C) This was confirmed by rt-PCR 
with mRNA expression significantly reduced in the DM+HTN animals compared to control 
animals. n=6, *** p<0.001 v control 
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Figure 48. Representative photomicrographs from renal tissue cortex from a control, injury 
and reversal animal. EGF protein expression was reduced focally in injured tubules in the 
DM+HTN and reversal animals (asterisks) compared with uninjured tubules (arrow) and 
tubules of control animals. Bars represent 100 M. 
175 






Figure 49. EGF and kidney injury molecule-1 (KIM-1) expression in sequential sections of 
renal cortex from control and DM+HTN animals (A) EGF protein expression was focally 
reduced especially in tubules in DM+HTN animals (arrow) (B) These tubules were injured as 
indicated by KIM-1 positivity (Betz, Jenks et al. 2016). Bars represent 100 M. 
3.2.7 Discussion 
The aim of the experiments in this chapter was the identification of urinary peptides 
that may reflect the underlying pathophysiology in the DN kidney and which could 
hence be used as non-invasive biomarkers of disease and/or repair. Therefore a 
peptidomic approach in urinary specimens from the Cyp1a1mRen2 DN model was 
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combined with the transcriptomic profile of the model. In addition, a comparison 
with human DN was sought in order to strengthen the translational approach. 
Preparation protocol 
In a first attempt to analyse peptide sequences in urinary samples from the DN model 
a conventional electrophoresis separation strategy was performed, as described by 
Schlatzer et al. who investigated a rat DN model with only moderate albuminuria 
(Schlatzer, Dazard et al. 2009). Unfortunately, the very high albuminuria in the 
combined DM+HTN animals hampered clear protein separation. The interference 
from albumin and other “contaminants” such as salt is well described in the urinary 
proteomic field and Afkarian et al. tested several strategies to overcome these 
problems in human urine (Afkarian, Bhasin et al. 2010). In the current study, dialysis 
of the sample to reduce salt content did result in a slightly better separation, however 
albumin remained dominant. Depletion of albumin by using specific 
immunoabsorption columns resulted in an overall reduction of protein detected. 
These results are in line with those from Afkarian et al. (Afkarian, Bhasin et al. 
2010). The option of increasing the volume of urine to compensate for the reduction 
in protein after immunoabsorption was not applicable given the limited volume of 
urine available in the rat DN model. In addition, Filip et al. reported limited success 
in the application of immunoabsorption columns in patients with CKD and 
macroalbuminuria (Filip, Vougas et al. 2015). Therefore the analysis of the urinary 
peptidome in the DN model seemed to be the preferable option. One hallmark in 
sample preparation for peptidomics is the removal of high-molecular weight proteins 
using a 10-20 kD cut-off filter thereby removing most of the overly abundant 
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albumin (app. 65 kD) (Merchant, Perkins et al. 2009, Good, Zurbig et al. 2010, Siwy, 
Zoja et al. 2012).  
Comparison of analytical devices for peptidomics 
The preparation of the samples was adapted to the technology available and was 
based on a modification of the in-house protocols of the Proteomics facility, Biology 
Department, University of Edinburgh and the protocol published by Rappsilber et al. 
(Rappsilber, Ishihama et al. 2003). The validity of preparation was tested initially 
using MALDI-TOF and a large number of peaks were detected consistent with 
successful identification of multiple peptides in the urine. After successful 
implementation of the protocol, samples were analysed by LC-MS/MS which 
resulted in a much higher number of detected peaks than MALDI-TOF. This is in 
line with other publications (Naseeb, Axelsson et al. 2015). Many other studies 
preferred to use CE-MS/MS over LC-MS/MS due to the following difficulties with 
LC-MS/MS analysis (Fliser, Novak et al. 2007, Mischak and Schanstra 2011, Klein, 
Bascands et al. 2016): 1. Long sample run time – however in the present study a 
relatively small number of samples had to be analysed. 2. Sensitivity to interfering 
compounds like salts - this was overcome in this work by including desalting and 
concentration steps into the preparation protocol 3. Problems in identification of 
larger peptides and low molecular weight proteins – in the present study the protease 
trypsin was used to make sure that all fragments are small enough to be detected.  
The use of LC-MS/MS provides analytical depth which makes it suitable for 
biomarker discovery studies.(Fliser, Novak et al. 2007, Mischak and Schanstra 2011) 
Furthermore, peptidomic analysis in DN had already been performed by CE-MS/MS 
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in another model, (Siwy, Zoja et al. 2012) therefore by using LC-MS/MS the goal 
was to generate complementary data (Klein, Papadopoulos et al. 2014, Mischak, 
Delles et al. 2015).  
In order to compensate for differences in diurnal excretion the use of albumin was 
not possible for obvious reasons. Other groups use housekeeping peptides(Good, 
Zurbig et al. 2010, Siwy, Zoja et al. 2012) but that approach depends on the detection 
of the respective peptides and is therefore restricted to the specific methodology (CE-
MS). In the current study samples were pre-diluted according to their ratio with the 
largest 24 hour volume of the measurement run. Since the 24 hour volume was not 
available for the human samples, urinary creatinine was used as a surrogate 
parameter. Due to the large volume differences between the baseline and injury 
phase in the DN reversal model normalization before measurement was considered to 
preferable because measurement errors would have been multiplied if a mathematical 
correction was performed after measurement. 
Peptidomics in the Cyp1a1mRen2 reversal DN model 
In terms of qualitative analysis, the total number of peptides identified is close to 
those obtained by Siwy et al. who investigated urinary peptidomics in Zucker 
Diabetic fatty rats (Siwy, Zoja et al. 2012). The majority of peptides were detected in 
the DM+HTN phase with fewer in the reversal and baseline phases. This correlates 
well with differences in urinary albumin concentration between the experimental 
phases and is in line with the renal molecular expression as most genes were up-
regulated during the injury phase followed by reversal phase compared to control 
(Conway, Betz et al. 2014).  
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Initial quantitative analysis was performed by two-group correlation using the 
program Perseus (max planck institute of biochemistry, Martinsried, Germany). The 
strongest correlation in peptide concentration was between the injury and reversal 
phases, in which the pattern of detected urinary peptides and up-regulated genes was 
similar. The moderate correlation between reversal and control phase might indicate 
a recovery effect following the removal of hypertension and hyperglycaemia. 
Peptides with increased peak intensities during injury phase in the reversal DN 
model 
Since Perseus is only able to perform a two paired comparison, an algorithm for 
determining the significance of differences in urinary peptide concentration between 
three groups was developed by Dr. Manning, University of Edinburgh (see Materials 
and Methods section). Most of the peptides did not change significantly during the 
three experimental stages. This again validates the methodical approach as many 
urinary proteins/peptides would be expected to be constantly excreted within the 
same species.  
Many peptides with increased peak intensities in the urine during the injury phase 
and decreased during the reversal phase were derived from serum proteins such as 
apolipoproteins, urinary fibrinogen or histidine-rich glycoproteins. Hence, it is likely 
that many of these changes simply reflect reduced filtration from serum alongside the 
reduction in albuminuria during the reversal phase, rather than changes in protein 
expression within the kidney. In keeping with this the results from the microarray 
analysis of the renal cortex determined that there was no increase in apolipoprotein 
gene expression within the kidney. Other peptides with increased abundance during 
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the injury phase were derived from osteopontin and clusterin, which are well 
established markers in DN (Alter, Kretschmer et al. 2012, Korrapati, Shaner et al. 
2012, Togashi and Miyamoto 2013). Osteopontin might play a pathophysiological 
role in DN as a macrophage chemoatactant (Kelly, Wilkinson-Berka et al. 2002). The 
expression of both the osteopontin and clusterin genes was upregulated in the renal 
cortex in this model suggesting that the increase in urinary osteopontin and clusterin 
might, at least in part, be due to increased production in the kidney. The presence of 
peptides from complement factors (C2, C3) in the urine could be easily explained by 
glomerular leakage. But interestingly microarray data indicates an upregulation of C2 
and C3 in renal tissue during the injury phase in the DN model. A potential causative 
link between C3 accumulation and the development of DN has been discussed in the 
introduction section (Wada and Nangaku 2013). Further investigations are necessary 
to explore the potential role of complement components in DN. 
Peptides with decreased abundances during injury phase in the reversal DN model 
For two parent proteins from peptides with reduced peak intensities during the injury 
phase, pro-epidermal growth factor (EGF) and Meprin A subunit alpha, there was 
reduced expression of the corresponding genes in the renal cortex of rats specifically 
during injury period. EGF will be discussed in the following paragraphs. Meprin A 
(subunit alpha) is a metalloproteinase which belongs to the brush border membrane 
protein family in the kidney. Decrease of Meprin A peptide resonates with 
downregulation of the Meprin A gene in the kidney during injury. Matthew et al. 
confirm that Meprin A expression is reduced on a genetic and protein level in a 
rodent DN model, however paradoxically they report increased Meprin A urinary 
excretion. This was explained by a more intense decrease of renal Meprin B 
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compared to Meprin A in DN as Meprin B is necessary for the attachment of Meprin 
A to the brush border of tubular cells (Mathew, Futterweit et al. 2005).  
Peptidomics in human kidney disease 
In general, some but not many peptides were detected in both the human and rodent 
peptidome. Siwy et al. also report a low level of congruency in the urinary peptide 
profile from humans and rodents with DN (Siwy, Zoja et al. 2012).  
One interesting peptide that has a reduced abundance in the urine of patients is 
vascular endothelial growth factor A (VEGF-A), which is constitutively expressed in 
tubular cells. As an angiogenic factor it may contribute to the maintenance of 
peritubular capillaries. Lindenmeyer et al. describe a distinct reduction of VEGF-A 
gene and protein expression in renal tissue biopsies from DN patients compared to 
healthy controls (Lindenmeyer, Kretzler et al. 2007). The list of parent proteins from 
urinary peptides that were increased in DN were enriched for serum proteins like 
Apolipoproteins and Alpha-2-glycoproteins, and this may reflect increase passage 
across a disrupted glomerular filtration barrier as it has been discussed in the rodent 
model. Similar to the rodent DN model, Osteopontin (SPP1), Clusterin (CLU) and 
Fibrinogen alpha chain (FGA) were identified as potential markers of renal damage. 
In addition, increased peak intensities of collagen peptides reflected results from the 
rodent reversal DN model. High levels of hepatocyte produced Fetuin-B (Fetub) that 
is assumed to impair actions of insulin, and C-X-C motif chemokine 16 (CXCL16), a 
scavenger receptor for oxidized low density lipoprotein and beta-2 microglobulin, 
have been reported to be increased in patients with diabetes (Aksun, Ozmen et al. 
2004, Zhao, Wu et al. 2014, Meex, Hoy et al. 2015) . Retinol-binding protein 4 
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(RBP4), is not only produced by hepatocytes but released by tubular cells early upon 
damage (Norden, Lapsley et al. 2014) and has been reported to be elevated in serum 
and/or urine of patients with DN (Raila, Henze et al. 2007, Titan, Vieira et al. 2012). 
Taken together, analysis of the DN reversal model and urinary human DN, reveals 
interesting known and potential novel biomarkers with some of those corresponding 
with the transcriptomic findings from the DN model. 
Peptidomics in the injury DN model using Progensis QI 
Next the DN injury model (without reversal cohort) (Conway, Rennie et al. 2012) 
was analysed by a different program (Progenesis QI) to first validate the results 
obtained by MaxQuant and second to extend the list of promising biomarker 
candidates: using two different search algorithms (Andromeda vs Mascot) may 
extend the list of potential candidate markers since up to 25% of peptides/proteins 
might be exclusively identified by only one analytical programme (Merl, Ueffing et 
al. 2012).  
Progenesis QI was used for data processing and label-free quantitation and the 
MASCOT search server for identification of peptides as performed by others in 
human urinary specimens (Rouillon, Zocevic et al. 2014, Beretov, Wasinger et al. 
2015, Cantley, Colangelo et al. 2016). Progenesis QI offers the advantage of map 
alignment based on centroid data using user-set orientation marks to assign the same 
peptide feature in different runs for comparison. The analysis approach described by 
Atrih et al. was applied with slight adaptations (see Materials and Methods) (Atrih, 
Mudaliar et al. 2014).  
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Peptides with increased urinary peak intensities in the DN injury model 
The distribution of peptides detected between the control, HTN, DM and HTN+DM 
groups resonates very closely with the distribution of the genes differentially 
expressed in the renal cortex in the same groups (see Introduction) (Conway, Rennie 
et al. 2012), thereby internally validating the results. For many parent proteins from 
urinary peptides with reduced or increased peak intensities in the HTN+DM group 
compared to control the corresponding genes were also up- or downregulated 
respectively. Furthermore, many of these genes were found to be similarly 
differentially expressed in the kidneys of patients with DN using data from the freely 
available online database “nephroseq.org” like osteopontin, clusterin and 
complement 3.  
In addition, interesting novel candidate peptides/proteins biomarkers were detected. 
Increased serum superoxide dismutase (SOD) has been associated with micro- and 
microvasculature complications in diabetic patients. In addition, SOD1 is 
upregulated in renal biopsies from patients with DN, suggesting that the increased 
urinary SOD excretion may be derived from either the serum or kidney(Kimura, 
Hasegawa et al. 2003). Plasma protease C1 inhibitor is increased in human DN renal 
biopsies (www.nephroseq.org). Collagen I alpha chain has been detected by others in 
animal models of DN but seems to lack human translation(Siwy, Zoja et al. 2012).  
Epidermal growth factor is decreased in urine and renal tissue in the DN injury 
model 
Regarding parent proteins from peptides with significantly decreased peak intensities 
in the injury group, only epidermal growth factor (EGF) was reported to be 
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downregulated on a gene expression level in the kidney in both humans with DN and 
the rodent DN model. EGF is produced in the kidney by cells of the distal tubules. 
Hence, urinary EGF excretion could be indicative for functional tubular mass. 
Indeed, a dramatic reduction in urinary excretion of EGF has been observed in 
animal models of renal fibrosis (Thulesen, Jorgensen et al. 1997). In a model of early 
DN increased EGF levels are associated with reduced renal apoptosis (Kelly, Cox et 
al. 2002). In the Cyp1a1mRen2 DN model urinary EGF regulation was measured by 
ELISA, which largely confirmed the findings from urinary peptidomics. 
Correspondingly, renal cortex expression of the EGF gene was reduced in the 
DM+HTN group compared to control or DM and HTN alone in the Cyp1a1mRen2 
DN model. A similar reduction in EGF protein expression was confirmed by 
immunohistochemical staining. However in contrast to uEGF that tends to increase 
during the reversal phase, renal expression of EGF remained downregulated in 
Cyp1a1mRen2 DN reversal model (microarray data). This discrepancy could be 
explained by leakage across an abnormal glomerular barrier in DN as an additional 
protein/peptide source. Another explanation might be the multiple possibilities of 
post-translational modification and proteolytic activity. 
Limitations for biomarker discovery due to the techniques applied 
In general, limitations of the techniques affect the stage of experimental design, they 
can be of procedural nature or issues can arise when raw data is processed and 
statistical analysis and interpretation of the results is performed: 
1. Limitations - experimental design 
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Due to the limited accuracy of “shot-gun analyses” like transcriptome by microarrays 
and peptidomic/proteomics by LC-MS/MS all identified results require a 
confirmation by more accurate methods like PCR and ELISA (Dallas, Guerrero et al. 
2015) (Jaksik, Iwanaszko et al. 2015). 
For microarray, there is a selection of genes on the chip. Though the probes on the 
chip used in this work (Affymetrix Rat Genome 230 2.0 GeneChip) cover for more 
than 28,000 genes, the chip cannot be comprehensive for all the variants of 
alternative splicing at the pre-mRNA stage.  
For peptidomics by LC-MS/MS there is no limitation for the number of peptide 
identification, however, the abundance of a few proteins/peptides mainly due to 
glomerular leakage in the injury group could mask those differences that a more 
subtle between the groups or inhibit the detection of peptides with very low 
concentration.  
The reproducibility of the results in peptidomics is restricted to the same MS-
platform as considerable variation has been reported when the same sample is 
analyzed with different MS techniques. Similarly, on the transcriptome level, 
reproducibility of the results depends on the microarray-chip utilized. 
2. Limitations - experimental performance 
Technical issues in the microarray array analysis have been discussed in Results 
Chapter 3.1. 
A disadvantage for peptidomics/proteomics concerning sample quality is the 
potential degradation that might have started not only at the time of sample collection 
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but already in the bladder. However, literature indicates that urinary peptides are 
rather resistant against degradation (Klein, Bascands et al. 2016).  
In urine salts and lipids might interfere with the LC-MS/MS analysis e.g. by 
dampening the ionization efficiency. The processes to remove these elements are 
elaborate and established but they are also time- and sample consuming and most 
likely reduce the reproducibility of the experiment. 
Using a filter to separate higher molecular-weight proteins from peptides in urine is 
simple, fast and well-established approach; however, it has to be taken into account 
that the separation is incomplete with a slight leakage of larger proteins and loss of 
small peptides (Dallas, Guerrero et al. 2015). 
Using a database searching engine (e.g. Mascot) for peptide identification performs 
well for most peptides but might a have sensitivity and accuracy issues (Merl, 
Ueffing et al. 2012). In this work the problem was reduced by combining two 
engines (Mascot and Maxquant/Andromeda), however, it has been demonstrated that 
incorporating identification by de-novo sequencing algorithms into database research 
could result in higher sensitivity and accuracy for peptide identification (Zhang, Xin 
et al. 2012). 
In all peptidomics analysis normalization is crucial. In urinary peptidomics this can 
be achieved by correcting for creatinine or urinary 24hours volume. Due to the large 
differences in volume in the DM+HTN DN model between the control and injury 
groups. Small mistakes when adapting the large volumes might result in masking 
minute but significant differences in peptides abundances between the groups. 
3. Limitations - data interpretation 
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Another disadvantage of the techniques chosen has been demonstrated by 
Ghazalpour et al.. They demonstrated that in mouse liver there is at best a moderate 
(50%) concordance between transcriptomic and proteomic expression changes 
(Ghazalpour, Bennett et al. 2011). This might limit the approach in this work to 
identify most promising biomarker candidates by referring to similar regulation of 
expression levels in renal genes and urinary peptides. 
Astonishingly, there is a stronger association between clinical traits and 
transcriptomic regulation compared to protein regulation (Ghazalpour, Bennett et al. 
2011). In the DM+HTN DN model there were much more significant differences 
between the individual groups control, DM alone, HTN alone and DM+HTN on the 
renal transcriptomic level than on the urinary peptidomic level. There are several 
possible explanations for this. Firstly, this could be explained by the experimental 
design as not tissue proteins/peptides but urinary peptides were related to renal 
transcripts. Changes in tissue protein level are not necessarily reflected in the urine 
that also contains a large number of proteins/peptides due to glomerular leakage. 
Secondly, as described above, accurate quantification by label-free LC-MS/MS is 
technically more challenging than microarray analysis. Thirdly, in the concept of 
“phenotypic buffering” the largest proportion of molecular variants is silent at the 
phenotypic level (Fu, Keurentjes et al. 2009). Fourthly, protein expression is not only 
affected by disease factors (e.g. hypertension and hyperglycemia) but also by 
numerous additional factors: translational efficiency, alternative splicing, assembly 
into complexes, covalent modification and degradation. For example, Clavo et al. 
have reported that the presence of upstream open reading frames (uORFs) reduces 
the translation of mRNA to protein for up to 50% (Calvo, Pagliarini et al. 2009). 
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Taking into consideration the limitations discussed in the previous paragraphs many 
candidate biomarkers were identified by analysing the renal transcriptome and the 
urinary peptidome in a rodent model and in patients with DN. Our group(Betz and 
Conway 2016) and leading groups in urinary peptidome research (Mischak, Delles et 
al. 2015, Klein, Bascands et al. 2016) suggest that results obtained from rodent 
models and human studies by “–omic” approaches should be compared and 
combined to redefine the evaluation of DN models. This might support researchers to 
select the most appropriate model for their specific research project and might 
thereby improve the translational application (Brosius, Alpers et al. 2009). The work 
of this chapter contributes to step one in the scheme for new biomarker/drug 
discovery as illustrated in Figure 50. 
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Figure 50: Schemata for the discovery of novel biomarkers 
 
Figure 50. “Schemata for discovery of novel biomarker and therapeutic agents. 1. High-
throughput, non-biased “-omic” approaches have identified hundreds of molecules that are 
associated with the development of human diabetic nephropathy. 2. Whether these 
molecules could be targeted to slow progression of nephropathy may be determined using 
the most appropriate animal model for the specific research question. 3. Genetically modified 
rodents may offer mechanistic insight and suggest whether development of a therapy is 
warranted. 4. Pharmaceutical agents may be tested for efficacy and potential side effects. 5. 
Therapies that are successful in robust animal studies may be taken forward into clinical 
trials. 6. Samples and data from these trials may be “biobanked” to provide further 
mechanistic insight toward refining therapies”. (Figure and legend are taken from Betz et 
Conway, “An Update on the Use of Animal Models in Diabetic Nephropathy Research”,  Curr 
Diab Rep 16(2): 18.) 
3.2.8 Summary 
The present chapter describes:  
- the development of a methodology for preparing, measuring and analysing the  
  urinary peptidome utilizing highly sensitive LC-MS/MS technology 
- the validation of the methodologic approach in several experimental cohorts    
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   including the Cyp1a1mRen2 DN model with induction of DM alone, HTN alone or    
   the combination DM+HTN, the DN reversal model and patients with DN. 
-  the identification of a candidate biomarker of tubular biomass, EGF, by two  
   different analytical approaches (MaxQuant, Progenesis) and the validation of EGF    
   protein regulation in urine and tissue.  
The translational validation of uEGF will be part of the next chapter. 
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3.3 Urinary Biomarkers 
3.3.1 Introduction 
In the previous two chapters the Cyp1a1mRen2 reversal DN model helped to identify 
pathological pathways and proteins that might be involved in the progression of 
diabetic kidney disease. These proteins might be used as potential new non-invasive 
biomarkers indicating the risk of incident CKD or renal deterioration as the 
established marker albuminuria is often not present in patients with advanced DN. 
The candidate biomarkers were first tested in a small pilot study and then quantified 
in urine samples from the large well-defined Edinburgh Type 2 Diabetes Study 
(ET2D) cohort. (Price, Reynolds et al. 2008) The degree of correlation between the 
novel biomarkers and kidney function or previously tested urinary biomarkers was 
then assessed. The previously tested biomarkers include kidney injury molecule 1 
(KIM-1) and Glycoprotein (Transmembrane) Nmb (Gpnmb) as potential indicators 
of disturbed tubular cellular integrity (Conway, Manoharan et al. 2012). Finally the 
predictive value of candidate biomarkers for renal deterioration was assessed. 
3.3.2 Biomarker candidates for translational validation 
Table 1 lists the biomarker candidates that were chosen from the previous chapters 
for validation in the human setting. Based on microarray data, all candidates were 
differentially expressed in the renal cortex in the rodent model and/or patients with 
DN compared with controls (Woroniecka, Park et al. 2011, Conway, Rennie et al. 
2012, Conway, Betz et al. 2014). Some genes were increased (MMP7, OPN) with 
others decreased (EGF, VEGF). Similarly the corresponding peptides were increased 
(OPN) or decreased (EGF, VEGF) in the urine from DM+HTN rats or from patients 
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with DN. To assess the ability of the ELISAs to detect their target molecules in the 
urine, a pilot cohort was tested that comprised healthy volunteers (n=4) and patients 
(n=4) with CKD stage II, III, IV, V, respectively. For vascular endothelial growth 
factor-A (VEGF-A) no measureable signal in human urine samples could be detected 
although the standard curve worked well. All other biomarker candidates were 
robustly detected in the pilot urine samples and were taken to larger cohorts for 
further validation. 












Epidermal Growth Factor (EGF) Genetics, Peptidomics 
(rodent) 
DY236 Detectable 
Osteopontin (OPN) Genetics, Peptidomics 
(rodent) 
DY1433 Detectable 





Table 13. List of the urinary candidate biomarkers, the rationale for selecting (details see 
text), the respective ordering number of the ELISA kit in R&D Systems and the results of 
preliminary testing in urinary samples. The pilot cohort comprised healthy volunteers (sample 
number 1-4) and samples from patients with chronic kidney disease stage II III, IV and V 
(sample number 5-8). 
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Figure 51: Optical density (OD) readout for the VEGF ELISA 
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Figure 51. Vascular endothelial growth factor (VEGF) was largely below the threshold for 
robust detection in urinary samples from healthy participants (n=4) and patients with CKD II-
V (n=4) by ELISA. 
3.3.3 OPN and MMP7 in ET2D trial cohorts 
A trial cohort from the Edinburgh Type 2 Diabetes Study was used for each of the 
candidates (Price, Reynolds et al. 2008). The study characteristics are described in 
more detail in the Material and Methods chapter. Urinary samples of the ET2D study 
were stored in 96-1ml-well plates, and for the test run several plates were defrosted. 
Since samples were sorted according to their anonymized study number each plate 
will have contained a random spread of patients with different severity of renal 
function. The baseline characteristics of the patients from the Edinburgh Type 2 
Diabetes cohort used for each analysis are provided in Table 14. Urinary osteopontin 
and MMP7 concentration correlated positively with KIM-1, a marker of tubular 
injury, but not with albuminuria (Table 15). 
In further analyses, the osteopontin and MMP7 concentration was referenced to 
urinary creatinine to correct for difference in urinary concentration. Urinary 
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osteopontin:creatinine ratio, but not urinary MMP7:creatinine ratio correlated with 
baseline GFR (Table 16, Figure 52) but both neither correlated with rate of renal 
decline nor were associated with death or eGFR after 4 years follow up (Table 17).  
Table 14: Characteristics of the trial cohorts for OPN and MMP7 
 
OPN MMP 7 
n 423 748 
urinary OPN : creatinine, ug/mmol  51.87 
(22.62-127.56) 
-- 
urinary MMP7 : creatinine, ug/mmol -- 2.63 
(0.77-8.61) 



















Systolic blood pressure,  





Diastolic blood pressure,  









Table 14. Characteristics of the cohorts in which urinary osteopontin (OPN) and 
metalloproteinase 7 (MMP7) were tested. Parameters are in mean and standard deviation or 
median and interquartile range as appropriate. N as given in the table.  
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Table 15: Correlation of OPN, MMP with other urinary renal markers 
Spearman’s rho Osteopontin MMP 7 
Osteopontin -- 0.03 
MMP 7 0.03 -- 
KIM 1 0.23* 0.1** 
EGF 0.35* 0.08* 
albumin 0.08 -0.04 
Table 15. Correlation between urinary OPN and MMP7 and with other urinary markers of 
renal dysfunction. Correlation was calculated by Spearman’s rho. * p<0.05, **p<0.01 
Table 16: Correlation of OPN and MMP with renal function 
Pearson Correlation 
Ln (urinary OPN : 
creatinine, ug/mmol) 




 0.13* 0.05 
Rate of change, ml/min/1.73m
2
/year 0.03 -0.02 
Table 16. Correlation of urinary OPN and MMP7 with baseline renal function (eGFR) and 
rate of change in renal function per year. OPN and MMP7 were rerferenced to urinary 
creatinine and logarithmized. Correlation was calculated by Pearson Correlation. * p<0.05 
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Figure 52: Visual correlation of OPN and MMP with renal function 
A B 
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Figure 52. Scatterplot demonstrating the relationship between renal function and urinary 
MMP7 (n=748) or OPN (n=423) to creatinine ratios in patients from the Edinburgh Type 2 
Diabetes Study. (A) Logarithmized urinary MMP7:creatinine did not but (B) logarithmized 
Osteopontin : creatinine did correlate with eGFR in the ET2D study cohort. 
Table 17: Association of OPN and MMP with GFR after four years and mortality 
Linear/Cox Regression 
Ln (urinary OPN : 
creatinine, ug/mmol)  
Ln (urinary MMP7 : 
creatinine, ug/mmol) 
Year 4 GFR beta 1.51 0.092 
 
CI (0.253-2.761) (-0.730-0.915) 
death beta 1.236 1.108 
 
CI (0.906-1.687) (0.958-1.282) 
Table 17. For eGFR after four years univariable Linear Regression, and for death univariable 
Cox Regression was calculated. CI=95% confidence interval 
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3.3.4 uEGF in the ET2D study 
uEGF and renal function in the ET2D study 
Urinary EGF was measured in 978 patients from the ET2D study. The characteristics 
of the patient cohort before and after stratification into quartiles according to urinary 
EGF:creatinine ratio (uEGF:Cr) are listed in Table 18. While sex, age, HbA1c, 
duration of diabetes and systolic blood pressure did not differ between the quartiles, 
diastolic blood pressure was slightly but significantly lower in the quartile with 
lowest uEGF:Cr. Mean eGFR increased across the quartiles of uEGF:Cr. Indeed 
there was a highly significant correlation between uEGF:Cr and baseline eGFR 
(Figure 53). Although ACR tended to be higher in the lowest EGF-quartile (p=0.09), 
there was no significant association between uEGF and ACR (Figure 53). Urinary 
KIM-1:creatinine ratio (uKIM-1:Cr) increased with increasing quartiles of uEGF:Cr 
(Table 18). In a linear regression analysis, the association between log(uEGF:Cr) and 
eGFR at baseline remained significant after adjustment for other baseline variables 
(Table 19) The significant correlation between log(uEGF:Cr) and eGFR at four years 
did not persist after adjustment for eGFR and ACR, there was no association 
between log(uEGF:Cr) and the rate of decline in eGFR per year (Table 19). 
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Figure 53: Correlation of uEGF with renal function and albuminuria 
A B 



















r= 0 .3 2
p < 0 .0 0 1
 



















r =  -0 .0 4
p =  0 .2
 
Figure 53. Urinary EGF:creatinine in the ET2D cohort correlated significantly with eGFR(A) 
but not ACR (B). The degree of correlation was assessed using Pearson correlation. In A) 
and C) a linear regression line is drawn with a 95 % confidence interval (dotted line). 
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Table 18: Characteristics of the ET2D study stratified into quartiles according to uEGF 
 
Table 18. Detailed characteristics of the ET2D study cohort separated according to the 
quartiles of uEGF:creatinine ratio. Parameters are means (+/- standard deviation) or 
medians (inter-quartile range) as appropriate. p-values are calculated by ANOVA or Kruskal-
Wallis test. 
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Table 19: Association of uEGF:creatinine ratio with eGFR at baseline, after four years 
and rate of decline in the ET2D study 
 
eGFR Baseline eGFR 4 years Rate of decline/year 
    
Log (uEGF / 
creatinine) 
Unadjusted 
13.4 11.9 -0.39 
CI (10.9 to 15.8) (9.3 to 14.5) (-0.95 to 0.16) 
p-value <0.001 <0.001 0.16 
    








CI (9.4 to 14.2) (-0.53 to 2.92) -- 
p-value <0.001 0.17 -- 
    
Table 19. Linear regression for eGFR at baseline, at 4 years and rate of decline per year 
with EGF:creatinine ratio as independent variable. 
a
Adjustment for age, sex, BP(sys+dia), 
HbA1c, Duration of Diabetes, Log(ACR), Log(uKIM1:creatinine), Log(uGpnmb:creatinine).  
b
Adjustment for the variables in model a and in addition baseline eGFR  
uEGF and the risk of death in the ET2D study 
Altogether 74 participants (7.6%) of the ET2D cohort died within four years. These 
participants were older, had a markedly lower baseline eGFR and uEGF:Cr, longer 
duration of diabetes and higher ACR and uKIM-1:Cr than those participants who 
survived (Table 8). In a Kaplan-Meyer analysis, participants in the lowest uEGF:Cr 
quartile had a significantly higher risk of death (Figure 54). In a Cox-Regression 
analysis the association between the quartile with lowest uEGF:Cr values and 
increased risk of death remained significant after adjustment for risk factors that 
were significantly different between death and survival (Table 20, Table 21).  
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Table 20: Characteristics of the ET2D study cohort are stratified for the endpoint 
death 
  No (n=904) Yes (n=74) 
p-
value 
male, n 473 (% 
 
52) 44 (% 
 
59) 0.28 
age, years  67.70 (+/- 
 





 78.23 (+/- 
 
18.07) 66.40 (+/- 
 
23.57) <0.01 
HbA1c, % 7.39 (+/- 
 
1.11) 7.39 (+/- 
 
0.97) 0.98 
Duration  of diabetes,  years   7.99 (+/- 
 
6.47) 9.92 (+/) 
 
7.46) 0.03 




16.37) 136.00 (+/- 
 
18.64) 0.15 




8.94) 67.05 (+/- 
 
10.18) 0.09 
ACR, mg/mmol 0.06 (-0.12 - 0.30) 0.21 (0.01 - 0.61) <0.01 
urinary EGF : creatinine, 
µg/mmol  
0.90 (0.62 - 1.13) 0.74 (0.35 - 1.09) 0.02 
urinary KIM-1 : creatinine, 
µg/mmol  
12.23 (7.46 - 22.67) 15.68 (9.01 - 30.30) 0.02 
urinary Gpnmb : creatinine, 
µg/mmol  
32.09 (21.07 - 50.68) 37.53 (25.81 - 52.95) 0.09 
Table 20. Characteristics of the ET2D study cohort are stratified for the endpoint death within 
four years. Parameters are expressed as mean (+/- standard deviation) or median 
(interquartile range). P-value for significant difference between the groups are given in the 
table and are calculated by T-test or Mann-Whitney test. Univariate and multivariate cox 
proportional hazards for death for the variables age, diastolic blood pressure, eGFR, ACR 
and KIM-1:creatinine and Gpnmb:creatinine in the ET2D cohort have already been published 
before (Conway, B. R., et al. (2012). "Measuring urinary tubular biomarkers in type 2 
diabetes does not add prognostic value beyond established risk factors." Kidney Int 82(7): 
812-818.). 
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Figure 54: Kaplan-Meyer Analysis of uEGF:Cr quartiles for the endpoint death in the 
ET2D study cohort 
 
Figure 54. Kaplan-Meyer Analysis for the endpoint death in the ET2D-cohort stratified 
according to uEGF:creatinine quartiles. Study participants in the quartile with lowest 
uEGF:creatinine (blue=1) have a significantly increased risk of death during observation 
time.  
Table 21: Association of uEGF with death in cox-regression analysis 
 death 
Log (uEGF:Cr) Quartile I, unadjusted 2.26 
CI (1.42 to 3.58) 
p-value 0.001 
  
Log (uEGF:Cr) Quartile I, adjusted* 1.76 
CI (1.04 to 2.96) 
p-value 0.034 
Table 21. Cox-Regression for the endpoint death with logarithmized uEGF:creatinine ratio as 
independent variable. In a multivariable analysis parameters which were significantly 
different for the outcome (refer to Table 8) were included: *=adjustment for age, eGFR, 
duration of diabetes, log (uKIM1:creatinine), log (ACR). 
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3.3.5 The ET2D subgroup of participants without “obvious renal 
damage” 
From the 978 ET2D study participants with urinary EGF measurements, 642 (66%) 
had no indicators of chronic kidney disease at baseline as defined by eGFR>60 
ml/min/1.73m
2
 and the absence of albuminuria (Stevens, Levin et al. 2013); this 
subgroup is referred to as “no obvious renal damage”. A quarter of participants had 
eGFR<60 ml/min/1.73m
2
, of those three quarters were normoalbuminuric. Ninety 
eight (10%) had an eGFR>60 ml/min/1.73m
2 
and micro- or macroalbuminuria (Table 
22).  
The subgroup “no obvious renal damage” was stratified into tertiles according to 
log(uEGF:creatinine) (Table 23). eGFR was borderline significantly (p=0.051) 
higher in the tertile with highest uEGF:Cr and correlated weakly but significantly 
with uEGF:Cr (r=0.11, p<0.01). A significantly greater proportion of patients in the 
tertile with the highest uEGF:Cr had an ACR greater than 0.5 mg/mmol. The 
biomarkers urinary KIM-1 and Gpnmb were included in the subgroup analysis as 
they have only been characterized for the complete (albuminuric and non-
albuminuric) ET2D study cohort before (Conway, Manoharan et al. 2012). Whilst 
Gpnmb:creatinine did not vary between tertiles, unexpectedly, uKIM-1:creatinine 
was significantly elevated in patients in the highest uEGF:Cr tertile. 
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Table 22: Classification of the ET2D cohort according to renal function and absence 
of albuminuria 
ET2D (n=978) 















 98 (10%) 63 (6%) 
Table 22. The ET2D study cohort was divided into four subgroups according to eGFR and 
the presence of proteinuria at baseline. 
1
 = ACR > 2.5 mg/mmol (males) and > 3.5 mg/mmol 
(females). 
2
 = ACR > 30 mg/mmol. 
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ACR <0.5 / 0.5-1 / 
1-2.5 (males) or 
1-3.5 (females),  






































































Table 23. Characteristics of the 642 patients from the ET2D study who had no obvious renal 
damage at baseline (Table 22), classified according to tertiles of baseline uEGF:Cr. 
Parameters are in mean (+/-standard deviation) or median (interquartile range) as 




3.3.6 Association of urinary EGF, KIM-1 and Gpnmb with renal 
endpoints  
During follow-up, 91 of the 642 patients (14%) developed an 
eGFR<60ml/min/1.73m
2
 and 133 (21%) suffered from a rapid decline in eGFR (>5% 
per annum). Altogether 161 (25%) participants developed either endpoint, with 63 
(10%) matching both criteria (Table 24). The frequency of endpoints was higher in 
patients from the lowest uEGF:Cr tertile.  
When stratifying patients according to whether or not they developed the composite 
endpoint, there were significant differences in the baseline characteristics between 
the groups including: renal function (eGFR), age, sex, systolic blood pressure, 
duration of diabetes, HbA1c, ACR and uEGF:Cr and Gpnmb:creatinine (Table 25). 
Results were similar when stratification was performed for either outcome alone with 
ACR ceasing to be significantly different and KIM-1:creatinine being significantly 
different for incident CKD III (Table 26, Table 27). Kaplan-Meier analysis 
demonstrated that patients in the tertile with the lowest uEGF concentration at 
baseline had a significantly higher risk of developing an eGFR<60ml/min/1.73m
2 
during the follow-up period, whilst patients in the tertile with lowest 
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Gpnmb:creatinine concentration had a significantly lower risk for incident CKD III. 
Conversely, tertiles of baseline ACR and uKIM-1 were not significantly associated 
with incident stage 3 CKD (Figure 55). Log(uKIM-1:creatinine), 
Log(uGpnmb:creatinine)  Log(uEGF:creatinine) were significantly associated with 
incident eGFR<60ml/min/1.73m
2
 (Table 28). Only uEGF:Cr had also a significant 
association with rapid decline in renal function or the combination of either outcome. 
After adjustment for baseline characteristics (eGFR, age, gender, ACR, HbA1c, 
duration of diabetes, systolic and diastolic blood pressure) the associations between 
uGpnmb:Cr and incident CKD III and the associations between uEGF:Cr and all 
outcomes remained significant. 
Table 24: Classification of the ET2D subgroup “without obvious renal damage” by 
end points and log(uEGF:creatinine) tertiles 











      










and/or >5% decline in 
eGFR/year 
161 (25%) 73 (45%) 48 (30%) 40 (25%) 0.001 
      
Table 24. Absolute frequency (percentage of total) of the outcomes decline in eGFR of more 
than 5% per year, incident eGFR<60ml/min/1.73m
2
 and the combination of either or both 
end points in patients from the ET2D study subgroup with “no obvious renal damage” at 
baseline, stratified into log(uEGF:creatinine) tertiles. P-values for significant differences are 




Table 25: Stratification of the ET2D subgroup “without obvious renal damage” by the 
combination of the outcomes Incident eGFR<60ml/min/1.73m
2
 or >5% 























































ACR <0.5 / 0.5-1 / 1-2.5 (males) or   


















Table 25. Characteristics of the ET2D study subgroup “without obvious renal damage” at 
baseline (Table 10) stratified according to whether they met the combined endpoint of 
incident eGFR<60ml/min/1.73m
2
 and/or >5% decline in eGFR/year. Parameters are 
expressed in mean (+/- standard deviation) or median (interquartile range) as appropriate. P-
values for differences between the groups are given in the table and are calculated by T-test, 





Table 26: Stratification of the ET2D subgroup “without obvious renal damage” by the 
outcome >5% decline in eGFR/year 











































ACR <0.5 / 0.5-1 / 1-2.5 (males) or   
















Table 26. Characteristics of the ET2D study subgroup “without obvious renal damage” 
(Table 10) at baseline are stratified according to the endpoint >5% decline in eGFR/year. 
Parameters are expressed in mean (+/- standard deviation) or median (interquartile range) 
as appropriate. P-values for differences between the groups are given in the table and are 






















































ACR <0.5 / 0.5-1 / 1-2.5 (males) or 
















Table 27. Characteristics of the ET2D study subgroup (Table 10) are stratified according to 
the endpoint incident eGFR<60ml/min/1.73m
2
. Parameters are expressed in mean (standard 
deviation) or median (interquartile-range) as appropriate. P-values for differences between 




Figure 55: Kaplan-Meier analysis for the endpoint Incident eGFR<60ml/min/1.73m
2
 in 





Figure 55. Kaplan-Meier analysis for the outcome “incident eGFR<60ml/min/1.73m
2
“ in the 
ET2D-subgroup “without obvious renal damage” at baseline (Table 10) stratified to (A) 
uEGF:creatinine, (C) uGpnmb:creatinine and (D) uKIM-1:creatinine tertiles. (B) ACR was 
stratified into the categories <0.5 (Cat1)/ 0.5-1 (Cat2) / 1-2.5 (males) or 1-3.5mg/mmol 
(females) mg/mmol (Cat3). p-value as indicated. 
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Table 28: Association of urinary EGF, KIM-1 and Gpnmb with renal outcomes in the 
ET2D subgroup "without obvious renal damage” 









    Log (KIM-1 / 
creatinine) 
unadjusted 1.344 1.770 1.358 
95% CI (0.827 to 2.813) (1.023 to 3.062) (0.860 to 2.144) 
p-value 0.233 0.041 0.189 
    Log (KIM-1 / 
creatinine) 
adjusted* 0.905 1.910 1.037 
95% CI (0.524 to 1.562) (0.983 to 3.708) (0.614 to 1.751) 
p-value 0.719 0.056 0.892 
    Log (Gpnmb / 
creatinine) 
unadjusted 2.105 3.120 2.435 
95% CI (1.050 to 4.219) (1.392 to 6.996) (1.263 to 4.697) 
p-value 0.036 0.006 0.008 
    Log (Gpnmb / 
creatinine) 
adjusted* 1.038 3.058 1.522 
95% CI (0.462 to 2.332) (1.034 to 9.044) (0.689 to 3.363) 
p-value 0.928 0.043 0.299 
    Log (uEGF / 
creatinine) 
unadjusted 0.542 0.487 0.450 
95% CI (0.349 to 0.840) (0.297 to 0.799) (0.296 to 0.683) 
p-value 0.006 0.004 <0.001 
    Log (uEGF / 
creatinine) 
adjusted* 0.444 0.480 0.382 
95% CI (0.273 to 0.722) (0.256 to 0.899) (0.236 to 0.618) 
p-value 0.001 0.022 <0.001 
    Table 28. Binary logistic regression for the outcomes decline in eGFR of more than 5% per 
year, incident eGFR<60ml/min/1.73m
2
 and the combination of either outcome with 
logarithmized KIM-1:creatinine, Gpnmb:creatinine or uEGF:creatinine ratio as independent 
variables. *In a multivariable analysis the following parameters were included: sex, age, 
eGFR, BP (systolic+diastolic), HbA1c, duration of diabetes, ACR. CI = Confidence interval 
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3.3.7 uEGF and risk prediction models  
A key aim was to assess whether the addition of log (uEGF:creatinine) improves 
prediction of renal outcomes above and beyond traditional risk factors. Hence a 
reference model that included traditional risk factors (age, gender, eGFR, ACR, 
duration of diabetes, HbA1c, systolic and diastolic blood pressure) was compared to 
a model that included these risk factors, but in addition incorporated log (uEGF:Cr). 
To test how well the two models fitted the data the Homser-Lemeshow goodness of 
fit analysis was used. Patients were stratified into deciles according to their predicted 
risk calculated by the model. The extent of the differences between the observed risk 
and the predicted risk for every decile defines the calibration quality of the model. 
The model is well calibrated if the difference between calculated and observed risk is 
not significant (p>0.05).The Homser-Lemeshow test statistic (Kundu, Aulchenko et 
al. 2011) confirmed that all models fulfilled the goodness of fit criteria as the null-
hypothesis (the “model does not fit”) was rejected (Table 29, Figure 56).  
Compared to the reference model the addition of log (uEGF:Cr) resulted in a small 
increase in AUC-ROC (Table 30), which was not significant (e.g. p=0.07 for the 
combined end-point, Figure 57).  
Calculating the Integrated Discrimination Improvement (IDI)(Pickering and Endre 
2012) there was a significant increase of IDI when log (uEGF:Cr) was added to the 
reference models for the endpoint rapid decline in eGFR and the combined outcome 
(0.017 and 0.023 respectively). The differences resulted mainly from an increase in 
IDIevents (0.014 and 0.017 respectively). The addition of log(uEGF:Cr) did not 
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significantly alter the IDI for incident eGFR<60ml/min/1.73m
2
 alone (Table 31, 
Figure 58).   
Table 29: Hosmer-Lemeshow goodness of fit analysis of the prediction models with 
or without EGF for renal outcomes in the ET2D study 









    
ROC-AUC REF 0.166 0.95 0.177 
ROC-AUC REF+EGF  0.704 0.99 0.300 
    
Table 29. Hosmer-Lemeshow goodness of fit analysis tests the calibration (details provided 
in the text) of the reference model (REF) including sex, age, eGFR, BP(systolic+diastolic), 
HbA1c, Duration of Diabetes, ACR(logarithmized) and the reference model additionally 
including Log(uEGF:Cr) for all outcomes by comparing the predicted and the observed risk. 
All patients are stratified into deciles according to their predicted risk calculated by the 
respective model. P-values above 0.05 indicate that the models are well calibrated. ROC-
AUC = area under the receiver operating characteristic curve, REF=refrence model 
Figure 56: Graphical illustration of the Hosmer-Lemeshow goodness of fit analysis 
A B 
  
Figure 56. Graphical illustration of the calibration plots for the combined endpoints from the 
Hosmer-Lemeshow goodness of fit analysis for the reference model (A) without [REF] and 
(B) with uEGF [REF+EGF]. Patients are stratified into deciles according to their predicted 
risk calculated by the respective model. 
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Table 30: ROC-AUC with and without uEGF for renal outcomes in the ET2D study 








ROC-AUC EGF 0.570 0.605 0.601 
(95% CI) (0.530 to 0.608) (0.566 to 0.643) (0.562 to 0.639) 
ROC-AUC REF  0.722 0.853 0.761 
(95% CI) (0.673 to 0.771) (0.811 to 0.896) (0.718 to 0.804) 
ROC-AUC 
EGF+REF  
0.740 0.855 0.777 
(95% CI) (0.693 to 0.787) (0.812 to 0.897) (0.735 to 0.818) 
Table 30. Analysis of the Receiver operating characteristics – area under curve (ROC-AUC) 
of log(uEGF:creatinine), a reference model (REF) including sex, age, eGFR, BP (sys+dia), 
HbA1c, Duration of Diabetes,  ACR (logarithmized) and the combination of both for the renal 
outcomes in the ET2D subgroup “without obvious renal damage”. CI =Confidence Interval. 
Figure 57: ROC graph with and without uEGF for the combined renal endpoint  
 
Figure 57. Graphical illustration of the receiver operating charcteristic (ROC) curve 
comparing the reference model without (ROC REF, green line) and with 
log(uEGF:creatinine) (ROC REF+EGF, blue line) for the combined endpoint in the ET2D 
subgroup “without obvious renal damage” at baseline. 
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Table 31: Integrated Discrimination Improvement (IDI) for prediction models including 
uEGF compared to model without uEGF for renal outcomes of the ET2D 
study  









    
IDI (CI) 0.017 (0.004 to 
0.030) 
0.011 (-0.001 to 0.023) 0.023 (0.009 to 
0.037) 
Relative IDI  14.8% 4.61% 13.5% 
IDI (events) 0.014 (0.001 to 
0.026) 
0.009 (-0.002 to 0.021) 0.017 (0.005 to 
0.030) 
IDI (non-events) 0.003 (-9e-04 to 
0.008) 
0.002 (-0.001 to 0.004) 0.006 (1e-04 to 
0.012) 
    
Table 31. Absolut and relative integrated discrimination improvement (IDI) and IDI for events 
and non-events when log(uEGF:creatinine) is added to the reference model including sex, 
age, eGFR, BP(systolic+diastolic), HbA1c, Duration of Diabetes,  ACR(logarithmized) . CI = 
95% Confidence Interval. IDI is calculated for all renal outcomes in the ET2D subgroup 
“without obvious renal damage” at baseline. 
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Figure 58: Graphical illustration of the IDIevents and IDInon-events comparing the reference 







Figure 58. Graphical illustration of the Integrated discrimination improvement for events 
(IDIevents, black) and for non-events (IDInon-events, red) comparing the reference model (REF) 
without (dotted line) and with log(uEGF:creatinine) (solid line) for the endpoints >5% decline 
in eGFR/year (A), Incident eGFR<60ml/min/1.73m
2
 (B)and the combination of both 
endpoints after four years (C) in ET2D subgroup “without obvious renal damage” at baseline. 
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3.3.8 Discussion 
In this chapter several candidate urinary biomarkers identified from patterns of gene 
expression or urinary peptidomics in the Cyp1a1mRen2 rat model of DN were tested 
for their ability to predict renal outcomes in patients with type 2 diabetes.  
MMP7 
The rationale for choosing MMP7 was based on the molecular and 
immunohistochemistry findings from this group(Conway, Betz et al. 2014) and a 
potential role for MMP7 in the homeostasis of ECM synthesis and degradation in 
diabetic nephropathy has been described before (Maahs, Siwy et al. 2010, Xu, Xiao 
et al. 2014, Mischak, Delles et al. 2015). However, there are conflicting results about 
MMP-7 expression in renal tissue in diabetic nephropathy. McLennan et al. 
demonstrate reduced molecular expression in both rodent STZ-induced and human 
DN (n=7)(McLennan, Kelly et al. 2007), whilst Woroniecka et al. and Ju et al. 
demonstrate an increased molecular MMP7 expression in renal biopsies of patients 
with DN (n=44 and n=17 respectively)(Woroniecka, Park et al. 2011, Ju, Nair et al. 
2015). . In the current study, the uMMP7:creatinine ratio did not correlate with either 
baseline renal function, rate of change in renal function or albuminuria in patients 
with type 2 diabetes. Ban et al. demonstrate an increase in serum MMP7 with 
decreasing eGFR, increasing albuminuria or increasing cardiac dysfunction(Ban, 
Twigg et al. 2010). A possible explanation for the lack of association with urinary 
MMP7 and renal parameters might be that urinary MMP7 concentration is derived 
from two sources, serum and kidney. In albuminuric patients the disruption of the 
glomerular filtration barrier might cause increased excretion of MMP7. Increased 
218 
serum MMP7 in DN patients (Ban, Twigg et al. 2010, Kadoglou, Sailer et al. 2014) 
and decreased renal MMP7 could compensate for each other in urinary excretion.  
There was a weak positive correlation of MMP7 with EGF. In the kidney, MMP7 is 
mainly expressed in tubular cells(He, Tan et al. 2012). Therefore, reduced MMP7 
excretion might reflect a loss of renal tubular mass similar to EGF. However this 
hypothesis requires further experimental and clinical proof.  
Osteopontin 
Osteopontin (OPN) was weakly positively correlated with baseline renal function. 
This finding was unexpected as OPN is known to be involved in the genesis of 
albuminuria (Lorenzen, Shah et al. 2008) and the inflammatory response in 
DN(Zhang, Shek et al. 2010). Expression of the OPN gene is upregulated in the renal 
cortex of patients with DN compared to healthy donors (Woroniecka, Park et al. 
2011, Ju, Nair et al. 2015). In patients with type 1 and type 2 diabetes elevated serum 
levels of OPN have been associated with an increased risk of diabetic nephropathy 
and rapid decline in renal function (Gordin, Forsblom et al. 2014, Looker, Colombo 
et al. 2015). A very weak positive correlation between urinary OPN and eGFR has 
previously been reported in a large cohort of patients with type 2 diabetes 
(O'Seaghdha, Hwang et al. 2013). As it has been demonstrated in the previous 
chapter, urinary peptide fragments of OPN are increased in the renal injury group of 
the Cyp1a1mRen2 DN model. One explanation for this discrepancy between human 
DN and rat models might be due species related differences as has been reported 
previously for collagen isoforms (Siwy, Zoja et al. 2012). Urinary OPN is reduced in 
patients with IgA-Nephropathy, however a 34 kD fragment resulting from cleavage 
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by serine proteases such as thrombin is increased compared to healthy controls 
(Gang, Ueki et al. 2001). This fragment was only detected by immunoblot but not by 
ELISA. Therefore, serine protease activity which is altered in DN (Kolset, Reinholt 
et al. 2012) might be reducing the non-fragmented urinary OPN concentration in 
diabetic nephropathy. 
Vascular endothelial growth factor A (VEGF-A) 
While most studies have focused on biomarkers that are excreted at higher levels in 
the urine of patients with DN compared to controls, those that are down-regulated 
may be more likely to reflect intrinsic renal pathophysiology than alterations in 
passage across a damaged glomerular filtration barrier. 
VEGF-A is an attractive candidate biomarker, as expression of the VEGF-A gene 
was down-regulated in the renal cortex of the Cyp1a1mRen2 model(Conway, Rennie 
et al. 2012) and in patients with DN compared to healthy donors(Woroniecka, Park et 
al. 2011, Ju, Nair et al. 2015). Furthermore, VEGF-derived peptides had decreased 
abundance in patients with DN versus controls (previous chapter). Unfortunately, no 
signal from the parent protein could be detected by the commercial ELISA used, 
despite the standards working effectively. It cannot be excluded that ELISA kits from 
other companies targeting other epitopes of the protein might result in a detectable 
signal.  
Rationale for EGF from previous rodent and human studies 
Similar to VEGF EGF is down-regulated in the Cyp1a1mRen2 DN model on a 
transcriptional level and urinary peptides of EGF are reduced (previous chapter). 
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A reduction of EGF levels in tissue and urine has also been reported in other rodent 
models of chronic kidney disease (Thulesen, Jorgensen et al. 1997, Kelly, Cox et al. 
2002, Siwy, Zoja et al. 2012). Consistent with the results from the animal models, a 
reduction in renal gene and protein EGF expression has also been observed in the 
renal tubulointerstitium in patients with DN (Lindenmeyer, Kretzler et al. 2007, 
Woroniecka, Park et al. 2011).  
EGF is constitutively produced in the kidney by tubular cells, therefore urinary EGF 
concentration could be a surrogate for functional tubular mass. Lindenmeyer et al. 
hypothesized that since EGF acts as a growth factor on tubular cells the reduced EGF 
production in DN might also be an important pathophysiological factor for 
progressive renal damage(Lindenmeyer, Kretzler et al. 2007). This is consistent with 
the focal reduction in EGF expression in atrophic and injured tubules observed in the 
diabetic and hypertensive Cyp1a1mRen2 rats (previous chapter).  
EGF correlates with renal function and is associated with mortality in the ET2D 
cohort 
The uKIM-1:creatinine ratio increased progressively across quartiles of uEGF:Cr 
(Conway, Manoharan et al. 2012). The correlation between uEGF and KIM-1 
remained significant even after removal of urinary creatinine as a correction factor 
(r=0.341 p<0.001, Spearman correlation). This was unexpected, given the inverse 
correlation between EGF and KIM-1 in rodent renal tissue. There is at the moment 
no explanation for this paradoxical correlation but possibly the presence of higher 
uEGF indicates more renal mass and tubular cells that can - upon damage - express 
KIM-1 as an early marker of injury(Bonventre 2009).   
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There was a strong positive correlation between uEGF:creatinine and renal function 
in the ET2D cohort, but not with ACR. Several studies have investigated the urinary 
concentration of EGF in patients with DN, almost always reporting a robust positive 
correlation with renal function but with conflicting results concerning the correlation 
with albuminuria (Dagogo-Jack, Marshall et al. 1989, Mathiesen, Nexo et al. 1989, 
Lev-Ran, Hwang et al. 1990, Kawaguchi, Kamiya et al. 1993, ter Meulen, Bilo et al. 
1994, Torffvit, Jorgensen et al. 1998). However, all these studies had only limited 
patient numbers.  
None of the studies aforementioned had evaluated the use of uEGF:creatinine as a 
prognostic biomarker. Whilst for the first time uEGF:creatinine has been 
demonstrated as a potential independent risk factor for all-cause mortality - what 
needs confirmation in larger study cohorts - uEGF:creatinine was not associated with 
the rate of decline in eGFR in the ET2D study cohort. Recently, Ju et al. 
demonstrated that the uEGF:creainine ratio predicts a marked decline in renal 
function (40% within 2-4 years) and end-stage renal disease in three large cohorts 
comprising patients with moderately to severely advanced CKD defined by reduced 
GFR and/or albuminuria(Ju, Nair et al. 2015). In contrast to the present study, there 
was a wide spectrum of aetiologies for CKD (including 50% with IgA Nephropathy) 
with only a minority of patients suffering from DN. The endpoints utilized in the 
study from Ju et al. were not applicable to the current study because after 4 years in 
the ET2D cohort only 4 patients (0.4%) had ESRD and 41 patients (4.2%) had a 
decline in eGFR of more than 40%.  
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EGF is associated with renal functional decline in normoalbuminuric ET2D patients 
While 24% of patients in the ET2D study had eGFR<60ml/min/1.73m
2
, only a 
quarter (6%) of these had evidence of micro-/macroalbuminuria. Hence, it is 
imperative to find prognostic biomarkers that predict the development of renal 
disease in those patients with type 2 diabetes and no microalbuminuria(Retnakaran, 
Cull et al. 2006). To this end the potential of uEGF:Cr to predict renal outcomes in 
the subgroups of 642 patients with eGFR>60ml/min/1.73m
2
 and no albuminuria at 
baseline was assessed.  
In these 642 patients with preserved renal function, the positive correlation of 
uEGF:creatinine ratio and baseline eGFR in patients was much weaker (r=0.11, 
p<0.01) than before when all participants with a broader range of renal function were 
included. The incidence of end-stage renal disease was too low to be used as a renal 
end-point, therefore incidence of new onset CKD (eGFR<60 ml/min/1.73m
2
) was 
employed as a key outcome measure. One caveat about using an eGFR threshold as a 
renal endpoint is that those starting with an eGFR of, for example, 64 ml/min/1.73m
2
 
are much more likely to meet the end-point than those starting at 85 ml/min/1.73m
2
. 
This is consistent with the fact that the mean eGFR in those developing CKD III was 
75.2 ml/min/1.73m
2
 versus 87.7 ml/min/1.73m
2
 in those whose renal function 
remained in the normal range.  Hence an additional endpoint based on rate of decline 
in renal function was used. The endpoint of a >5% decline in eGFR/year has been 
used as an indicator for renal deterioration in addition to incident CKD III by 
previous studies (Park, Shlipak et al. 2012, Driver, Shlipak et al. 2014) and the 
incidence rates in the current study were concordant with those reported in the 
Multi-Ethnic Study of Atherosclerosis.(Park, Shlipak et al. 2012)  
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When the cohort was stratified according to renal endpoints, as anticipated, classical 
risk factors for renal deterioration in patients with type 2 diabetes were higher in 
those who progressed (Retnakaran, Cull et al. 2006). However, albumin was 
relatively poor at predicting either rate of decline in renal function or new onset 
eGFR <60 ml/min/1.73m
2
. This again highlights the importance of identifying 
additional predictors of renal outcomes in patients with type 2 diabetes and 
normoalbuminuria. Moreover that might reflect the heterogeneity of renal injury in 
type 2 diabetes with hypertension, dyslipidaemia and loss of autoregulation being 
essential additional contributors to renal damage besides hyperglycaemia (Mogensen 
2003). These additional renal risk factors can be found with variable severity in T2D 
patients. Nosadini al. demonstrate in a group of patients with type 2 diabetes who 
had all a similar level of renal function and microalbuminuria, that the extent of 
glomerular damage varied considerably within the group and was a risk for renal 
deterioration(Nosadini, Velussi et al. 2000). Recently, Fufaa at al. demonstrated in 
Amercian Indians with type 2 diabetes that a histological glomerulopathy index is 
independent from albuminuria for prediction rapid renal function loss (Fufaa, Weil et 
al. 2016). Both aforementioned pathological studies did not investigate 
tubulointerstitial fibrosis (TIF) in detail though the severity of TIF can be an even 
more useful indicator for renal deterioration in DN than glomerular 
observations(Gilbert and Cooper 1999). EGF as a marker of tubular mass might 
provide precious information about the extent of tubular cell loss due to TIF and 
complement albuminuria especially in patients with type 2 diabetes.  
Indeed, in the current study the lowest tertile of uEGF:creatinine but not 




. uEGF was also associated with the combined outcome of 
incident CKD or rapid decline in renal function independently from albuminuria, 
eGFR and other risk factors. 
The addition of uEGF/Cr ratio to a panel of established risk factors resulted only in a 
very modest increase in the ROC-AUC. However the comparison between ROC-
AUCs of prediction models with and without the potential risk factor might be 
insensitive for small but actually significant improvements especially if the 
underlying model is already strong (Cook 2008, Parikh and Thiessen-Philbrook 
2014). The index of discrimination improvement (IDI) is an alternative metric that 
summarizes the changes in calculated risk for every individual with event (IDIevent) 
and without event (IDInon-event) when applying the new prediction model compared to 
the old model. The total IDI is the sum of IDIevent and IDInon-event. However there is 
no established criterion regarding how a significantly positive increase in IDI should 
be statistically interpreted (Parikh and Thiessen-Philbrook 2014). For this, the 
relative IDI is calculated that is the absolute IDI divided by the discrimination slope 
of the reference model. It has been suggested that an IDI is relevant if the relative IDI 
> 1/number of variables in the reference model(Parikh and Thiessen-Philbrook 
2014). In the current study, this is the case for the endpoints rapid decline in eGFR 
and the combination of rapid decline and incident CKD III (14.8% and 13.5% > 
12.5%). In conclusion, although by logistic regression analysis uEGF:Cr was highly 
significantly associated with all three endpoints after adjustment for known risk 
factors, it seems to add predictive value beyond the reference model only for the 
endpoints of rapid decline in eGFR and the combined outcome. 
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uKIM-1 and uGpnmb in the normoalbuminuric ET2D cohort with eGFR>60 
ml/min/1.732 
Kidney injury molecule 1 and Glycoprotein Transmembrane nmb have been 
characterized in the ET2D cohort before and no prognostic value in addition to 
established risk factors had been found (Conway, Manoharan et al. 2012). However, 
their potential predictive value has not been investigated in the subgroup of patients 
with normoalbuminuria and preserved renal function. In Kaplan-Meier analysis 
urinary KIM-1:Cr did not predict renal decline. The failure of KIM-1 to be a relevant 
predictor of decline in eGFR is in line with most of the previous reports (Conway, 
Manoharan et al. 2012, Park, Shlipak et al. 2012, O'Seaghdha, Hwang et al. 2013). In 
both Kaplan-Meier analysis and binary logistic regression uGpnmb was associated 
with incident eGFR<60 ml/min/1.73
2 
even after multivariate adjustment. For the first 
time, elevated urinary Gpnmb:creatinine is demonstrated to be an independent 
predictive marker for renal deterioration in patients with type 2 Diabetes. As a 
marker of renal repair(Li, Castano et al. 2010) elevated uGpnmb might indicate 
increased tubular damage/fibrosis that is an important predictor of renal function 
(Gilbert and Cooper 1999). 
Limitations 
Some limitations for the ET2D cohort and the endpoints need to be mentioned. Since 
biopsies were rarely performed in the ET2D study patients, the histological cause for 
decline in renal function and incident CKD cannot be determined. For assessment of 
decline in renal function only two timepoints for eGFR measurement were used 
whereas linear regression based on multiple eGFR measurements may provide a 
more accurate measure of rate of decline in renal function. Additionally, only a 
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single measurement of uEGF was assessed since 4 year follow up urinary samples 
had not been available. Those who died were not included in the endpoint 
calculations and this might have introduced survival bias, though the mortality was 
rather low (7.6%).  Finally the homogeneity of the study cohort (Caucasians, type 2 
diabetes, older age) restricts generalization of the marker uEGF to other patient 
groups. 
Since a loss of 5% eGFR per year resulted in a minimum loss of GFR of 12 
ml/min/1.73m
2
 during a four year period for patients with a baseline eGFR of 60 
ml/min/1.73m
2
, all study participants who matched the endpoint fulfilled the NICE 
(National Institute for Healthcare and Excellence) criteria for progression of CKD 
from 2008: In the version of 2008 one definition for progressive CKD is “a decline in 
eGFR of >10 ml/min/1.73m
2
 within 5 years” (NICE 2014). However, in the NICE 
guideline for CKD from 2014 this definition and the term “progressive” CKD have 
been removed. The new definition refers to “accelerated progression of CKD” as a 
“sustained decrease in GFR of 25% or more and a change in GFR category within 12 
months or a sustained decrease in GFR of 15 ml/min/1.73 m2 per year” (NICE 
2014). Therefore the chosen endpoint of 5% loss in eGFR per year does not single 
out patients with “accelerated progression of CKD” as defined by the new NICE 
guideline from 2014. However, the chosen endpoint has been used for progression of 
CKD in studies before and had been associated with increased risk for CVD 




In this chapter a panel of biomarker candidates generated by a rodent model of DN 
were examined for their utility in predicting renal outcomes in patients with type 2 
diabetes. The laborious process of biomarker-selection and its correlation with the 
amount of time, effort and materials/samples utilized has been nicely illustrated by 
Leichtle et al. as the “biomarkers bottleneck”(Leichtle, Dufour et al. 2013) (Figure 
59). From the biomarker candidates tested, only one, uEGF:Cr, could be identified to 
be of potential clinical value but requires validation in in other populations, including 
those with type 1 diabetes. 
Figure 59: "Biomarker bottleneck" 
 
Figure 59. Steps in of biomarker discovery: Each stage in the biomarker development 
process results in a significant loss of candidates and an exponential increase in time, 







3.4 Urinary Extracellular Vesicles 
3.4.1 Introduction 
The last chapter focused on the translational validation of biomarker candidate 
proteins by conventional measurement techniques (ELISA). The proteins had been 
selected based upon findings from the transcriptome and urinary peptidome of the 
Cyp1a1mRen2 DN model. Analysis of the ontology categories that were enriched 
with genes up-regulated in the kidney during injury phase compared to baseline 
identified the exosome pathway to be amongst the most significantly enriched (Table 
32). Extracellular vesicles categories were also highly enriched with genes related to 
urinary peptides with increased relative abundance during injury phase in the 
Cyp1a1mRen2 model and from patients with DN (Table 33). 
Extracellular vesicles are defined by their size (1µm) and can be further divided into 
exosomes (20-100nm) and microvesicles (100-1000nm) and in their cellular 
generation process (see Introduction section). Though they are present at high 
concentrations in all body fluids the established process for measuring EVs required 
hitherto large sample volumes (e.g. several hundred millilitres of urine), long 
preparation time (e.g. several hours for exosomes) and specialized equipment 
(Ultracentrifuge). Therefore, their application as biomarkers in large cohorts like DM 
patients was limited as this necessitates a brief, high-throughput methodology. 
The nanoparticle tracking analysis (NanoSight LM10) and flow-cytometry using 
acoustic focusing (Attune Flow Cytometer) might allow quick and reproducible 
quantification of EVs in small samples volumes. 
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The aim of following chapter is to explore the possibilities but as well the potential 
pitfalls of these novel techniques for EV measurement. After being established in the 
Cyp1a1mRen2 DN model the methodology will be tested in human samples that had 
been collected in the Diabetes and Renal Medicine outpatients clinics (Renal 
DiseaseS (RDS) Study) and (for exosomes) in samples from the ET2D cohort 
(Figure 60). 
Finally, when measurements in the following paragraphs are carried out by 
NanoSight LM 10 on unstained urinary specimens the appropriate term to use would 
be “total urinary unlabelled exosome-like particles concentration” since no 
confirmatory electron-microscopy was performed. For the cause of simplicity and 
clarity the term “total exosome concentration” will be used with the reader reminded 
of the limitation mentioned here. 






extracellular matrix 30 8.356546 5.39E-17 
proteinaceous extracellular matrix 23 6.406685 2.01E-07 
extracellular space 55 15.32033 3.25E-07 
cell surface 33 9.192201 5.42E-06 
extracellular exosome 84 23.39833 2.48E-05 
Table 32. ”Top 5” (according to p-value) list of ontology categories which are most 
significantly overrepresented amongst genes that are up-regulated in the kidney in 
the injury cohort compared to control using DAVID and QuickGo ontology 
databases. The extracellular exosome category was of interest as it accounted for the 
most gene counts of all categories. Only categories with p<0.01 and a gene count > 
20 were retained. FDR = false discovery rate calculated with Benjamini-Hochberg 
formula.  
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Table 33: Ontology analysis from genes related to urinary peptides with increased 
relative abundance in rodent and human DN 
A 





GO:0005615 extracellular space 24 2.49E-21 
GO:0005576 extracellular region 31 5.48E-20 
GO:0044421 extracellular region part 24 3.66E-14 
GO:0072562 blood microparticle 7 3.28E-10 
GO:0031988 membrane-bounded vesicle 15 0.0000184 









GO:0005615 extracellular space 30 5.37E-26 
GO:0070062 extracellular exosome 34 2.89E-22 
GO:0072562 blood microparticle 14 2.34E-20 
GO:0031988 membrane-bounded vesicle 34 1.84E-19 
GO:0044421 extracellular region part 32 6.25E-16 
    
 
Table 33. List of ontology categories which are most significantly enriched for genes related 
to urinary peptides with increased abundance from the injury group of A) the Cyp1a1mRen2 
DN model and B) from human DN. The STRING v10.0 database (www.string-db.org) and 
QuickGo ontology database are used. Extracellular vesicle pathways are among the top five 
when sorted for lowest false discovery rate in both species. FDR = false discovery rate 
calculated with Benjamini-Hochberg formula. 
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Figure 60: Overview of NTA and FCM measurements 
 
Figure 60. Schematic summary of experiments performed in this chapter: Urinary 
microparticles were measured using different methodologies in samples from rats and 
humans with different degree of renal impairment. The concentrations in the exosomal range 
(20nm-100nm; blue arrows) and in the microvesicular range (300nm-1000nm, red arrows) 
were determined by NanoSight using Nanotracking technology. Bodipy-Maleimide positive 
microvesicles were measured by the dedicated Attune flow cytometer. Arrows point to the 
analysed cohorts: the rat Cyp1a1mRen2 DN model, samples from the  ”renal 
diseases“ study and in the Edinburgh type 2 Diabetes study.  
3.4.2 Assessing conditions for measurement of urinary exosomes 
concentration  
As published before there is an approximately 10-fold increase in the 24 hours 
urinary volume between rats after 28 weeks of injury (DM+HTN) phase compared to 
control (Figure 61). Generally, there are two ways for compensating for differences 
in urinary volume. First, measurements are corrected by urinary creatinine and this 
approach is especially appropriate when the 24 hours volume is not known or volume 
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fluctuations are expected to be in a moderate range. Due to high differences in 
urinary volume in the Cyp1a1mRen2 DN model it seemed more appropriate to pre-
dilute urinary samples before measurement, rather than measuring first and 
correcting later. Hence urine samples were diluted by a factor equivalent to the ratio 
between the 24hr volume from each rat to the rat with the highest 24hr volume. 
Dilution medium was PBS filtered through a 100µm filter and checked for the 
absence of signal on the NanoSight. Therefore, a much smaller volume of control 
samples was used for measurements compared to injury samples. This approach was 
chosen for all animal experiments. For human studies the 24 hours urinary volume 
was not known and a correction for urinary creatinine was applied. 
 A laser with 540nm excitation coupled with a long-pass filter allows the application 
of antibodies conjugated to fluorophores to identify exosomes with specific surface 
antigens.  Qdots are fluorescent nanocrystals (15-20nm) that can be conjugated with 
specific antibodies. Due to their small size and bright but narrow long-lasting 
emission spectrum Qdots are well suited for application in the NanoSight 
LM10(Dragovic, Gardiner et al. 2011, Oosthuyzen, Sime et al. 2013).   
The optimal time for incubating the urine with antibodies bound to Qdots was 
evaluated first. From two animals two urinary samples each collected at baseline and 
after 28 weeks of injury phase were incubated with Aquaporin2 conjugated with 
Qdots for several time periods. A signal was already present within 15-20 minutes 
and peaked after roughly 35-45 minutes with a sharp decline after 5 hours (Figure 
61). The results were similar when other antibodies conjugated to the same Qdot 
(540nm) were used (data not shown).  The Coefficient of variation was 
approximately 20% for the first two time-points (20mins and 40mins) and 35% for 
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70-80 minutes based on triplicate readings. Repeating a measurement 8 times after an 
incubation of 40 minutes in one injury (DM+HTN) phase urinary sample reduced the 
coefficient of variation to 16%. Using IgG Rabbit as isotype control demonstrated a 
signal about 5-8% of the sample (Figure 61). Since measurements of total urinary 
exosome concentration in large study cohorts required several runs on different days, 
the intra-, inter- and total variability (imprecision) were calculated using aliquots of 
silica beads of a known size and a known concentration. Formulas of for the 
calculations are further specified in the Materials & Methods section. For three 
replicates performed daily across 8 days the intra-assay CV (coefficient of variation) 
was 14.34%, the inter-assay CV was 10.63% and the total (=within-laboratory) CV 
was 17.62% (Figure 61). 
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Figure 61: Quality control for NTA measurements 
A B 




























































































































































































Figure 61. A) Urinary volume within 24 hours in the injury group from the Cyp1a1mRen2 
model was ten times higher than in the control group. n=12 in each group, ***=p<0.001, B) 
30-40 minutes seemed to be an ideal incubation period for binding of Aquaporin2 antibody 
conjugated to Qdots to urinary exosomes (n=4 with two baseline and two injury phase 
(HTN+DM) samples, all measurements in triplicates). C) Incubation (40 min) of an Isotype 
(IgG Rabbit) conjugated to Qdots does not result in a relevant signal compared to 
Aquaporin2. Measurements are performed on urine from one injury animal (n=1) (HTN+DM) 
and are repeated 8 times (Aquaporin2) for calculation of intra-assay precision or 4 times 
(Isotype). D) For calculation of inter- and intra- assay precision average AUC of aliquots from 




3.4.3 Urinary exosome concentrations in the DM+HTN rat model 
Total and cell-specific exosome concentration in the urine samples from the 
Cyp1a1mRen2 DN reversal model (Conway, Betz et al. 2014) collected at baseline 
and injury phase (28 weeks) was assessed initially using the NanoSight. Total 
(unlabelled) exosome concentration increased almost 4-fold in the injury phase in 
comparison to baseline. Similarly the concentration of nephrin
+
 (a podocyte marker) 
and cubilin
+
 (a proximal tubular marker) exosomes rose more than 50% in the injury 
period compared to baseline. To a lesser extent, but still significantly different, 
Aquaporin 2
+
 (AQP2) (a collecting duct marker) exosomes were at a higher 
concentration during injury than in baseline (Figure 3). Consistently, cell-specific 
exosomes were at lower concentrations than total exosomes. After 8 weeks of 
reversal of hyperglycaemia and hypertension only the total exosome concentration 






 exosome concentrations 
tended to decline, but were not significantly different from either the injury phase or 
from baseline. 
Total exosome concentration and albuminuria:creatinine ratio were significantly 
positively correlated with each other when injury and reversal groups were combined 
or when the reversal group was analysed individually to avoid group bias (Figure 
62). 
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Figure 62: NTA measurement in the Cyp1a1mRen2 DN model 
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Figure 62. Urinary A) total, B) Nephrin +ve, C) Cubilin +ve and D) Aquaporin 2 +ve exosome 
concentrations in the Cyp1a1mRen2 reversal DN model increase at the end of the injury 
phase (28 weeks HTN+DM) compared with baseline but only the total exosome 
concentration decreases significantly from injury to reversal phase (additional 8 weeks with 
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normotension and normoglycemia). Neither the total nor cell-specific exosome concentration 
in the reversal phase was significantly different from baseline. Significant positive Pearson 
correlation was observed between ACR and urinary total exosome concentration from E) 
injury and reversal phase (n=20) and F) only reversal phase (n=10). Concentration is 
expressed in area under curve concentration (AUC) and injected sample volumes are 
corrected for 24 hours urinary volume, n=10. .  In E) and F) a linear regression line is drawn 
with a 95 % confidence interval (dotted line). Data is presented as median (IQR). 
3.4.4 Urinary exosome concentrations in the RDS study 
Characteristics of patients from the RDS study  
To evaluate whether the results from the DM+HTN rat model could be translated 
towards clinical practice, urinary specimens were collected from 151 patients at the 
Renal Medicine and Renal Diabetes outpatient clinics at the Royal Infirmary, 
Edinburgh. The pilot study had been approved as part the South East Scotland 
SAHSC Human Annotated BioResource bank (see Materials and Methodes and 
Appendix for consent form and patient information). The characteristics of the 
patients are depicted in Table 34.  
Mean age was 63 years and two thirds of participants were male. The patients had a 
wide range of renal function, with 30% having normal renal function and 42% with 
severe renal failure (CKD 4 or 5). The primary aetiologies of chronic kidney disease 
in the patients are given in Table 35, with diabetic nephropathy being by far the most 
common cause of CKD.  
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Table 34: Patient characteristics in the RDS study 
Participants, n 151 
age, years 63 (+/-13) 
male, n 98 (64.9%) 
eGFR, ml/min/1.73m2 36.2 (22.6 - 66.3) 
         GFR > 60 ml/min (CKD I&II), n 45 (30%) 
         GFR <= 60 ml/min, GFR => 30 ml/min, (CKD III), n 43 (29%) 
         GFR < 30 ml/min (CKD IV&V), n 63 (42%) 
ACR, mg/mmol 29.7 (3.8 - 107.7) 
uCystatin C : uCreatinine, µg/mmol 70 (29 – 330) 
Hemoglobin, g/L 120 (+/-22) 
LDL Cholesterol, mmol/L 4.2 (3.6 - 5.2) 
AUC20-100nm , 106 / l / mmol creatinine                                                       
(number of particles x106) : uCreatinine, mmol/l 
6.1 (3.6 – 12.5) 
Table 34. Patient characteristics of the pilot RDS (RenalDiseaseS) study. Values are given 
as count number (with percentage from total), as mean (with standard deviation) or as 
median (with quartiles) depending on the Kolmogorov-Smirnov test for normal distribution. 
The total unlabelled exsosome concentration AUC20-100nm was logarithmized and corrected 
for urinary creatinine. eGFR=estimated glomerular filtration rate, CKD=chronic kidney 
disease with stage, ACR=urinary albumin to creatinine ratio, uEGF=urinary epidermal growth 
factor. 
Table 35: Aetiology of chronic kidney disease in the RDS study 
Diabetic Nephropathy (with or without hypertension) 70 (46.4%) 
Other Glomerulonephritis 26 (17.2%) 
Hypertension (without DN) 13 (8.5%) 
Vasculitis 8 (5.3%) 
IgA-Nephrophathy 6 (4.0%) 
Lupus-Nephritis 5 (3.3%) 
Interstitial Nephritis 6 (4.0%) 
other/unknown reason for CKD 17 (11.3%) 
Table 35. Primary aetiology of chronic kidney disease in patients from the RDS-study 
(number, with percentage of total). 
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Correlation of urinary exosome concentration with markers of renal function 
Total urinary exosome concentration correlated weakly with urinary creatinine. 
There was a moderate correlation between total exosome concentration and urinary 
albumin and urinary cystatin C, a biomarker of renal damage (see Discussion below) 
(Figure 63).  
Participants were divided into groups of approximately equal number according to 
their renal function: minor to moderately advanced chronic kidney disease (CKD) 
stage I-IIIa (eGFR >= 45ml/min, n=68) or severe CKD stage IIIb-V (eGFR =< 
45ml/min, n=83). Total exosome concentration tended to be higher in the CKD IIIb-
V group while urinary creatinine was significantly lower. The ratio between urinary 
exosomes and urinary creatinine was significantly different between those with CKD 
I-IIIa and those with CKD IIIb-V (Figure 64).  
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Figure 63: Correlation of total exosome concentration with urinary markers in the RDS 
study 
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Figure 63. Pearson correlation between total exosome concentration and A) urinary 
creatinine, B) urinary Cystatin C and C) urinary albumin (all log-transformed).  Exosome 
concentration is expressed in area under curve concentration (AUC), in each group.  In B) 
and C) a linear regression line is drawn with a 95 % confidence interval (dotted line). 
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Figure 64. A) Median (IQR) Urinary creatinine is decreased in patients with advanced CKD 
(stage IIIb-V, n=83) compared to patients with preserved renal function (CKD stage I-IIIa, 
n=68). Median (IQR) total exosome concentration is increased in patients with advanced 
CKD non-significantly before (B) but significantly after correction for urinary creatinine (C). 
Mann-Whitney-U test. 
AQP2+ : CD24+ exosome ratio and markers of renal function  
To determine their cellular origin urinary exosomes were stained with antibodies 
against nephrin, cubilin, aquaporin 2 and CD24 (a potential pan-exosome marker) 
coupled to a Qdot fluorophore. Unfortunately the antibodies against nephrin and 
cubilin did not produce a robust signal on human urine on the NanoSight and were 
not further analysed. The AQP2 positive exosome concentrations were normalized 
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for the CD24 positive exosomes as described previously (Oosthuyzen, Sime et al. 
2013). The AQP 2 : CD 24 ratio was negatively correlated with renal function 
(defined by eGFR) and positively with urinary Cystatin C : creatinine ratio as a 
potential marker for renal damage. There was no correlation of the AQP 2 : CD 24 
ratio with urinary creatinine indicating that urinary volume had no major effect on 
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Figure 65. Ratio of AUC for aquaporin 2
+
 exosomes (20nm-100nm) to CD24 positive 
exosomes correlates A) with estimated Glomerular filtration rate (negatively) and B) with 
urinary Cystatin C : creatinine ratio (positively). But it does not correlate with urinary 
creatinine (C). n = 41. Pearson correlation. .  In A) and B) a linear regression line is drawn 
with a 95 % confidence interval (dotted line). 
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3.4.5 Total urinary exosomes concentration in a subset of the ET2D 
study  
Total urinary exosome concentration was measured in a subset of 128 participants 
randomly selected from the Edinburgh Type 2 Diabetes (ET2D) subpopulation 
comprising 642 patients with preserved renal function (eGFR >60 ml/min/1.73m
2
) 
and no evidence of micro- or macroalbuminuria (<2.5 mg/mmol men or <3.5 
mg/mmol) at baseline (see previous Results chapter). The characteristics of this 
subset (20%) are listed in Table 36 and were not significantly different from the 
profile of all 642 patients from the ET2D study who had no evidence of renal disease 
at baseline (Results Chapter 3) except for duration of diabetes (5.0 years in the subset 
vs 7.4 years in the whole cohort). After categorising the patients into tertiles 
according to the urinary total exosome concentration corrected for creatinine the 
baseline characteristics in each tertile were not significantly different except for 
tubular injury marker urinary KIM-1 and total exosome concentration (Table 36).  
The total urinary exosome concentration corrected for creatinine weakly but 
significantly correlated positively with the KIM-1:Cr ratio, there was no association 
with urinary EGF:Cr as a marker of tubular mass (Figure 66).  
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age, years 67 (+/-4) 66 (+/-4) 66 (+/-4) 67 (+/-4) 0.53 
male, n 67 (52%) 24 (57%) 22 (51%) 21 (49%) 0.73 
eGFR, ml/min/1.73m
2
 86.7       
(+/-9.8) 
85.7      
(+/-9.7) 
89.1      
(+/-9.0) 
85.2      
(+/-10.4) 
0.14 
HbA1c, % 7.1 
(6.5 – 7.5) 
7.0 
(6.6 – 7.3) 
7.1 
(6.6 – 7.7) 
7.1 
(6.5 – 7.5) 
0.70 
Duration  of diabetes,   
years 
5.0 
(3.0 - 9.2) 
5.0 
(3.0 - 10.0) 
5.0 
(2.0 - 8.5) 
6.0 
(4.0 - 11) 
0.27 
Systolic blood pressure,  
mm Hg 
134 (+/-15) 135 (+/-15) 132 (+/-16) 134 (+/-13) 0.70 
Diastolic blood pressure, 
 mm Hg 
69 (+/-8) 70 (+/-8) 67 (+/-8) 68 (+/-8) 0.28 
ACR 0.5-2.5 (males) or 
0.5-3.5 mg/mmol (females), 
 n (%) 
32 (25%) 10 (24%) 11 (26%) 11 (26%) 0.98 
urinary creatinine, mmol/l 7.1 
(4.9 – 9.8) 
7.1 





(4.6 – 8.6) 
0.58 
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Table 36. A) Patient characteristics of the subset of the Edinburgh Type 2 Diabetes Study in 
which urinary total exosome concentration was measured. Only patients with an eGFR>60 
ml/min/1.73m2 and without albuminuria (ACR <2.5mg/mmol or <3.5 mg/mmol for females) 
were included. Values are given as count number (with percentage from total), as mean 
(with standard deviation) or as median (with quartiles) depending on the Kolmogorov-
Smirnov test for normal distribution. When participants were stratified into tertiles according 
to total exosome concentration corrected for urinary creatinine, there was no significant 
difference regarding the other variables except for the renal injury marker KIM-1. Variables 
were compared between the groups by ANOVA or Kruskal-Wallis test. 
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Figure 66: Correlation of total exosome concentration and urinary markers in the ET2D 
subset 
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Figure 66. Total exosome concentration corrected for creatinine correlated significantly with 
urinary KIM1 : creatinine (A) but not with EGF:creatinine in a subset of patients from the 
ET2D study who had no evidence of CKD at baseline. Pearson correlation had been 
calculated after all variables had been log-transformed. In A) a linear regression line is drawn 
with a 95 % confidence interval (dotted line). 
Urinary exosome concentration could predict incident CKD III  
Study participants in the upper third of urinary total exosome:creatinine ratio had a 
significantly higher risk of developing CKD III over a period of 4 years (22 out of 
128 patients) as defined by new onset eGFR<60 ml/min/1.73m
2
 compared to 
participants in the lower two thirds. The presence of ACR >0.5mg/mmol did not 
indicate a higher risk for developing CKD III. On the other hand the risk for 
developing micro- or macroalbuminuria (>2.5 mg/mmol male, >3.5mg/mmol 
female) (27 patients in four years) was not associated with the total exosome 
concentration but with the presence of ACR >0.5mg/mmol at baseline (Figure 67). 
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Figure 67: Kaplan Meier Curves for total exosome concentration and ACR for the 





Figure 67. Kaplan Meier Curves from patients from the EDT2D study with no CKD at 
baseline demonstrating the risk for developing incident CKD III defined as 
eGFR<60ml/min/1.72m
2
 in (A) and (B) or albuminuria defined as ACR > 2.5mg/mmol (> 3.5 
mg/mmol for females) in (C) and (D) during a period of four years. The upper third of patients 
with the highest total exosome concentration had a significantly increased risk for incident 
CKD (A) but not albuminuria (C). Conversely, the presence of albuminuria (>0.5 mg/mmol) 
did not indicate a risk for incident CKD (B) but did for the development of micro-
/macroalbuminuria.  
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Urinary exosomes are independently associated with incident CKD III  
The calculated hazard ratio for development of CKD III was significantly increased 
in the upper third of total urinary exosome to creatinine ratio. This association 
remained significant after adjustment for the variables albuminuria, eGFR, sex, age 
and urinary KIM-1 at baseline (Table 37). After additional adjustment for HbA1c, 
duration of diabetes and systolic and diastolic blood pressure the association was not 
significant anymore (Hazard Ratio 1.9 [0.7-5.9], p=0.23, not shown), however, with 
regard to the number of outcomes an adjustment for so many variables is statistically 
not recommended and would require a higher number of participants and outcomes. 







   
 unadjusted adjusted* 
Hazard ratio 2.54 2.91 
CI (1.09 to 5.90) (1.20 to 7.03) 
p-value 0.030 0.041 
   
Table 37. Hazard ratio demonstrates an increased risk of developing CKD III defined as 
eGFR<60ml/min/1.73m
2 
for patients in the upper third according to total exosome 
concentration compared to the lower two thirds. *After adjustment for presence of 
albuminuria >0.5mmg/mmol, eGFR at baseline, age and sex 
3.4.6 Protocol for the measurement of microvesicles 
As microvesicles (100-1000nm) are larger than exosomes (20-100nm), they can be 
detected on a modified flow cytometer (Attune).  
Since the concentration of microvesicles with a size range of 300nm-1000nm 
(approximate detection threshold of the Attune) is about only a tenth of total 
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extracellular vesicle (20nm-1000nm) concentration in urine (Dragovic, Gardiner et 
al. 2011), an enrichment protocol as described by Burger et al. (Burger, Thibodeau et 
al. 2014) with slight adaptions was performed and results were checked by 
NanoSight. Following enrichment, the concentration of microvesicles (AUC300-
1000nm) increased ten-fold, while concentration of smaller vesicles (AUC20-200nm) did 
not increase significantly (Figure 68).  
Next, a gating strategy for microvesicles was applied as published by Burger et al. 
with small adaptions. The first step was to define a threshold for detection of Bodipy-
Maleimide (a dye that is incorporated into membranes and acts as a pan-marker for 
microvesicles) positive particles. This was achieved by measuring the signal from 
diluent (PBS) with the dye, a sample without dye and the combination of dye and 
sample. Then the size of the gate was defined by using 200nm and 1000nm 
polystyrene beads at a concentration of 10
5
/ul which was chosen after several 
dilutions steps had been tested (Figure 69). 
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Figure 68: Enrichment of urinary microvesicles 
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Figure 68. A) Schematic protocol for the enrichment of microvesicles (300nm-1000nm) in 
urine.  B) The meanSEM concentration of microvesicles in urinary samples significantly 
increased after application of the protocol while C) the change in exosome concentration 
was not significant. n=9.  
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Figure 69. A) Schematic protocol for the analysis process for measurement of microvesicles 
in urine. B,C) Representative traces from flow cytometry analysis of microvesicles derived 
from human urinary samples. B) The threshold for Bodipy-Maleimide (BoM) positive events 
was set by comparing diluent with dye and an urinary sample measured without dye 
(autofluorescent control) with the combinatory measurement of dye and sample. BoM 
positivity is regarded as recorded events above the threshold. C) The gate for size (R14) 
was set to capture microvesicles in the 200-1000nm range using 200nm (left figure) and 
1000nm diameter silica beads (right figure). SSC, side scatter; FSC, forward scatter; BoM, 
Bodipy Maleimide. 
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Coefficient of Variationof BoM and comparison with Annexin V Pacific blue 
The coefficient of variation (CV) of the measurement for BoM positive events was 
16.9% and below the maximum accepted value of 20%, which is in contrast to the 
CV of all (stained+unstained) recorded events (29.2%).  Unstained events may 
represent background noise (Figure 70).  
Annexin V is an established marker for microvesicles though its dependence on a 
high concentration of calcium can affect measurements (Enjeti, Lincz et al. 2008). 
Here it was tested whether Annexin V Pacific Blue could be replaced by Bodipy-
Maleimide adequately as described by Enjeti et al. for blood samples (Enjeti, Lincz 
et al. 2008). Urinary samples were divided into two equal parts and stained by each 
marker separately. The recorded number of positive events did not differ 
significantly between the two staining techniques. A strong correlation between both 
markers was confirmed by double staining (Figure 70). 
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Figure 70: CoV of Bodipy Maleimide measurements and correlation with Annexin V - 
Pacific blue 
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Figure 70. A) The coefficient of Variation (CoV) was calculated by repeating measurements 
of the same sample for total events (stained and unstained) and Bodipy-Maleimide positive 
events. N=7 samples with 6 repeats each. Data is presented as meanSEM B) Number of 
Bodipy-Maleimide and Annexin V- Pacific blue positive events in the same urinary samples 
(n=12) incubated with each dye separately did not differ significantly. C) Representative 
urinary sample incubated with each marker alone or with both markers together. The vast 
majority of particles that bind annexin V also bind Bodipy-Maleimide (upper right gate). 
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3.4.7 BodipyMaleimide positive particles in the DM+HTN rat model  
For measurement of microvesicles in the urine samples of the Cyp1a1mRen2 DN rat 
model a pre-dilution to correct for large variation in 24 hours urinary volume was 
performed as already described for the exosome measurements. The concentration of 
BodipyMaleimide positive events increased significantly in the combinatory diabetes 
+ hypertension group in comparison to control. The level of total recorded events 
(stained+unstained) remained unchanged in the 200-1000nm size gate which was 
encouraging as total recorded events assumedly comprise stained microvesicles and 
unstained non-specific background noise. BodipyMaleimide positive events and the 
concentration of unlabelled particles (AUC300-1000nm) as measured by NanoSight were 
positively correlated (Figure 71).  
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Figure 71: Measurement of Bodipy Maleimide positive events in the Cyp1a1mRen2 DN 
model 
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Figure 71. A) Bodipy-Maleimide positive events in urine samples increase in the group with 
Diabetes+Hypertension compared to control samples in the Cyp1a1mRen2 DN model. B) 
Concentration of total (stained+unstained) recorded events in the 200nm-1000nm size gate 
did not differ between the groups. Data is presented as median and IQR C) Positive Pearson 
correlation of microvesicle concentration between measurement by Nanosight and Attune 
FCM. Concentration is expressed per events/µl (Attune) or as area under curve (Nanosight). 
N=6 in each group. BoM – Bodipy maleimide. .  In C) a linear regression line is drawn with a 




3.4.8 BoM and podocalyxin positive particles in a subset of the RDS 
study 
As proof of principle of the ability to translate some of the findings from the rodent 
model into human disease, BodipyMaleimide and podocalyxin-like (PODXL) PerCP 
positive events were next measured in a subset (20%, n=34) of urine samples from 
patients recruited from the RDS study.  These comprised 17 patients with moderately 
reduced renal function (CKD III, mean eGFR 46.0 (+/-8.5 SD) ml/min/1.73
2
; mean 
age 67.5 (+/- 11.0 SD) years; 18% female) and 17 patients with severely reduced 
renal function (CKD IV or V, mean eGFR 21.7 (+/- 4.9 SD) ml/min/1.73
2
; mean age 
66.5 (+/- 24.5 SD) years; 35% female). The rationale for the selection of patients 
with reduced renal function was to have positive control as PODXL positive 
microvesicles concentration is expected to increase in patients with renal impairment 
(Burger, Thibodeau et al. 2014). 
There was a weak, but significant positive correlation between BoM
+
 events and 










 positive events but not of BoM
+
 events was 
significantly increased in patients with severely reduced renal function compared to 





 positive events also correlated negatively with eGFR in this subset 






 positive events 
were significantly correlated with  urinary creatinine (Spearman’s rho r=0.22 p=0.15 
and r=-0.23 p=0.18, respectively). 
257 
Figure 72: Measurement of BodipyMaleimide positive and BiodipyMaleimide and 
Podocalyxin double positive particles in a subset of patients from the RDS 
study 
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Figure 72. A, B) Pearson correlation between the concentrations of (A) Bodipy-Maleimide 
positive events [significantly positive] and (B) Bodipy-Maleimide and podocalyxin-like positive 
events [not significant] and unlabeled particles (AUC300-1000nm) measured by NanoSight. 
(N=34) C) Concentration of Bodipy-Maleimide positive events and Bodipy-Maleimide and 
podocalyxin-like dual positive events in patients with moderately (n =17) and severely (n=17) 
reduced renal function. Data is presented as meanSEM D) Negative Pearson correlation 
between the concentration of Bodipy-Maleimide and podocalyxin-like positive events 
corrected for urinary creatinine and eGFR (n=34). .  In A) and D) a linear regression line is 
drawn with a 95 % confidence interval (dotted line). MV - microvesicle; BoM – Bodipy 
Maleimide; PODXL – podocalyxin-like; AUC – area under curve 
258 
3.4.9 Discussion 
This chapter focuses on microparticles (20nm-1000nm) as potential biomarkers. 
They are readily present in urine and pathway analysis from genes and urinary 
peptides in the Cyp1a1mRen2 DN reversal model indicate an increasing 
concentration in microparticle-derived proteins during the injury phase. Using 
NanoSight Tracking Technology total and antibody-specific exosome concentration 
was demonstrated to increase during the injury phase in the model. Moreover, 
urinary exosomes seem to not only correlate with current renal function in patients 
with kidney disease but might predictive of future renal deterioration. 
Quality control of exosome analysis 
Due to their small size the reliable quantification of urinary exosomes is challenging. 
Methods like Western-Blotting or electron microscopy offer qualitative but only 
semi-quantitative information.  
According to the guidelines of the International Society for Extracellular Vesicles 
(ISEV), Nanotracking Technology is a recognized way for sizing and quantifying 
exosomes. While the a reasonable accuracy of the NTA had been demonstrated 
before(van der Pol, Coumans et al. 2014), for biomarker analysis a high level of 
precision is mandatory as sample measurements must be comparable within runs and 
between runs (from different days or even labs). Therefore, the first priority was to 
determine the intra-run, inter-run and total precision on the NanoSight to assess 
reproducibility: silica beads were employed as standards in these studies. They were 
preferred to polystyrene beads due to their refractive index being more similar to 
vesicles in fresh urine (Gardiner, Ferreira et al. 2013, van der Pol, Coumans et al. 
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2014). Precision ranged between 10% (intra-assay) and 17% (total within-
laboratory).  Oosthuyzen et al. reported an intra-assay variation in unprocessed urine 
for light-scattered measurement of up to 47%, however the number of repeats was 
not given and there was no processing of urine, which was highly diluted 
(Oosthuyzen, Sime et al. 2013). Gardiner et al. report a variation of around 20% with 
no detailed information about how this was calculated (Gardiner, Ferreira et al. 
2013). Hole et al. determined the inter-laboratory CV in for 100nm diameter silica 
beads to be around 10% (Hole, Sillence et al. 2013), which is in line with the CV 
obtained with similar size beads in this work. In summary, the degree of variation 
was considered to be acceptable, being below 20% and concordant with thresholds 
from other laboratories. To ensure standardisation of before each new run of samples 
silica beads with a known concentration (50nm and 100nm) were analysed.  
For studies using antibodies, an isotype control was employed to ensure that the 
signal detected was not due to non-specific binding. The signal with the isotype was 
10-fold less than with the actual antibodies. The optimal incubation time required to 
label antibodies with Qdots (15-30min) was in line with previous publications from 
other groups (Dragovic, Gardiner et al. 2011, Oosthuyzen, Sime et al. 2013). 
Potential role of urinary nephrin and cubilin positive exosomes as a non-invasive 
biomarker of renal injury  
Nephrin is located at the lateral site of the podocyte foot process. The 180kD protein 
is a constituting part of the slit diaphragm. Increased intrarenal and urinary 
expression is associated with glomerular/podocyte damage (Sekulic and Pichler 
Sekulic 2013).  In FVB/NJ Akita mice or in rats injected with STZ as rodent models 
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of diabetic nephropathy an elevated level of urinary nephrin is associated with renal 
damage (Chang, Paik et al. 2012) and intra-renal nephrin-mRNA upregulation 
(Aaltonen, Luimula et al. 2001) and might even precede albuminuria as a marker of 
glomerular damage(Sekulic and Pichler Sekulic 2013). This is in line with the current 
study in which urinary nephrin positive exosome-like particles were increased during 
injury assessed by nanoparticle tracking analysis.  
Cubilin is an app. 460kD membrane glycoprotein expressed at the luminal site of 
proximal tubular cells. Forming a complex with the transmembrane protein megalin 
it re-absorbs most of the filtered small-molecular weight proteins, most importantly 
albumin but also other molecules, such as hormones and lipoproteins (Thrailkill, 
Nimmo et al. 2009). While in rodent models of diabetic nephropathy a decrease of 
cubilin in renal tissue is observed (Feng, Zhang et al. 2006, Ke, Li et al. 2014) which 
could partly contribute to albuminuria, there were no reports on urinary cubilin 
excretion. In humans the presence of cubilin in urinary exosomes has been 
demonstrated in many publications (listed in Vesiclepedia at www.microvesicles.org 
and Pisktun et al. (Pisitkun, Shen et al. 2004)). In patients with type 1 diabetes 
urinary cubilin concentration increased with the development of albuminuria 
(Thrailkill, Nimmo et al. 2009). This is in line with findings in the present study of a 
robust increase of cubilin positive exosomes- in the rodent DN model. 
Potential role of urinary aquaporin 2 positive exosomes as biomarkers of collecting 
duct injury and impaired urinary concentrating ability  
Exosome aquaporin 2 (AQP2) excretion has previously been shown to correlate with 
urinary osmolality when assessed by NanoSight technique (Oosthuyzen, Sime et al. 
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2013) or exosome-specific ELISA (Salih, Fenton et al. 2016). A decreased ability to 
concentrate urine was associated with decreased urinary AQP2 excretion in patients 
suffering type 2 diabetes (Nakamura, Saito et al. 2002). Consequently, a decrease in 
urinary AQP2 positive particle concentration was expected in DM+HTN animals that 
excreted large volumes of urine (Conway, Betz et al. 2014). However, in this study a 
small increase in DM+HTN animals was measured. Results from the human study 
were in line with the animal data with AQP2 correlating inversely with renal 
dysfunction as assessed by eGFR. AQP2 concentration was corrected by the urinary 
pan-exosomal marker CD 24 (Keller, Rupp et al. 2007, Oosthuyzen, Sime et al. 
2013, Salih, Zietse et al. 2014), as employed by Oosthuyzen. In a similar way CD9 
was used as a pan-marker for the AQP2 ELISA (Salih, Fenton et al. 2016). Reasons 
for the positive correlation with renal dysfunction could be explained by the fact that 
increased exosome shedding could be an indicator of cellular damage (Borges, Melo 
et al. 2013). Tubular damage is well described in the rat model (Conway, Betz et al. 
2014) and is probably present in most patients from the human RDS pilot study. 
Urinary Cystatine C to creatinine ratio (uCystC:Cr) is markedly increased in patients 
with tubulointerstitial diseases(Conti, Moutereau et al. 2006, Herget-Rosenthal, van 
Wijk et al. 2007) or CKD patients with a metabolic syndrome(Satoh-Asahara, 
Suganami et al. 2011) compared to patients with primarily glomerular diseases or 
healthy controls. uCystC:Cr is a predictor of renal outcome in patients with DN(Kim, 
Song et al. 2013). Hence uCystC:Cr might be a marker of renal impairment caused 
by tubular dysfunction. In the current study there was a significant positive 
correlation between uCystC:Cr and total exosome:creatinine  and Aquaporin2:CD24 
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exosome concentration potentially supporting the hypothesis of increased exosome 
and Aquaporin2 excretion from tubular cells upon damage.  
Total urinary exosome concentration and markers of renal function in humans 
The current work demonstrates an association between renal function and total 
urinary exosome concentration in patients with mild (ET2D-subcohort) and advanced 
(RDS study) CKD. Correspondingly, urinary exosome concentration correlated with 
urinary markers of renal dysfunction like Cystatin C or albumin. The fact that these 
results were obtained from to different cohorts strengthens the validity of the results. 
In the ET2D subgroup  urinary exosome concentration  did not correlate with uEGF 
which is regarded to be a marker of renal mass, but correlated with urinary KIM-1 
that is regarded to be a marker of renal injury. This is in line with the fact that cells 
tend to release more microparticles upon direct damage (Borges, Melo et al. 2013).  
Dimuccio et al. compared total urinary exosome concentration in patients at day one 
and day seven after renal transplant detecting no significant difference (Dimuccio, 
Ranghino et al. 2014). Their measurements might have been affected by firstly the 
fact that the urine required processing and therefore a significant particle loss could 
not be excluded, and secondly the fact that the sample was taken from a six-hours 
and not 24 hours collection, thereby possibly neglecting diurnal fluctuations of 
exosome excretion.  
Over a time period of four years, the tertile with the highest exosome concentration 
had a significantly higher risk for developing CKD III defined by eGFR<60 
ml/min/1.73m
2
. However, the presence of albumin in urine was not a risk factor. On 
the other hand albuminuria was a risk factor for developing moderately to severely 
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increased albuminuria, while concentration of exosomes was not. This might indicate 
that urinary exosomes are a marker for tubular rather than glomerular cell damage.  
The association between urinary exosomes and incident CKD III remained 
significant after adjusting for age, sex, eGFR and albuminuria in the Cox regression 
analysis.  Including additional predictors (systolic BP, diastolic BP, HbA1c, duration 
of diabetes) rendered the association non-significant. However, such a step would 
result in an outcome event per predictor variable (EVP) ratio below 5 and is 
statistically not advisable due to loss of power (Vittinghoff and McCulloch 2007). 
Instead, future work will focus on increasing number of participants and outcome 
events thereby allowing the inclusion of more potentially confounding variables. 
Limitations 
A limitation of this work is the single use of methodology for measurement of 
urinary exosomes. A contamination with non-exosome particles like protein-
aggregates (Filipe, Hawe et al. 2010) and lipoproteins (Gardiner, Ferreira et al. 2013) 
cannot be excluded especially when the scatter-mode is used. Therefore it is 
recommended to combine two different methods (Lotvall, Hill et al. 2014, van der 
Pol, Coumans et al. 2014). At the moment no recognized gold standard for 
measurement of extracellular vesicles exists and there are advantages and 
disadvantages for every methodology (van der Pol, Coumans et al. 2014). The 
established methods for measurement of microparticles like western blot (WB), flow 
cytometry or transmission electron microscopy (TEM) are either technically or 
logistically not feasible for exosome analysis in  a high-throughput approach. WB 
and TEM require multiple processing steps including ultracentrifugation before 
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measurement which might also result in a substantial loss of exosomes. Additionally 
since there is no consensus pan-marker for exosomes therefore quantitative 
assessment by WB or FCM remains difficult.  Recently, ELISA kits for exosome 
measurement have been developed that might allow high-throughput measurement 
even in unprocessed urine (Isobe, Mori et al. 2013, Duijvesz, Versluis et al. 2015, 
Salih, Fenton et al. 2016). Future studies should compare performance of ELISA-kits 
using pan-marker candidates like CD9, CD24 or CD63 with the measurements of 
urinary exosomes by NanoSight LM10.  
Measurement and analysis of microvesicles in urine 
In contrast to exosomes, microvesicles with a size range from 100nm-1000nm are 
much less abundant in urine (Oosthuyzen, Sime et al. 2013). For valid measurement 
urinary MVs must be above a certain concentration threshold (Burger, Thibodeau et 
al. 2014). Therefore, in the current work a concentrating procedure proposed by 
Burger et al. (Burger, Thibodeau et al. 2014) is employed with modifications and 
then applied in the Cyp1a1mRen2 DN model and in a subset of patients from the 
RDS study as a proof-of-principle. 20.000g spin was enough to pellet larger 
microparticles (Zhou, Yuen et al. 2006). Exosome-like particles were not enriched as 
most were retained in the supernatant, however some also appeared in the pellet. This 
might be due to Tamm-Horsfall protein that forms a polymer-network entrapping and 
pelleting exosomes(Fernandez-Llama, Khositseth et al. 2010). Contamination with 
exosomes was considered to be negligible for further analysis since exosomes are 
below the detectable range of the Attune flow cytometer (Danielson, Estanislau et al. 
2016) (Burger, Schock et al. 2013). The mean coefficient of variation for the 
measurement method was well below 20% which is regarded to be an acceptable 
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level of repeatability of results. Annexin-V (AV) and Bodipy-Maleimide (BoM) can 
be used for staining MPs interchangeably in blood (Enjeti, Lincz et al. 2008). Similar 
results were obtained for urine for the first time in the current work. Gating for size 
was performed using non-fluorescent beads as described before (Nielsen, Beck-
Nielsen et al. 2014) including several dilution steps to avoid swarm detection(van der 
Pol, Coumans et al. 2014).  
Microvesicles as potential urinary biomarkers 
Whilst urinary MV concentrations were massively higher in the diabetes and 





) in the gating window (200nm-1000nm) did not 
significantly differ between the groups, implying that this was specific for 
microvesicles. The results are in line with Burger et al. who demonstrated an increase 
of AV positive particles in three mouse models after induction of diabetic 
nephropathy (Burger, Thibodeau et al. 2014). The significant positive correlation 
between BoM
+
 microvesicle and AUC300-1000nm measured by NanoSight not only 
strengthened the validity of the results but also the validity of the methodology of 
isolation.  
In a subset of the RDS study which included patients with moderately to severely 
reduced renal function similar results were obtained as in the rodent study with a 
significant but lower correlation factor between NanoSight and Attune 
measurements. This could be explained by interferences such as medication or 
impurities from contamination during the non-sterile way of collection as Nanosight 




) in the specific size range. 
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Blood from patients with severe CKD IV-V has increased concentration of Annexin 
V
+
 positive particles (Trappenburg, van Schilfgaarde et al. 2012): They originated 
mainly from platelets and endothelial cells, with the cytotoxic effect of uraemia 
potentially being a contributing cause. In subset of the RDS study in this work, the 
concentration of BoM
+ 
tended to be higher in the urine of patients with CKD stage 





 (podocalyxin-like protein) microvesicles negatively 
correlated with renal function. This is in line with other studies suggesting that 
glomerular damage promotes increased release of particles (Hara, Yanagihara et al. 
2005, Burger, Thibodeau et al. 2014). It is intriguing to speculate that cells of other 
renal compartments might behave similarly. If this was true, then a panel with 
antibodies against renal compartment-specific surface markers could not only detect 
early cell stress/injury but also help to localize it. The panel might also contain an 
injury specific marker like KIM-1 or NGAL. Alvarez et al. demonstrated that 
uNGAL is also present in the urinary microparticle fraction and might be a more 
sensitive indicator for renal function than total urinary NGAL concentration 
(Alvarez, Suazo et al. 2013).  At the moment there is, to the author’s knowledge, no 
full characterization of the microparticle profile in urine. Unfortunately, none of the 
kidney-specific antibodies tested in this work beside podocalyxin could render a 
sufficient signal for MV detection (data not shown). The challenging task remains to 
find antibodies that target the correct externalized peptide sequence of the antigen on 
MVs and that are conjugated appropriately to comprise a panel. Another clear 
limitation of the present MV study is the small number of patients, so the results 
warrant validation in larger cohorts. However, the aim of the present study was to 
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demonstrate the feasibility of the modified protocol to enrich and measure urinary 




microvesicle concentration with renal function in a RDS subset was demonstrated. 
3.4.10 Summary 
In this chapter it had been demonstrated that labelled and unlabelled exosomes might 
be useful markers to inform about renal injury and function in the rodent 
Cyp1a1mRen2 DN model and in patient cohorts with mild (ET2D subgroup) and 
advanced (RDS study)  renal damage. In the former group urinary exosomes might 
indicate the risk for decline in renal function. Larger study cohorts are necessary to 
confirm these results. Even more importantly, validation by another methodology of 
measurement is required with the recently published ELISA(Isobe, Mori et al. 2013, 
Duijvesz, Versluis et al. 2015, Salih, Fenton et al. 2016) probably the best fit for 
high-throughput biomarker approach. 
A protocol for the measurement of microvesicles by Attune flow cytometry was 
developed and successfully applied in urine samples from the Cyp1a1mRen2 DN 
model and in samples from patients with reduced renal function. In humans, 





4. GENERAL SUMMARY AND FUTURE WORK 
4.1 Summary 
In this thesis a novel transgenic rat Cyp1a1mRen2 model of diabetic nephropathy has 
been utilized to study markers of progression and regression of diabetic nephropathy. 
Analysis of transcriptomic data from the rodent model identified key pathways 
involved in renal inflammation and fibrosis and these were biochemically validated. 
The transcriptomic data was then integrated with the urinary peptidomic profile to 
identify urinary biomarkers which may reflect the underlying renal pathophysiology. 
The urinary biomarkers were quantified in patients with DN and linked with clinical 
outcome. Figure 73 summarizes major findings that had been described in this work 
and their relation to each other. The removal of damaging stimuli caused significant 
changes as depicted in Figure 74.  
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Figure 73: Pathways and biomarkers of progression predominate during the "Injury 
Phase" in the Cyp1a1mRen2 reversal model of diabetic nephropathy 
 
Figure 73. Simplified schematic illustration of pathophysiological pathways in the “injury 
phase” of the Cyp1a1mRen2 model of DN tailored to the findings of this work. 
Hyperglycemia and advanced glycation end products as well as glomerular hypertension are 
regarded the initiators of pathophysiologic changes (as outlined in more detail in the 
introduction section). One consequence is increased permeability of the glomerular barrier 
(large red arrow). In addition the inflammatory cascade is initiated which in turn activates 
pro-fibrotic pathways. All these factors result in cellular damage and destruction of renal 
architecture that can be assessed by the reduction of structural constitutively expressed 
proteins and increase of injury markers. Markers for all these changes can be measured in 
the urine. Of note, markers of tissue repair are increased during the injury stage indicating 
the presence of MMPs, phagocytic Macrophagesand regulatory T-cells. So during injury 
phase, the foundations for renal repair are already laid out. 
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Figure 74: Pathway and markers of regression predominant during the "Reversal 
Phase" in the Cyp1a1mRen2 reversal model of diabetic nephropathy 
 
Figure 74. Schematic illustration of the assumed pathophysiological situation during the 
“reversal phase” of the Cyp1a1mRen2 model of DN. After the damaging stimuli had been 
removed the intraglomerular pressure lowers and the leakage of plasma proteins through the 
filtration barrier is reduced (reduced large red arrow). The removal of injurious stimuli down-
regulates genetic expression of pro-inflammatory markers and of pro-fibrotic markers. This is 
reflected by a reduction of many inflammatory and pro-fibrotic markers in the urine. However 
myofibroblasts as well as TIMPs persists what might explain the failure of collagen/ECM 
degradation. The persistently reduced concentration of structural markers in the urine 
confirms the unaltered histological findings of tissue fibrosis in the reversal phase.  
MMP and Gpnmb have not been detected in rat urine but in patients with DN. C3 – 
complement factor C3, EGF – epidermal growth factor, KIM1 – kidney injury molecule 1, 
MMP – metalloproteinase, TIMP – Tissue inhibitor of MMP, Treg – regulatory lymphocyte, 
M1 – classically activated macrophages type 1, M2- alternatively activated macrophages 
type 2, Gpnmb - glycoprotein (transmembrane) nmb, exosomes – unlabeled total exosomes, 
(C) – cubulin positive exosomes, (N) – nephrin positive exosomes,  (A) – aquaporin2 positive 
exosomes 
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In summary, the pathological stimuli hypertension and hyperglycaemia do not only 
activate injurious but also reparative pathways in the kidney. During disease 
progression, renal damage increases and ECM accumulates as the reparative 
pathways are assumedly either blocked or outnumbered by injurious ones. Removal 
of the injurious stimuli may facilitate regression of disease. The persistent fibrosis 
observed despite a period of normotension and normoglycaemia may reflect 
persistent inhibition of reparative pathways, such as by Timp1. This might explain 
clinical observations that regression of renal fibrosis can be demonstrated only after 
ten years of normoglycaemia in patients with pancreatic transplants. 
In urine samples from the DN model peptidomic analysis was performed at basline, 
injury phase (Figure 73) and reversal phase (Figure 74). In the injury phase many 
peptides with increased and decreased peak intensities compared to baseline were 
identified and could be linked to pathophysiological pathways in the kidney. 
Peptidomic analysis in patients with DN reflected the increased peak intensities of 
some of these markers. Pathophysiological alterations during the reversal phase were 
to a certain degree resonated by changes in the urinary peptidomic profile with a 
reduction of serum derived and inflammatory markers but a persistently low 
excretion of structural markers. The regulation of EGF, a structural marker for renal 
(tubular) mass, was confirmed by ELISA and IHC in the model. 
Markers for inflammation (osteopontin, Gpnmb), ECM metabolism (MMP7) and 
renal cellular integrity and damage (EGF, KIM-1) that had been identified in the 
transcriptomic and/or peptidomic analysis of the DN model were measured in urine 
samples from patients of the ET2D study cohort. uEGF independently correlated 
with renal function and was associated with an increased mortality risk. In study 
273 
participants with sustained renal function increased uEGF was significantly 
associated with incident CKD III and/or a rapid decline in renal function even after 
adjustment for major risk factors like eGFR and ACR.  
In pathway analysis microvesicle categories were found to be amongst the most 
significantly enriched for genes and urinary peptides with increased expression or 
peak intensities respectively during DN compared to control. Nanoparticle tracking 
analysis confirmed an increased total unlabelled urinary exosome-like particles (20-







 urinary exosomes that might originate from different 
compartments of the tubule are also elevated in the injury phase (Figure 74). In the 
RDS study unlabelled and labelled urinary exosome concentration correlated with 
reduced renal function and in the ET2D study exosome concentration might be an 
early sensitive biomarker for renal deterioration. 
The urinary microvesicles concentration measured by the Attune FCM as BoM 
positive events with 300-1000nm diameter also increases in the Cyp1a1mRen2 DN 
model compared to control. However, in a proof-of-principle study in patients with 
reduced renal function, only urinary levels of microvesicles that also expressed a 
kindey-specific surface marker (podocalyxin) correlated with renal function. 
4.2 Limitations and Future Work 
Extending the reversal phase 
The short time period for the reversal compared to injury phase is a limitation of the 
study. For future work it would be intriguing to prolong the reversal period to 
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potentially achieve histologic regression of fibrosis. However, performing such an 
experiment that would exceed a year, (e.g. 28 weeks injury phase followed by 28 
weeks reversal phase) would be technically very challenging to perform. The number 
of animals would have to be increased to ensure statistical significance since a 
considerable dropout due to stress/illness or severe hypo-/hyperglycemia is likely to 
happen throughout the experiment. To compensate for the confounding effects of 
aging an additional untreated control for the complete duration of the experiment 
also needs to be added.  Recently, a mouse DN model employing combined 
hyperglycemia and hypertension has been published using TTRhRen 
mice(Thibodeau, Holterman et al. 2014). TTRhRen mice may develop biochemical 
and pathological evidence of DN earlier than Cyp1a1mRen2 rats, and might 
therefore be an alternative model for extending the experimental time frame. 
However the transcriptome of the TTRhRen model has not yet been characterized to 
demonstrate relevance to human DN. 
Repeating the experiment it might be also useful to include partial reversal groups in 
which either hypertension or hyperglycaemia alone persist. In this way the individual 
contribution of these two components in preventing regression of fibrosis could be 
dissected.  
Markers deriving from serum and renal tissue 
A limitation of the urinary analysis is the inability to determine whether changes in 
marker concentrations stem from alterations in renal expression or in leakage of 
serum proteins across a disrupted glomerular barrier. In fact, both components might 
influence urinary biomarker concentration, and especially if occuring in opposite 
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directions, this might explain the our inability to detect altered urinary concentration 
of important tissue markers like MMP7 and osteopontin. Unless kidney specific 
variants of these proteins can be identified and detected, their use as urinary markers 
for renal pathophysiological processes will remain limited. 
The identification of peptides C3 in the urine could easily be explained as serum-
derived. However, increased expression of the C3 gene in the Cyp1a1mRen2 reversal 
DN model and in humans with DN indicates that both markers could play a 
pathophysiological role within the kidney. For C3, an involvement in the 
inflammatory cascade had been postulated(Wada and Nangaku 2013). Though 
limited in fully reflecting the complex interaction of different cell types involved in 
the development of diabetic nephropathy, in vitro models can be very helpful in 
supporting hypotheses. The novel RPTEC/TERT1 DN model based on the renal 
proximal tubule epithelial cells (RPTEC) that had been immortalized by using a 
human telomerase reverse transcriptase (hTERT) seems to recapitulate many features 
of human DN (Slyne, Slattery et al. 2015). Here the increased expression of C3 in a 
hyperglycemic milieu might be another important hint for its pathophysiological role 
and prompt further investigations.  
Manipulating the inflammatory and profibrotic cascades 
One limitation is that the suggested involvement of  B- and T-cells and macrophages 
and the  production and degradation of fibrosis are descriptive. There is no definitive 
proof for the hypothesized functions of these immune cells in the progression or 
regression of the disease. For macrophages, a lineage tracing approach could support 
the suggested regulation of M1 and M2 activated macrophages during the reversal 
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phase of the experiment. This could for example clarify whether M2 macrophages 
stem from the M1 phenotype or derive from resident macrophages or a different type 
of circulating monocytes. Unfortunately, the markers of specific macrophage subsets 
are not yet well characterized in rats. The depletion of B-cells as performed in other 
studies of renal fibrosis (Novobrantseva, Majeau et al. 2005) might help to further 
characterize their potential pro-fibrotic role in DN. Similarly, specific depletion of T-
cells especially regulatory T-cells (Hobeika, Morse et al. 2011) could help to 
understand the involvement of the T-cells in DN.  
The results in chapter 3 suggest that silencing of TIMP is an effective way to fasten 
degradation of ECM. However, such an experiment would have pharmaceutically to 
target both TIMP1 and TIMP2 at the same time as they appear to be able to 
compensate for each other(Kim, Oda et al. 2001). On the other hand a pan-TIMP 
blockade might be counterproductive as TIMP3 has been demonstrated to anti-
inflammatory and anti-fibrotic characteristics (Wang, Famulski et al. 2014). 
Potential effect of alternative splicing in the DM+HTN model 
Given the fact that more than 94% of human genes can be alternatively spliced, 
abnormal regulation of alternative splicing (AS) is most likely involved in the 
pathogenesis of DN and there is evolving evidence in literature supporting this 
assumption (Stevens and Oltean 2016). 
Gerold et al. demonstrate that the splice variant CTLA-4 potentiates regulatory T-cell 
function and delays the development of type 1 diabetes in a mice DN model (Gerold, 
Zheng et al. 2011). Notably, regulatory T-cells are assumed to play a protective role 
in the DM+HTN rat DN model as they are present during injury and reversal phase.  
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EGF activates SR-Protein kinases which in turn phosphorylate normally inactive SR 
proteins massively modifying AS patterns in the nucleus (Zhou, Qiu et al. 2012). 
This could be one potential mechanism by which EGF exerts its protective effect in 
renal disease. 
An alternative splicing isoform of VEGF-A is VEGF-A165b that has anti-angiogenic 
properties. VEGF-A165b is increased in early but not in late DN stages and helps to 
stabilize the glomerular filtration barrier (Oltean, Qiu et al. 2015). Interestingly, in 
the hypertensive & hyperglycaemic DN model, that reflects moderately advanced 
human DN, total VEGF-A gene expression is markedly reduced (Conway, Rennie et 
al. 2012), however no AS isoforms have been differentiated in this work.  
Finally, the AS isoform in the extradomain (EDA+) of fibronectin which is an 
important contributor to extracellular matrix is increased by TGF-beta1 stimulation 
via PI3 kinase-AKT signalling and SRp40 expression in human primary proximal 
tubule epithelial cells (Phanish, Heidebrecht et al. 2015). In the DM+HTN rat model 
TGF-beta1 and fibronectin gene expression were up-regulated but the AS isoforms of 
fibronectin had not been analysed.  
In conclusion, the investigation of AS in the DM+HTN rat model might help to 
detect and explore novel pathophysiological pathways in DN what could result in the 
development of new treatment strategies. 
Markers of tubular cell loss – more than biomarkers? 
EGF and meprinA might not only indicate loss of renal cell mass but also have 
pathophysiological functions.  Mathew et al. hypothesize that in the db/db mouse DN 
model meprinA in the renal tubules might directly mediate the therapeutical effects 
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of angiotensin-converting-enzyme-inhibitor (ACI) or ARB treatment (Mathew, 
Futterweit et al. 2005). As many ET2D patients had received ACI or ARB as first-
line therapy for hypertension (2013), it might  be possible to demonstrate a 
correlation between meprinA concentration, renal function and renin-angiotensin 
blockade in the study cohort.  
In a model of early diabetic nephropathy the administration of EGF has proven to be 
protective against renal damage in an early model of diabetic nephropathy (Suarez-
Pinzon, Yan et al. 2005). In addition, EGF administration prevented diabetes 
recurrence in NOD mice after transplantation with syngeneic islets (Suarez-Pinzon 
and Rabinovitch 2008) and improved wound-healing in diabetic NOD mice (Nagy, 
Nagashima et al. 2001). The administration of exogenous EGF in the Cyp1a1mRen2 
model might be an interesting therapeutic experiment. 
Peptidomics – beyond urinary analysis 
As it has already been discussed in the respective result chapter, the exclusion of 
higher molecular-weight proteins by passing urine through a 10kDa exclusion filter 
might have reduced the spectrum of detectable proteins and hampered quantification 
in the LC-MS/MS analysis. The removal of abundant proteins (esp. albumin) is 
necessary to detect less abundant peptides, however targeted removal of albumin 
remains technically challenging (Filip, Vougas et al. 2015), therefore alternative 
approaches are needed. One option favoured by Raimondo et al. is to perform the 
analysis on urinary exosomes (Raimondo, Corbetta et al. 2013), however this 
potentially useful approach is complicated by the time-consuming process of 
exosome isolation. Proteomics/peptidomics in serum might be less “kidney-specific” 
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in patients with diabetes mellitus as the proteins will be derived from multiple 
organs, most importantly from the liver, but it could provide complementary 
information to the urinary peptidomics. Although - similar to urine - the abundance 
of serum albumin and immunoglobulins imposes technical challenges in sample 
preparation, several studies with promising biomarker panels have been published 
recently (e.g. Looker et al.(Looker, Colombo et al. 2015)  and reviewed by Pena et 
al. (Pena, Mischak et al. 2016)). Direct analysis of renal tissue might circumvent the 
problem of abundant albumin in serum and urine. Beside the detection of new 
marker candidates (Zubiri, Posada-Ayala et al. 2015), it might in the Cyp1a1mRen2 
reversal DN model help to gain deeper insight into the dissociation in the results 
between transcriptomic and immunohistochemistry/zymography analysis that was 
observed during the reversal phase - for example the fibrotic response persisted 
despite a marked reduction in collagen gene expression. Peptidomic analysis in tissue 
has been problematic due to its rapid degradation, but recently a new elegant 
protocol for peptidomic tissue analysis has been published that might forward the 
field (Secher, Kelstrup et al. 2016).  
Extracellular vesicles – a potential new class of biomarkers 
It is known that exosomes may pass from the serum to the urine (Oosthuyzen, 
Scullion et al. 2016), therefore whether unlabelled exosomes originate from serum or 
renal tissue cannot be distinguished. A further characterization of the exosomes 
urinary profile requires the labelling of exosomes for blood or kidney specific 
markers (e.g. nephrin, cubilin and aquarporin 2). The correct normalization of 
labelled exosome concentrations might be however a difficult task in large cohort 
studies: correcting for urinary creatinine is problematic since the total exosome 
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concentration does not well correlate with urinary creatinine as demonstrated in the 
ET2D cohort. Alternatively, correction can be made by reference to a “pan-exosomal 
marker” like CD24 or by measurement of the total exosome concentration. These 
options are time-consuming since the Nanosight LM10 can only measure light scatter 
or a single fluorochrome at a time and hence these methodologies are not feasible for 
high throughput cohort studies. Other methods of measurement are dynamic light 
scattering, resistive pulse sensing or, with some restriction due to the higher 
threshold of size detection,  flow cytometry (van der Pol, Coumans et al. 2014) 
(Erdbrugger and Le 2016). However, the practicability for application in large 
studies remains to be elucidated for most of these techniques. The immunoassay 
based methodology for measurement of exosomes that has been published recently 
by Salih et al.(Salih, Fenton et al. 2016) seems to be quick and highly applicable for 
use in clinical studies. A comparative study between the immunoassay and NTA in 
larger cohorts for validation would be very informative. 
The potential involvement of exosomes in the pathophysiology of DN was not 
investigated in this work but they probably play a role considering studies that 
demonstrate their modulating function in renal diseases (Salih, Zietse et al. 2014, 
Erdbrugger and Le 2016, Morrison, Bailey et al. 2016, Oosthuyzen, Scullion et al. 
2016).  
Microvesicles (100-1000nm) are measured by Flow Cytometry in many studies 
(Salih, Zietse et al. 2014) and this methodology seems reliable and applicable for  
large study cohorts. However, the construction of a panel of antibodies containing 
cell-specific surface markers from different renal compartments (cubilin, nephrin, 
aquaporin 2) and an injury-related marker (KIM-1) is challenging. At the moment, 
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only podocalyxin antibody seems to produce a signal that is sufficient for reliable 
measurement. Future work needs to focus on testing antibodies to find those target 
peptide sequences that are externalized by microvesicles. The coupling of Imaging 
with FCM (IFCM) might be a promising technical advance in the field because it has 
the potential to increase sensitivity and reduce the background noise at the lower size 
range of microvesicles (Erdbrugger, Rudy et al. 2014). 
4.3 Concluding remark 
Only recently, Ju et al. (Ju, Nair et al. 2015) applied an integrative transcriptomic 
approach to identify urinary EGF as a very sensitive and specific marker for renal 
deterioration in patients with CKD due to various aetiologies. Their work is 
complementary to this thesis that focuses on the predictive value of uEGF in patients 
with CKD due to Diabetes mellitus. Though uEGF as a marker needs further 
confirmation in other study cohorts including a prospective approach, it may in the 
future help to identify patients at risk for renal deterioration. This could support 
clinical decision-making relating to diagnosis (e.g. the necessity for renal biopsy) and 
intensification of therapeutic treatment and measurements. uEGF might be also 
useful in clinical research to select participants who are at higher risk of progression 
thereby reducing the number of patients required to achieve adequate power in the 
randomized-controlled trials of new therapeutics for CKD . 
Future work will have to elaborate whether other markers discussed in this work 





Aaltonen, P., P. Luimula, E. Astrom, T. Palmen, T. Gronholm, E. Palojoki, I. Jaakkola, H. 
Ahola, I. Tikkanen and H. Holthofer (2001). "Changes in the expression of nephrin gene and 
protein in experimental diabetic nephropathy." Lab Invest 81(9): 1185-1190. 
Advani, A., K. J. Wiggins, A. J. Cox, Y. Zhang, R. E. Gilbert and D. J. Kelly (2011). "Inhibition of 
the epidermal growth factor receptor preserves podocytes and attenuates albuminuria in 
experimental diabetic nephropathy." Nephrology (Carlton) 16(6): 573-581. 
Afkarian, M., M. Bhasin, S. T. Dillon, M. C. Guerrero, R. G. Nelson, W. C. Knowler, R. 
Thadhani and T. A. Libermann (2010). "Optimizing a proteomics platform for urine 
biomarker discovery." Mol Cell Proteomics 9(10): 2195-2204. 
Agarwal, R. and M. J. Andersen (2006). "Prognostic importance of ambulatory blood 
pressure recordings in patients with chronic kidney disease." Kidney Int 69(7): 1175-1180. 
Ahmed, A. K., J. L. Haylor, A. M. El Nahas and T. S. Johnson (2007). "Localization of matrix 
metalloproteinases and their inhibitors in experimental progressive kidney scarring." Kidney 
Int 71(8): 755-763. 
Aksun, S. A., D. Ozmen, B. Ozmen, Z. Parildar, I. Mutaf, N. Turgan, S. Habif, K. Kumanliogluc 
and O. Bayindir (2004). "Beta2-microglobulin and cystatin C in type 2 diabetes: assessment 
of diabetic nephropathy." Exp Clin Endocrinol Diabetes 112(4): 195-200. 
Alter, M. L., A. Kretschmer, K. Von Websky, O. Tsuprykov, C. Reichetzeder, A. Simon, J. P. 
Stasch and B. Hocher (2012). "Early urinary and plasma biomarkers for experimental 
diabetic nephropathy." Clin Lab 58(7-8): 659-671. 
Alvarez, M. L., M. Khosroheidari, R. Kanchi Ravi and J. K. DiStefano (2012). "Comparison of 
protein, microRNA, and mRNA yields using different methods of urinary exosome isolation 
for the discovery of kidney disease biomarkers." Kidney Int 82(9): 1024-1032. 
Alvarez, S., C. Suazo, A. Boltansky, M. Ursu, D. Carvajal, G. Innocenti, A. Vukusich, M. 
Hurtado, S. Villanueva, J. E. Carreno, A. Rogelio and C. E. Irarrazabal (2013). "Urinary 
exosomes as a source of kidney dysfunction biomarker in renal transplantation." Transplant 
Proc 45(10): 3719-3723. 
American Diabetes, A. (2016). "9. Microvascular Complications and Foot Care." Diabetes 
Care 39 Suppl 1: S72-80. 
Anders, H. J. and M. Ryu (2011). "Renal microenvironments and macrophage phenotypes 
determine progression or resolution of renal inflammation and fibrosis." Kidney Int 80(9): 
915-925. 
Andresdottir, G., M. L. Jensen, B. Carstensen, H. H. Parving, K. Rossing, T. W. Hansen and P. 
Rossing (2014). "Improved survival and renal prognosis of patients with type 2 diabetes and 
nephropathy with improved control of risk factors." Diabetes Care 37(6): 1660-1667. 
Araki, S., M. Haneda, D. Koya, T. Sugaya, K. Isshiki, S. Kume, A. Kashiwagi, T. Uzu and H. 
Maegawa (2013). "Predictive effects of urinary liver-type fatty acid-binding protein for 
deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic 
patients without advanced nephropathy." Diabetes Care 36(5): 1248-1253. 
Atrih, A., M. A. Mudaliar, P. Zakikhani, D. J. Lamont, J. T. Huang, S. E. Bray, G. Barton, S. 
Fleming and G. Nabi (2014). "Quantitative proteomics in resected renal cancer tissue for 
biomarker discovery and profiling." Br J Cancer 110(6): 1622-1633. 
Ban, C. R., S. M. Twigg, B. Franjic, B. A. Brooks, D. Celermajer, D. K. Yue and S. V. McLennan 
(2010). "Serum MMP-7 is increased in diabetic renal disease and diabetic diastolic 
dysfunction." Diabetes Res Clin Pract 87(3): 335-341. 
284 
Barutta, F., M. Tricarico, A. Corbelli, L. Annaratone, S. Pinach, S. Grimaldi, G. Bruno, D. 
Cimino, D. Taverna, M. C. Deregibus, M. P. Rastaldi, P. C. Perin and G. Gruden (2013). 
"Urinary exosomal microRNAs in incipient diabetic nephropathy." PLoS One 8(11): e73798. 
Beretov, J., V. C. Wasinger, E. K. Millar, P. Schwartz, P. H. Graham and Y. Li (2015). 
"Proteomic Analysis of Urine to Identify Breast Cancer Biomarker Candidates Using a Label-
Free LC-MS/MS Approach." PLoS One 10(11): e0141876. 
Berkman, J. and H. Rifkin (1973). "Unilateral nodular diabetic glomerulosclerosis 
(Kimmelstiel-Wilson): report of a case." Metabolism 22(5): 715-722. 
Beroniade, V. C., R. Lefebvre and P. Falardeau (1987). "Unilateral nodular diabetic 
glomerulosclerosis: recurrence of an experiment of nature." Am J Nephrol 7(1): 55-59. 
Betz, B. and B. R. Conway (2014). "Recent advances in animal models of diabetic 
nephropathy." Nephron Exp Nephrol 126(4): 191-195. 
Betz, B. and B. R. Conway (2016). "An Update on the Use of Animal Models in Diabetic 
Nephropathy Research." Curr Diab Rep 16(2): 18. 
Betz, B. B., S. J. Jenks, A. D. Cronshaw, D. J. Lamont, C. Cairns, J. R. Manning, J. Goddard, D. 
J. Webb, J. J. Mullins, J. Hughes, S. McLachlan, M. W. Strachan, J. F. Price and B. R. Conway 
(2016). "Urinary peptidomics in a rodent model of diabetic nephropathy highlights 
epidermal growth factor as a biomarker for renal deterioration in patients with type 2 
diabetes." Kidney Int 89(5): 1125-1135. 
Bhensdadia, N. M., K. J. Hunt, M. F. Lopes-Virella, J. Michael Tucker, M. R. Mataria, J. L. 
Alge, B. A. Neely, M. G. Janech, J. M. Arthur and g. Veterans Affairs Diabetes Trial study 
(2013). "Urine haptoglobin levels predict early renal functional decline in patients with type 
2 diabetes." Kidney Int 83(6): 1136-1143. 
Bonventre, J. V. (2009). "Kidney injury molecule-1 (KIM-1): a urinary biomarker and much 
more." Nephrol Dial Transplant 24(11): 3265-3268. 
Borges, F. T., S. A. Melo, B. C. Ozdemir, N. Kato, I. Revuelta, C. A. Miller, V. H. Gattone, 2nd, 
V. S. LeBleu and R. Kalluri (2013). "TGF-beta1-containing exosomes from injured epithelial 
cells activate fibroblasts to initiate tissue regenerative responses and fibrosis." J Am Soc 
Nephrol 24(3): 385-392. 
Braga, T. T., J. S. Agudelo and N. O. Camara (2015). "Macrophages During the Fibrotic 
Process: M2 as Friend and Foe." Front Immunol 6: 602. 
Brosius, F. C., 3rd (2008). "New insights into the mechanisms of fibrosis and sclerosis in 
diabetic nephropathy." Rev Endocr Metab Disord 9(4): 245-254. 
Brosius, F. C., 3rd, C. E. Alpers, E. P. Bottinger, M. D. Breyer, T. M. Coffman, S. B. Gurley, R. 
C. Harris, M. Kakoki, M. Kretzler, E. H. Leiter, M. Levi, R. A. McIndoe, K. Sharma, O. Smithies, 
K. Susztak, N. Takahashi, T. Takahashi and C. Animal Models of Diabetic Complications 
(2009). "Mouse models of diabetic nephropathy." J Am Soc Nephrol 20(12): 2503-2512. 
Brosius, F. C. and S. Pennathur (2013). "How to find a prognostic biomarker for progressive 
diabetic nephropathy." Kidney Int 83(6): 996-998. 
Burger, D., S. Schock, C. S. Thompson, A. C. Montezano, A. M. Hakim and R. M. Touyz 
(2013). "Microparticles: biomarkers and beyond." Clin Sci (Lond) 124(7): 423-441. 
Burger, D., J. F. Thibodeau, C. E. Holterman, K. D. Burns, R. M. Touyz and C. R. Kennedy 
(2014). "Urinary podocyte microparticles identify prealbuminuric diabetic glomerular 
injury." J Am Soc Nephrol 25(7): 1401-1407. 
Calvo, S. E., D. J. Pagliarini and V. K. Mootha (2009). "Upstream open reading frames cause 
widespread reduction of protein expression and are polymorphic among humans." Proc 
Natl Acad Sci U S A 106(18): 7507-7512. 
285 
Cantley, L. G., C. M. Colangelo, K. L. Stone, L. Chung, J. Belcher, T. Abbott, J. L. Cantley, K. R. 
Williams and C. R. Parikh (2016). "Development of a Targeted Urine Proteome Assay for 
kidney diseases." Proteomics Clin Appl 10(1): 58-74. 
Chang, J. H., S. Y. Paik, L. Mao, W. Eisner, P. J. Flannery, L. Wang, Y. Tang, N. Mattocks, S. 
Hadjadj, J. M. Goujon, P. Ruiz, S. B. Gurley and R. F. Spurney (2012). "Diabetic kidney 
disease in FVB/NJ Akita mice: temporal pattern of kidney injury and urinary nephrin 
excretion." PLoS One 7(4): e33942. 
Chesher, D. (2008). "Evaluating assay precision." Clin Biochem Rev 29 Suppl 1: S23-26. 
Chevalier, R. L., M. S. Forbes and B. A. Thornhill (2009). "Ureteral obstruction as a model of 
renal interstitial fibrosis and obstructive nephropathy." Kidney Int 75(11): 1145-1152. 
Chou, K. M., C. C. Lee, C. H. Chen and C. Y. Sun (2013). "Clinical value of NGAL, L-FABP and 
albuminuria in predicting GFR decline in type 2 diabetes mellitus patients." PLoS One 8(1): 
e54863. 
Chow, F. Y., D. J. Nikolic-Paterson, R. C. Atkins and G. H. Tesch (2004). "Macrophages in 
streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis." Nephrol Dial 
Transplant 19(12): 2987-2996. 
Cochrane, A. L., M. M. Kett, C. S. Samuel, N. V. Campanale, W. P. Anderson, D. A. Hume, M. 
H. Little, J. F. Bertram and S. D. Ricardo (2005). "Renal structural and functional repair in a 
mouse model of reversal of ureteral obstruction." J Am Soc Nephrol 16(12): 3623-3630. 
Cohen, C. D., M. T. Lindenmeyer, F. Eichinger, A. Hahn, M. Seifert, A. G. Moll, H. Schmid, E. 
Kiss, E. Grone, H. J. Grone, M. Kretzler, T. Werner and P. J. Nelson (2008). "Improved 
elucidation of biological processes linked to diabetic nephropathy by single probe-based 
microarray data analysis." PLoS One 3(8): e2937. 
Conserva, F., L. Gesualdo and M. Papale (2016). "A Systems Biology Overview on Human 
Diabetic Nephropathy: From Genetic Susceptibility to Post-Transcriptional and Post-
Translational Modifications." J Diabetes Res 2016: 7934504. 
Conti, M., S. Moutereau, M. Zater, K. Lallali, A. Durrbach, P. Manivet, P. Eschwege and S. 
Loric (2006). "Urinary cystatin C as a specific marker of tubular dysfunction." Clin Chem Lab 
Med 44(3): 288-291. 
Conway, B. and J. Hughes (2012). "Cellular orchestrators of renal fibrosis." QJM 105(7): 611-
615. 
Conway, B. R., B. Betz, T. A. Sheldrake, J. R. Manning, D. R. Dunbar, A. Dobyns, J. Hughes 
and J. J. Mullins (2014). "Tight blood glycaemic and blood pressure control in experimental 
diabetic nephropathy reduces extracellular matrix production without regression of 
fibrosis." Nephrology (Carlton) 19(12): 802-813. 
Conway, B. R., D. Manoharan, D. Manoharan, S. Jenks, J. W. Dear, S. McLachlan, M. W. 
Strachan and J. F. Price (2012). "Measuring urinary tubular biomarkers in type 2 diabetes 
does not add prognostic value beyond established risk factors." Kidney Int 82(7): 812-818. 
Conway, B. R., J. Rennie, M. A. Bailey, D. R. Dunbar, J. R. Manning, C. O. Bellamy, J. Hughes 
and J. J. Mullins (2012). "Hyperglycemia and renin-dependent hypertension synergize to 
model diabetic nephropathy." J Am Soc Nephrol 23(3): 405-411. 
Cook, N. R. (2008). "Statistical evaluation of prognostic versus diagnostic models: beyond 
the ROC curve." Clin Chem 54(1): 17-23. 
Cox, J. and M. Mann (2008). "MaxQuant enables high peptide identification rates, 
individualized p.p.b.-range mass accuracies and proteome-wide protein quantification." Nat 
Biotechnol 26(12): 1367-1372. 
Dagogo-Jack, S., S. M. Marshall, P. Kendall-Taylor and K. G. Alberti (1989). "Urinary 
excretion of human epidermal growth factor in the various stages of diabetic nephropathy." 
Clin Endocrinol (Oxf) 31(2): 167-173. 
286 
Dallas, D. C., A. Guerrero, E. A. Parker, R. C. Robinson, J. Gan, J. B. German, D. Barile and C. 
B. Lebrilla (2015). "Current peptidomics: applications, purification, identification, 
quantification, and functional analysis." Proteomics 15(5-6): 1026-1038. 
Danielson, K. M., J. Estanislau, J. Tigges, V. Toxavidis, V. Camacho, E. J. Felton, J. Khoory, S. 
Kreimer, A. R. Ivanov, P. Y. Mantel, J. Jones, P. Akuthota, S. Das and I. Ghiran (2016). 
"Diurnal Variations of Circulating Extracellular Vesicles Measured by Nano Flow Cytometry." 
PLoS One 11(1): e0144678. 
Dear, J. W. (2014). "Urinary exosomes join the fight against infection." J Am Soc Nephrol 
25(9): 1889-1891. 
Diabetes, C., I. Complications Trial/Epidemiology of Diabetes, G. Complications Research, D. 
M. Nathan, B. Zinman, P. A. Cleary, J. Y. Backlund, S. Genuth, R. Miller and T. J. Orchard 
(2009). "Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the 
diabetes control and complications trial/epidemiology of diabetes interventions and 
complications and Pittsburgh epidemiology of diabetes complications experience (1983-
2005)." Arch Intern Med 169(14): 1307-1316. 
Dimuccio, V., A. Ranghino, L. Pratico Barbato, F. Fop, L. Biancone, G. Camussi and B. 
Bussolati (2014). "Urinary CD133+ extracellular vesicles are decreased in kidney 
transplanted patients with slow graft function and vascular damage." PLoS One 9(8): 
e104490. 
Dragovic, R. A., C. Gardiner, A. S. Brooks, D. S. Tannetta, D. J. Ferguson, P. Hole, B. Carr, C. 
W. Redman, A. L. Harris, P. J. Dobson, P. Harrison and I. L. Sargent (2011). "Sizing and 
phenotyping of cellular vesicles using Nanoparticle Tracking Analysis." Nanomedicine 7(6): 
780-788. 
Driver, T. H., M. G. Shlipak, R. Katz, L. Goldenstein, M. J. Sarnak, A. N. Hoofnagle, D. S. 
Siscovick, B. Kestenbaum, I. H. de Boer and J. H. Ix (2014). "Low serum bicarbonate and 
kidney function decline: the Multi-Ethnic Study of Atherosclerosis (MESA)." Am J Kidney Dis 
64(4): 534-541. 
Duffield, J. S. (2014). "Cellular and molecular mechanisms in kidney fibrosis." J Clin Invest 
124(6): 2299-2306. 
Duffield, J. S., S. J. Forbes, C. M. Constandinou, S. Clay, M. Partolina, S. Vuthoori, S. Wu, R. 
Lang and J. P. Iredale (2005). "Selective depletion of macrophages reveals distinct, opposing 
roles during liver injury and repair." J Clin Invest 115(1): 56-65. 
Duijvesz, D., C. Y. Versluis, C. A. van der Fels, M. S. Vredenbregt-van den Berg, J. Leivo, M. T. 
Peltola, C. H. Bangma, K. S. Pettersson and G. Jenster (2015). "Immuno-based detection of 
extracellular vesicles in urine as diagnostic marker for prostate cancer." Int J Cancer 
137(12): 2869-2878. 
Edgar, J. R. (2016). "Q&A: What are exosomes, exactly?" BMC Biol 14(1): 46. 
Enjeti, A. K., L. Lincz and M. Seldon (2008). "Bio-maleimide as a generic stain for detection 
and quantitation of microparticles." Int J Lab Hematol 30(3): 196-199. 
Erdbrugger, U. and T. H. Le (2016). "Extracellular Vesicles in Renal Diseases: More than 
Novel Biomarkers?" J Am Soc Nephrol 27(1): 12-26. 
Erdbrugger, U., C. K. Rudy, M. E. Etter, K. A. Dryden, M. Yeager, A. L. Klibanov and J. 
Lannigan (2014). "Imaging flow cytometry elucidates limitations of microparticle analysis by 
conventional flow cytometry." Cytometry A 85(9): 756-770. 
Fallowfield, J. A., M. Mizuno, T. J. Kendall, C. M. Constandinou, R. C. Benyon, J. S. Duffield 
and J. P. Iredale (2007). "Scar-associated macrophages are a major source of hepatic matrix 
metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis." J Immunol 
178(8): 5288-5295. 
287 
Feng, M., Z. Zhang, P. Fu, S. M. Huang, Y. B. Yang, K. L. Su, Z. J. Chen and W. X. Tang (2006). 
"[Expression level of cubilin in the rat model of diabetic nephropathy]." Sichuan Da Xue Xue 
Bao Yi Xue Ban 37(5): 738-741. 
Fernandez-Llama, P., S. Khositseth, P. A. Gonzales, R. A. Star, T. Pisitkun and M. A. Knepper 
(2010). "Tamm-Horsfall protein and urinary exosome isolation." Kidney Int 77(8): 736-742. 
Filip, S., K. Vougas, J. Zoidakis, A. Latosinska, W. Mullen, G. Spasovski, H. Mischak, A. Vlahou 
and J. Jankowski (2015). "Comparison of Depletion Strategies for the Enrichment of Low-
Abundance Proteins in Urine." PLoS One 10(7): e0133773. 
Filipe, V., A. Hawe and W. Jiskoot (2010). "Critical evaluation of Nanoparticle Tracking 
Analysis (NTA) by NanoSight for the measurement of nanoparticles and protein 
aggregates." Pharm Res 27(5): 796-810. 
Fioretto, P. and M. Mauer (2007). "Histopathology of diabetic nephropathy." Semin 
Nephrol 27(2): 195-207. 
Fioretto, P., M. W. Steffes, D. E. Sutherland, F. C. Goetz and M. Mauer (1998). "Reversal of 
lesions of diabetic nephropathy after pancreas transplantation." N Engl J Med 339(2): 69-
75. 
Fioretto, P., D. E. Sutherland, B. Najafian and M. Mauer (2006). "Remodeling of renal 
interstitial and tubular lesions in pancreas transplant recipients." Kidney Int 69(5): 907-912. 
Fliser, D., J. Novak, V. Thongboonkerd, A. Argiles, V. Jankowski, M. A. Girolami, J. Jankowski 
and H. Mischak (2007). "Advances in urinary proteome analysis and biomarker discovery." J 
Am Soc Nephrol 18(4): 1057-1071. 
Fu, J., J. J. Keurentjes, H. Bouwmeester, T. America, F. W. Verstappen, J. L. Ward, M. H. 
Beale, R. C. de Vos, M. Dijkstra, R. A. Scheltema, F. Johannes, M. Koornneef, D. Vreugdenhil, 
R. Breitling and R. C. Jansen (2009). "System-wide molecular evidence for phenotypic 
buffering in Arabidopsis." Nat Genet 41(2): 166-167. 
Fufaa, G. D., E. J. Weil, K. V. Lemley, W. C. Knowler, F. C. Brosius, 3rd, B. Yee, M. Mauer and 
R. G. Nelson (2016). "Structural Predictors of Loss of Renal Function in American Indians 
with Type 2 Diabetes." Clin J Am Soc Nephrol 11(2): 254-261. 
Gandolfo, M. T., H. R. Jang, S. M. Bagnasco, G. J. Ko, P. Agreda, S. R. Satpute, M. T. Crow, L. 
S. King and H. Rabb (2009). "Foxp3+ regulatory T cells participate in repair of ischemic acute 
kidney injury." Kidney Int 76(7): 717-729. 
Gang, X., K. Ueki, S. Kon, M. Maeda, T. Naruse and Y. Nojima (2001). "Reduced urinary 
excretion of intact osteopontin in patients with IgA nephropathy." Am J Kidney Dis 37(2): 
374-379. 
Gardiner, C., Y. J. Ferreira, R. A. Dragovic, C. W. Redman and I. L. Sargent (2013). 
"Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis." J Extracell 
Vesicles 2. 
Gene Ontology, C. (2015). "Gene Ontology Consortium: going forward." Nucleic Acids Res 
43(Database issue): D1049-1056. 
Gerold, K. D., P. Zheng, D. B. Rainbow, A. Zernecke, L. S. Wicker and S. Kissler (2011). "The 
soluble CTLA-4 splice variant protects from type 1 diabetes and potentiates regulatory T-
cell function." Diabetes 60(7): 1955-1963. 
Ghazalpour, A., B. Bennett, V. A. Petyuk, L. Orozco, R. Hagopian, I. N. Mungrue, C. R. Farber, 
J. Sinsheimer, H. M. Kang, N. Furlotte, C. C. Park, P. Z. Wen, H. Brewer, K. Weitz, D. G. Camp, 
2nd, C. Pan, R. Yordanova, I. Neuhaus, C. Tilford, N. Siemers, P. Gargalovic, E. Eskin, T. 
Kirchgessner, D. J. Smith, R. D. Smith and A. J. Lusis (2011). "Comparative analysis of 
proteome and transcriptome variation in mouse." PLoS Genet 7(6): e1001393. 
Gilbert, R. E. and M. E. Cooper (1999). "The tubulointerstitium in progressive diabetic 
kidney disease: more than an aftermath of glomerular injury?" Kidney Int 56(5): 1627-1637. 
288 
Giusti, I., S. D'Ascenzo and V. Dolo (2013). "Microvesicles as potential ovarian cancer 
biomarkers." Biomed Res Int 2013: 703048. 
Good, D. M., P. Zurbig, A. Argiles, H. W. Bauer, G. Behrens, J. J. Coon, M. Dakna, S. 
Decramer, C. Delles, A. F. Dominiczak, J. H. Ehrich, F. Eitner, D. Fliser, M. Frommberger, A. 
Ganser, M. A. Girolami, I. Golovko, W. Gwinner, M. Haubitz, S. Herget-Rosenthal, J. 
Jankowski, H. Jahn, G. Jerums, B. A. Julian, M. Kellmann, V. Kliem, W. Kolch, A. S. Krolewski, 
M. Luppi, Z. Massy, M. Melter, C. Neususs, J. Novak, K. Peter, K. Rossing, H. Rupprecht, J. P. 
Schanstra, E. Schiffer, J. U. Stolzenburg, L. Tarnow, D. Theodorescu, V. Thongboonkerd, R. 
Vanholder, E. M. Weissinger, H. Mischak and P. Schmitt-Kopplin (2010). "Naturally 
occurring human urinary peptides for use in diagnosis of chronic kidney disease." Mol Cell 
Proteomics 9(11): 2424-2437. 
Gordin, D., C. Forsblom, N. M. Panduru, M. C. Thomas, M. Bjerre, A. Soro-Paavonen, N. 
Tolonen, N. Sandholm, A. Flyvbjerg, V. Harjutsalo, P. H. Groop and G. FinnDiane Study 
(2014). "Osteopontin is a strong predictor of incipient diabetic nephropathy, cardiovascular 
disease, and all-cause mortality in patients with type 1 diabetes." Diabetes Care 37(9): 
2593-2600. 
Hadler-Olsen, E., P. Kanapathippillai, E. Berg, G. Svineng, J. O. Winberg and L. Uhlin-Hansen 
(2010). "Gelatin in situ zymography on fixed, paraffin-embedded tissue: zinc and ethanol 
fixation preserve enzyme activity." J Histochem Cytochem 58(1): 29-39. 
Hara, M., T. Yanagihara, I. Kihara, K. Higashi, K. Fujimoto and T. Kajita (2005). "Apical cell 
membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte 
injury." J Am Soc Nephrol 16(2): 408-416. 
Harder, J. L., J. B. Hodgin and M. Kretzler (2015). "Integrative Biology of Diabetic Kidney 
Disease." Kidney Dis (Basel) 1(3): 194-203. 
Hartner, A., N. Cordasic, B. Klanke, M. Wittmann, R. Veelken and K. F. Hilgers (2007). "Renal 
injury in streptozotocin-diabetic Ren2-transgenic rats is mainly dependent on hypertension, 
not on diabetes." Am J Physiol Renal Physiol 292(2): F820-827. 
He, W., R. J. Tan, Y. Li, D. Wang, J. Nie, F. F. Hou and Y. Liu (2012). "Matrix 
metalloproteinase-7 as a surrogate marker predicts renal Wnt/beta-catenin activity in 
CKD." J Am Soc Nephrol 23(2): 294-304. 
Heilig, C. W., L. A. Concepcion, B. L. Riser, S. O. Freytag, M. Zhu and P. Cortes (1995). 
"Overexpression of glucose transporters in rat mesangial cells cultured in a normal glucose 
milieu mimics the diabetic phenotype." J Clin Invest 96(4): 1802-1814. 
Herget-Rosenthal, S., J. A. van Wijk, M. Brocker-Preuss and A. Bokenkamp (2007). 
"Increased urinary cystatin C reflects structural and functional renal tubular impairment 
independent of glomerular filtration rate." Clin Biochem 40(13-14): 946-951. 
Hesketh, E. E., D. C. Kluth and J. Hughes (2014). "Apoptotic cell administration is 
detrimental in murine renal ischaemia reperfusion injury." J Inflamm (Lond) 11(1): 31. 
Hesketh, E. E., M. A. Vernon, P. Ding, S. Clay, G. Borthwick, B. Conway and J. Hughes (2014). 
"A murine model of irreversible and reversible unilateral ureteric obstruction." J Vis 
Exp(94). 
Hiemstra, T. F., P. D. Charles, T. Gracia, S. S. Hester, L. Gatto, R. Al-Lamki, R. A. Floto, Y. Su, J. 
N. Skepper, K. S. Lilley and F. E. Karet Frankl (2014). "Human urinary exosomes as innate 
immune effectors." J Am Soc Nephrol 25(9): 2017-2027. 
Hobeika, A. C., M. A. Morse, T. Osada, S. Peplinski, H. K. Lyerly and T. M. Clay (2011). 
"Depletion of human regulatory T cells." Methods Mol Biol 707: 219-231. 
Hodgin, J. B., V. Nair, H. Zhang, A. Randolph, R. C. Harris, R. G. Nelson, E. J. Weil, J. D. 
Cavalcoli, J. M. Patel, F. C. Brosius, 3rd and M. Kretzler (2013). "Identification of cross-
289 
species shared transcriptional networks of diabetic nephropathy in human and mouse 
glomeruli." Diabetes 62(1): 299-308. 
Hogan, M. C., K. L. Johnson, R. M. Zenka, M. C. Charlesworth, B. J. Madden, D. W. Mahoney, 
A. L. Oberg, B. Q. Huang, A. A. Leontovich, L. L. Nesbitt, J. L. Bakeberg, D. J. McCormick, H. R. 
Bergen and C. J. Ward (2014). "Subfractionation, characterization, and in-depth proteomic 
analysis of glomerular membrane vesicles in human urine." Kidney Int 85(5): 1225-1237. 
Hole, P., K. Sillence, C. Hannell, C. M. Maguire, M. Roesslein, G. Suarez, S. Capracotta, Z. 
Magdolenova, L. Horev-Azaria, A. Dybowska, L. Cooke, A. Haase, S. Contal, S. Mano, A. 
Vennemann, J. J. Sauvain, K. C. Staunton, S. Anguissola, A. Luch, M. Dusinska, R. Korenstein, 
A. C. Gutleb, M. Wiemann, A. Prina-Mello, M. Riediker and P. Wick (2013). "Interlaboratory 
comparison of size measurements on nanoparticles using nanoparticle tracking analysis 
(NTA)." J Nanopart Res 15: 2101. 
Huang da, W., B. T. Sherman and R. A. Lempicki (2009). "Systematic and integrative analysis 
of large gene lists using DAVID bioinformatics resources." Nat Protoc 4(1): 44-57. 
Hudkins, K. L., W. Pichaiwong, T. Wietecha, J. Kowalewska, M. C. Banas, M. W. Spencer, A. 
Muhlfeld, M. Koelling, J. W. Pippin, S. J. Shankland, B. Askari, M. E. Rabaglia, M. P. Keller, A. 
D. Attie and C. E. Alpers (2010). "BTBR Ob/Ob mutant mice model progressive diabetic 
nephropathy." J Am Soc Nephrol 21(9): 1533-1542. 
Humphreys, B. D., S. L. Lin, A. Kobayashi, T. E. Hudson, B. T. Nowlin, J. V. Bonventre, M. T. 
Valerius, A. P. McMahon and J. S. Duffield (2010). "Fate tracing reveals the pericyte and not 
epithelial origin of myofibroblasts in kidney fibrosis." Am J Pathol 176(1): 85-97. 
Iimura, O., H. Takahashi, T. Yashiro, S. Madoiwa, Y. Sakata, Y. Asano and E. Kusano (2004). 
"Effect of ureteral obstruction on matrix metalloproteinase-2 in rat renal cortex." Clin Exp 
Nephrol 8(3): 223-229. 
Isobe, K., T. Mori, T. Asano, H. Kawaguchi, S. Nonoyama, N. Kumagai, F. Kamada, T. 
Morimoto, M. Hayashi, E. Sohara, T. Rai, S. Sasaki and S. Uchida (2013). "Development of 
enzyme-linked immunosorbent assays for urinary thiazide-sensitive Na-Cl cotransporter 
measurement." Am J Physiol Renal Physiol 305(9): F1374-1381. 
Ito, K., J. Chen, M. El Chaar, J. M. Stern, S. V. Seshan, J. J. Khodadadian, I. Richardson, M. J. 
Hyman, E. D. Vaughan, Jr., D. P. Poppas and D. Felsen (2004). "Renal damage progresses 
despite improvement of renal function after relief of unilateral ureteral obstruction in adult 
rats." Am J Physiol Renal Physiol 287(6): F1283-1293. 
Jaksik, R., M. Iwanaszko, J. Rzeszowska-Wolny and M. Kimmel (2015). "Microarray 
experiments and factors which affect their reliability." Biol Direct 10: 46. 
Ju, W., V. Nair, S. Smith, L. Zhu, K. Shedden, P. X. Song, L. H. Mariani, F. H. Eichinger, C. C. 
Berthier, A. Randolph, J. Y. Lai, Y. Zhou, J. J. Hawkins, M. Bitzer, M. G. Sampson, M. Thier, C. 
Solier, G. C. Duran-Pacheco, G. Duchateau-Nguyen, L. Essioux, B. Schott, I. Formentini, M. C. 
Magnone, M. Bobadilla, C. D. Cohen, S. M. Bagnasco, L. Barisoni, J. Lv, H. Zhang, H. Y. Wang, 
F. C. Brosius, C. A. Gadegbeku, M. Kretzler, C. P. N. Ercb and P. K.-I. Consortium (2015). 
"Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney 
disease biomarker." Sci Transl Med 7(316): 316ra193. 
Kadoglou, N. P., N. Sailer, G. Fotiadis, A. Kapelouzou and C. D. Liapis (2014). "The impact of 
type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8." Exp 
Clin Endocrinol Diabetes 122(1): 44-49. 
Kalani, A., A. Mohan, M. M. Godbole, E. Bhatia, A. Gupta, R. K. Sharma and S. Tiwari (2013). 
"Wilm's tumor-1 protein levels in urinary exosomes from diabetic patients with or without 
proteinuria." PLoS One 8(3): e60177. 
Kamijo-Ikemori, A., T. Sugaya, T. Yasuda, T. Kawata, A. Ota, S. Tatsunami, R. Kaise, T. 
Ishimitsu, Y. Tanaka and K. Kimura (2011). "Clinical significance of urinary liver-type fatty 
290 
acid-binding protein in diabetic nephropathy of type 2 diabetic patients." Diabetes Care 
34(3): 691-696. 
Kanehisa, M., Y. Sato, M. Kawashima, M. Furumichi and M. Tanabe (2016). "KEGG as a 
reference resource for gene and protein annotation." Nucleic Acids Res 44(D1): D457-462. 
Kantachuvesiri, S., S. Fleming, J. Peters, B. Peters, G. Brooker, A. G. Lammie, I. McGrath, Y. 
Kotelevtsev and J. J. Mullins (2001). "Controlled hypertension, a transgenic toggle switch 
reveals differential mechanisms underlying vascular disease." J Biol Chem 276(39): 36727-
36733. 
Kanwar, Y. S., L. Sun, P. Xie, F. Y. Liu and S. Chen (2011). "A glimpse of various pathogenetic 
mechanisms of diabetic nephropathy." Annu Rev Pathol 6: 395-423. 
Kawaguchi, M., Y. Kamiya, J. Ito, T. Fujii, F. Hayakawa, N. Sakuma and T. Fujinami (1993). 
"Excretion of urinary epidermal growth factor in non-insulin dependent diabetes mellitus." 
Life Sci 52(14): 1181-1186. 
KDIGO, C. W. G. (2013). "KDIGO 2012 Clinical Practice Guideline for the Evaluation and 
Management of Chronic Kidney Disease." Kidney Int Suppl (2011) 3(1): 4. 
Ke, J. T., M. Li, S. Q. Xu, W. J. Zhang, Y. W. Jiang, L. Y. Cheng, L. Chen, J. N. Lou and W. Wu 
(2014). "Gliquidone decreases urinary protein by promoting tubular reabsorption in 
diabetic Goto-Kakizaki rats." J Endocrinol 220(2): 129-141. 
Keller, S., C. Rupp, A. Stoeck, S. Runz, M. Fogel, S. Lugert, H. D. Hager, M. S. Abdel-Bakky, P. 
Gutwein and P. Altevogt (2007). "CD24 is a marker of exosomes secreted into urine and 
amniotic fluid." Kidney Int 72(9): 1095-1102. 
Kelly, D. J., A. J. Cox, M. Tolcos, M. E. Cooper, J. L. Wilkinson-Berka and R. E. Gilbert (2002). 
"Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic 
Ren-2 rats." Kidney Int 61(1): 31-39. 
Kelly, D. J., J. L. Wilkinson-Berka, T. J. Allen, M. E. Cooper and S. L. Skinner (1998). "A new 
model of diabetic nephropathy with progressive renal impairment in the transgenic (mRen-
2)27 rat (TGR)." Kidney Int 54(2): 343-352. 
Kelly, D. J., J. L. Wilkinson-Berka, S. D. Ricardo, A. J. Cox and R. E. Gilbert (2002). 
"Progression of tubulointerstitial injury by osteopontin-induced macrophage recruitment in 
advanced diabetic nephropathy of transgenic (mRen-2)27 rats." Nephrol Dial Transplant 
17(6): 985-991. 
Khokha, R., A. Murthy and A. Weiss (2013). "Metalloproteinases and their natural inhibitors 
in inflammation and immunity." Nat Rev Immunol 13(9): 649-665. 
Kikuchi, Y., R. Ikee, N. Hemmi, N. Hyodo, T. Saigusa, T. Namikoshi, M. Yamada, S. Suzuki and 
S. Miura (2004). "Fractalkine and its receptor, CX3CR1, upregulation in streptozotocin-
induced diabetic kidneys." Nephron Exp Nephrol 97(1): e17-25. 
Kim, H., T. Oda, J. Lopez-Guisa, D. Wing, D. R. Edwards, P. D. Soloway and A. A. Eddy (2001). 
"TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy." J Am 
Soc Nephrol 12(4): 736-748. 
Kim, S. S., S. H. Song, I. J. Kim, Y. K. Jeon, B. H. Kim, I. S. Kwak, E. K. Lee and Y. K. Kim (2013). 
"Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy." 
Diabetes Care 36(3): 656-661. 
Kimura, F., G. Hasegawa, H. Obayashi, T. Adachi, H. Hara, M. Ohta, M. Fukui, Y. Kitagawa, H. 
Park, N. Nakamura, K. Nakano and T. Yoshikawa (2003). "Serum extracellular superoxide 
dismutase in patients with type 2 diabetes: relationship to the development of micro- and 
macrovascular complications." Diabetes Care 26(4): 1246-1250. 
Kisseleva, T., M. Cong, Y. Paik, D. Scholten, C. Jiang, C. Benner, K. Iwaisako, T. Moore-
Morris, B. Scott, H. Tsukamoto, S. M. Evans, W. Dillmann, C. K. Glass and D. A. Brenner 
291 
(2012). "Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis." 
Proc Natl Acad Sci U S A 109(24): 9448-9453. 
Klein, J., J. L. Bascands, H. Mischak and J. P. Schanstra (2016). "The role of urinary 
peptidomics in kidney disease research." Kidney Int 89(3): 539-545. 
Klein, J., T. Papadopoulos, H. Mischak and W. Mullen (2014). "Comparison of CE-MS/MS 
and LC-MS/MS sequencing demonstrates significant complementarity in natural peptide 
identification in human urine." Electrophoresis 35(7): 1060-1064. 
Kolset, S. O., F. P. Reinholt and T. Jenssen (2012). "Diabetic nephropathy and extracellular 
matrix." J Histochem Cytochem 60(12): 976-986. 
Korrapati, M. C., B. E. Shaner, B. A. Neely, J. L. Alge, J. M. Arthur and R. G. Schnellmann 
(2012). "Diabetes-induced renal injury in rats is attenuated by suramin." J Pharmacol Exp 
Ther 343(1): 34-43. 
Kowal, J., M. Tkach and C. Thery (2014). "Biogenesis and secretion of exosomes." Curr Opin 
Cell Biol 29: 116-125. 
Kriz, W., B. Kaissling and M. Le Hir (2011). "Epithelial-mesenchymal transition (EMT) in 
kidney fibrosis: fact or fantasy?" J Clin Invest 121(2): 468-474. 
Krolewski, A. S., M. A. Niewczas, J. Skupien, T. Gohda, A. Smiles, J. H. Eckfeldt, A. Doria and 
J. H. Warram (2014). "Early progressive renal decline precedes the onset of 
microalbuminuria and its progression to macroalbuminuria." Diabetes Care 37(1): 226-234. 
Kundu, S., Y. S. Aulchenko, C. M. van Duijn and A. C. Janssens (2011). "PredictABEL: an R 
package for the assessment of risk prediction models." Eur J Epidemiol 26(4): 261-264. 
Leichtle, A. B., J. F. Dufour and G. M. Fiedler (2013). "Potentials and pitfalls of clinical 
peptidomics and metabolomics." Swiss Med Wkly 143: w13801. 
Lev-Ran, A., D. L. Hwang, J. D. Miller and Z. Josefsberg (1990). "Excretion of epidermal 
growth factor (EGF) in diabetes." Clin Chim Acta 192(3): 201-206. 
Levey, A. S., L. A. Stevens, C. H. Schmid, Y. L. Zhang, A. F. Castro, 3rd, H. I. Feldman, J. W. 
Kusek, P. Eggers, F. Van Lente, T. Greene, J. Coresh and E. P. I. Ckd (2009). "A new equation 
to estimate glomerular filtration rate." Ann Intern Med 150(9): 604-612. 
Li, B., A. P. Castano, T. E. Hudson, B. T. Nowlin, S. L. Lin, J. V. Bonventre, K. D. Swanson and 
J. S. Duffield (2010). "The melanoma-associated transmembrane glycoprotein Gpnmb 
controls trafficking of cellular debris for degradation and is essential for tissue repair." 
FASEB J 24(12): 4767-4781. 
Li, C., C. W. Yang, C. W. Park, H. J. Ahn, W. Y. Kim, K. H. Yoon, S. H. Suh, S. W. Lim, J. H. Cha, 
Y. S. Kim, J. Kim, Y. S. Chang and B. K. Bang (2003). "Long-term treatment with ramipril 
attenuates renal osteopontin expression in diabetic rats." Kidney Int 63(2): 454-463. 
Li, F. and T. E. Curry, Jr. (2009). "Regulation and function of tissue inhibitor of 
metalloproteinase (TIMP) 1 and TIMP3 in periovulatory rat granulosa cells." Endocrinology 
150(8): 3903-3912. 
Lin, S. L., T. Kisseleva, D. A. Brenner and J. S. Duffield (2008). "Pericytes and perivascular 
fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the 
kidney." Am J Pathol 173(6): 1617-1627. 
Lindenmeyer, M. T., M. Kretzler, A. Boucherot, S. Berra, Y. Yasuda, A. Henger, F. Eichinger, 
S. Gaiser, H. Schmid, M. P. Rastaldi, R. W. Schrier, D. Schlondorff and C. D. Cohen (2007). 
"Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic 
nephropathy." J Am Soc Nephrol 18(6): 1765-1776. 
Looker, H. C., M. Colombo, S. Hess, M. J. Brosnan, B. Farran, R. N. Dalton, M. C. Wong, C. 
Turner, C. N. Palmer, E. Nogoceke, L. Groop, V. Salomaa, D. B. Dunger, F. Agakov, P. M. 
McKeigue, H. M. Colhoun and S. Investigators (2015). "Biomarkers of rapid chronic kidney 
disease progression in type 2 diabetes." Kidney Int 88(4): 888-896. 
292 
Lorenzen, J., R. Shah, A. Biser, S. A. Staicu, T. Niranjan, A. M. Garcia, A. Gruenwald, D. B. 
Thomas, I. F. Shatat, K. Supe, R. P. Woroniecki and K. Susztak (2008). "The role of 
osteopontin in the development of albuminuria." J Am Soc Nephrol 19(5): 884-890. 
Lotvall, J., A. F. Hill, F. Hochberg, E. I. Buzas, D. Di Vizio, C. Gardiner, Y. S. Gho, I. V. 
Kurochkin, S. Mathivanan, P. Quesenberry, S. Sahoo, H. Tahara, M. H. Wauben, K. W. 
Witwer and C. Thery (2014). "Minimal experimental requirements for definition of 
extracellular vesicles and their functions: a position statement from the International 
Society for Extracellular Vesicles." J Extracell Vesicles 3: 26913. 
Lurbe, E., J. Redon, A. Kesani, J. M. Pascual, J. Tacons, V. Alvarez and D. Batlle (2002). 
"Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 
diabetes." N Engl J Med 347(11): 797-805. 
Maahs, D. M., J. Siwy, A. Argiles, M. Cerna, C. Delles, A. F. Dominiczak, N. Gayrard, A. 
Iphofer, L. Jansch, G. Jerums, K. Medek, H. Mischak, G. J. Navis, J. M. Roob, K. Rossing, P. 
Rossing, I. Rychlik, E. Schiffer, R. E. Schmieder, T. C. Wascher, B. M. Winklhofer-Roob, L. U. 
Zimmerli, P. Zurbig and J. K. Snell-Bergeon (2010). "Urinary collagen fragments are 
significantly altered in diabetes: a link to pathophysiology." PLoS One 5(9). 
Macisaac, R. J., E. I. Ekinci and G. Jerums (2014). "Markers of and risk factors for the 
development and progression of diabetic kidney disease." Am J Kidney Dis 63(2 Suppl 2): 
S39-62. 
Marioni, R. E., M. W. Strachan, R. M. Reynolds, G. D. Lowe, R. J. Mitchell, F. G. Fowkes, B. M. 
Frier, A. J. Lee, I. Butcher, A. Rumley, G. D. Murray, I. J. Deary and J. F. Price (2010). 
"Association between raised inflammatory markers and cognitive decline in elderly people 
with type 2 diabetes: the Edinburgh Type 2 Diabetes Study." Diabetes 59(3): 710-713. 
Mathew, R., S. Futterweit, E. Valderrama, A. A. Tarectecan, J. E. Bylander, J. S. Bond and H. 
Trachtman (2005). "Meprin-alpha in chronic diabetic nephropathy: interaction with the 
renin-angiotensin axis." Am J Physiol Renal Physiol 289(4): F911-921. 
Mathiesen, E. R., E. Nexo, E. Hommel and H. H. Parving (1989). "Reduced urinary excretion 
of epidermal growth factor in incipient and overt diabetic nephropathy." Diabet Med 6(2): 
121-126. 
Mauer, M. and P. Fioretto (2013). "Pancreas transplantation and reversal of diabetic 
nephropathy lesions." Med Clin North Am 97(1): 109-114. 
McKittrick, I. B., Y. Bogaert, K. Nadeau, J. Snell-Bergeon, A. Hull, T. Jiang, X. Wang, M. Levi 
and K. S. Moulton (2011). "Urinary matrix metalloproteinase activities: biomarkers for 
plaque angiogenesis and nephropathy in diabetes." Am J Physiol Renal Physiol 301(6): 
F1326-1333. 
McLennan, S. V., D. J. Kelly, A. J. Cox, Z. Cao, J. G. Lyons, D. K. Yue and R. E. Gilbert (2002). 
"Decreased matrix degradation in diabetic nephropathy: effects of ACE inhibition on the 
expression and activities of matrix metalloproteinases." Diabetologia 45(2): 268-275. 
McLennan, S. V., D. J. Kelly, M. Schache, M. Waltham, V. Dy, R. G. Langham, D. K. Yue and R. 
E. Gilbert (2007). "Advanced glycation end products decrease mesangial cell MMP-7: a role 
in matrix accumulation in diabetic nephropathy?" Kidney Int 72(4): 481-488. 
McLennan, S. V., X. Y. Wang, V. Moreno, D. K. Yue and S. M. Twigg (2004). "Connective 
tissue growth factor mediates high glucose effects on matrix degradation through tissue 
inhibitor of matrix metalloproteinase type 1: implications for diabetic nephropathy." 
Endocrinology 145(12): 5646-5655. 
Meex, R. C., A. J. Hoy, A. Morris, R. D. Brown, J. C. Lo, M. Burke, R. J. Goode, B. A. Kingwell, 
M. J. Kraakman, M. A. Febbraio, J. W. Greve, S. S. Rensen, M. P. Molloy, G. I. Lancaster, C. R. 
Bruce and M. J. Watt (2015). "Fetuin B Is a Secreted Hepatocyte Factor Linking Steatosis to 
Impaired Glucose Metabolism." Cell Metab 22(6): 1078-1089. 
293 
Meran, S. and R. Steadman (2011). "Fibroblasts and myofibroblasts in renal fibrosis." Int J 
Exp Pathol 92(3): 158-167. 
Merchant, M. L., B. A. Perkins, G. M. Boratyn, L. H. Ficociello, D. W. Wilkey, M. T. Barati, C. 
C. Bertram, G. P. Page, B. H. Rovin, J. H. Warram, A. S. Krolewski and J. B. Klein (2009). 
"Urinary peptidome may predict renal function decline in type 1 diabetes and 
microalbuminuria." J Am Soc Nephrol 20(9): 2065-2074. 
Merl, J., M. Ueffing, S. M. Hauck and C. von Toerne (2012). "Direct comparison of MS-based 
label-free and SILAC quantitative proteome profiling strategies in primary retinal Muller 
cells." Proteomics 12(12): 1902-1911. 
Miranda, K. C., D. T. Bond, M. McKee, J. Skog, T. G. Paunescu, N. Da Silva, D. Brown and L. 
M. Russo (2010). "Nucleic acids within urinary exosomes/microvesicles are potential 
biomarkers for renal disease." Kidney Int 78(2): 191-199. 
Mischak, H., C. Delles, A. Vlahou and R. Vanholder (2015). "Proteomic biomarkers in kidney 
disease: issues in development and implementation." Nat Rev Nephrol 11(4): 221-232. 
Mischak, H. and J. P. Schanstra (2011). "CE-MS in biomarker discovery, validation, and 
clinical application." Proteomics Clin Appl 5(1-2): 9-23. 
Mogensen, C. E. (1998). "Combined high blood pressure and glucose in type 2 diabetes: 
double jeopardy. British trial shows clear effects of treatment, especially blood pressure 
reduction." BMJ 317(7160): 693-694. 
Mogensen, C. E. (2003). "Microalbuminuria and hypertension with focus on type 1 and type 
2 diabetes." J Intern Med 254(1): 45-66. 
Mogensen, C. E., R. Osterby and H. J. Gundersen (1979). "Early functional and morphologic 
vascular renal consequences of the diabetic state." Diabetologia 17(2): 71-76. 
Molitch, M. E., A. I. Adler, A. Flyvbjerg, R. G. Nelson, W. Y. So, C. Wanner, B. L. Kasiske, D. C. 
Wheeler, D. de Zeeuw and C. E. Mogensen (2015). "Diabetic kidney disease: a clinical 
update from Kidney Disease: Improving Global Outcomes." Kidney Int 87(1): 20-30. 
Morrison, E. E., M. A. Bailey and J. W. Dear (2016). "Renal extracellular vesicles: from 
physiology to clinical application." J Physiol. 
Nagai, Y., L. Yao, H. Kobori, K. Miyata, Y. Ozawa, A. Miyatake, T. Yukimura, T. Shokoji, S. 
Kimura, H. Kiyomoto, M. Kohno, Y. Abe and A. Nishiyama (2005). "Temporary angiotensin II 
blockade at the prediabetic stage attenuates the development of renal injury in type 2 
diabetic rats." J Am Soc Nephrol 16(3): 703-711. 
Nagy, A., H. Nagashima, S. Cha, G. E. Oxford, T. Zelles, A. B. Peck and M. G. Humphreys-
Beher (2001). "Reduced oral wound healing in the NOD mouse model for type 1 
autoimmune diabetes and its reversal by epidermal growth factor supplementation." 
Diabetes 50(9): 2100-2104. 
Nakamura, T., T. Saito, I. Kusaka, M. Higashiyama, S. Nagasaka, S. Ishibashi and S. E. 
Ishikawa (2002). "Decrease in urinary excretion of aquaporin-2 associated with impaired 
urinary concentrating ability in diabetic nephropathy." Nephron 92(2): 445-448. 
Naseeb, U., J. Axelsson, T. Jagerbrink, J. Shafqat, S. Zarina and H. Jornvall (2015). 
"Complementary LC-MS/MS Proteomic Analysis of Uremic Plasma Proteins." J Coll 
Physicians Surg Pak 25(8): 606-609. 
Nguyen, T. Q., L. Tarnow, A. Jorsal, N. Oliver, P. Roestenberg, Y. Ito, H. H. Parving, P. 
Rossing, F. A. van Nieuwenhoven and R. Goldschmeding (2008). "Plasma connective tissue 
growth factor is an independent predictor of end-stage renal disease and mortality in type 
1 diabetic nephropathy." Diabetes Care 31(6): 1177-1182. 
NICE, N. C. G. C. (2014). Chronic Kidney Disease (Partial Update): Early Identification and 
Management of Chronic Kidney Disease in Adults in Primary and Secondary Care. Chronic 
294 
Kidney Disease (Partial Update): Early Identification and Management of Chronic Kidney 
Disease in Adults in Primary and Secondary Care. London. 
Nicholas, S. B., J. Liu, J. Kim, Y. Ren, A. R. Collins, L. Nguyen and W. A. Hsueh (2010). "Critical 
role for osteopontin in diabetic nephropathy." Kidney Int 77(7): 588-600. 
Nielsen, M. H., H. Beck-Nielsen, M. N. Andersen and A. Handberg (2014). "A flow cytometric 
method for characterization of circulating cell-derived microparticles in plasma." J Extracell 
Vesicles 3. 
Nielsen, S. E., H. Reinhard, D. Zdunek, G. Hess, O. M. Gutierrez, M. Wolf, H. H. Parving, P. K. 
Jacobsen and P. Rossing (2012). "Tubular markers are associated with decline in kidney 
function in proteinuric type 2 diabetic patients." Diabetes Res Clin Pract 97(1): 71-76. 
Niewczas, M. A., T. Gohda, J. Skupien, A. M. Smiles, W. H. Walker, F. Rosetti, X. Cullere, J. H. 
Eckfeldt, A. Doria, T. N. Mayadas, J. H. Warram and A. S. Krolewski (2012). "Circulating TNF 
receptors 1 and 2 predict ESRD in type 2 diabetes." J Am Soc Nephrol 23(3): 507-515. 
Nkuipou-Kenfack, E., A. Bhat, J. Klein, V. Jankowski, W. Mullen, A. Vlahou, M. Dakna, T. 
Koeck, J. P. Schanstra, P. Zurbig, K. L. Rudolph, B. Schumacher, A. Pich and H. Mischak 
(2015). "Identification of ageing-associated naturally occurring peptides in human urine." 
Oncotarget 6(33): 34106-34117. 
Norden, A. G., M. Lapsley and R. J. Unwin (2014). "Urine retinol-binding protein 4: a 
functional biomarker of the proximal renal tubule." Adv Clin Chem 63: 85-122. 
Nosadini, R., M. Velussi, E. Brocco, M. Bruseghin, C. Abaterusso, A. Saller, M. Dalla Vestra, 
A. Carraro, E. Bortoloso, M. Sambataro, I. Barzon, F. Frigato, B. Muollo, M. Chiesura-Corona, 
G. Pacini, B. Baggio, F. Piarulli, A. Sfriso and P. Fioretto (2000). "Course of renal function in 
type 2 diabetic patients with abnormalities of albumin excretion rate." Diabetes 49(3): 476-
484. 
Novobrantseva, T. I., G. R. Majeau, A. Amatucci, S. Kogan, I. Brenner, S. Casola, M. J. 
Shlomchik, V. Koteliansky, P. S. Hochman and A. Ibraghimov (2005). "Attenuated liver 
fibrosis in the absence of B cells." J Clin Invest 115(11): 3072-3082. 
O'Seaghdha, C. M., S. J. Hwang, M. G. Larson, J. B. Meigs, R. S. Vasan and C. S. Fox (2013). 
"Analysis of a urinary biomarker panel for incident kidney disease and clinical outcomes." J 
Am Soc Nephrol 24(11): 1880-1888. 
Obro, N. F., U. Lademann, K. Birkenkamp-Demtroder, L. Holten-Andersen, N. Brunner and 
H. Offenberg (2008). "A TIMP-1 splice variant transcript: possible role in regulation of TIMP-
1 expression." Cancer Lett 262(1): 64-70. 
Ohta, S., J. C. Bukowski-Wills, L. Sanchez-Pulido, L. Alves Fde, L. Wood, Z. A. Chen, M. 
Platani, L. Fischer, D. F. Hudson, C. P. Ponting, T. Fukagawa, W. C. Earnshaw and J. 
Rappsilber (2010). "The protein composition of mitotic chromosomes determined using 
multiclassifier combinatorial proteomics." Cell 142(5): 810-821. 
Oltean, S., Y. Qiu, J. K. Ferguson, M. Stevens, C. Neal, A. Russell, A. Kaura, K. P. Arkill, K. 
Harris, C. Symonds, K. Lacey, L. Wijeyaratne, M. Gammons, E. Wylie, R. P. Hulse, C. Alsop, G. 
Cope, G. Damodaran, K. B. Betteridge, R. Ramnath, S. C. Satchell, R. R. Foster, K. Ballmer-
Hofer, L. F. Donaldson, J. Barratt, H. J. Baelde, S. J. Harper, D. O. Bates and A. H. Salmon 
(2015). "Vascular Endothelial Growth Factor-A165b Is Protective and Restores Endothelial 
Glycocalyx in Diabetic Nephropathy." J Am Soc Nephrol 26(8): 1889-1904. 
Oosthuyzen, W., K. M. Scullion, J. R. Ivy, E. E. Morrison, R. W. Hunter, P. J. Starkey Lewis, E. 
O'Duibhir, J. M. Street, A. Caporali, C. D. Gregory, S. J. Forbes, D. J. Webb, M. A. Bailey and J. 
W. Dear (2016). "Vasopressin Regulates Extracellular Vesicle Uptake by Kidney Collecting 
Duct Cells." J Am Soc Nephrol. 
295 
Oosthuyzen, W., N. E. Sime, J. R. Ivy, E. J. Turtle, J. M. Street, J. Pound, L. E. Bath, D. J. 
Webb, C. D. Gregory, M. A. Bailey and J. W. Dear (2013). "Quantification of human urinary 
exosomes by nanoparticle tracking analysis." J Physiol 591(Pt 23): 5833-5842. 
Parikh, C. R. and H. Thiessen-Philbrook (2014). "Key concepts and limitations of statistical 
methods for evaluating biomarkers of kidney disease." J Am Soc Nephrol 25(8): 1621-1629. 
Park, M., M. G. Shlipak, R. Katz, S. Agarwal, J. H. Ix, C. Y. Hsu and C. A. Peralta (2012). 
"Subclinical cardiac abnormalities and kidney function decline: the multi-ethnic study of 
atherosclerosis." Clin J Am Soc Nephrol 7(7): 1137-1144. 
Parving, H. H., J. B. Lewis, M. Ravid, G. Remuzzi, L. G. Hunsicker and D. investigators (2006). 
"Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic 
patients: a global perspective." Kidney Int 69(11): 2057-2063. 
Pena, M. J., A. Heinzel, G. Heinze, A. Alkhalaf, S. J. Bakker, T. Q. Nguyen, R. Goldschmeding, 
H. J. Bilo, P. Perco, B. Mayer, D. de Zeeuw and H. J. Lambers Heerspink (2015). "A panel of 
novel biomarkers representing different disease pathways improves prediction of renal 
function decline in type 2 diabetes." PLoS One 10(5): e0120995. 
Pena, M. J., H. Mischak and H. J. Heerspink (2016). "Proteomics for prediction of disease 
progression and response to therapy in diabetic kidney disease." Diabetologia. 
Perkins, B. A., L. H. Ficociello, B. Roshan, J. H. Warram and A. S. Krolewski (2010). "In 
patients with type 1 diabetes and new-onset microalbuminuria the development of 
advanced chronic kidney disease may not require progression to proteinuria." Kidney Int 
77(1): 57-64. 
Perkins, B. A., L. H. Ficociello, K. H. Silva, D. M. Finkelstein, J. H. Warram and A. S. Krolewski 
(2003). "Regression of microalbuminuria in type 1 diabetes." N Engl J Med 348(23): 2285-
2293. 
Phanish, M. K., F. Heidebrecht, M. E. Nabi, N. Shah, I. Niculescu-Duvaz and M. E. Dockrell 
(2015). "The Regulation of TGFbeta1 Induced Fibronectin EDA Exon Alternative Splicing in 
Human Renal Proximal Tubule Epithelial Cells." J Cell Physiol 230(2): 286-295. 
Pichaiwong, W., K. L. Hudkins, T. Wietecha, T. Q. Nguyen, C. Tachaudomdach, W. Li, B. 
Askari, T. Kobayashi, K. D. O'Brien, J. W. Pippin, S. J. Shankland and C. E. Alpers (2013). 
"Reversibility of structural and functional damage in a model of advanced diabetic 
nephropathy." J Am Soc Nephrol 24(7): 1088-1102. 
Pickering, J. W. and Z. H. Endre (2012). "New metrics for assessing diagnostic potential of 
candidate biomarkers." Clin J Am Soc Nephrol 7(8): 1355-1364. 
Pisitkun, T., R. F. Shen and M. A. Knepper (2004). "Identification and proteomic profiling of 
exosomes in human urine." Proc Natl Acad Sci U S A 101(36): 13368-13373. 
Price, J. F., R. M. Reynolds, R. J. Mitchell, R. M. Williamson, F. G. Fowkes, I. J. Deary, A. J. 
Lee, B. M. Frier, P. C. Hayes and M. W. Strachan (2008). "The Edinburgh Type 2 Diabetes 
Study: study protocol." BMC Endocr Disord 8: 18. 
Qi, Z., H. Fujita, J. Jin, L. S. Davis, Y. Wang, A. B. Fogo and M. D. Breyer (2005). 
"Characterization of susceptibility of inbred mouse strains to diabetic nephropathy." 
Diabetes 54(9): 2628-2637. 
Raila, J., A. Henze, J. Spranger, M. Mohlig, A. F. Pfeiffer and F. J. Schweigert (2007). 
"Microalbuminuria is a major determinant of elevated plasma retinol-binding protein 4 in 
type 2 diabetic patients." Kidney Int 72(4): 505-511. 
Raimondo, F., S. Corbetta, L. Morosi, C. Chinello, E. Gianazza, G. Castoldi, C. Di Gioia, C. 
Bombardi, A. Stella, C. Battaglia, C. Bianchi, F. Magni and M. Pitto (2013). "Urinary 
exosomes and diabetic nephropathy: a proteomic approach." Mol Biosyst 9(6): 1139-1146. 
Ramachandran, P., A. Pellicoro, M. A. Vernon, L. Boulter, R. L. Aucott, A. Ali, S. N. Hartland, 
V. K. Snowdon, A. Cappon, T. T. Gordon-Walker, M. J. Williams, D. R. Dunbar, J. R. Manning, 
296 
N. van Rooijen, J. A. Fallowfield, S. J. Forbes and J. P. Iredale (2012). "Differential Ly-6C 
expression identifies the recruited macrophage phenotype, which orchestrates the 
regression of murine liver fibrosis." Proc Natl Acad Sci U S A 109(46): E3186-3195. 
Rappsilber, J., Y. Ishihama and M. Mann (2003). "Stop and go extraction tips for matrix-
assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in 
proteomics." Anal Chem 75(3): 663-670. 
Reidy, K., H. M. Kang, T. Hostetter and K. Susztak (2014). "Molecular mechanisms of 
diabetic kidney disease." J Clin Invest 124(6): 2333-2340. 
Retnakaran, R., C. A. Cull, K. I. Thorne, A. I. Adler, R. R. Holman and U. S. Group (2006). "Risk 
factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74." 
Diabetes 55(6): 1832-1839. 
Rouillon, J., A. Zocevic, T. Leger, C. Garcia, J. M. Camadro, B. Udd, B. Wong, L. Servais, T. 
Voit and F. Svinartchouk (2014). "Proteomics profiling of urine reveals specific titin 
fragments as biomarkers of Duchenne muscular dystrophy." Neuromuscul Disord 24(7): 
563-573. 
Salih, M., R. A. Fenton, J. Knipscheer, J. W. Janssen, M. S. Vredenbregt-van den Berg, G. 
Jenster, R. Zietse and E. J. Hoorn (2016). "An Immunoassay for Urinary Extracellular 
Vesicles." Am J Physiol Renal Physiol: ajprenal 00463 02015. 
Salih, M., R. Zietse and E. J. Hoorn (2014). "Urinary extracellular vesicles and the kidney: 
biomarkers and beyond." Am J Physiol Renal Physiol 306(11): F1251-1259. 
Satoh-Asahara, N., T. Suganami, T. Majima, K. Kotani, Y. Kato, R. Araki, K. Koyama, T. 
Okajima, M. Tanabe, M. Oishi, A. Himeno, S. Kono, A. Sugawara, M. Hattori, Y. Ogawa, A. 
Shimatsu, O. Japan and G. Metabolic Syndrome Study (2011). "Urinary cystatin C as a 
potential risk marker for cardiovascular disease and chronic kidney disease in patients with 
obesity and metabolic syndrome." Clin J Am Soc Nephrol 6(2): 265-273. 
Schanstra, J. P., P. Zurbig, A. Alkhalaf, A. Argiles, S. J. Bakker, J. Beige, H. J. Bilo, C. 
Chatzikyrkou, M. Dakna, J. Dawson, C. Delles, H. Haller, M. Haubitz, H. Husi, J. Jankowski, G. 
Jerums, N. Kleefstra, T. Kuznetsova, D. M. Maahs, J. Menne, W. Mullen, A. Ortiz, F. Persson, 
P. Rossing, P. Ruggenenti, I. Rychlik, A. L. Serra, J. Siwy, J. Snell-Bergeon, G. Spasovski, J. A. 
Staessen, A. Vlahou, H. Mischak and R. Vanholder (2015). "Diagnosis and Prediction of CKD 
Progression by Assessment of Urinary Peptides." J Am Soc Nephrol 26(8): 1999-2010. 
Schlatzer, D., D. M. Maahs, M. R. Chance, J. E. Dazard, X. Li, F. Hazlett, M. Rewers and J. K. 
Snell-Bergeon (2012). "Novel urinary protein biomarkers predicting the development of 
microalbuminuria and renal function decline in type 1 diabetes." Diabetes Care 35(3): 549-
555. 
Schlatzer, D. M., J. E. Dazard, M. Dharsee, R. M. Ewing, S. Ilchenko, I. Stewart, G. Christ and 
M. R. Chance (2009). "Urinary protein profiles in a rat model for diabetic complications." 
Mol Cell Proteomics 8(9): 2145-2158. 
Scilabra, S. D., L. Troeberg, K. Yamamoto, H. Emonard, I. Thogersen, J. J. Enghild, D. K. 
Strickland and H. Nagase (2013). "Differential regulation of extracellular tissue inhibitor of 
metalloproteinases-3 levels by cell membrane-bound and shed low density lipoprotein 
receptor-related protein 1." J Biol Chem 288(1): 332-342. 
Secher, A., C. D. Kelstrup, K. W. Conde-Frieboes, C. Pyke, K. Raun, B. S. Wulff and J. V. Olsen 
(2016). "Analytic framework for peptidomics applied to large-scale neuropeptide 
identification." Nat Commun 7: 11436. 
Sekulic, M. and S. Pichler Sekulic (2013). "A compendium of urinary biomarkers indicative of 
glomerular podocytopathy." Patholog Res Int 2013: 782395. 
Sheen, Y. J. and W. H. Sheu (2014). "Risks of rapid decline renal function in patients with 
type 2 diabetes." World J Diabetes 5(6): 835-846. 
297 
Shlipak, M. G., R. Katz, B. Kestenbaum, D. Siscovick, L. Fried, A. Newman, D. Rifkin and M. J. 
Sarnak (2009). "Rapid decline of kidney function increases cardiovascular risk in the 
elderly." J Am Soc Nephrol 20(12): 2625-2630. 
Siwy, J., C. Zoja, J. Klein, A. Benigni, W. Mullen, B. Mayer, H. Mischak, J. Jankowski, R. 
Stevens, A. Vlahou, S. Kossida, P. Perco and F. H. Bahlmann (2012). "Evaluation of the 
Zucker diabetic fatty (ZDF) rat as a model for human disease based on urinary peptidomic 
profiles." PLoS One 7(12): e51334. 
Slyne, J., C. Slattery, T. McMorrow and M. P. Ryan (2015). "New developments concerning 
the proximal tubule in diabetic nephropathy: in vitro models and mechanisms." Nephrol 
Dial Transplant 30 Suppl 4: iv60-67. 
Stevens, M. and S. Oltean (2016). "Alternative Splicing in CKD." J Am Soc Nephrol 27(6): 
1596-1603. 
Stevens, P. E., A. Levin and M. Kidney Disease: Improving Global Outcomes Chronic Kidney 
Disease Guideline Development Work Group (2013). "Evaluation and management of 
chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 
clinical practice guideline." Ann Intern Med 158(11): 825-830. 
Suarez-Pinzon, W. L. and A. Rabinovitch (2008). "Combination therapy with epidermal 
growth factor and gastrin delays autoimmune diabetes recurrence in nonobese diabetic 
mice transplanted with syngeneic islets." Transplant Proc 40(2): 529-532. 
Suarez-Pinzon, W. L., Y. Yan, R. Power, S. J. Brand and A. Rabinovitch (2005). "Combination 
therapy with epidermal growth factor and gastrin increases beta-cell mass and reverses 
hyperglycemia in diabetic NOD mice." Diabetes 54(9): 2596-2601. 
Sun, A. L., J. T. Deng, G. J. Guan, S. H. Chen, Y. T. Liu, J. Cheng, Z. W. Li, X. H. Zhuang, F. D. 
Sun and H. P. Deng (2012). "Dipeptidyl peptidase-IV is a potential molecular biomarker in 
diabetic kidney disease." Diab Vasc Dis Res 9(4): 301-308. 
Sun, S. Z., Y. Wang, Q. Li, Y. J. Tian, M. H. Liu and Y. H. Yu (2006). "Effects of benazepril on 
renal function and kidney expression of matrix metalloproteinase-2 and tissue inhibitor of 
metalloproteinase-2 in diabetic rats." Chin Med J (Engl) 119(10): 814-821. 
Szklarczyk, D., A. Franceschini, S. Wyder, K. Forslund, D. Heller, J. Huerta-Cepas, M. 
Simonovic, A. Roth, A. Santos, K. P. Tsafou, M. Kuhn, P. Bork, L. J. Jensen and C. von Mering 
(2015). "STRING v10: protein-protein interaction networks, integrated over the tree of life." 
Nucleic Acids Res 43(Database issue): D447-452. 
Takamiya, Y., K. Fukami, S. Yamagishi, Y. Kaida, Y. Nakayama, N. Obara, R. Iwatani, R. Ando, 
K. Koike, T. Matsui, Y. Nishino, S. Ueda, M. E. Cooper and S. Okuda (2013). "Experimental 
diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice." Nephrol 
Dial Transplant 28(1): 55-62. 
Tapmeier, T. T., K. L. Brown, Z. Tang, S. H. Sacks, N. S. Sheerin and W. Wong (2008). 
"Reimplantation of the ureter after unilateral ureteral obstruction provides a model that 
allows functional evaluation." Kidney Int 73(7): 885-889. 
ter Meulen, C. G., H. J. Bilo, G. J. van Kamp, R. O. Gans and A. J. Donker (1994). "Urinary 
epidermal growth factor excretion is correlated to renal function loss per se and not to the 
degree of diabetic renal failure." Neth J Med 44(1): 12-17. 
Tervaert, T. W., A. L. Mooyaart, K. Amann, A. H. Cohen, H. T. Cook, C. B. Drachenberg, F. 
Ferrario, A. B. Fogo, M. Haas, E. de Heer, K. Joh, L. H. Noel, J. Radhakrishnan, S. V. Seshan, I. 
M. Bajema, J. A. Bruijn and S. Renal Pathology (2010). "Pathologic classification of diabetic 
nephropathy." J Am Soc Nephrol 21(4): 556-563. 
Tesch, G. H. (2010). "Macrophages and diabetic nephropathy." Semin Nephrol 30(3): 290-
301. 
298 
Thery, C., M. Ostrowski and E. Segura (2009). "Membrane vesicles as conveyors of immune 
responses." Nat Rev Immunol 9(8): 581-593. 
Thibodeau, J. F., C. E. Holterman, D. Burger, N. C. Read, T. L. Reudelhuber and C. R. Kennedy 
(2014). "A novel mouse model of advanced diabetic kidney disease." PLoS One 9(12): 
e113459. 
Thomas, M. C., M. E. Cooper and P. Zimmet (2016). "Changing epidemiology of type 2 
diabetes mellitus and associated chronic kidney disease." Nat Rev Nephrol 12(2): 73-81. 
Thrailkill, K. M., R. Clay Bunn and J. L. Fowlkes (2009). "Matrix metalloproteinases: their 
potential role in the pathogenesis of diabetic nephropathy." Endocrine 35(1): 1-10. 
Thrailkill, K. M., T. Nimmo, R. C. Bunn, G. E. Cockrell, C. S. Moreau, S. Mackintosh, R. D. 
Edmondson and J. L. Fowlkes (2009). "Microalbuminuria in type 1 diabetes is associated 
with enhanced excretion of the endocytic multiligand receptors megalin and cubilin." 
Diabetes Care 32(7): 1266-1268. 
Thulesen, J., P. E. Jorgensen, O. Torffvit, E. Nexo and S. S. Poulsen (1997). "Urinary excretion 
of epidermal growth factor and Tamm-Horsfall protein in three rat models with increased 
renal excretion of urine." Regul Pept 72(2-3): 179-186. 
Titan, S. M., J. M. Vieira, Jr., W. V. Dominguez, S. R. Moreira, A. B. Pereira, R. T. Barros and 
R. Zatz (2012). "Urinary MCP-1 and RBP: independent predictors of renal outcome in 
macroalbuminuric diabetic nephropathy." J Diabetes Complications 26(6): 546-553. 
Togashi, Y. and Y. Miyamoto (2013). "Urinary cystatin C as a biomarker for diabetic 
nephropathy and its immunohistochemical localization in kidney in Zucker diabetic fatty 
(ZDF) rats." Exp Toxicol Pathol 65(5): 615-622. 
Torffvit, O., P. E. Jorgensen, A. L. Kamper, N. H. Holstein-Rathlou, P. P. Leyssac, S. S. Poulsen 
and S. Strandgaard (1998). "Urinary excretion of Tamm-Horsfall protein and epidermal 
growth factor in chronic nephropathy." Nephron 79(2): 167-172. 
Trappenburg, M. C., M. van Schilfgaarde, F. C. Frerichs, H. M. Spronk, H. ten Cate, C. W. de 
Fijter, W. E. Terpstra and A. Leyte (2012). "Chronic renal failure is accompanied by 
endothelial activation and a large increase in microparticle numbers with reduced 
procoagulant capacity." Nephrol Dial Transplant 27(4): 1446-1453. 
Tse, G. H., C. J. Johnston, D. Kluth, M. Gray, D. Gray, J. Hughes and L. P. Marson (2015). 
"Intrarenal B Cell Cytokines Promote Transplant Fibrosis and Tubular Atrophy." Am J 
Transplant 15(12): 3067-3080. 
Tuttle, K. R., G. L. Bakris, R. W. Bilous, J. L. Chiang, I. H. de Boer, J. Goldstein-Fuchs, I. B. 
Hirsch, K. Kalantar-Zadeh, A. S. Narva, S. D. Navaneethan, J. J. Neumiller, U. D. Patel, R. E. 
Ratner, A. T. Whaley-Connell and M. E. Molitch (2014). "Diabetic kidney disease: a report 
from an ADA Consensus Conference." Diabetes Care 37(10): 2864-2883. 
Tyanova, S., T. Temu, P. Sinitcyn, A. Carlson, M. Y. Hein, T. Geiger, M. Mann and J. Cox 
(2016). "The Perseus computational platform for comprehensive analysis of (prote)omics 
data." Nat Methods. 
Urbanelli, L., A. Magini, S. Buratta, A. Brozzi, K. Sagini, A. Polchi, B. Tancini and C. Emiliani 
(2013). "Signaling pathways in exosomes biogenesis, secretion and fate." Genes (Basel) 
4(2): 152-170. 
van der Pol, E., F. A. Coumans, A. E. Grootemaat, C. Gardiner, I. L. Sargent, P. Harrison, A. 
Sturk, T. G. van Leeuwen and R. Nieuwland (2014). "Particle size distribution of exosomes 
and microvesicles determined by transmission electron microscopy, flow cytometry, 
nanoparticle tracking analysis, and resistive pulse sensing." J Thromb Haemost 12(7): 1182-
1192. 
Vittinghoff, E. and C. E. McCulloch (2007). "Relaxing the rule of ten events per variable in 
logistic and Cox regression." Am J Epidemiol 165(6): 710-718. 
299 
Wada, J. and H. Makino (2013). "Inflammation and the pathogenesis of diabetic 
nephropathy." Clin Sci (Lond) 124(3): 139-152. 
Wada, T. and M. Nangaku (2013). "Novel roles of complement in renal diseases and their 
therapeutic consequences." Kidney Int 84(3): 441-450. 
Wang, Z., K. Famulski, J. Lee, S. K. Das, X. Wang, P. Halloran, G. Y. Oudit and Z. Kassiri 
(2014). "TIMP2 and TIMP3 have divergent roles in early renal tubulointerstitial injury." 
Kidney Int 85(1): 82-93. 
Woroniecka, K. I., A. S. Park, D. Mohtat, D. B. Thomas, J. M. Pullman and K. Susztak (2011). 
"Transcriptome analysis of human diabetic kidney disease." Diabetes 60(9): 2354-2369. 
Xu, X., L. Xiao, P. Xiao, S. Yang, G. Chen, F. Liu, Y. S. Kanwar and L. Sun (2014). "A glimpse of 
matrix metalloproteinases in diabetic nephropathy." Curr Med Chem 21(28): 3244-3260. 
Yamamoto, K., G. Murphy and L. Troeberg (2015). "Extracellular regulation of 
metalloproteinases." Matrix Biol 44-46: 255-263. 
Zhang, J., L. Xin, B. Shan, W. Chen, M. Xie, D. Yuen, W. Zhang, Z. Zhang, G. A. Lajoie and B. 
Ma (2012). "PEAKS DB: de novo sequencing assisted database search for sensitive and 
accurate peptide identification." Mol Cell Proteomics 11(4): M111 010587. 
Zhang, Z. X., K. Shek, S. Wang, X. Huang, A. Lau, Z. Yin, H. Sun, W. Liu, B. Garcia, S. Rittling 
and A. M. Jevnikar (2010). "Osteopontin expressed in tubular epithelial cells regulates NK 
cell-mediated kidney ischemia reperfusion injury." J Immunol 185(2): 967-973. 
Zhao, H. J., S. Wang, H. Cheng, M. Z. Zhang, T. Takahashi, A. B. Fogo, M. D. Breyer and R. C. 
Harris (2006). "Endothelial nitric oxide synthase deficiency produces accelerated 
nephropathy in diabetic mice." J Am Soc Nephrol 17(10): 2664-2669. 
Zhao, L., F. Wu, L. Jin, T. Lu, L. Yang, X. Pan, C. Shao, X. Li and Z. Lin (2014). "Serum CXCL16 
as a novel marker of renal injury in type 2 diabetes mellitus." PLoS One 9(1): e87786. 
Zhou, H., P. S. Yuen, T. Pisitkun, P. A. Gonzales, H. Yasuda, J. W. Dear, P. Gross, M. A. 
Knepper and R. A. Star (2006). "Collection, storage, preservation, and normalization of 
human urinary exosomes for biomarker discovery." Kidney Int 69(8): 1471-1476. 
Zhou, Z., J. Qiu, W. Liu, Y. Zhou, R. M. Plocinik, H. Li, Q. Hu, G. Ghosh, J. A. Adams, M. G. 
Rosenfeld and X. D. Fu (2012). "The Akt-SRPK-SR axis constitutes a major pathway in 
transducing EGF signaling to regulate alternative splicing in the nucleus." Mol Cell 47(3): 
422-433. 
Zubiri, I., M. Posada-Ayala, A. Benito-Martin, A. S. Maroto, M. Martin-Lorenzo, P. Cannata-
Ortiz, F. de la Cuesta, L. Gonzalez-Calero, M. G. Barderas, B. Fernandez-Fernandez, A. Ortiz, 
F. Vivanco and G. Alvarez-Llamas (2015). "Kidney tissue proteomics reveals regucalcin 
downregulation in response to diabetic nephropathy with reflection in urinary exosomes." 
Transl Res 166(5): 474-484 e474. 
Zubiri, I., M. Posada-Ayala, A. Sanz-Maroto, E. Calvo, M. Martin-Lorenzo, L. Gonzalez-Calero, 
F. de la Cuesta, J. A. Lopez, B. Fernandez-Fernandez, A. Ortiz, F. Vivanco and G. Alvarez-
Llamas (2014). "Diabetic nephropathy induces changes in the proteome of human urinary 
exosomes as revealed by label-free comparative analysis." J Proteomics 96: 92-102. 
Zurbig, P., G. Jerums, P. Hovind, R. J. Macisaac, H. Mischak, S. E. Nielsen, S. 
Panagiotopoulos, F. Persson and P. Rossing (2012). "Urinary proteomics for early diagnosis 



















ii. Genes upregulated specifically during injury 
phase in the Cyp1a1mRen2 reversal model 
The list has been published(Conway, Betz et al. 2014) and is available online at: 
http://onlinelibrary.wiley.com/doi/10.1111/nep.12335/suppinfo 
iii. Genes upregulated during the injury and reversal 
phase in the Cyp1a1mRen2 reversal model 
The list has been published (Conway, Betz et al. 2014) and is available online at: 
http://onlinelibrary.wiley.com/doi/10.1111/nep.12335/suppinfo 
 
iv. Urinary Peptides significantly changed in 
precursor peak intensities between baseline and 
injury phase and injury and reversal phase in the 
Cyp1a1mRen2 reversal model 
Mean intensity per group, p-value between two respective groups, peptide 
sequence are provided. The group indicates the significance between baseline and 
injury and between injury and reversal phase. The respective numbers per group 
are given in the table. 
group injury to baseline reversal to injury 
number of 
peptides 
1 increase unchanged 29 
2 increase decrease 26 
3 decrease unchanged 120 
4 decrease increase 13 
5 increase increase 3 
6 decrease decrease 3 
7 unchanged increase 47 
























SPVASVESASGEVLHSPK P24090 Ahsg Alpha-2-HS-glycoprotein 0.00025 0 0.978874008 1.79E+06 1.92E+09 1.62E+09 1
SVESASGEVLHSPK P24090 Ahsg Alpha-2-HS-glycoprotein 0.032904762 0.010151899 0.582085926 4.91E+05 4.80E+08 2.09E+08 1
VASVESASGEVLHSPK P24090 Ahsg Alpha-2-HS-glycoprotein 0.015089552 0.007934211 0.732908629 0.00E+00 7.10E+08 2.47E+08 1
AEFQPLVEEPK P02770 Alb Serum albumin 0.00032 0 0.808848341 3.08E+06 1.71E+09 1.32E+09 1
ATIDQNLEDLR P02651 Apoa4 Apolipoprotein A-IV 0.000210526 0.003640625 0.968861682 7.11E+05 2.06E+09 6.11E+08 1
NLAPLVEDVQSK P02651 Apoa4 Apolipoprotein A-IV 0 9.38E-05 0.121588889 0.00E+00 5.13E+09 9.27E+08 1
EDVPAADLSDQVPDTDSETR M0RBJ7 C3 0.000227273 0.028457143 0.241641278 0.00E+00 1.49E+09 1.66E+08 1
SEETKQNEGFSLTAK M0RBJ7 C3 Complement C3 0 6.67E-05 0.293689888 9.00E+05 4.58E+09 7.93E+08 1
TLDPEHLGQGGVQR M0RBJ7 C3 0 5.00E-04 0.24688835 0.00E+00 1.64E+09 3.77E+08 1
TLDPEHLGQGGVQREDVPAADLS M0RBJ7 C3 0 0.016604396 0.190298817 0.00E+00 2.00E+09 5.31E+08 1
TENYEEQFEMFK Q62930 C9 Complement component C9 0.029024691 0 0.431849265 0.00E+00 2.32E+09 3.86E+09 1
SLLNSLEEAK P05371 Clu Clusterin 0.003565217 6.45E-05 0.832206857 2.60E+06 1.87E+09 9.91E+08 1
SLLNSLEEAKK P05371 Clu Clusterin 0.000238095 0.000225 0.675897119 2.60E+06 5.19E+09 7.66E+08 1
ILGSDVQQIAVT Q01177 Plg Plasminogen 0 0.000509804 0.739911392 0.00E+00 1.59E+09 4.41E+08 1
ILGSDVQQIAVTK Q01177 Plg T 0 0 0.190354167 0.00E+00 1.28E+10 2.45E+09 1
LKEAQLPVIENK Q01177 Plg Plasminogen 0.000710526 0.019483871 0.395829588 0.00E+00 9.95E+08 1.97E+08 1
LVLEPNDADIALLK Q01177 Plg Plasminogen 0.000125 0.012870588 0.065184834 0.00E+00 1.18E+09 2.59E+08 1
VLEPNDADIAL Q01177 Plg Plasminogen 0.000333333 0.007527778 0.247891304 1.19E+06 1.40E+09 4.48E+08 1
VLEPNDADIALL Q01177 Plg Plasminogen 0.000527778 0.001 0.437732639 0.00E+00 8.33E+08 4.51E+08 1
VLEPNDADIALLK Q01177 Plg Plasminogen 0.000344828 0.026058252 0.081465217 1.72E+07 5.64E+09 8.43E+08 1
IVESETQSPLFVGK P17475 Serpina1 Alpha-1-antiproteinase 0.003959184 0.000111111 0.812716895 1.27E+07 2.04E+09 1.77E+09 1
LYQAEAFVADFK P05545 Serpina3k Serine protease inhibitor A3K 0.015897059 0.034517857 0.490461412 0.00E+00 9.56E+08 2.86E+08 1
DGILGRDTLPHEDQGKGR P05545 Serpina3k Serine protease inhibitor A3K 0 0.000574074 0.413306422 9.21E+07 7.41E+09 3.61E+09 1
FIDKEQPILSEFQEK P05544 Serpina3k Serine protease inhibitor A3K 0.000235294 0.047635593 0.5111504 2.08E+07 2.20E+09 1.90E+09 1
IDELYLPK P09006 Serpina3n Serine protease inhibitor A3N 0.026948052 0.004942029 0.919797325 0.00E+00 1.47E+09 2.34E+08 1
ATEEDVLEQKVPEATNRR Q5M7T5 Serpinc1 0.004377358 0.000205128 0.737663706 0.00E+00 9.02E+08 7.47E+08 1
LGNQDLGDHATLK Q68FT8 Serpinf2 0.002837209 0.008636364 0.731014085 3.45E+05 1.11E+09 2.77E+08 1
DTGESGVDLADRLDLVEK Q08420 Sod3 Extracellular superoxide dismutase [Cu-Zn] 0.000424242 0.019431579 0.146329932 0.00E+00 8.69E+08 2.07E+08 1
DAVATWLKPDPSQK P08721 Spp1 Osteopontin 0.000133333 0.008641026 0.089618257 0.00E+00 1.05E+09 2.16E+08 1
AKPALDDLGQGL P04639 Apoa1 Apolipoprotein A-I 0.001853659 99 0.002411765 0.00E+00 1.41E+09 1.59E+06 2
LTEIKNHPTL P04639 Apoa1 Apolipoprotein A-I 0.008737705 0.578393293 0.007615385 0.00E+00 9.84E+08 1.14E+07 2
NLEKETDWLRNE P04639 Apoa1 Apolipoprotein A-I 0.004230769 0.562376766 0 0.00E+00 5.50E+08 2.22E+07 2
DEFQEKWNEEVE P04639 Apoa1 Apolipoprotein A-I 0.040522727 0.74486783 0.006787879 0.00E+00 4.23E+08 2.18E+07 2
DEPQSQWDRVKD P04639 Apoa1 Apolipoprotein A-I 0.030414634 0.46570674 0.005821429 2.98E+06 9.86E+08 2.66E+06 2
HLDEFQEKWNEE P04639 Apoa1 Apolipoprotein A-I 0 0.578737762 0.003857143 0.00E+00 2.42E+09 1.46E+08 2
NHPTLIEYHTK P04639 Apoa1 Apolipoprotein A-I 0.014515152 0.971180685 0.009 0.00E+00 6.13E+08 5.03E+07 2
LEPLGTELHK P04639 Apoa1 Apolipoprotein A-I 0.006517241 0.866504225 0.012890625 3.84E+06 1.60E+09 4.12E+07 2
DSGDVESHLSF P02651 Apoa4 Apolipoprotein A-IV 0.033253012 0.613960813 0.006034483 0.00E+00 5.65E+08 9.44E+06 2
DDPGSSALLDTVQEHL G3V8D4 Apoc2 0.016828571 0.734637046 0.0095 0.00E+00 7.33E+08 3.86E+07 2
DEGEGSLLLGSMQGYMEQASK P06759 Apoc3 Apolipoprotein C-III 0.005875 0.864176966 0.009095238 0.00E+00 4.61E+08 5.52E+07 2























SSPTVFRL M0RBJ7 C3 Complement C3 0.003901961 99 0.003954545 0.00E+00 1.06E+09 0.00E+00 2
TLDPEHLGQGGVQRE M0RBJ7 C3 0.011435484 0.21417734 0.049186047 2.65E+05 5.57E+08 9.46E+07 2
TLDPEHLGQGGVQRED M0RBJ7 C3 0 0.079917293 0.044403727 1.38E+06 2.20E+09 1.56E+08 2
TLDPEHLGQGGVQREDVPAADLSD M0RBJ7 C3 0.000322581 0.58527931 0.0161 0.00E+00 9.18E+08 1.46E+08 2
DNELQELSTQGSR P05371 Clu Clusterin 0.020520548 0.281612565 0.016494505 2.28E+06 2.13E+09 4.40E+06 2
DTGTTSEFIEAGGDIR F7EUB6 Fga Fibrinogen alpha chain 0.000648649 0.931207082 0.010490196 0.00E+00 7.69E+08 2.70E+07 2
DNSDRPPLQEGALPQ Q99PS8 Hrg Histidine-rich glycoprotein 0 0.931023622 0.030625 0.00E+00 2.84E+09 2.43E+07 2
DNSDRPPLQEGALPQM Q99PS8 Hrg Histidine-rich glycoprotein 0 0.149101266 0.007028571 0.00E+00 2.86E+09 8.00E+07 2
DGILGRDTLPHEDQG P05545 Serpina3k Serine protease inhibitor A3K 0.011253968 0.683910547 0.00988 0.00E+00 5.83E+08 7.10E+07 2
LQVLAEFQEK P09006 Serpina3n Serine protease inhibitor A3N 0.005894737 0 0.001365854 2.73E+07 2.65E+10 1.51E+10 2
DLPGQQPVSEQAQQKLPPL Q68FT8 Serpinf2 0.026855263 0.550759171 0.006911765 0.00E+00 6.12E+08 9.85E+07 2
SQESDEAIKVIPVAQR P08721 Spp1 Osteopontin 0.000974359 0.45323506 0.047957576 1.06E+07 1.87E+09 2.40E+08 2
GLQPDPNGGQIGV G3V947 Vcsa1 SMR1 protein 0.005589041 0 0.04928655 2.54E+07 2.81E+08 1.17E+06 2
DGVLDSVTDQDSKDSTYSM P01836 Ig kappa chain C region, A allele 0.006348993 0 0.018938144 1.96E+07 2.29E+07 0.00E+00 2
DHVGEAIREK Q6AYQ2 Akr1c21 Aldo-keto reductase family 1 member C21 0.03044 0.009326667 99 3.12E+06 0.00E+00 0.00E+00 3
EAPVASSEQSVAVKE Q05175 Basp1 Brain acid soluble protein 1 0.00995092 0.005083969 99 1.13E+07 0.00E+00 0.00E+00 3
DLEDVAGHGGR B4F7A5 Cd99 0.011680473 0.004722222 99 1.42E+07 0.00E+00 0.00E+00 3
DRDLEDVAGHGGR B4F7A5 Cd99 0 0 0.752125155 7.63E+07 1.13E+07 2.81E+06 3
SITGPGADKPPVG Q9R0T4 Cdh1 Cadherin-1 0 0 99 2.85E+07 0.00E+00 0.00E+00 3
DADLEPAFR G3V7L4 Cdh16 0.015583333 0.004867188 99 8.77E+06 0.00E+00 0.00E+00 3
TDADLEPAFR G3V7L4 Cdh16 0.016132597 0.005037594 99 2.24E+07 0.00E+00 0.00E+00 3
SQADFDKAAEEVK P11030 Dbi Acyl-CoA-binding protein 0.0001875 0.001270833 0.618698571 3.27E+07 1.96E+06 1.81E+06 3
ERLITEGVD F1M959 Egf 0 0 99 7.70E+07 0.00E+00 5.32E+05 3
HMHFDGTDYKT F1M959 Egf Pro-epidermal growth factor 4.65E-05 0 99 8.06E+07 1.60E+06 0.00E+00 3
ALDYDPVESK F1M959 Egf Pro-epidermal growth factor 0.033769608 0.001607843 0.319774194 3.58E+07 2.03E+07 6.52E+05 3
EGLAVDWIGR F1M959 Egf Pro-epidermal growth factor 0 0 0.895002033 1.02E+08 0.00E+00 1.51E+07 3
RIYWTDSGK F1M959 Egf Pro-epidermal growth factor 3.51E-05 0.003512821 0.936175153 1.97E+07 0.00E+00 1.16E+07 3
TPEGLAVDWIGR F1M959 Egf Pro-epidermal growth factor 2.86E-05 0.003855932 0.262608911 1.07E+08 2.17E+06 4.78E+07 3
HMHFDGTDYK F1M959 Egf Pro-epidermal growth factor 0 0.000827586 0.51575817 1.53E+08 4.69E+07 9.29E+07 3
DNVGTESTKPQSQEAQDGLR Q04807 Glycam1 Glycosylation-dependent cell adhesion molecule 1 0.003731884 9.26E-05 0.238108642 2.37E+07 1.43E+07 1.71E+05 3
DIDSINEELQ Q62781 Kap Kidney androgen-regulated protein 0.011637427 0.004464 99 6.09E+06 0.00E+00 0.00E+00 3
SLDIDSINEELQ Q62781 Kap Kidney androgen-regulated protein 0 0 0.526435484 3.81E+08 4.85E+06 3.22E+07 3
SPENSQEQPQQTNPEEKPPAPK D4A0S3 LOC100365252 Submandibular gland secretory Glx-rich protein CA 5.00E-05 0 99 2.79E+07 0.00E+00 1.25E+05 3
NNMVCAGFLEGGKDS D4A5M0 LOC100366131 0.011959538 0.001625 0.879969795 1.12E+09 4.26E+07 7.73E+07 3
REKIEENGSMR P02761 LOC100909412 Major urinary protein 0.016763736 0.029762431 0.484551155 1.06E+07 1.05E+06 2.41E+06 3
DRFTGSGSGTDFT F1LZH0 LOC100912707 0.038307692 0.011279221 99 1.39E+07 0.00E+00 2.54E+06 3
DDVDVGEQQKDISEINS Q64230 Mep1a Meprin A subunit alpha 0.001605263 0.009708609 0.857281849 3.82E+07 1.86E+06 5.40E+06 3
EREIQNAGDQAQENR F1M7H2 Pigr Polymeric immunoglobulin receptor 0.006317568 0.001221053 99 2.45E+06 0.00E+00 0.00E+00 3
EVSQVPEFPNDTH F1M7H2 Pigr Polymeric immunoglobulin receptor 0.00696 0.000405063 0.18525228 1.44E+07 5.92E+06 0.00E+00 3
ADEREIQNAGDQAQENR F1M7H2 Pigr Polymeric immunoglobulin receptor 0.003318182 9.62E-05 0.229246851 1.47E+07 1.37E+07 6.30E+05 3























EVEQLILHE Q3KR76 Plau Urokinase-type plasminogen activator 0.000526316 0.00028169 0.543976994 1.28E+07 2.67E+06 3.81E+06 3
EDFAQELVECKSSR D3ZLD7 Ppp2r3a 0.00076699 0.000487805 0.69874328 8.13E+08 5.45E+06 9.60E+06 3
DQELTITSEAIR E9PT75 Prp2l1 7.81E-05 0 99 3.46E+07 2.88E+06 0.00E+00 3
DQELTLSSQPHG E9PT75 Prp2l1 0.007072368 0.003431034 99 9.43E+06 0.00E+00 0.00E+00 3
HEVTGPPLGHGQVH E9PT75 Prp2l1 0.013446328 0.003967213 99 3.92E+06 0.00E+00 0.00E+00 3
TPDKIYLH E9PT75 Prp2l1 0.004545455 0.001119565 99 1.32E+07 0.00E+00 0.00E+00 3
NENFEEYLR P02696 Rbp1 Retinol-binding protein 1 0.018854054 0.004298387 99 4.88E+06 0.00E+00 0.00E+00 3
QRIDEFEAM E9PT65 Rdx Ezrin 4.26E-05 0.0021875 0.659042818 1.48E+07 0.00E+00 5.01E+06 3
GSGSGTDFTLTIDPVEA M0RCN6 RGD1563231 0.000554455 9.52E-05 99 1.25E+07 0.00E+00 0.00E+00 3
TFNDPNERIM D3ZS19 RGD1565709 0.010006173 0.000837209 0.460446309 2.93E+07 1.63E+07 5.37E+06 3
ETEVIDPQDLLEGR P34901 Sdc4 Syndecan-4 3.13E-05 1.00E-04 0.615182209 3.23E+07 5.90E+06 1.04E+07 3
DLSQFGQQRQ Q6P6X2 Semg1 Seminal vesicle secretory protein 2 0.008151899 0.001621359 99 8.10E+06 0.00E+00 0.00E+00 3
GFSQQTQQKG Q6P6X2 Semg1 Seminal vesicle secretory protein 2 0.023162304 0.002646018 0.315785558 3.52E+06 1.16E+06 1.28E+05 3
LKGGSEEAAEESIFMQ Q6P6X2 Semg1 Seminal vesicle secretory protein 2 0.007201299 0.047385787 0.723934469 9.67E+07 0.00E+00 6.87E+06 3
KGQVSQLKSQESQIKS Q6P6X2 Semg1 Seminal vesicle secretory protein 2 0.033802956 0.019576687 0.678199454 1.58E+07 6.32E+06 7.34E+06 3
TEGAAATAVTAALK P05545 Serpina3k Serine protease inhibitor A3K 4.35E-05 0.00550365 0.441181159 4.38E+07 0.00E+00 3.27E+07 3
DKNVVFSPL P05544 Serpina3k Serine protease inhibitor A3K 0.001092593 0.0004375 99 1.32E+07 0.00E+00 1.31E+06 3
DKNVVFSPLS P05544 Serpina3k Serine protease inhibitor A3K 0.00025 0.001223404 0.442846552 1.85E+07 0.00E+00 4.96E+06 3
NPDKNVVF P05544 Serpina3k Serine protease inhibitor A3K 4.00E-05 9.68E-05 0.51161465 3.53E+07 9.73E+06 1.31E+07 3
DGTLGRDTLSH P05544 Serpina3l Serine protease inhibitor A3L 0.00056 0.003941667 0.539294299 1.31E+07 0.00E+00 2.77E+06 3
DLSPEEIQLR O70377 Snap23 Synaptosomal-associated protein 23 3.03E-05 0 0.39269434 2.70E+07 0.00E+00 1.04E+06 3
DELVRDKPY P02783 Svs4 Seminal vesicle secretory protein 4 0.000256098 0.000105263 99 3.81E+06 0.00E+00 4.80E+05 3
EEASEEISSRR P02783 Svs4 Seminal vesicle secretory protein 4 0.002464 0.000107143 99 6.85E+07 9.36E+05 0.00E+00 3
EKYSQSEEVVSE P02783 Svs4 Seminal vesicle secretory protein 4 0.000234568 8.89E-05 99 9.61E+06 2.86E+06 0.00E+00 3
EKYSQSEEVVSESFAS P02783 Svs4 Seminal vesicle secretory protein 4 0.000144737 0.00327193 99 1.57E+07 0.00E+00 1.65E+06 3
EVVSESFASGPSSGSS P02783 Svs4 Seminal vesicle secretory protein 4 0.000303371 0.001609524 99 1.00E+07 0.00E+00 1.11E+06 3
GSFGEEASEEISSRR P02783 Svs4 Seminal vesicle secretory protein 4 0.000189873 0.000102041 99 3.31E+07 0.00E+00 0.00E+00 3
YSQSEEVVS P02783 Svs4 Seminal vesicle secretory protein 4 0.000298851 1.00E-04 99 8.58E+06 0.00E+00 0.00E+00 3
EKYSQSEEVVS P02783 Svs4 Seminal vesicle secretory protein 4 0 0 0.862645304 2.92E+08 0.00E+00 1.24E+07 3
SEEVVSESFASGPSSGSS P02783 Svs4 Seminal vesicle secretory protein 4 0.000253012 9.38E-05 0.490564648 6.92E+07 9.31E+06 1.96E+07 3
SSGGSNMEGESSYAK P02783 Svs4 Seminal vesicle secretory protein 4 0.004177305 0.008932886 0.609927746 9.19E+06 2.34E+05 2.58E+06 3
SSGGSNMEGESSYAKK P02783 Svs4 Seminal vesicle secretory protein 4 0.000114286 0.00149 0.829453502 1.29E+07 0.00E+00 3.07E+06 3
FGEEASEEISSR P02783 Svs4 Seminal vesicle secretory protein 4 0.012829545 0.004945736 0.894428571 2.27E+08 1.69E+08 9.41E+07 3
FGEEASEEISSRR P02783 Svs4 Seminal vesicle secretory protein 4 0.018919355 0.009809211 0.499151007 2.17E+08 4.92E+07 7.54E+07 3
GGSFGEEASEEISSR P02783 Svs4 Seminal vesicle secretory protein 4 0.013730337 0.000287879 0.759532436 6.27E+09 2.88E+09 2.07E+09 3
GSFGEEASEEISSR P02783 Svs4 Seminal vesicle secretory protein 4 2.78E-05 0 0.726443878 3.01E+08 5.63E+07 7.99E+07 3
SFGEEASEEISSR P02783 Svs4 Seminal vesicle secretory protein 4 5.26E-05 0 0.916955624 1.74E+08 4.26E+07 5.58E+07 3
SRFAQDVLN P02783 Svs4 Seminal vesicle secretory protein 4 0.000903846 0.005075758 0.329104803 3.69E+08 2.35E+07 2.75E+08 3
DPYSENMNLK P04812 Svs5 Seminal vesicle secretory protein 5 0.00055102 0.000279412 0.45374744 2.26E+07 5.23E+06 6.03E+06 3
EDPYSENMNLKI P04812 Svs5 Seminal vesicle secretory protein 5 0.000112676 0 99 3.13E+07 4.23E+06 0.00E+00 3























SEMSSTSSHFGLK P04812 Svs5 Seminal vesicle secretory protein 5 0.018456522 0.00159434 0.485327842 1.73E+07 8.47E+06 6.81E+06 3
DFSSESSEAK D3ZJA4 Svs6 0.003503704 9.80E-05 0.185752266 5.81E+06 1.04E+06 2.39E+06 3
SVIHEDVYE D3ZJA4 Svs6 0.000135135 0.000101695 0.393141777 1.45E+07 0.00E+00 2.74E+06 3
VIHEDVYEEKK D3ZJA4 Svs6 0.002515873 9.43E-05 0.296910515 4.32E+06 1.57E+06 2.06E+06 3
DFSSESSEAKIPKS D3ZJA4 Svs6 0 0 0.688172087 1.27E+08 1.41E+07 1.32E+07 3
VIHEDVYEEK D3ZJA4 Svs6 0.001890756 0.000493827 0.422234973 1.23E+07 1.06E+06 2.96E+06 3
DFSSESSEAKIPK D3ZJA4 Svs6 0.001557522 0.025202312 0.896052953 3.69E+08 2.48E+08 1.97E+08 3
SLSAGEIER D3ZJA4 Svs6 0.011290909 0.001454545 0.947951466 9.44E+07 4.61E+07 1.98E+07 3
DTDEEYLFR Q9ESG3 Tmem27 Collectrin 4.17E-05 0 99 2.09E+07 0.00E+00 0.00E+00 3
GNFIDQTRV P27590 Umod Uromodulin 0.002 0.036285714 0.873473461 7.85E+08 1.16E+08 8.16E+07 3
NFIDQTRV P27590 Umod Uromodulin 0.000541667 0.039072917 0.56384858 5.84E+08 2.83E+08 4.79E+08 3
VLNLGPITR P27590 Umod Uromodulin 0.00027907 0.006143885 0.100376068 3.84E+08 8.12E+07 1.83E+08 3
GFITGPPLVVQ G3V947 Vcsa1 SMR1 protein 0 9.09E-05 99 3.23E+07 0.00E+00 4.88E+06 3
GFITGPPLVVQG G3V947 Vcsa1 SMR1 protein 0 0 99 4.35E+07 0.00E+00 0.00E+00 3
GTTEYQYQW G3V947 Vcsa1 SMR1 protein 0.000536082 0.001131868 0.190677326 2.97E+07 2.65E+07 2.92E+06 3
ITGPPLVVQ G3V947 Vcsa1 SMR1 protein 0.001844828 0.000275362 0.569575301 2.94E+07 2.68E+07 1.62E+07 3
LQPDPNGGQIGVT G3V947 Vcsa1 SMR1 protein 0.003447761 0.021470238 0.392122411 9.74E+07 1.90E+07 7.41E+06 3
LTAPDPTPLS G3V947 Vcsa1 SMR1 protein 3.92E-05 0 99 1.37E+07 0.00E+00 0.00E+00 3
QLTAPDPTPL G3V947 Vcsa1 SMR1 protein 3.45E-05 0.000106383 0.176110063 6.85E+07 5.24E+06 1.72E+06 3
QWQLTAPDPTPLS G3V947 Vcsa1 SMR1 protein 3.70E-05 0.000104167 0.238237624 3.47E+07 3.42E+06 5.03E+06 3
TGPPLVVQGTTEYQ G3V947 Vcsa1 SMR1 protein 0 0 99 2.85E+07 0.00E+00 0.00E+00 3
TTATTQNSTDIFEGGG G3V947 Vcsa1 SMR1 protein 4.76E-05 0 99 1.72E+07 0.00E+00 0.00E+00 3
TTEYQYQWQLTAPDPTPLS G3V947 Vcsa1 SMR1 protein 3.28E-05 0 99 1.57E+07 0.00E+00 0.00E+00 3
WQLTAPDPTPLS G3V947 Vcsa1 SMR1 protein 3.85E-05 0 99 1.72E+07 0.00E+00 0.00E+00 3
YQWQLTAPDPTPLS G3V947 Vcsa1 SMR1 protein 6.35E-05 0.001663551 99 9.44E+06 0.00E+00 1.56E+06 3
FITGPPLVVQ G3V947 Vcsa1 SMR1 protein 0 0 0.743392677 2.33E+08 2.86E+07 1.53E+07 3
GTTEYQYQWQL G3V947 Vcsa1 SMR1 protein 0.000340659 0 0.190566372 5.77E+07 4.65E+07 6.70E+06 3
QLTAPDPTPLS G3V947 Vcsa1 SMR1 protein 0 0 0.528564743 6.44E+08 1.59E+07 1.53E+07 3
TTEYQYQWQ G3V947 Vcsa1 SMR1 protein 0.001491071 0 0.208225275 5.88E+07 5.71E+07 1.03E+07 3
DPSTLPHY G3V947 Vcsa1 SMR1 protein 4.44E-05 0.001144444 0.399324627 6.49E+08 1.22E+08 1.19E+08 3
DPSTLPHYL G3V947 Vcsa1 SMR1 protein 0.030651741 0.02247929 0.815157159 3.99E+08 1.96E+08 1.03E+08 3
DPSTLPHYLG G3V947 Vcsa1 SMR1 protein 4.17E-05 0.000103448 0.815950116 4.95E+09 4.60E+08 2.27E+09 3
FITGPPLVVQG G3V947 Vcsa1 SMR1 protein 0 0 0.539912037 3.83E+08 2.42E+07 8.14E+06 3
ITGPPLVVQG G3V947 Vcsa1 SMR1 protein 3.39E-05 0 0.196937322 7.21E+07 7.18E+07 1.43E+07 3
QDPSTLPHYLG G3V947 Vcsa1 SMR1 protein 4.08E-05 0.000702381 0.512053055 1.57E+08 1.27E+08 1.05E+08 3
TTEYQYQWQL G3V947 Vcsa1 SMR1 protein 0.000141026 0 0.470058236 9.22E+07 8.85E+07 1.50E+07 3
DGVLDSVTDQDSKD P01836 Ig kappa chain C region, A allele 3.33E-05 0 99 3.85E+07 0.00E+00 0.00E+00 3
DGVLDSVTDQDSKDS P01836 Ig kappa chain C region, A allele 0.001028302 0.002163636 0.390632887 1.23E+07 1.03E+07 8.64E+06 3
GNLDVAKL P02761 Major urinary protein 5.13E-05 0 99 1.92E+08 0.00E+00 0.00E+00 3
IDGSEQRDGVLDSVTDQDSKDSTY P01836 Ig kappa chain C region, A allele 6.45E-05 0.004284553 99 1.29E+07 0.00E+00 2.56E+06 3























STLSLTKVE P01836 Ig kappa chain C region, A allele 9.09E-05 0 99 2.58E+07 0.00E+00 0.00E+00 3
STLSLTKVEY P01836 Ig kappa chain C region, A allele 3.45E-05 0.015063291 0.371244618 1.14E+07 0.00E+00 4.31E+06 3
SVTDQDSKDSTYSMSSTL P01836 Ig kappa chain C region, A allele 9.23E-05 0 99 1.98E+07 1.39E+06 0.00E+00 3
SVTDQDSKDSTYSMSSTLS P01836 Ig kappa chain C region, A allele 4.00E-05 0.027775281 0.372011834 1.32E+07 0.00E+00 7.32E+06 3
TLSLTKVEY P01836 Ig kappa chain C region, A allele 3.77E-05 4.65E-05 99 2.86E+07 0.00E+00 5.23E+06 3
DGVLDSVTDQ P01836 Ig kappa chain C region, A allele 0 0.000811765 0.714710938 6.15E+07 1.30E+07 2.76E+07 3
DGVLDSVTDQDSKDSTY P01836 Ig kappa chain C region, A allele 0.000333333 0.03079235 0.72427668 1.20E+08 3.51E+07 1.02E+07 3
DGVLDSVTDQDSKDSTYS P01836 Ig kappa chain C region, A allele 0 0.000271429 0.379413655 9.69E+07 5.23E+07 6.42E+07 3
DGVLDSVTDQDSKDSTYSMS P01836 Ig kappa chain C region, A allele 0 0.000292308 0.895460446 1.24E+08 0.00E+00 2.39E+07 3
ERHNLYTCEVVHK P01836 Ig kappa chain C region, A allele 0.001201835 0.00769863 0.917093194 7.29E+06 9.73E+05 3.61E+06 3
IDGSEQRDGVLDSVTD P01836 Ig kappa chain C region, A allele 0 0.003840336 0.851379464 1.12E+08 0.00E+00 4.24E+07 3
GEACKALEGSVLSPGPAGDFPMA F1M8B2 Adad2 0.04850463 0.436078585 0.031227848 6.55E+07 5.97E+07 1.47E+08 4
SVIEMADLDGSK F1M959 Egf Pro-epidermal growth factor 0.045140845 0.548925 0.026986667 1.69E+07 8.13E+06 1.46E+08 4
IQTFQGDSDHNWK Q64230 Mep1a Meprin A subunit alpha 0.003053846 0.663195862 0.005981481 1.89E+07 1.13E+07 2.71E+08 4
KKIEGNWR P15399-2 Pbsn Probasin 0.000123288 0.694844648 0.031075 4.23E+07 2.65E+06 1.06E+08 4
GHLNFGLK Q6P6X2 Semg1 Seminal vesicle secretory protein 2 0.014497207 0.946996805 0.013815385 4.59E+07 3.37E+07 2.79E+08 4
KQFDDDDLSVQQK Q6P6X2 Semg1 Seminal vesicle secretory protein 2 0.001074766 0.15784669 0.048842697 3.68E+08 1.00E+08 6.10E+08 4
EDAQETDTSQQDQSPTYR P17475 Serpina1 Alpha-1-antiproteinase 0.000146667 0.4353 0.001435897 1.03E+08 3.19E+07 1.19E+09 4
ELFSELDER P05545 Serpina3k Serine protease inhibitor A3K 0.045221698 0.097092199 0.000307692 6.03E+07 1.45E+07 6.21E+08 4
TLASSNTDFALS P05544 Serpina3l Serine protease inhibitor A3L 0.000555556 0.787633172 0.007589286 2.79E+07 2.59E+07 2.73E+08 4
VLNLGPIT P27590 Umod Uromodulin 4.55E-05 0.620203438 0.030192308 3.19E+07 0.00E+00 9.94E+07 4
NLDWYQQK D3ZMS7 4.35E-05 0.896103261 0.013757576 8.22E+06 0.00E+00 2.16E+08 4
WKIDGSEQR P01836 Ig kappa chain C region, A allele 0 0.332874419 0.000896552 4.27E+07 1.61E+06 2.23E+08 4
DGVLDSVTDQDSK P01836 Ig kappa chain C region, A allele 0.000142857 0.313014528 0.013111111 2.09E+08 8.93E+07 6.37E+08 4
ASDSSINWNNLKG P12346 Tf Serotransferrin 0.004570423 4.17E-05 0 9.05E+05 1.51E+06 1.04E+09 5
SSTKDLLFR P12346 Tf Serotransferrin 0.044900474 0.000117647 9.09E-05 0.00E+00 1.33E+07 1.14E+09 5
STPTLTVFPPSTEELQGNK P20767 Ig lambda-2 chain C region 0.020673797 0.002603175 0.000518519 1.06E+06 4.27E+07 5.64E+08 5
GLQPDPNGGQIG G3V947 Vcsa1 SMR1 protein 0.007119205 0 0.025732143 5.55E+07 3.61E+07 0.00E+00 6
TEYQYQWQ G3V947 Vcsa1 SMR1 protein 0 0 0.028733871 7.45E+07 1.08E+07 0.00E+00 6
TEYQYQWQL G3V947 Vcsa1 SMR1 protein 0.001837607 0 0.012967742 1.11E+08 8.23E+07 0.00E+00 6
ETGLMAFTNLK P14046 A1i3 Alpha-1-inhibitor 3 99 0.007621622 0.004612245 0.00E+00 6.97E+07 2.21E+09 7
DKLVLATEKLEAEDR P01015 Agt Angiotensinogen 0.904315663 0.000297872 0.001181818 0.00E+00 5.37E+08 1.17E+09 7
LSTLLGAEANLGK P01015 Agt Angiotensinogen 99 0.026039604 0.023712329 0.00E+00 3.35E+08 7.68E+08 7
SLDLSTDPVLAAQK P01015 Agt Angiotensinogen 0.618752363 0.00052 0 4.87E+06 2.85E+08 1.81E+09 7
EAHKSEIAHRFK P02770 Alb Serum albumin 0.653332727 0.033645455 0.000785714 8.07E+04 4.21E+05 6.96E+08 7
FKDLGEQHF P02770 Alb Serum albumin 0.889361858 0 0.001194444 5.66E+05 3.85E+08 8.70E+09 7
QTALAELVK P02770 Alb Serum albumin 0.640332215 0.001 0.009965517 4.23E+06 1.77E+08 2.36E+09 7
FKDLGEQHFKG P02770 Alb Serum albumin 0.765244767 0 0 4.21E+06 4.36E+07 7.79E+09 7
SSPSIVLGQEQDTYGGGFDK P23680 Apcs Serum amyloid P-component 99 0.004823529 0.001809524 0.00E+00 4.23E+07 3.62E+08 7
GLSQSLSVQWDEK Q63678 Azgp1 Zinc-alpha-2-glycoprotein 0.854294469 0.000304348 0.001 1.17E+07 2.42E+08 9.53E+08 7























RVPVVTQGSDAQALTQDDGVAK M0RBJ7 C3 Complement C3 99 0.0036 0.005673077 0.00E+00 3.07E+08 8.75E+08 7
VLIEDGSGEAVLSRK M0RBJ7 C3 Complement C3 99 0.000785714 0.001421053 0.00E+00 5.35E+08 1.14E+09 7
GYTQQLAFK M0RBJ7 C3 Complement C3 0.85038009 0.000238095 0.00462 0.00E+00 3.92E+07 6.09E+08 7
SDVDEDIIPEEDIISR M0RBJ7 C3 Complement C3 0.131503497 0.000114286 0 1.11E+07 1.01E+10 1.65E+10 7
KALYSEYTDGTFTK G3V7K3 Cp Ceruloplasmin 99 0 0 0.00E+00 2.47E+09 6.55E+09 7
MFTTAPENVDKEDEDFQESNK G3V7K3 Cp Ceruloplasmin 0.927195479 0 0 0.00E+00 5.44E+08 5.98E+09 7
RDTANLFPHK G3V7K3 Cp Ceruloplasmin 99 0.028679245 0.002869565 0.00E+00 0.00E+00 1.75E+08 7
ALYSEYTDGTFTK G3V7K3 Cp Ceruloplasmin 0.812310734 0 0 3.24E+06 3.30E+09 5.07E+09 7
SSTVAPTLPGEVR G3V7K3 Cp Ceruloplasmin 0.563906504 0.01545977 0.007327273 5.96E+06 8.24E+07 2.49E+09 7
NTEPVMDSDGSFFMYSK P20761 Igh-1a Ig gamma-2B chain C region 99 0.000232558 0 0.00E+00 0.00E+00 1.18E+09 7
AREVAFDVEIPK B2RYM3 Itih1 99 3.85E-05 0 0.00E+00 1.33E+09 2.56E+09 7
EVQLVESGGGLVQPKG F1M5X4 LOC100362687 99 0.029850467 0.012532258 0.00E+00 6.84E+07 1.98E+08 7
YNAELESGNQFVLYR P01048 Map1 T-kininogen 1 0.355719072 0.019864583 0.001162162 2.03E+06 7.06E+07 5.55E+08 7
DGAETLYSFK P01048 Map1 T-kininogen 1 0.916773224 0 0.000217391 0.00E+00 1.27E+08 1.19E+09 7
SVDGKEDSIQELLR E9PST1 RGD1310507 99 0.010725 0.01580597 0.00E+00 6.53E+08 1.05E+09 7
SAILYFPK P17475 Serpina1 Alpha-1-antiproteinase 0.897899576 0.000490566 0.018695652 0.00E+00 4.11E+08 1.10E+09 7
SVKVPMMK P05544 Serpina3k Serine protease inhibitor A3K 0.055651786 0.000690909 0 2.60E+06 9.95E+06 9.59E+08 7
MQQVESSLQPETLK P05544 Serpina3k Serine protease inhibitor A3K 0.898764624 0.000311111 0.028792208 6.69E+06 4.15E+08 2.60E+09 7
MQQVESSLQPETLKK P05544 Serpina3k Serine protease inhibitor A3K 0.783331395 0 0.016632353 5.15E+06 1.12E+09 5.02E+09 7
EELSCSVLELK P05544 Serpina3k Serine protease inhibitor A3K 99 0.021092784 0.005215686 0.00E+00 9.75E+06 2.09E+08 7
IINDLRMPK P05544 Serpina3l Serine protease inhibitor A3L 99 0.046179487 0.036134146 0.00E+00 2.19E+08 4.49E+08 7
ALYQAEAFIADFK P05544 Serpina3l Serine protease inhibitor A3L 0.917272851 0.003727273 0.038604651 8.69E+05 4.70E+08 1.83E+09 7
EAFIADFKQPNEAK P05544 Serpina3l Serine protease inhibitor A3L 0.918166891 0.002344262 0.022142857 6.86E+06 2.11E+08 7.31E+08 7
FSISTDYSLK P05544 Serpina3l Serine protease inhibitor A3L 0.863599407 0 0 2.26E+06 5.99E+08 4.12E+09 7
KIDELYLPR F1LR92 Serpina3m Serine protease inhibitor A3M 99 0.004477612 0.002244444 0.00E+00 1.09E+09 1.88E+09 7
KLINDYVSK P09006 Serpina3n Serine protease inhibitor A3N 0.915229858 0.000162162 0.011491525 7.55E+05 4.88E+08 7.10E+08 7
GTDFQLNQLQGK P12346 Tf Serotransferrin 99 3.57E-05 0 0.00E+00 1.06E+08 1.23E+09 7
GTDFQLNQLQGKK P12346 Tf Serotransferrin 99 3.70E-05 0 0.00E+00 2.90E+07 1.81E+09 7
GYYAVAVVK P12346 Tf Serotransferrin 99 0 0 0.00E+00 1.50E+08 2.28E+09 7
KGTDFQLNQLQGKK P12346 Tf Serotransferrin 0.07507438 0 0 0.00E+00 3.34E+07 1.88E+09 7
SKDFQLFGSPLGK P12346 Tf Serotransferrin 0.609915385 0.000227273 0.000208333 1.01E+06 1.35E+09 3.47E+09 7
ASDSSINWNNLK P12346 Tf Serotransferrin 0.362038363 0 0 3.61E+06 1.01E+08 7.56E+09 7
DSAFGLLR P12346 Tf Serotransferrin 0.315169399 0.000243902 0.002162791 0.00E+00 1.81E+08 1.01E+09 7
KTADGSWEPFASGK P02767 Ttr Transthyretin 0.062665236 0 0 0.00E+00 2.33E+07 1.01E+10 7
TADGSWEPFASGK P02767 Ttr Transthyretin 0.080285714 0.000367347 0.001142857 0.00E+00 1.71E+07 7.20E+08 7
TAESGELHGLTTDEKFTEGVYR P02767 Ttr Transthyretin 99 0.020918367 0.011633333 0.00E+00 3.08E+07 1.83E+09 7
PPPPGPPPP O08816 Enah Neural Wiskott-Aldrich syndrome protein 0.812879688 0.000291667 0.00755 1.19E+07 7.87E+07 1.18E+06 8
SDRPPLQEGALPQM Q99PS8 Hrg Histidine-rich glycoprotein 0.092228571 0.036268421 0.001333333 1.65E+06 7.73E+08 0.00E+00 8
THEIGCPPPPEGKDNSDRPPLQ Q99PS8 Hrg Histidine-rich glycoprotein 0.263177143 0.02822905 0.012984127 1.61E+07 6.23E+08 0.00E+00 8
DIVENVDSLK F1LWZ1 LOC690507 0.970301688 0.022930233 0.027795082 4.01E+06 7.97E+07 0.00E+00 8























LQPLDFKENPEQS Q5M7T5 Serpinc1 0.131541667 0.000287671 0.025540541 3.84E+06 8.96E+07 0.00E+00 8
TEEDVLEQKVPEATNR Q5M7T5 Serpinc1 0.870838663 0.003983471 0.015894118 7.79E+07 9.58E+08 3.77E+07 8
DQDQEDSALLAL E9PU79 Spt1 0.535733475 0.001731481 0.030669173 1.00E+07 4.85E+07 2.91E+06 8
LGLQPDPNGGQIGVT G3V947 Vcsa1 SMR1 protein 0.161082192 0.006678322 0.012934426 1.53E+07 9.60E+08 2.80E+06 8
GLQPDPNGGQIGVT G3V947 Vcsa1 SMR1 protein 0.089519685 0 0.013273973 1.44E+08 4.13E+08 3.21E+06 8
QDPSTLPHY G3V947 Vcsa1 SMR1 protein 0.727851536 0.000368421 0.0015 6.48E+07 3.94E+08 2.87E+06 8
TAPDPTPLSNPPTQ G3V947 Vcsa1 SMR1 protein 0.401797561 9.84E-05 0.030813433 2.62E+07 2.63E+08 2.34E+06 8
TAPDPTPLSNPPTQL G3V947 Vcsa1 SMR1 protein 0.926967366 0.001034091 0.002428571 1.64E+07 3.31E+08 1.77E+06 8
v. List of the peptide sequences that were 
significantly different in precursor peak intensities 
between healthy volunteers and patients with DN  
Peptide sequence, gene symbol, protein name are provided p-value and mean 
intensity per group are provided. Only the significantly different peptides between 
healthy volunteers and patients with DN are listed.  
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AHCTF1 Protein ELYS YEVCQEMGLME 0.004735 4.57E+06 1.92E+09
AHSG Alpha-2-HS-glycoprotein;Alpha-2-HS-glycoprotein chain A;Alpha-2-HS-glycoprotein chain B MGVVSLGSPSGEVSHP 0.00025 9.66E+06 7.29E+08
AHSG Alpha-2-HS-glycoprotein;Alpha-2-HS-glycoprotein chain A;Alpha-2-HS-glycoprotein chain B MGVVSLGSPSGEVSHPR 0.000458 1.90E+08 1.87E+09
AHSG Alpha-2-HS-glycoprotein;Alpha-2-HS-glycoprotein chain A;Alpha-2-HS-glycoprotein chain B VVSLGSPSGEVSHPR 0.002404 7.25E+06 1.02E+09
AMBP Protein AMBP;Alpha-1-microglobulin;Inter-alpha-trypsin inhibitor light chain;Trypstatin ADRGECVPGEQEPEPILIPR 0.004658 6.23E+07 6.91E+08
AMBP Protein AMBP;Alpha-1-microglobulin;Inter-alpha-trypsin inhibitor light chain;Trypstatin ADRGECVPGEQEPEPILIPRV 0.007155 6.29E+07 2.01E+08
APOA1 Apolipoprotein A-I;Truncated apolipoprotein A-I DEPPQSPWDRVKDL 0.009811 1.32E+07 1.32E+09
APOA1 Apolipoprotein A-I;Truncated apolipoprotein A-I DEPPQSPWDRVKDLA 0.002366 4.69E+08 7.57E+08
APOA1 Apolipoprotein A-I;Truncated apolipoprotein A-I DEPPQSPWDRVKDLAT 0.00261 8.50E+07 3.86E+09
APOA1 Apolipoprotein A-I;Truncated apolipoprotein A-I HLAPYSDELR 0.003387 1.77E+08 7.05E+08
APOA1 Apolipoprotein A-I;Truncated apolipoprotein A-I LEALKENGGAR 0.004838 1.22E+07 1.33E+09
APOA1 Apolipoprotein A-I;Truncated apolipoprotein A-I LSALEEYTKK 0.000279 9.05E+07 1.67E+09
APOA1 Apolipoprotein A-I;Truncated apolipoprotein A-I LSALEEYTKKLNTQ 0.003014 6.56E+05 1.53E+09
APOA1 Apolipoprotein A-I;Truncated apolipoprotein A-I SALEEYTK 0.004739 6.07E+05 5.22E+08
APOA1 Apolipoprotein A-I;Truncated apolipoprotein A-I SALEEYTKK 0.006946 4.59E+06 1.77E+07
APOA2 Apolipoprotein A-II;Truncated apolipoprotein A-II EPCVESLVSQY 0.009767 4.08E+06 6.89E+07
APOA2 Apolipoprotein A-II;Truncated apolipoprotein A-II FVELGTQPATQ 0.0002 1.35E+07 1.94E+07
APOA2 Apolipoprotein A-II;Truncated apolipoprotein A-II QAKEPCVESLVSQY 0.000375 6.95E+06 4.50E+07
APOA4 Apolipoprotein A-IV ALVQQMEQL 0.000386 3.65E+06 3.02E+09
APOA4 Apolipoprotein A-IV EVSADQVATVMWD 0.000461 2.45E+07 2.65E+07
APOA4 Apolipoprotein A-IV FKEKESQDK 0.002313 3.48E+06 2.81E+09
APOA4 Apolipoprotein A-IV FSTFKEKESQDK 0.003844 1.36E+06 2.16E+09
APOA4 Apolipoprotein A-IV KVKIDQTVEEL 0.000272 9.74E+06 7.86E+07
APOA4 Apolipoprotein A-IV LGPHAGDVEGHLS 0.002635 1.37E+07 1.73E+07
APOA4 Apolipoprotein A-IV LGPHAGDVEGHLSF 0.002758 2.21E+06 9.29E+08
APOA4 Apolipoprotein A-IV NKALVQQMEQL 0.00289 8.14E+07 2.65E+08
APOA4 Apolipoprotein A-IV SLAELGGHLDQQVEEF 0.00442 3.63E+07 6.87E+08
APOA4 Apolipoprotein A-IV TFKEKESQDK 0.00542 1.32E+08 1.17E+09
APOA4 Apolipoprotein A-IV TLSLPELEQQQEQQQEQQQEQVQ 0.007826 6.61E+07 1.67E+09
APOA4 Apolipoprotein A-IV TLSLPELEQQQEQQQEQQQEQVQM 0.009604 1.93E+07 8.10E+08
APOC3 Apolipoprotein C-III WDLDPEVRPTSAVA 0.002431 1.33E+08 1.39E+08
B2M Beta-2-microglobulin;Beta-2-microglobulin form pI 5.3 NGERIEKVEHSDLSFSKDWS 0.0027 4.62E+06 1.96E+08
B2M Beta-2-microglobulin;Beta-2-microglobulin form pI 5.3 YVSGFHPSDIEVD 0.002823 5.42E+06 7.09E+07
CALR Calreticulin IHPEIDNPEYSPDPSIY 0.003527 6.10E+06 1.41E+07
CD99 CD99 antigen EGEEADAPGVIPGIVGAV 0.006513 2.83E+07 3.15E+07
CD99 CD99 antigen KEGEEADAPGVIPGIVGAV 0.007331 4.63E+06 2.56E+07
CD99 CD99 antigen KEGEEADAPGVIPGIVGAVV 0.007565 6.08E+07 7.96E+07
CDH1 Cadherin-1;E-Cad/CTF1;E-Cad/CTF2;E-Cad/CTF3 FSHAVSSNGNAVEDPMEIL 0.000281 1.55E+07 6.02E+07
CDH1 Cadherin-1;E-Cad/CTF1;E-Cad/CTF2;E-Cad/CTF3 KVTDADAPNTPAWEAVY 0.00821 4.14E+07 2.48E+08
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CDH11 Cadherin-11 AVDRDTNRPLEPPSEF 0.00963 7.17E+05 3.93E+08
CFB Complement factor B;Complement factor B Ba fragment;Complement factor B Bb fragment LSSLTETIEGVDAEDGHGPGEQ 6.08E-08 4.45E+06 1.34E+07
CFB Complement factor B;Complement factor B Ba fragment;Complement factor B Bb fragment LSSLTETIEGVDAEDGHGPGEQQ 0.000411 9.24E+06 2.53E+07
CFB Complement factor B;Complement factor B Ba fragment;Complement factor B Bb fragment LSSLTETIEGVDAEDGHGPGEQQK 0.002912 5.90E+06 2.46E+07
CFB Complement factor B;Complement factor B Ba fragment;Complement factor B Bb fragment LSSLTETIEGVDAEDGHGPGEQQKR 0.003297 8.28E+05 1.22E+08
CFD Complement factor D RAVPHPDSQPDTIDHDLL 0.00717 1.63E+07 1.56E+08
CLU Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin ASHTSDSDVPSGVTEVVVK 0.006086 4.05E+06 8.57E+06
CLU Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin ASHTSDSDVPSGVTEVVVKL 0.0078 2.25E+07 2.36E+08
CLU Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin FDSDPITVTVPVE 0.00811 1.56E+07 4.84E+07
CLU Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin FDSDPITVTVPVEVS 0.007204 5.84E+07 1.10E+08
CLU Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin FDSDPITVTVPVEVSR 0.007803 1.11E+07 2.39E+07
CLU Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin HTSDSDVPSGVTEVVVKL 0.008315 4.77E+06 1.07E+08
CLU Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin SDSDVPSGVTEVVVKL 0.000365 9.76E+06 2.64E+07
CLU Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin SHTSDSDVPSGVTEVVVK 0.00242 2.92E+07 5.17E+07
CLU Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin SHTSDSDVPSGVTEVVVKL 0.003227 1.02E+07 1.03E+07
CLU Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin TSDSDVPSGVTEVVVKL 0.004103 7.59E+06 7.91E+07
CLU Clusterin;Clusterin beta chain;Clusterin alpha chain;Clusterin TVASHTSDSDVPSGVTEVVVKL 0.007029 5.78E+07 6.37E+07
COL15A1 Collagen alpha-1(XV) chain;Endostatin GATETASQGHLDLTQL 0.000293 2.43E+07 2.86E+08
COL18A1 Collagen alpha-1(XVIII) chain;Endostatin DDILASPPRLPEPQPYPGAP 0.000377 1.63E+07 4.63E+08
COL18A1 Collagen alpha-1(XVIII) chain;Endostatin DDILASPPRLPEPQPYPGAPHHS 0.002648 1.68E+07 2.35E+07
COL18A1 Collagen alpha-1(XVIII) chain;Endostatin DDILASPPRLPEPQPYPGAPHHSS 0.002672 4.44E+06 7.12E+07
COL18A1 Collagen alpha-1(XVIII) chain;Endostatin ERISEEVGLLQ 0.00381 1.79E+07 3.58E+08
COL1A1 Collagen alpha-1(I) chain GDKGETGEQGDR 0.004643 2.77E+07 3.22E+08
CXCL16 C-X-C motif chemokine 16 EAGENQKQPEKNAGPTAR 0.000309 2.94E+08 3.71E+08
FETUB Fetuin-B FLEPMEEKL 0.0027 1.03E+08 8.31E+08
FGB Fibrinogen beta chain;Fibrinopeptide B;Fibrinogen beta chain DKKREEAPSLRPAPPPISGGGY 0.00509 1.93E+07 1.79E+08
GSN Gelsolin WVGTGASEAEKTGAQEL 0.006616 8.26E+07 2.27E+08
HLA-C Cw-1 alpha chain Color [DarkGray] 0.009893 2.80E+08 3.67E+08
IGF2 Insulin-like growth factor II;Insulin-like growth factor II;Insulin-like growth factor II Ala-25 Del;Preptin PAHGGAPPEMASN 2.7E-05 3.39E+08 7.39E+08
INS Insulin;Insulin B chain;Insulin A chain EAEDLQVGQVELGGGPGAGSLQ 0.000461 5.86E+08 4.77E+10
ITGA7 Integrin alpha-7;Integrin alpha-7 heavy chain;Integrin alpha-7 light chain;Integrin alpha-7 70 kDa form ELEPPEQQEPGERQEPSMSW 0.003973 2.86E+08 5.05E+08
ITIH2 Inter-alpha-trypsin inhibitor heavy chain H2 FEIPINGLSE 0.006861 4.24E+08 2.49E+09
KNG1 Kininogen-1;Kininogen-1 heavy chain;T-kinin;Bradykinin;Lysyl-bradykinin;Kininogen-1 light chain;Low molecular weight growth-promoting factorKRPPGFSPF 0.007539 9.57E+07 4.41E+08
KNG1 Kininogen-1;Kininogen-1 heavy chain;T-kinin;Bradykinin;Lysyl-bradykinin;Kininogen-1 light chain;Low molecular weight growth-promoting factorKRPPGFSPFR 0.008866 2.02E+08 3.76E+09
KNG1 Kininogen-1;Kininogen-1 heavy chain;T-kinin;Bradykinin;Lysyl-bradykinin;Kininogen-1 light chain;Low molecular weight growth-promoting factorRPPGFSPF 0.00899 2.16E+08 7.12E+09
KNG1 Kininogen-1;Kininogen-1 heavy chain;T-kinin;Bradykinin;Lysyl-bradykinin;Kininogen-1 light chain;Low molecular weight growth-promoting factorRPPGFSPFR 0.002593 3.31E+08 4.45E+08
LMAN2 Vesicular integral-membrane protein VIP36 FGASAGTGDLSDNHDIIS 4.23E-06 1.25E+08 4.67E+08
LMAN2 Vesicular integral-membrane protein VIP36 FGASAGTGDLSDNHDIISMK 0.000264 1.00E+08 1.73E+08
LMAN2 Vesicular integral-membrane protein VIP36 FGASAGTGDLSDNHDIISMKL 0.002584 2.10E+08 4.22E+08
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LMAN2 Vesicular integral-membrane protein VIP36 LDTYPNDETTERVFPY 0.002669 4.53E+08 8.13E+08
LMAN2 Vesicular integral-membrane protein VIP36 MVEHTPDEESIDWTKIEPSVN 0.003137 3.64E+06 3.06E+08
MB Myoglobin GKVEADIPGHGQEVL 0.005096 8.50E+06 2.92E+08
MB Myoglobin NVWGKVEADIPGHGQEVL 0.007638 3.08E+06 8.76E+08
PCSK1N ProSAAS;KEP;Big SAAS;Little SAAS;Big PEN-LEN;PEN;Little LEN;Big LEN DHDVGSELPPEGVLGAL 0.004301 8.89E+06 3.50E+08
PI16 Peptidase inhibitor 16 LMVELHNL 0.006692 2.60E+06 6.30E+08
RBP4 Retinol-binding protein 4;Plasma retinol-binding protein(1-182);Plasma retinol-binding protein(1-181);Plasma retinol-binding protein(1-179);Plasma retinol-binding protein(1-176)AKKDPEGLFLQDNIVAE 0.002362 7.74E+06 5.49E+08
RBP4 Retinol-binding protein 4;Plasma retinol-binding protein(1-182);Plasma retinol-binding protein(1-181);Plasma retinol-binding protein(1-179);Plasma retinol-binding protein(1-176)KDPEGLFLQDNIVAE 0.005394 3.70E+07 2.08E+08
RUSC2 Iporin GVGEPGLGDLYDDSIGD 0.002332 3.63E+06 4.75E+07
SERPINA1 Alpha-1-antitrypsin;Short peptide from AAT DAAQKTDTSHHDQDHPTFNK 0.007246 1.17E+06 1.52E+09
SERPINA1 Alpha-1-antitrypsin;Short peptide from AAT EAIPMSIPPEVK 0.007695 1.96E+06 1.28E+08
SERPINA1 Alpha-1-antitrypsin;Short peptide from AAT EDPQGDAAQKTDTSHHDQDHPTFNK 0.000264 2.31E+06 3.48E+08
SERPINA1 Alpha-1-antitrypsin;Short peptide from AAT LRTLNQPDSQLQLTTGNGL 0.000346 1.49E+07 1.32E+08
SERPINA1 Alpha-1-antitrypsin;Short peptide from AAT MIEQNTKSPLFMGKVVNPTQK 0.005572 3.34E+07 1.25E+08
SERPINA1 Alpha-1-antitrypsin;Short peptide from AAT TDTSHHDQDHPTFNK 0.007847 1.42E+07 5.34E+08
SERPINA1 Alpha-1-antitrypsin;Short peptide from AAT TEIPEAQIHEGFQEL 0.002455 1.36E+07 3.44E+08
SERPINA1 Alpha-1-antitrypsin;Short peptide from AAT TIDEKGTEAAGAMF 0.003589 3.86E+07 8.32E+08
SERPINA1 Alpha-1-antitrypsin;Short peptide from AAT TIDEKGTEAAGAMFL 0.002357 2.92E+06 1.56E+08
SERPINA1 Alpha-1-antitrypsin;Short peptide from AAT VKELDRDTVF 0.003053 7.24E+06 4.92E+07
SERPINA6 Corticosteroid-binding globulin AKSDTSLEMTMGNAL 0.003251 6.57E+06 1.26E+08
SERPINA6 Corticosteroid-binding globulin YVDETTVVKVPM 0.003611 6.39E+06 4.88E+08
SERPINC1 Antithrombin-III SKLPGIVAEGRDDL 0.004011 1.43E+07 3.03E+08
SERPINC1 Antithrombin-III YQHLADSKNDNDNIFLSPLSISTA 0.005153 1.15E+06 3.53E+08
SERPING1 Plasma protease C1 inhibitor ELTETGVEAAAASAISVAR 0.007091 3.16E+06 9.24E+07
SERPING1 Plasma protease C1 inhibitor WDQQHKFPV 0.008942 3.28E+05 5.41E+08
SH3BGRL3 SH3 domain-binding glutamic acid-rich-like protein 3 FVEAVEQNTLQEF 1.89E-05 2.12E+07 1.61E+08
SPINK5 Serine protease inhibitor Kazal-type 5;Hemofiltrate peptide HF6478;Hemofiltrate peptide HF7665 ENDPVLGPDGKTHGNK 0.002755 2.75E+07 2.24E+08
SPP1;opn Osteopontin AIPVAQDLNAPSDWDSR 0.003065 9.90E+07 1.79E+08
SPP1;opn Osteopontin AQDLNAPSDWDSR 0.003082 7.21E+06 1.12E+08
SPP1;opn Osteopontin GKDSYETSQLDDQSAETHSHKQS 0.004415 1.36E+06 3.04E+09
TMSB4X Thymosin beta-4;Hematopoietic system regulatory peptide KTETQEKNPLPSKETIEQEKQAGES 0.005479 1.23E+06 6.46E+07
TMSB4X Thymosin beta-4;Hematopoietic system regulatory peptide TETQEKNPLPSKETIEQEKQAGES 0.006731 1.53E+06 5.40E+08
TMSB4X;TMSL4 Thymosin beta-4;Hematopoietic system regulatory peptide SDKPDMAEIEKFDK 0.007015 1.55E+06 1.23E+07
TMSB4X;TMSL4 Thymosin beta-4;Hematopoietic system regulatory peptide SDKPDMAEIEKFDKSK 0.008009 2.21E+06 2.49E+06
TMSB4X;TMSL4 Thymosin beta-4;Hematopoietic system regulatory peptide SDKPDMAEIEKFDKSKLK 0.000479 9.52E+06 1.03E+07
TSTD1 Thiosulfate sulfurtransferase/rhodanese-like domain-containing protein 1 YSAEKPKLEDEHLV 0.003111 1.67E+06 1.70E+10
TTR Transthyretin ALLSPYSYSTTA 0.003439 4.75E+06 3.89E+07
TTR Transthyretin ALLSPYSYSTTAVVTNPKE 0.004638 4.78E+05 7.36E+08
TTR Transthyretin GISPFHEHAEVV 0.002757 7.45E+06 1.16E+08
Significantly increased in diabetic nephropathy vs control






TTR Transthyretin LLSPYSYSTTAVVTNPKE 0.00515 2.04E+06 1.09E+07
TTR Transthyretin LSPYSYSTTAVVTNPKE 3.68E-06 5.64E+05 5.19E+09
UMOD Uromodulin;Uromodulinsecreted form Color [DarkGray] 2E-05 2.75E+06 2.70E+08
Significantly increased in control vs diabetic nephropathy






MGP Matrix Gla protein ACDDYRLCE 0.008745 1.03E+08 5.31E+06
PGRMC1 Membrane-associated progesterone receptor component 1 DDDEPPPLPRL 0.000743 3.06E+08 2.15E+07
VEGFA;VEGF Vascular endothelial growth factor A RCGGCCNDEGLECVPT 0.002518 2.92E+08 2.11E+07
FXYD2 Sodium/potassium-transporting ATPase subunit gamma TGLSMDGGGSPK 0.000145 8.16E+07 9.04E+06
ANGPTL2 Angiopoietin-related protein 2 EFIYLNRY 0.000528 8.76E+08 2.40E+07
CD59 CD59 glycoprotein CWKFEHCN 0.001737 7.81E+08 5.93E+06
TSPAN9 Tetraspanin-9 EGLLLYHTENNVGL 0.000591 3.16E+08 2.82E+05
vi. Urinary peptides that were significantly different 
between the groups control, diabetes (DM), 
hypertension (HTN) and the combinatory diabetes 
and hypertension (DM+HTN) 
Peptide sequence, protein symbol and uniprot name, mean intensity per group, p-
value, description are provided. The complete list of peptides detected in the 
control group and diabetes and hypertension group has been published (Betz, 
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Q6P6X2 SQGGQLQSYGQMK 3.12E+06 0.00E+00 0.00E+00 2.40E+05 Protein Semg1 OS=Rattus norvegicus GN=Semg1 PE=2 SV=1 9.27E-05
Q63461 DQELTITSEAIR 1.13E+07 0.00E+00 5.79E+06 8.55E+06 Proline-rich protein (Fragment) n=1 Tax=Rattus norvegicus RepID=Q63461_RAT 1.11E-04
P08568 SPENSQEQPQQTNPEEKPPAPK 1.42E+07 3.31E+06 0.00E+00 4.95E+06 Submandibular gland secretory Glx-rich protein CA n=1 Tax=Rattus norvegicus RepID=GRPA_RAT 1.13E-04
G3V947 LQPDPNGGQIGVT 7.63E+07 9.27E+06 8.94E+06 1.03E+07 SMR1 protein (Fragment) OS=Rattus norvegicus GN=Vcsa1 PE=4 SV=2 1.76E-04
Q5I0L0 TGSGGIENYNDAAQVR 2.85E+07 1.41E+07 4.67E+06 1.91E+06 Amy1a protein OS=Rattus norvegicus GN=Amy1a PE=2 SV=1 4.78E-04
P02783 GGSFGEEASEEISSR 8.77E+06 0.00E+00 7.85E+06 5.77E+06 Seminal vesicle secretory protein 4 n=1 Tax=Rattus norvegicus RepID=SVS4_RAT 4.82E-04
Q6P6X2 KQFDDDDLSVQQK 2.24E+07 4.05E+06 1.53E+07 2.21E+07 Protein Semg1 OS=Rattus norvegicus GN=Semg1 PE=2 SV=1 1.97E-03
P02783 GGSFGEEASEEISSR 3.27E+07 6.46E+06 1.29E+07 6.66E+06 Seminal vesicle secretory protein 4 n=1 Tax=Rattus norvegicus RepID=SVS4_RAT 3.60E-03
Q9ESG3 DTDEEYLFR 7.70E+08 6.41E+06 6.52E+07 5.18E+06 Collectrin OS=Rattus norvegicus GN=Tmem27 PE=1 SV=2 3.82E-03
P18897 EEVSNAEISDVKQQPDS 3.82E+08 8.03E+06 1.60E+07 2.52E+06 SMR2 protein n=1 Tax=Rattus norvegicus RepID=SMR2_RAT 5.07E-03
P07522 DYDPVESKIY 2.45E+08 1.94E+07 4.22E+07 3.66E+06 Pro-epidermal growth factor n=1 Tax=Rattus norvegicus RepID=EGF_RAT 6.44E-03
I3PMS6 ESIRETEVIDPQDLLEGR 1.02E+09 0.00E+00 1.12E+08 1.81E+07 Syndecan (Fragment) OS=Rattus exulans GN=SDC4 PE=2 SV=1 6.79E-03
Q6IFV4 TRLEQEIATYR 1.47E+07 2.65E+06 0.00E+00 4.13E+06 Keratin, type I cytoskeletal 13 n=1 Tax=Rattus norvegicus RepID=K1C13_RAT 6.82E-03
Q6P6X2 KQFDDDDLSVQQK 2.95E+08 0.00E+00 9.40E+07 4.98E+05 Protein Semg1 OS=Rattus norvegicus GN=Semg1 PE=2 SV=1 6.90E-03
P02783 GGSFGEEASEEISSR 1.28E+09 0.00E+00 3.78E+08 9.86E+07 Seminal vesicle secretory protein 4 n=1 Tax=Rattus norvegicus RepID=SVS4_RAT 7.55E-03
M0R8W8 TAHLSVVSEDGSAVAAT 1.66E+08 0.00E+00 1.00E+08 3.45E+07 Gamma-glutamyltranspeptidase 1 (Fragment) OS=Rattus norvegicus GN=Ggt1 PE=4 SV=1 9.72E-03
Q01177 ILGSDVQQIAVT 2.60E+06 7.93E+08 2.11E+09 1.75E+08 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 2.68E-05 0.002052 3.01E-09
P05545 DQAEINTGSALFIDK 0.00E+00 2.20E+10 1.07E+08 2.66E+07 Serine protease inhibitor A3K n=1 Tax=Rattus norvegicus RepID=SPA3K_RAT 1.17E-04 0.000165 4.38E-09
B2RYM3 DGSEIVVAGRI 0.00E+00 2.56E+08 4.33E+07 2.36E+06 Inter-alpha trypsin inhibitor, heavy chain 1 (Predicted), isoform CRA_a n=1 Tax=Rattus norvegicus RepID=B2RYM3_RAT 3.16E-04 0.001086 8.87E-09
M0R8A9 DSGDVESHLSFLEK 0.00E+00 2.87E+08 5.02E+07 9.25E+06 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=M0R8A9_RAT 1.08E-03 0.001514 1.26E-08
P01015 DKLVLATEKLEAEDR 2.60E+06 3.30E+07 3.51E+07 6.62E+07 Angiotensinogen n=1 Tax=Rattus norvegicus RepID=ANGT_RAT 1.95E-03 0.003277 3.38E-08
P24090 TDCTGQEVTDPAKC 2.60E+06 3.89E+07 2.25E+08 2.59E+08 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=FETUA_RAT 2.38E-03 0.008707 4.90E-08
E0A3N4 SLRPSMIDELYLPK 0.00E+00 1.06E+07 4.80E+07 6.74E+07 Serpina3n-like protein n=1 Tax=Rattus norvegicus RepID=E0A3N4_RAT 3.03E-03 4.15E-07 1.05E-07
Q01177 VLEPNDADIALLK 0.00E+00 2.97E+06 1.30E+07 3.88E+06 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 3.55E-03 0.001444 1.41E-07
P05544 DQVEINTGSALF 0.00E+00 4.98E+07 1.54E+08 1.12E+07 Serine protease inhibitor A3L n=1 Tax=Rattus norvegicus RepID=SPA3L_RAT 4.62E-03 1.86E-05 1.55E-07
E0A3N4 LQVLAEFQEKA 0.00E+00 1.38E+08 3.35E+07 5.70E+07 Serpina3n-like protein n=1 Tax=Rattus norvegicus RepID=E0A3N4_RAT 5.76E-03 0.000101 5.29E-07
F1LM19 SPVASVESASGEVLH 1.19E+06 2.71E+07 1.65E+07 2.43E+07 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=F1LM19_RAT 6.51E-03 0.000104 7.45E-07
P24090 AFSPVASVESASGEVL 0.00E+00 3.59E+08 4.90E+07 1.44E+06 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=FETUA_RAT 7.48E-03 0.0012 8.89E-07
Q01177 VILGAHEER 1.72E+06 8.16E+08 6.92E+07 2.34E+08 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 7.84E-03 0.001501 1.03E-06
Q5M7T5 DDICIAKPR 1.27E+06 1.49E+07 8.66E+07 6.18E+06 Protein Serpinc1 OS=Rattus norvegicus GN=Serpinc1 PE=2 SV=1 9.97E-03 0.004451 1.21E-06
P17475 IVESETQSPLFVGK 0.00E+00 6.86E+06 2.86E+08 2.34E+08 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 5.39E-03 0.005176 1.61E-06
P09006 DSLRPSMIDELYLP 9.21E+05 5.30E+07 3.14E+07 6.18E+06 Serine protease inhibitor A3N n=1 Tax=Rattus norvegicus RepID=SPA3N_RAT 3.97E-04 0.00706 1.83E-06
Q80ZA3 LAAAVSNFGYDLYR 2.08E+05 2.35E+08 5.46E+08 3.25E+07 Alpha-2 antiplasmin OS=Rattus norvegicus GN=Serpinf1 PE=2 SV=1 6.40E-07 5.60E-04 2.59E-06
P05544 EAFIADFKQPNE 0.00E+00 8.62E+07 7.07E+07 1.11E+07 Serine protease inhibitor A3L n=1 Tax=Rattus norvegicus RepID=SPA3L_RAT 4.11E-05 4.29E-03 2.80E-06
Q6IFV4 QSVEADINGLR 0.00E+00 3.80E+08 1.58E+09 3.47E+07 Keratin, type I cytoskeletal 13 n=1 Tax=Rattus norvegicus RepID=K1C13_RAT 9.71E-03 9.92E-03 3.13E-06
P06759 WESGPEDQLTTPTLE 3.45E+05 6.11E+06 2.33E+09 6.41E+07 Apolipoprotein C-III n=1 Tax=Rattus norvegicus RepID=APOC3_RAT 1.57E-03 5.13E-04 3.35E-06
Q63556 IDELYLPR 0.00E+00 1.65E+07 6.71E+08 2.11E+07 Serine protease inhibitor A3M (Fragment) n=1 Tax=Rattus norvegicus RepID=SPA3M_RAT 4.77E-07 5.84E-05 3.61E-06
P04639 KPALDDLGQGL 0.00E+00 3.79E+07 1.95E+08 2.22E+07 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 4.82E-03 8.97E-03 3.73E-06
P02770 LAEIEHDNIPADLPSIAADFVEDK 0.00E+00 1.08E+07 1.29E+08 3.13E+07 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 7.89E-04 0.000178 5.06E-06
P01015 DKLVLATEKLEAEDR 0.00E+00 3.01E+06 6.85E+07 1.40E+08 Angiotensinogen n=1 Tax=Rattus norvegicus RepID=ANGT_RAT 1.66E-03 0.005153 6.68E-06
A1EC93 TCAELCSGDWDCGPGEQCVSTGCSNVCATS 0.00E+00 7.61E+05 1.93E+07 1.22E+08 Protein LOC360228 OS=Rattus norvegicus GN=LOC360228 PE=4 SV=1 1.92E-03 0.001408 7.14E-06
Q80ZA3 LAAAVSNFGYDLY 0.00E+00 5.40E+08 1.16E+07 2.84E+07 Alpha-2 antiplasmin OS=Rattus norvegicus GN=Serpinf1 PE=2 SV=1 4.42E-03 0.005672 7.80E-06
Q01177 LVLEPNDADIALLK 2.98E+05 4.98E+07 2.27E+06 2.41E+07 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 1.00E+00 0.00811
P02770 TCVADENAENCDK 0.00E+00 9.14E+07 2.38E+07 1.12E+07 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 8.59E-03 2.7E-05
P02770 GLVLIAFSQYLQK 0.00E+00 2.07E+09 1.73E+07 0.00E+00 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 1.99E-03 4.5E-05
P02767 TADGSWEPFASGK 3.84E+06 8.88E+06 1.24E+08 7.14E+07 Transthyretin n=1 Tax=Rattus norvegicus RepID=TTHY_RAT 5.00E-03 0.00227
Q7M0D3 SIVHPSYNSN 0.00E+00 2.97E+08 3.68E+07 2.69E+07 Dentin phosphophoryn OS=Rattus norvegicus PE=1 SV=1 5.53E-03 0.002431
P01026 LLWESGSLL 0.00E+00 1.45E+09 2.13E+07 2.28E+07 Complement C3 n=1 Tax=Rattus norvegicus RepID=CO3_RAT 3.85E-03 0.00261
P12346 SKDFQLFGSPLG 0.00E+00 1.30E+08 2.86E+08 6.29E+07 Serotransferrin n=1 Tax=Rattus norvegicus RepID=TRFE_RAT 4.06E-03 0.003844
M0R8A9 NLAPLVEDVQSKL 0.00E+00 5.71E+08 7.79E+07 5.37E+06 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=M0R8A9_RAT 1.62E-05 0.00717
M0RBF1 VGLVAVDKGVFVLN 0.00E+00 2.93E+08 1.06E+08 1.12E+06 Complement C3 OS=Rattus norvegicus GN=C3 PE=4 SV=1 6.17E-04 0.000177
M0R8A9 VQEQVQEQVQPKPLES 2.65E+05 9.34E+07 0.00E+00 1.40E+07 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=M0R8A9_RAT 0.000393 2.31E-05
P04639 WNEEVEAYR 1.38E+06 1.23E+08 4.00E+07 4.81E+07 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 0.000345 2.53E-05
P02454 GDRGETGPAGPAGPIGPAG 0.00E+00 1.64E+07 1.88E+08 1.23E+08 Collagen alpha-1(I) chain n=1 Tax=Rattus norvegicus RepID=CO1A1_RAT 0.002338 2.77E-05
P04639 LDNWDTLGSTVGR 2.28E+06 3.61E+07 4.09E+07 1.00E+07 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 0.000281 2.91E-05
P01026 LWESGSLLR 0.00E+00 3.24E+07 1.07E+07 2.78E+07 Complement C3 n=1 Tax=Rattus norvegicus RepID=CO3_RAT 0.003288 2.93E-05
P04639 DYVSQFESSTLGK 0.00E+00 8.58E+07 0.00E+00 1.25E+07 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 0.00365 3.20E-05
UPI0002AB826B DLQLLHQKVEEQ 0.00E+00 1.34E+07 4.36E+08 7.27E+07 UPI0002AB826B related cluster n=1 Tax=Rattus norvegicus RepID=UPI0002AB826B 0.008 3.67E-05
P08721 DAVATWLKPDP 0.00E+00 1.08E+07 9.08E+07 1.84E+07 Osteopontin n=1 Tax=Rattus norvegicus RepID=OSTP_RAT 0.000939 3.97E-05




















A1L114 DTGTTSEFIEAGGDIR 0.00E+00 1.60E+07 5.79E+08 3.76E+07 Fga protein OS=Rattus norvegicus GN=Fga PE=2 SV=1 8.53E-05 4.73E-05
G3V836 EQEFSDNELQELSTQGSRY 1.06E+06 4.01E+06 1.25E+09 3.13E+08 Clusterin OS=Rattus norvegicus GN=Clu PE=3 SV=1 0.005206 5.83E-05
F1LM19 HAFSPVASVESASGEVLHSPK 2.54E+07 3.20E+07 1.10E+08 2.69E+07 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=F1LM19_RAT 0.005664 6.17E-05
Q64240 DNVPTLPDIQVQENFNEAR 1.96E+06 1.92E+07 9.75E+07 1.93E+07 Protein AMBP n=1 Tax=Rattus norvegicus RepID=AMBP_RAT 0.003392 6.35E-05
A1L114 MSPVPDLVPGSFK 9.05E+04 9.13E+05 0.00E+00 5.91E+07 Fga protein OS=Rattus norvegicus GN=Fga PE=2 SV=1 0.009787 7.06E-05
P05544 LSQPEDQVEINTGSAL 0.00E+00 4.63E+07 4.89E+06 5.43E+07 Serine protease inhibitor A3L n=1 Tax=Rattus norvegicus RepID=SPA3L_RAT 0.00019 7.36E-05
P24090 AFSPVASVESASGEVLH 1.06E+06 4.53E+06 0.00E+00 4.85E+07 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=FETUA_RAT 0.000214 7.82E-05
B3DM95 SVEAAAELSAK 0.00E+00 8.84E+06 5.23E+07 6.00E+07 Parathymosin OS=Rattus norvegicus GN=Ptms PE=2 SV=1 0.007199 8.47E-05
P13635 ELISVDTEQSNFYLR 0.00E+00 1.03E+08 0.00E+00 2.42E+07 Ceruloplasmin n=1 Tax=Rattus norvegicus RepID=CERU_RAT 0.000627 8.63E-05
Q6P6X2 KSQGGQLQSYGQMK 2.70E+06 2.42E+07 0.00E+00 9.12E+06 Protein Semg1 OS=Rattus norvegicus GN=Semg1 PE=2 SV=1 8.65E-05
P17475 IVESETQSPLFVGK 0.00E+00 7.18E+07 0.00E+00 4.71E+07 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 9.00E-05
M0RBF1 TLDPEHLGQGGVQRE 0.00E+00 3.19E+07 1.03E+08 1.50E+08 Complement C3 OS=Rattus norvegicus GN=C3 PE=4 SV=1 7.32E-06 9.03E-05
M0R8A9 GSPDQPLALPLPEQVQ 0.00E+00 0.00E+00 4.38E+08 7.61E+05 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=M0R8A9_RAT 0.003424 9.52E-05
Q01177 VLEPNDADIAL 0.00E+00 0.00E+00 4.31E+08 3.09E+06 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 0.005206 1.03E-04
Q5M7T5 ATEEDVLEQKVPEATNR 0.00E+00 0.00E+00 1.80E+08 2.19E+07 Protein Serpinc1 OS=Rattus norvegicus GN=Serpinc1 PE=2 SV=1 2.55E-07 1.04E-04
A1L114 DEAASEAHQEGDTR 0.00E+00 0.00E+00 1.57E+08 4.80E+05 Fga protein OS=Rattus norvegicus GN=Fga PE=2 SV=1 0.001393 1.08E-04
Q01177 LVLEPNDADIALLK 0.00E+00 0.00E+00 9.11E+07 4.41E+05 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 0.002735 1.18E-04
P05544 VLDVDETGTEATAATGVAT 0.00E+00 0.00E+00 2.68E+08 1.14E+06 Serine protease inhibitor A3L n=1 Tax=Rattus norvegicus RepID=SPA3L_RAT 0.002975 1.26E-04
F1LR92 ALYQVEAFTADFQQPR 0.00E+00 0.00E+00 7.62E+07 4.29E+07 Serine protease inhibitor A3M (Fragment) n=2 Tax=Rattus norvegicus RepID=F1LR92_RAT 0.003138 1.28E-04
P17475 MIVESETQSPLFVGK 8.63E+05 0.00E+00 2.37E+08 1.08E+08 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 0.004663 1.37E-04
P02651 VQEQVQEQVQPKPLE 0.00E+00 0.00E+00 2.15E+07 6.57E+07 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 0.001153 1.45E-04
P02770 AEFQPLVEEPK 0.00E+00 0.00E+00 4.85E+06 1.55E+07 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 0.008303 1.47E-04
Q6P6X2 QFDDDDLSVQQK 0.00E+00 0.00E+00 8.36E+07 1.93E+08 Protein Semg1 OS=Rattus norvegicus GN=Semg1 PE=2 SV=1 0.008865 1.58E-04
A1L114 TSDSDIFTDIENPSSHVPEFSSSS 0.00E+00 0.00E+00 3.02E+08 1.00E+09 Fga protein OS=Rattus norvegicus GN=Fga PE=2 SV=1 0.004757 1.68E-04
P05544 FSISTDYSLKE 0.00E+00 0.00E+00 5.12E+07 7.83E+07 Serine protease inhibitor A3L n=1 Tax=Rattus norvegicus RepID=SPA3L_RAT 0.000426 1.74E-04
F1M7X5 VLEDNSALDK 0.00E+00 0.00E+00 8.32E+06 7.76E+07 Dipeptidyl peptidase 4 OS=Rattus norvegicus GN=Dpp4 PE=2 SV=1 0.003899 1.83E-04
P02651 TDVTQQLNTLFQDK 0.00E+00 0.00E+00 4.22E+06 9.72E+06 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 0.004087 1.96E-04
Q01177 LVLEPNDADIAL 0.00E+00 0.00E+00 5.28E+07 2.42E+08 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 0.008718 2.04E-04
Q01177 LVLEPNDADIAL 0.00E+00 0.00E+00 3.63E+07 1.14E+09 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 0.000115 2.17E-04
P17475 EDAQETDTSQQDQSPTYR 0.00E+00 0.00E+00 9.64E+07 1.64E+08 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 0.005876 2.32E-04
P02783 EEASEEISSR 2.74E+07 0.00E+00 1.37E+08 4.13E+08 Seminal vesicle secretory protein 4 n=1 Tax=Rattus norvegicus RepID=SVS4_RAT 0.006879 2.37E-04
P17475 TDTSQQDQSPTYR 0.00E+00 0.00E+00 1.70E+07 9.65E+08 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 0.008106 2.40E-04
P24090 ESASGEVLHSPK 0.00E+00 0.00E+00 1.27E+08 8.62E+06 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=FETUA_RAT 0.008516 2.45E-04
F1LM05 AVLDVAETGTEAAAATGV 0.00E+00 0.00E+00 1.07E+09 2.03E+06 Protein LOC299282 n=1 Tax=Rattus norvegicus RepID=F1LM05_RAT 1.95E-05 2.61E-04
P17475 EDAQETDTSQQDQSPTYR 0.00E+00 0.00E+00 2.89E+08 8.09E+07 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 2.63E-04
P02770 EAHKSEIAHR 0.00E+00 9.42E+07 7.42E+08 1.50E+07 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 2.92E-04
P24090 DCTGQEVTDPAKC 1.28E+06 0.00E+00 5.27E+08 7.95E+07 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=FETUA_RAT 3.03E-04
P17475 EDAQETDTSQQDQSPTYRK 8.64E+06 4.12E+05 4.58E+08 1.14E+08 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 3.22E-04
P17475 EDAQETDTSQQDQSPTYR 1.77E+08 0.00E+00 1.32E+09 1.99E+08 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 3.32E-04
P02770 EKCCAEGDPPAC 9.06E+06 0.00E+00 1.86E+09 1.21E+08 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 3.43E-04
P17475 EDAQETDTSQQDQSPTYRK 5.45E+07 0.00E+00 8.38E+08 1.16E+08 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 3.44E-04
P02770 DICTLPDKE 1.34E+07 0.00E+00 1.38E+09 1.97E+08 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 3.63E-04
P12346 HQTVLENTNGK 3.79E+06 0.00E+00 5.53E+08 1.03E+08 Serotransferrin n=1 Tax=Rattus norvegicus RepID=TRFE_RAT 3.67E-04
M0R620 LNGDWFSIVVASNKR 1.36E+07 0.00E+00 9.91E+08 0.00E+00 Protein LOC100912565 n=1 Tax=Rattus norvegicus RepID=M0R620_RAT 3.75E-04
P17475 EDAQETDTSQQDQSPTYRK 8.69E+06 0.00E+00 1.13E+09 4.77E+08 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 3.84E-04
P12346 VSTVLTAQK 6.11E+07 0.00E+00 1.19E+09 9.95E+07 Serotransferrin n=1 Tax=Rattus norvegicus RepID=TRFE_RAT 4.27E-04
P12346 DGGGDVAFVK 7.09E+07 0.00E+00 1.92E+09 4.57E+07 Serotransferrin n=1 Tax=Rattus norvegicus RepID=TRFE_RAT 4.40E-04
G3V836 SLLNSLEEA 8.04E+06 8.69E+05 6.50E+08 9.66E+06 Clusterin OS=Rattus norvegicus GN=Clu PE=3 SV=1 4.69E-04
F1LS40 GIDGRPGPIGPAGPRGEAG 5.39E+06 4.58E+06 4.14E+06 1.84E+07 Collagen alpha-2(I) chain OS=Rattus norvegicus GN=Col1a2 PE=2 SV=2 4.80E-04
P04639 HLDEFQEKWNEE 1.00E+06 0.00E+00 0.00E+00 1.09E+08 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 4.96E-04
F1LNT3 HPPPPPPPP 0.00E+00 1.92E+07 4.97E+07 1.38E+08 Protein R3hdm1 OS=Rattus norvegicus GN=R3hdm1 PE=2 SV=1 5.12E-04
P02454 DRGETGPAGPAGPIGPAG 0.00E+00 3.29E+07 2.05E+08 5.24E+07 Collagen alpha-1(I) chain n=1 Tax=Rattus norvegicus RepID=CO1A1_RAT 5.27E-04
P02651 NLAPLVEDVQSK 5.68E+05 3.69E+07 0.00E+00 5.99E+07 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 5.35E-04
Q99PS8 DNSDRPPLQEGALPQ 0.00E+00 4.39E+07 7.66E+05 5.26E+06 Histidine-rich glycoprotein OS=Rattus norvegicus GN=Hrg PE=2 SV=1 5.52E-04
M0RBF1 SEETKQNEGFSLTAK 1.18E+06 1.58E+08 1.76E+06 1.14E+08 Complement C3 OS=Rattus norvegicus GN=C3 PE=4 SV=1 5.61E-04
P02651 RAVEPLGDKFN 1.26E+07 3.60E+08 6.82E+07 1.60E+08 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 5.68E-04
P17475 VFNNDADLSGITEDAPLK 0.00E+00 0.00E+00 9.55E+06 1.09E+07 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 5.83E-04
M0RBF1 EDVPAADLSDQVPDTDSETR 2.31E+07 8.90E+07 2.51E+08 1.42E+08 Complement C3 OS=Rattus norvegicus GN=C3 PE=4 SV=1 5.89E-04
Q99PS8 DNSDRPPLQEGALPQMLPGHSGPSGTN 0.00E+00 2.24E+07 1.08E+08 1.03E+08 Histidine-rich glycoprotein OS=Rattus norvegicus GN=Hrg PE=2 SV=1 6.15E-04




















M0R8A9 VQEQVQEQVQPKPLES 0.00E+00 0.00E+00 1.25E+08 2.39E+08 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=M0R8A9_RAT 6.23E-04
M0RBF1 TLDPEHLGQGGVQRED 0.00E+00 3.02E+07 4.14E+07 1.82E+07 Complement C3 OS=Rattus norvegicus GN=C3 PE=4 SV=1 6.30E-04
A1L114 DTGTTSEFIEAGGDIR 6.99E+05 4.68E+07 4.05E+08 1.38E+07 Fga protein OS=Rattus norvegicus GN=Fga PE=2 SV=1 6.33E-04
P02651 ATIDQNLEDLR 2.19E+06 3.86E+07 4.75E+07 3.82E+07 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 6.52E-04
P04639 KLEPLGTELHK 6.22E+06 5.23E+09 2.80E+08 6.88E+07 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 6.96E-04
P15083 FADEREIQNAGDQAQENR 0.00E+00 2.46E+08 3.36E+08 9.73E+07 Polymeric immunoglobulin receptor OS=Rattus norvegicus GN=Pigr PE=1 SV=1 7.06E-04
P02651 KGSPDQPLALPLPEQVQ 0.00E+00 2.26E+08 8.59E+07 1.03E+07 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 7.21E-04
P17475 MIVESETQSPLFVGK 0.00E+00 7.40E+07 8.72E+06 2.55E+07 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 7.49E-04
Q5M7T5 ATEEDVLEQKVPEATNRR 0.00E+00 6.24E+07 2.53E+07 4.43E+07 Protein Serpinc1 OS=Rattus norvegicus GN=Serpinc1 PE=2 SV=1 7.59E-04
Q6P6X2 FGQDGGDMAQTSVSQEHTGVK 0.00E+00 7.96E+07 3.25E+07 2.62E+07 Protein Semg1 OS=Rattus norvegicus GN=Semg1 PE=2 SV=1 7.65E-04
P09034 TQDPAKAPNTPDVLEIE 7.40E+05 0.00E+00 6.12E+07 2.12E+07 Argininosuccinate synthase OS=Rattus norvegicus GN=Ass1 PE=2 SV=1 7.79E-04
Q68FT8 DLPGQQPVSEQAQQKLPPL 7.78E+05 4.21E+07 3.86E+07 1.24E+08 Protein Serpinf2 OS=Rattus norvegicus GN=Serpinf2 PE=2 SV=1 8.53E-04
Q08420 SDTGESGVDLADRLDLVEK 0.00E+00 1.30E+07 2.95E+07 4.55E+07 Extracellular superoxide dismutase [Cu-Zn] n=1 Tax=Rattus norvegicus RepID=SODE_RAT 8.69E-04
P04639 DEFQEKWNEEVEAY 0.00E+00 1.65E+07 3.08E+08 2.72E+08 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 9.15E-04
P08721 DAIDSAEKPDAIDSAERSDAIDSQASSK 0.00E+00 1.76E+07 4.21E+08 2.14E+08 Osteopontin n=1 Tax=Rattus norvegicus RepID=OSTP_RAT 9.21E-04
Q68FT8 RLDQNDKADIPGGK 0.00E+00 8.03E+06 7.68E+08 6.22E+08 Protein Serpinf2 OS=Rattus norvegicus GN=Serpinf2 PE=2 SV=1 9.55E-04
D3ZVB6 LEGQDLQSENQR 0.00E+00 1.33E+08 1.11E+08 1.12E+08 Protein LOC690326 OS=Rattus norvegicus GN=LOC690326 PE=4 SV=1 9.83E-04
P05545 DGILGRDTLPHEDQGKGR 0.00E+00 1.06E+09 0.00E+00 5.76E+06 Serine protease inhibitor A3K n=1 Tax=Rattus norvegicus RepID=SPA3K_RAT 9.85E-04
Q5BKC4 TENYEEQFEMFK 0.00E+00 0.00E+00 2.77E+08 4.92E+07 C9 protein OS=Rattus norvegicus GN=C9 PE=2 SV=1 1.01E-03
P02454 AVGPAGKDGEAGAQGAPGPAGPAGERGEQGPAG 0.00E+00 0.00E+00 1.13E+07 6.31E+07 Collagen alpha-1(I) chain n=1 Tax=Rattus norvegicus RepID=CO1A1_RAT 1.03E-03
Q5BKC4 TENYEEQFEMFK 0.00E+00 1.33E+07 0.00E+00 1.73E+08 C9 protein OS=Rattus norvegicus GN=C9 PE=2 SV=1 1.09E-03
P17475 IVESETQSPLFVGKVIDPT 0.00E+00 9.30E+06 7.05E+06 4.82E+06 Alpha-1-antiproteinase n=1 Tax=Rattus norvegicus RepID=A1AT_RAT 1.11E-03
Q5M7T5 EEGSEAAASTSVVITGR 0.00E+00 6.40E+07 9.68E+06 7.18E+07 Protein Serpinc1 OS=Rattus norvegicus GN=Serpinc1 PE=2 SV=1 1.14E-03
P02650 ELEEQLGPVAEETR 3.15E+06 2.04E+07 4.56E+08 3.69E+08 Apolipoprotein E n=1 Tax=Rattus norvegicus RepID=APOE_RAT 1.14E-03
P02770 TVDETYVPKEF 0.00E+00 4.55E+06 3.49E+08 3.56E+07 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 1.16E-03
P02770 TQKAPQVSTPTLVEAAR 3.37E+06 1.44E+08 2.79E+07 3.41E+07 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 1.18E-03
P24090 SPVASVESASGEVLHSP 0.00E+00 4.33E+08 1.10E+08 2.65E+08 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=FETUA_RAT 1.21E-03
F1LM19 SPVASVESASGEVLH 0.00E+00 3.02E+07 1.01E+07 3.35E+06 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=F1LM19_RAT 1.29E-03
P05544 AEAFIADFKQPNE 0.00E+00 0.00E+00 5.26E+07 4.76E+07 Serine protease inhibitor A3L n=1 Tax=Rattus norvegicus RepID=SPA3L_RAT 1.29E-03
P04639 EQLGPVTQEF 0.00E+00 0.00E+00 0.00E+00 1.50E+07 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 1.32E-03
Q6P734 DSEVTSHSSQDPLVVQEGSR 4.87E+05 0.00E+00 2.63E+08 1.62E+07 Plasma protease C1 inhibitor OS=Rattus norvegicus GN=Serping1 PE=2 SV=1 1.36E-03
Q68FT8 MDLPGQQPVSEQAQQKLPPL 1.78E+05 1.10E+08 1.59E+08 1.58E+06 Protein Serpinf2 OS=Rattus norvegicus GN=Serpinf2 PE=2 SV=1 1.44E-03
Q6P734 DSEVTSHSSQDPLVVQEGSR 0.00E+00 0.00E+00 9.25E+06 2.18E+07 Plasma protease C1 inhibitor OS=Rattus norvegicus GN=Serping1 PE=2 SV=1 1.46E-03
Q6P734 DSEVTSHSSQDPLVVQEGSR 0.00E+00 1.39E+07 0.00E+00 9.77E+06 Plasma protease C1 inhibitor OS=Rattus norvegicus GN=Serping1 PE=2 SV=1 1.50E-03
P04639 DYVSQFESSTLGKQ 1.55E+06 1.33E+07 0.00E+00 1.30E+07 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 1.50E-03
P04639 QKLEPLGTELHK 0.00E+00 2.97E+06 1.40E+06 2.79E+06 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 1.52E-03
P24090 SPVASVESASGEVL 5.80E+06 6.96E+07 3.62E+06 3.17E+07 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=FETUA_RAT 1.60E-03
P05545 DQAEINTGSALFIDKEQP 3.57E+07 4.31E+08 1.03E+08 8.03E+07 Serine protease inhibitor A3K n=1 Tax=Rattus norvegicus RepID=SPA3K_RAT 1.65E-03
Q68FT8 LGNQDLGDHATLK 9.03E+06 1.12E+08 2.77E+08 8.97E+07 Protein Serpinf2 OS=Rattus norvegicus GN=Serpinf2 PE=2 SV=1 1.71E-03
P04639 DNWDTLGSTVGR 5.05E+07 1.32E+09 1.31E+09 3.86E+08 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 1.81E-03
P24090 VASVESASGEVLHSPK 7.41E+05 4.04E+07 4.40E+06 2.02E+07 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=FETUA_RAT 1.83E-03
A9UMV1 DDPGSSALLDTVQEHL 0.00E+00 3.57E+07 0.00E+00 2.77E+07 Uncharacterized protein (Fragment) OS=Rattus norvegicus GN=Apoc2 PE=2 SV=1 1.85E-03
P05545 ILGRDTLPHEDQGKGR 0.00E+00 5.21E+07 0.00E+00 1.17E+08 Serine protease inhibitor A3K n=1 Tax=Rattus norvegicus RepID=SPA3K_RAT 1.85E-03
P05545 QVESSLQPETLKK 0.00E+00 4.02E+07 0.00E+00 5.31E+07 Serine protease inhibitor A3K n=1 Tax=Rattus norvegicus RepID=SPA3K_RAT 1.89E-03
P05545 LSQPEDQAEINTGSAL 3.55E+05 1.37E+08 0.00E+00 8.28E+07 Serine protease inhibitor A3K n=1 Tax=Rattus norvegicus RepID=SPA3K_RAT 1.92E-03
D4A6E3 VVLSAPAVESELSPR 0.00E+00 6.47E+07 0.00E+00 2.47E+08 Protein LOC100911833 OS=Rattus norvegicus GN=LOC100911833 PE=2 SV=1 1.93E-03
Q5BKC4 TENYEEQFEMF 0.00E+00 8.63E+07 0.00E+00 2.03E+08 C9 protein OS=Rattus norvegicus GN=C9 PE=2 SV=1 1.93E-03
Q68FT8 RLDQNDKADIPGGKTF 1.55E+07 2.47E+08 3.59E+06 8.60E+07 Protein Serpinf2 OS=Rattus norvegicus GN=Serpinf2 PE=2 SV=1 2.01E-03
Q99PS8 SDRPPLQEGALPQM 0.00E+00 0.00E+00 4.48E+06 4.53E+08 Histidine-rich glycoprotein OS=Rattus norvegicus GN=Hrg PE=2 SV=1 2.07E-03
Q01177 ILGSDVQQIAVTK 0.00E+00 1.57E+08 0.00E+00 3.86E+07 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 2.09E-03
G3V947 LGLQPDPNGGQIGV 0.00E+00 1.95E+08 1.53E+06 1.20E+09 SMR1 protein (Fragment) OS=Rattus norvegicus GN=Vcsa1 PE=4 SV=2 2.11E-03
Q01177 ILGSDVQQIAVTKL 0.00E+00 5.44E+08 4.43E+06 8.82E+09 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 2.16E-03
M0RBF1 DLNMDVSLHLPS 0.00E+00 2.84E+07 4.42E+07 1.78E+08 Complement C3 OS=Rattus norvegicus GN=C3 PE=4 SV=1 2.17E-03
B2RYM3 YDGSEIVVAGRI 0.00E+00 6.84E+07 1.95E+06 7.09E+09 Inter-alpha trypsin inhibitor, heavy chain 1 (Predicted), isoform CRA_a n=1 Tax=Rattus norvegicus RepID=B2RYM3_RAT 2.21E-03
G3V615 SLTETIEGADAEDGHSPGEQQ 0.00E+00 1.07E+08 4.23E+06 7.70E+08 Complement factor B, isoform CRA_b OS=Rattus norvegicus GN=C2 PE=3 SV=1 2.23E-03
P02770 LTVDETYVPKEF 0.00E+00 6.97E+07 7.37E+06 5.46E+10 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 2.27E-03
P02651 SRLAPLAEGVQEK 0.00E+00 1.03E+08 6.42E+06 2.12E+08 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 2.37E-03
P02770 AEFQPLVEEPKN 0.00E+00 1.72E+08 6.06E+07 5.10E+08 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 2.37E-03
E0A3N4 DSLRPSMIDELYLPK 0.00E+00 5.54E+08 3.81E+07 7.61E+07 Serpina3n-like protein n=1 Tax=Rattus norvegicus RepID=E0A3N4_RAT 2.47E-03




















P02651 FRQQLGSDSGDVESHLS 0.00E+00 5.58E+07 2.15E+07 1.33E+08 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 2.54E-03
P08721 DAIDSAEKPDAIDSAER 0.00E+00 2.16E+08 5.28E+06 2.39E+09 Osteopontin n=1 Tax=Rattus norvegicus RepID=OSTP_RAT 2.66E-03
P01835 DGVLDSVTDQDSKDSTYSMSSTL 0.00E+00 1.71E+08 3.32E+07 3.03E+07 Ig kappa chain C region, B allele n=2 Tax=Rattus norvegicus RepID=KACB_RAT 2.72E-03
P02651 AVEPLGDKFNMA 0.00E+00 5.53E+08 2.44E+07 1.86E+07 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 2.74E-03
P02651 SRLAPLAEGVQEK 5.83E+06 4.78E+08 6.48E+07 1.18E+08 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 3.07E-03
P08721 DAVATWLKPDPSQ 5.64E+05 7.69E+07 4.01E+06 6.89E+07 Osteopontin n=1 Tax=Rattus norvegicus RepID=OSTP_RAT 3.15E-03
P05544 AVLDVDETGTEATAATGVAT 0.00E+00 3.43E+08 3.91E+07 9.04E+07 Serine protease inhibitor A3L n=1 Tax=Rattus norvegicus RepID=SPA3L_RAT 3.18E-03
Q01177 KEAQLPVIENK 0.00E+00 2.27E+08 5.37E+07 1.67E+09 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 3.31E-03
P04639 QEQLGPVTQEF 0.00E+00 4.17E+08 1.27E+08 4.51E+07 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 3.32E-03
G3V947 ISNTTATTQNSTDIFEGGG 0.00E+00 2.80E+07 2.59E+07 3.00E+08 SMR1 protein (Fragment) OS=Rattus norvegicus GN=Vcsa1 PE=4 SV=2 3.36E-03
Q01177 GSDVQQIAVTKL 0.00E+00 1.22E+08 1.68E+08 6.48E+08 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 3.38E-03
B4F7A5 GGGAGDRGTDGAESEGQPQGLIPGVV 5.59E+05 1.37E+08 0.00E+00 3.16E+07 Cd99 protein OS=Rattus norvegicus GN=Cd99 PE=2 SV=1 3.38E-03
P08721 DAIDSAEKPDAIDSAER 0.00E+00 3.40E+07 1.99E+06 3.36E+07 Osteopontin n=1 Tax=Rattus norvegicus RepID=OSTP_RAT 3.41E-03
P02651 AVEPLGDKFNMA 0.00E+00 2.49E+08 7.17E+07 1.82E+08 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 3.51E-03
P08721 DEAIKVIPVAQR 0.00E+00 9.18E+07 4.67E+06 4.44E+07 Osteopontin n=1 Tax=Rattus norvegicus RepID=OSTP_RAT 3.52E-03
P05545 QRLSQPEDQAEINTGSAL 1.56E+05 7.76E+07 3.15E+07 1.89E+07 Serine protease inhibitor A3K n=1 Tax=Rattus norvegicus RepID=SPA3K_RAT 3.60E-03
P02651 LPLPEQVQEQVQEQVQPKPLES 0.00E+00 8.49E+08 3.30E+07 1.27E+08 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 3.62E-03
P08721 DEQYPDATDEDLTSRM 0.00E+00 1.26E+08 1.03E+07 5.90E+07 Osteopontin n=1 Tax=Rattus norvegicus RepID=OSTP_RAT 3.65E-03
P02770 RHPDYSVSLLLR 1.32E+07 7.31E+09 6.85E+08 3.57E+07 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 3.66E-03
M0R8A9 EQVQEQVQPKPLE 4.38E+06 3.71E+08 8.85E+07 1.12E+08 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=M0R8A9_RAT 3.68E-03
P09006 YQAEAFTADFQQSR 8.03E+06 3.00E+08 3.78E+08 7.42E+08 Serine protease inhibitor A3N n=1 Tax=Rattus norvegicus RepID=SPA3N_RAT 3.69E-03
Q99PS8 DNSDRPPLQEGALPQMLPGHSGPSGTN 1.19E+07 5.31E+07 4.45E+07 3.79E+07 Histidine-rich glycoprotein OS=Rattus norvegicus GN=Hrg PE=2 SV=1 3.71E-03
G3V947 YLGLQPDPNGGQIGVT 0.00E+00 1.09E+08 1.01E+07 4.73E+07 SMR1 protein (Fragment) OS=Rattus norvegicus GN=Vcsa1 PE=4 SV=2 3.72E-03
M0RBF1 EDVPAADLSDQVPDTDSETR 1.39E+05 0.00E+00 2.48E+06 2.97E+07 Complement C3 OS=Rattus norvegicus GN=C3 PE=4 SV=1 3.84E-03
G3V836 EQEFSDNELQELSTQGSR 0.00E+00 5.09E+05 0.00E+00 1.13E+06 Clusterin OS=Rattus norvegicus GN=Clu PE=3 SV=1 3.96E-03
G3V836 DNELQELSTQGSR 2.11E+07 2.48E+08 9.31E+07 2.72E+07 Clusterin OS=Rattus norvegicus GN=Clu PE=3 SV=1 3.99E-03
UPI0002AB826B DDLIVTTGYSSGLA 1.21E+06 1.44E+08 5.65E+06 1.22E+08 UPI0002AB826B related cluster n=1 Tax=Rattus norvegicus RepID=UPI0002AB826B 4.08E-03
Q01177 ILGSDVQQIAVTK 1.99E+06 0.00E+00 2.05E+07 9.82E+07 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 4.45E-03
P05545 DQAEINTGSALFIDKEQPILSEFQEK 0.00E+00 8.26E+07 8.87E+05 1.80E+08 Serine protease inhibitor A3K n=1 Tax=Rattus norvegicus RepID=SPA3K_RAT 4.49E-03
P08721 SQESDEAIKVIPVAQR 0.00E+00 5.86E+07 0.00E+00 9.10E+07 Osteopontin n=1 Tax=Rattus norvegicus RepID=OSTP_RAT 4.69E-03
P04639 DEPQSQWDRVKDF 0.00E+00 4.96E+07 0.00E+00 8.59E+07 Apolipoprotein A-I n=1 Tax=Rattus norvegicus RepID=APOA1_RAT 4.71E-03
M0R8A9 AVEPLGDKFN 5.54E+05 1.19E+07 1.20E+07 4.82E+07 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=M0R8A9_RAT 4.85E-03
P02651 VQEQVQEQVQPKPLE 1.14E+07 2.19E+08 2.35E+07 5.83E+07 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 4.93E-03
G3V8D4 GSSALLDTVQEHL 0.00E+00 0.00E+00 7.93E+07 3.25E+08 Apolipoprotein C-II (Predicted) OS=Rattus norvegicus GN=Apoc2 PE=4 SV=1 5.07E-03
P02770 YTQKAPQVSTPTLVEAAR 7.30E+05 5.47E+06 1.84E+07 2.43E+09 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 5.13E-03
Q7TPI9 LQPLDFKENPEQSR 0.00E+00 1.64E+07 3.29E+07 9.37E+08 Ac2-248 n=1 Tax=Rattus norvegicus RepID=Q7TPI9_RAT 5.20E-03
M0R8A9 DSGDVESHLSF 0.00E+00 1.80E+07 2.20E+07 2.95E+07 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=M0R8A9_RAT 5.23E-03
Q80ZA3 TTLQDFHLDEDRTVR 0.00E+00 0.00E+00 1.06E+07 6.32E+08 Alpha-2 antiplasmin OS=Rattus norvegicus GN=Serpinf1 PE=2 SV=1 5.31E-03
Q9WUW3 SDQGGETEIETEETEMLTPDMDTERK 0.00E+00 1.20E+08 4.64E+07 8.53E+07 Complement factor I OS=Rattus norvegicus GN=Cfi PE=2 SV=1 5.32E-03
P05544 LSQPEDQVEINTGSALFIDKEQPIL 0.00E+00 2.33E+07 5.41E+08 1.51E+07 Serine protease inhibitor A3L n=1 Tax=Rattus norvegicus RepID=SPA3L_RAT 5.32E-03
UPI0002AB826B ESYAGVTLDPR 0.00E+00 7.30E+06 3.27E+07 2.58E+07 UPI0002AB826B related cluster n=1 Tax=Rattus norvegicus RepID=UPI0002AB826B 5.32E-03
Q01177 KVILGAHEER 0.00E+00 9.55E+06 1.65E+08 2.39E+07 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 5.34E-03
P06759 LWESGPEDQLTTPT 0.00E+00 5.21E+07 7.08E+07 1.90E+08 Apolipoprotein C-III n=1 Tax=Rattus norvegicus RepID=APOC3_RAT 5.45E-03
G3V615 LSSLTETIEGADAEDGHSPGEQQ 0.00E+00 8.09E+07 2.22E+08 2.35E+07 Complement factor B, isoform CRA_b OS=Rattus norvegicus GN=C2 PE=3 SV=1 5.47E-03
P06759 WESGPEDQLTTPT 0.00E+00 2.09E+08 1.30E+08 8.08E+07 Apolipoprotein C-III n=1 Tax=Rattus norvegicus RepID=APOC3_RAT 5.59E-03
P02650 DQVQEELQSSQVTQEL 0.00E+00 0.00E+00 4.60E+07 2.57E+07 Apolipoprotein E n=1 Tax=Rattus norvegicus RepID=APOE_RAT 5.77E-03
Q08420 DTGESGVDLADRLDLVEK 0.00E+00 0.00E+00 5.85E+07 1.66E+08 Extracellular superoxide dismutase [Cu-Zn] n=1 Tax=Rattus norvegicus RepID=SODE_RAT 5.79E-03
P15399 TVYLAASSVEK 0.00E+00 0.00E+00 5.72E+07 6.01E+07 Probasin n=3 Tax=Rattus RepID=PBAS_RAT 5.80E-03
P09006 IDELYLPK 0.00E+00 3.30E+08 7.59E+07 9.05E+07 Serine protease inhibitor A3N n=1 Tax=Rattus norvegicus RepID=SPA3N_RAT 5.83E-03
P02770 QVSTPTLVEAAR 1.91E+05 1.34E+08 1.03E+08 5.18E+06 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 6.01E-03
P28902 VTVQDGDLSFPLESVK 0.00E+00 1.74E+07 6.82E+07 2.32E+08 Guanylin n=1 Tax=Rattus norvegicus RepID=GUC2A_RAT 6.07E-03
P02770 QTALAELVK 5.04E+05 0.00E+00 6.87E+06 6.57E+07 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 6.20E-03
P02770 VDETYVPKEF 0.00E+00 4.04E+06 9.75E+06 1.84E+07 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 6.34E-03
P05544 LFSDLEERTS 0.00E+00 0.00E+00 3.89E+07 1.12E+09 Serine protease inhibitor A3L n=1 Tax=Rattus norvegicus RepID=SPA3L_RAT 6.35E-03
G3V947 VVQGTTEYQYQWQL 0.00E+00 3.95E+06 2.56E+07 2.12E+07 SMR1 protein (Fragment) OS=Rattus norvegicus GN=Vcsa1 PE=4 SV=2 6.37E-03
Q99PS8 THEIGCPPPPEGK 1.88E+06 3.63E+07 4.90E+07 2.68E+07 Histidine-rich glycoprotein OS=Rattus norvegicus GN=Hrg PE=2 SV=1 6.38E-03
Q68FY8 DIDPEDEELELGPR 3.05E+06 7.15E+07 1.79E+07 1.55E+07 Protein C OS=Rattus norvegicus GN=Proc PE=2 SV=1 6.50E-03
Q68FT8 MDLPGQQPVSEQAQQK 1.84E+07 1.13E+08 4.12E+07 1.42E+08 Protein Serpinf2 OS=Rattus norvegicus GN=Serpinf2 PE=2 SV=1 6.61E-03
P24090 HAFSPVASVESASGEVLH 3.43E+05 1.74E+06 8.19E+05 2.65E+07 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=FETUA_RAT 6.71E-03




















G3V836 SLLNSLEEAK 0.00E+00 1.90E+07 7.81E+07 3.09E+07 Clusterin OS=Rattus norvegicus GN=Clu PE=3 SV=1 6.87E-03
P02454 DRGETGPAGPAGPIGP 0.00E+00 0.00E+00 2.01E+07 1.91E+07 Collagen alpha-1(I) chain n=1 Tax=Rattus norvegicus RepID=CO1A1_RAT 6.92E-03
E0A3N4 DSLRPSMIDELYLPK 0.00E+00 4.06E+05 4.46E+05 7.73E+09 Serpina3n-like protein n=1 Tax=Rattus norvegicus RepID=E0A3N4_RAT 7.01E-03
D3ZBS2 FYDGSEIVVAGR 6.84E+06 6.96E+06 1.20E+07 2.55E+09 Inter-alpha-trypsin inhibitor heavy chain H3 OS=Rattus norvegicus GN=Itih3 PE=2 SV=2 7.03E-03
G3V615 LSSLTETIEGADAEDGHSPGEQQK 0.00E+00 1.10E+08 3.89E+06 2.56E+09 Complement factor B, isoform CRA_b OS=Rattus norvegicus GN=C2 PE=3 SV=1 7.37E-03
M0R8A9 LGSDSGDVESHLSF 1.00E+08 7.05E+07 4.63E+07 3.27E+09 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=M0R8A9_RAT 7.41E-03
P05544 DQVEINTGSALFIDKEQP 2.69E+06 2.72E+08 1.20E+08 1.89E+07 Serine protease inhibitor A3L n=1 Tax=Rattus norvegicus RepID=SPA3L_RAT 7.59E-03
G3V947 TAPDPTPLSNPPTQL 5.63E+07 3.01E+08 1.91E+08 1.46E+08 SMR1 protein (Fragment) OS=Rattus norvegicus GN=Vcsa1 PE=4 SV=2 7.82E-03
Q5M7T5 DVLEQKVPEATNR 8.93E+06 4.94E+07 1.40E+08 9.87E+06 Protein Serpinc1 OS=Rattus norvegicus GN=Serpinc1 PE=2 SV=1 7.95E-03
P24090 FSPVASVESASGEVLH 1.67E+07 5.02E+06 0.00E+00 3.04E+07 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=FETUA_RAT 8.07E-03
P05545 MQQVESSLQPETLKK 2.87E+07 1.53E+07 5.23E+07 1.62E+08 Serine protease inhibitor A3K n=1 Tax=Rattus norvegicus RepID=SPA3K_RAT 8.10E-03
P02651 KGSPDQPLALPLPEQVQEQ 0.00E+00 7.08E+07 0.00E+00 1.03E+08 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 8.13E-03
P05545 DQAEINTGSALFIDKEQPI 0.00E+00 0.00E+00 3.77E+07 1.59E+07 Serine protease inhibitor A3K n=1 Tax=Rattus norvegicus RepID=SPA3K_RAT 8.35E-03
A1L114 TSDSDIFTDIENPSSHVPEFSSSSK 0.00E+00 1.05E+07 9.65E+07 4.54E+07 Fga protein OS=Rattus norvegicus GN=Fga PE=2 SV=1 8.42E-03
P05544 AEAFIADFK 0.00E+00 2.74E+07 7.96E+07 4.59E+07 Serine protease inhibitor A3L n=1 Tax=Rattus norvegicus RepID=SPA3L_RAT 8.58E-03
Q5BKC4 NFRTENYEEQFEMF 0.00E+00 3.06E+08 3.76E+08 1.39E+07 C9 protein OS=Rattus norvegicus GN=C9 PE=2 SV=1 8.65E-03
Q6IRS6 GKSPEEPFPVQLDLTTNPQG 6.53E+06 2.74E+07 7.01E+07 7.32E+06 Fetub protein OS=Rattus norvegicus GN=Fetub PE=2 SV=1 8.69E-03
Q01177 LKEAQLPVIENK 0.00E+00 1.11E+07 4.65E+06 1.60E+07 Plasminogen n=1 Tax=Rattus norvegicus RepID=PLMN_RAT 8.75E-03
Q68FT8 DLPGQQPVSEQAQQK 0.00E+00 8.31E+07 0.00E+00 3.17E+07 Protein Serpinf2 OS=Rattus norvegicus GN=Serpinf2 PE=2 SV=1 8.91E-03
P08721 DEPSVETHSLEQSKEY 0.00E+00 6.09E+06 7.29E+07 3.13E+07 Osteopontin n=1 Tax=Rattus norvegicus RepID=OSTP_RAT 9.00E-03
P02770 YTQKAPQVSTPTLVEAAR 0.00E+00 0.00E+00 1.26E+07 4.79E+07 Serum albumin n=1 Tax=Rattus norvegicus RepID=ALBU_RAT 9.01E-03
P24090 SPVASVESASGEVLHSPK 0.00E+00 3.57E+06 1.52E+07 1.78E+08 Alpha-2-HS-glycoprotein n=1 Tax=Rattus norvegicus RepID=FETUA_RAT 9.09E-03
G3V836 EQEFSDNELQELSTQGSR 0.00E+00 3.25E+07 0.00E+00 3.42E+07 Clusterin OS=Rattus norvegicus GN=Clu PE=3 SV=1 9.17E-03
P14480 QAATTDSDKVDLSIAR 0.00E+00 0.00E+00 6.62E+06 1.85E+07 Fibrinogen beta chain n=1 Tax=Rattus norvegicus RepID=FIBB_RAT 9.19E-03
P09006 QAEAFTADFQQSR 0.00E+00 3.78E+07 5.02E+06 5.77E+06 Serine protease inhibitor A3N n=1 Tax=Rattus norvegicus RepID=SPA3N_RAT 9.20E-03
P02651 INTYADDLQNKLV 0.00E+00 0.00E+00 4.65E+07 2.84E+06 Apolipoprotein A-IV n=1 Tax=Rattus norvegicus RepID=APOA4_RAT 9.45E-03
F1LM05 TQADLSGITGDKDL 0.00E+00 9.73E+07 1.03E+08 6.77E+07 Protein LOC299282 n=1 Tax=Rattus norvegicus RepID=F1LM05_RAT 9.57E-03
M0RBF1 TLDPEHLGQGGVQRE 0.00E+00 1.82E+07 3.43E+07 1.04E+08 Complement C3 OS=Rattus norvegicus GN=C3 PE=4 SV=1 9.64E-03
P08721 HSDAVATWLKPDP 6.65E+06 1.63E+08 4.41E+07 3.96E+07 Osteopontin n=1 Tax=Rattus norvegicus RepID=OSTP_RAT 9.96E-03
